,PMID,Other_terms
1470,31427038,goitre multinodulaire
1471,31427038,hyperthyroïdie infra-clinique
1472,31427038,multinodular goiter
1473,31427038,subclinical hyperthyroidism
1474,31427038,tsh
1475,31427038,thyroid
1476,31427038,thyroïde
1477,31542786,*nodular goiter
1478,31542786,*thyroid cancer cois
1479,31477522,*substernal goiter
1480,31477522,*thyroid
1481,31477522,*thyroidectomy cois disclose.
1482,29950539,american thyroid association (ata)
1483,29950539,european thyroid association (eta)
1484,29950539,grave's disease
1485,29950539,japan thyroid association/ japan endocrine society
1486,29950539,thyroid
1487,31583517,ectopic goiter
1488,31583517,ectopic thyroid
1489,31583517,intrapericardial goiter
1490,31583517,intrathoracic goiter
1491,31129908,*art
1492,31129908,*history
1493,31129908,*thyroid swelling
1496,32233333,nodules
1497,32233333,thyroid
1498,30788771,art
1499,30788771,endemic goiter
1500,30788771,history
1501,30788771,thyroid swelling
1502,30105567,goiter
1503,30105567,iodine deficiency
1504,30105567,prevalence
1505,30105567,school children
1506,30105567,urinary iodine
1507,30224035,fetal ultrasound
1508,30224035,graves’ disease
1509,30224035,maladie de basedow
1510,30224035,multidisciplinarity
1511,30224035,multidisciplinarité
1512,30224035,neonatal monitoring
1513,30224035,surveillance néonatale
1514,30224035,trab
1515,30224035,teratogenicity
1516,30224035,tératogénicité
1517,30224035,échographie fœtale
1521,30193753,antithyroid drugs
1522,30193753,antithyroïdien
1523,30193753,chirurgie
1524,30193753,graves’ disease
1525,30193753,grossesse
1526,30193753,maladie de basedow
1527,30193753,myxœdeme prétibial
1528,30193753,orbitopathie
1529,30193753,orbitopathy
1530,30193753,pregnancy
1531,30193753,radioiode
1532,30193753,radioiodine
1533,30193753,surgery
1534,30193753,thyroid dermopathy
1538,32041923,graves’ ophthalmopathy
1539,32041923,diagnosis
1540,32041923,management
1542,30342794,epidemiology
1543,30342794,graves’ disease
1544,30342794,pathophysiology
1545,31464605,children
1546,31464605,ethiopia
1547,31464605,goiter
1548,31464605,meta-analysis cois
1551,31221571,*continuous neuromonitoring
1552,31221571,*intraoperative neuromonitoring
1553,31221571,*recurrent laryngeal nerve
1554,31221571,*staged thyroidectomy
1555,31221571,*thyroidectomy
1556,31221571,*vagus nerve stimulation
1559,30177259,chirurgie ophtalmologique
1560,30177259,corticotherapy
1561,30177259,corticothérapie
1562,30177259,eugogo
1563,30177259,graves’ orbitopathy
1564,30177259,immunosuppression treatment
1565,30177259,orbitopathie basedowienne
1566,30177259,smoking
1567,30177259,tabac
1568,30177259,traitement immunosuppresseur
1569,30880038,deep vein thrombosis
1570,30880038,goiter
1571,30880038,upper-extremity
1573,30180972,adolescent
1574,30180972,carbimazole
1575,30180972,child
1576,30180972,chirurgie
1577,30180972,enfant
1578,30180972,graves’ disease
1579,30180972,hyperthyroidism
1580,30180972,hyperthyroïdie
1581,30180972,iode radioactif
1582,30180972,long term
1583,30180972,long terme
1584,30180972,maladie de basedow
1585,30180972,prognosis
1586,30180972,pronostic
1587,30180972,radioactive iodine treatment
1588,30180972,surgery
1589,30180972,thiamazole
1590,30017236,computed tomography
1591,30017236,retrosternal goiter
1592,30017236,sternotomy
1593,30017236,thyroidectomy
1594,30778906,fine arts
1595,30778906,goiter
1596,30778906,history
1597,30778906,moretto da brescia
1598,30778906,renaissance
1600,31614658,goiter
1601,31614658,iodine deficiency
1602,31614658,iodine prophylaxis
1603,31614658,urinary iodine concentration cois
1606,30055961,neck approach
1607,30055961,sternotomy
1608,30055961,substernal goiter
1609,30055961,tertiary center
1610,30055961,thyroidectomy
1612,31552848,goiter
1613,31552848,iodine
1614,31552848,reproductive age
1615,31552848,salt iodine
1616,31552848,urinary iodine
1617,31552848,women cois
1618,31691192,iodine
1619,31691192,nodular goiter
1620,31691192,selenium
1621,31691192,thyroid gland
1622,31691192,thyroid hormones
1625,30803411,*longterm
1626,30803411,*methimazole
1627,30803411,*radioiodine
1628,30803411,*toxic multinodular goiter
1629,31074402,cervico-mediastinal goiter
1630,31074402,sternotomy
1631,31074402,thyroidectomy
1632,31074402,thyroiditis cois
1634,30900322,microwave
1635,30900322,substernal goiter
1636,30900322,thermal ablation
1637,30900322,thyroid
1638,30900322,ultrasound
1640,31447477,coronary artery
1641,31447477,ectopic goiter
1642,31447477,intrapericardial tumor
1643,31447477,thyroid tissue
1644,30694184,*endocrine disruptor
1645,30694184,*goiter
1646,30694184,*groundwater
1647,30694184,*subclinical hypothyroidism
1649,31270773,*art
1650,31270773,*goiter
1651,31270773,*history of medicine
1652,31270773,*thyroid
1654,31376092,genetic interaction analysis
1655,31376092,goiter
1656,31376092,hif-1α
1657,31376092,multifactor dimensionality reduction methodology
1658,31376092,polymorphisms
1659,31376092,vegf
1660,31376092,vegfr-2
1661,31668873,*adipocyte complement factors
1662,31668873,*adipokines
1663,31668873,*brown fat commitment
1664,31668873,*brown fat differentiation
1665,31668873,*extracellular matrix proteins
1666,31668873,*human batokines
1667,31668873,*human brown adipocytes
1668,31668873,*human brown fat
1669,31668873,*mitochondria
1670,31668873,*secretomics
1672,28840845,*sternotomy
1673,28840845,*computerized tomography
1674,28840845,*retrosternal goiter substernal.
1675,28840845,*surgery
1676,28840845,*thyroid
1677,28840845,*thyroidectomy
1681,29897006,*copy-number variation
1682,29897006,*genome-wide linkage analysis
1683,29897006,*multinodular goiter
1684,29897006,*next-generation sequencing
1685,29315620,amyloid goiter
1686,29315620,subacute thyroiditis
1687,29315620,thyroid
1688,29315620,ultrasonography
1689,30146569,*fdg-pet
1690,30146569,*hashimoto's thyroiditis
1691,30146569,*malignant lymphoma cois
1693,30306416,advances
1694,30306416,decade
1695,30306416,thyroid cois
1700,30141079,artificial pneumothorax
1701,30141079,carina
1702,30141079,mediastinal goiter
1703,30141079,prone position
1704,30141079,two-lung ventilation
1706,29310524,*art
1707,29310524,*goiter
1708,29310524,*sculptures
1709,31030636,*french-canadian
1710,31030636,*airway compromise
1711,31030636,*congenital hypothyroidism
1712,31030636,*dyshormonogenesis
1713,31811573,colloid goiter
1714,31811573,metals
1715,31811573,oxidative stress
1716,31811573,papillary thyroid carcinoma
1717,31285663,*dicer1
1718,31285663,*sertoli–leydig
1719,31285663,*genetic mutation
1720,31285663,*microrna
1721,31285663,*multinodular goiter
1722,31285663,"*sex cord–stromal tumour cois policy on disclosing conflicts of interest, and we declare that we have none."
1723,29275168,*goiter
1724,29275168,*hypothyroidism
1725,29275168,*mutation
1726,29275168,*thyroglobulin gene
1727,29275168,*truncated thyroglobulin protein
1728,28602544,*sternotomy
1729,28602544,*substernal goiter
1730,28602544,*thyroidectomy
1731,29548512,developed world
1732,29548512,developing world
1733,29548512,iodine deficiency
1734,29548512,low-resource setting
1735,29548512,thyroid cancer
1736,29548512,thyroid disease
1737,29548512,thyroid surgery
1738,29242007,*ecmo
1739,29242007,*extracorporeal membrane oxygenation
1740,29242007,*airway management
1741,29242007,*airway obstruction
1742,29242007,*mediastinal goiter
1743,29242007,*thyroid surgery
1744,30989520,*thyroid nodule
1745,30989520,*benign adenoma
1746,30989520,*multinodular goiter
1747,30989520,*thyroid cancer
1748,30037617,goiter
1749,30037617,hypothyroidism
1750,30037617,iodine deficiency
1751,30037617,native americans
1752,30037617,paleopathology
1755,31740871,thyroid papillary cancer haemogram
1756,29406821,graves' disease
1757,29406821,traditional chinese medicine
1758,29406821,goiter dispersion formula
1759,29406821,hyperthyroidism
1760,29406821,neurologic manifestations
1762,29215302,traditional chinese medicine
1763,29215302,goiter
1764,29215302,herbal regimen
1765,30055100,children
1766,30055100,iodine supply
1767,30055100,thyroid diseases
1768,30055100,thyromegaly
1769,29452573,metformin
1770,29452573,diffuse/nodular goiter
1771,29452573,insulin resistance
1772,29452573,obesity
1773,29452573,thyroid
1774,30820869,acute external compression of the trachea
1775,30820869,basedow’s goiter
1776,30820869,death
1777,30820869,intra-thyroid hemorrhage
1779,30084100,*euthyroid nodular goiter
1780,30084100,*insulin resistance
1781,30084100,*pulse wave velocity
1782,30084100,*strain index
1787,30506185,intrathoracic goitres
1788,30506185,retrosternal goitres
1789,30506185,substernal goitres
1790,30506185,thyroidectomy
1795,30220410,diagnosis
1796,30220410,diagnostic
1797,30220410,graves’ disease
1798,30220410,hyperthyroidism
1799,30220410,hyperthyroïdie
1800,30220410,maladie de basedow
1801,30843179,graves’ disease
1802,30843179,n-glycosylation
1803,30843179,tshr
1804,30843179,sialylation
1805,30843179,thyroid
1807,29360235,*avoiding sternotomy
1808,29360235,*intracapsular thyroidectomy
1809,29360235,*microdebrider
1810,29360235,*retrosternal goiter
1811,29360235,*thyroidectomy
1813,29348117,*graves' disease
1814,29348117,*carbimazole
1815,29348117,*radioiodine
1816,29348117,*thyroid
1817,29348117,*thyrotoxicosis cois
1823,30583800,completion thyroidectomy
1824,30583800,complications
1825,30583800,hemithyroidectomy
1826,30583800,hormone replacement
1827,30583800,isthmolobectomie
1828,30583800,supplémentation hormonale
1829,30583800,thyroïdectomie totale
1830,30583800,total thyroidectomy
1831,30583800,totalisation
1833,31813786,*antigen-specific immunotherapy
1834,31813786,*autoimmune thyroid disorders
1835,31813786,*corticosteroids
1836,31813786,*rituximab
1837,31813786,*teprotumumab
1838,31813786,*tocilizumab cois
1841,31281088,*asymmetrical nodular goitre
1842,31281088,*benign thyroid disease
1843,31281088,*hemithyroidectomy
1844,31281088,*thyroid surgery
1846,30634005,fetal therapy
1847,30634005,fetal thyroid
1848,30634005,thyroid disorders
1849,30158361,bone mineral density
1850,30158361,multinodular goiter
1851,30158361,thyroxine
1855,30044192,goitre
1856,30044192,theodor kocher
1857,30044192,thyroidectomy
1864,30701789,graves’ disease
1865,30701789,hyperthyroidism
1866,30701789,thyroid
1867,30701789,thyrotoxicosis
1868,30701789,toxic multinodular goiter
1869,31512191,graves’ disease
1870,31512191,graves’s orbithopathy
1871,31512191,lenin
1872,31512191,theodor kocher
1873,30417713,autoimmune thyroid disease
1874,30417713,graves’ disease
1875,30417713,hashitoxicosis
1876,30417713,fetal and neonatal hyperthyroidism
1877,30417713,methimazole treatment
1878,30417713,pediatric age
1879,30417713,radioiodine therapy
1880,30417713,thyroidectomy
1881,30456548,goiter
1882,30456548,graves’ disease
1883,30456548,iodine
1884,30456548,thyroid function tests
1885,30456548,thyroid gland
1887,31250924,*endocrinology
1888,31250924,*head and neck surgery
1889,31250924,*thyroid diseases
1890,31250924,*thyroid hormones
1898,31533103,acne
1899,31533103,minocycline
1900,31533103,tetracycline
1901,31533103,thyroiditis
1902,31235068,acfa
1903,31235068,atrial fibrillation
1904,31235068,complication
1905,31235068,complications
1906,31235068,heart failure
1907,31235068,hyperthyroidism
1908,31235068,hyperthyroïdie
1909,31235068,insuffisance cardiaque
1911,30637676,*goiter
1912,30637676,*hypothyroidism
1913,30637676,*iodine deficiency disorders
1915,31127592,goiter
1916,31127592,medical diagnosis
1917,31127592,painting
1918,31127592,saints
1920,31757411,*graves disease
1921,31757411,*hyperthyroidism
1922,31757411,*nodular goiter
1923,31757411,*thyroid cancer
1926,31721133,antithyroid drugs
1927,31721133,dietary supplements
1928,31721133,graves’ disease
1929,31721133,graves’ orbitopathy
1930,31721133,hyperthyroidism
1931,31721133,selenium cois assessment and supplementation.
1932,30835061,euthyroid
1933,30835061,medical diagnosis
1934,30835061,portrait
1936,28879586,amyloid
1937,28879586,amyloid goiter
1938,28879586,frozen section
1939,28879586,medullary thyroid carcinoma
1940,28879586,parathyroid cois interest to disclose. ethical approval: this article does not contain any studies with human participants or animals performed by any of the authors.
1942,29374396,adenolipoma
1943,29374396,thyroid
1944,29374396,ultrasound cois informed consent: written informed consent was obtained from the patient for the publication of this case report and accompanying images. ethical approval: all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 helsinki declaration and its later amendments or comparable ethical standards.
1946,30196262,emergency medicine
1947,30196262,haematology (incl blood transfusion)
1948,30196262,radiology (diagnostics)
1949,30196262,thyroid disease cois
1951,30989613,endocrinology
1952,30989613,frederic bazille
1953,30989613,painting cois conflict of interest.
1958,31651072,*graves' disease
1959,31651072,*hashimoto's thyroiditis
1960,31651072,*difficulty
1961,31651072,*outcomes
1962,31651072,*thyroidectomy
1964,31182347,hipocalcemia
1965,31182347,hipoparatiroidismo
1966,31182347,hormona paratiroidea
1967,31182347,hypocalcemia
1968,31182347,hypoparathyroidism
1969,31182347,parathyroid hormone
1970,31182347,thyroidectomy
1971,31182347,tiroidectomía
1972,29911397,hyperthyroidism
1973,29911397,thyroiditis
1974,29911397,thyrotoxicosis
1975,29911397,ultrasonography
1976,29911397,ultrasonography/adverse effects
1979,31007819,hyperthyroidism
1980,31007819,senegal
1981,31007819,jaundice cois
1983,28887209,*biomarkers
1984,28887209,*gas-phase fractionation (gpf)
1985,28887209,*proteomics
1986,28887209,*tandem mass tag™ (tmt)
1987,28887209,*tears
1988,28887209,*thyroid-associated orbitopathy
1989,29319139,99mtc-dtpa
1990,29319139,go
1991,29319139,hyperthyroidism
1992,31691668,balanced orbital decompression
1993,31691668,bony orbital decompression
1994,31691668,lateral orbital wall
1995,31691668,medial orbital wall
1996,31691668,optic neuropathy
1997,31691668,strabismus
1999,30918569,hyperthyroidism
2000,30918569,surgery
2001,30918569,thyroidectomy cois
2003,29395824,*airway obstruction
2004,29395824,*cardiopulmonary bypass
2005,29395824,*morbid
2006,29395824,*obese
2007,29395824,*retrosternal goiter
2008,29395824,*thyroid disease
2009,29395824,*tracheal compression
2010,30333321,*endocrinology
2011,30333321,*genetics
2012,30333321,*molecular genetics
2013,30333321,*monogenic diseases
2014,30333321,*thyroid disease cois exists
2015,30375286,* gene
2016,30375286,*congenital hypothyroidism
2017,30375286,*oligogenic mutations cois
2018,29461666,*ligament of berry
2019,29461666,*laryngeal
2020,29461666,*nerve
2021,29461666,*recurrent
2022,29461666,*thyroidectomy
2024,29729448,graves' disease
2025,29729448,graves' orbitopathy
2026,29729448,neuropsychiatric disorders
2027,29729448,quality of life
2033,31400860,ambulatoire
2034,31400860,chirurgie
2035,31400860,facteurs de risque
2036,31400860,outpatient
2037,31400860,risk factors
2038,31400860,surgery
2039,31400860,thyroid
2040,31400860,thyroïde
2041,30843109,*children
2042,30843109,*graves’ disease
2043,30843109,*proteinuria
2044,30213303,epigenetics
2045,30213303,genetics
2046,30213303,graves’disease
2047,30213303,génétique
2048,30213303,maladie de basedow
2049,30213303,prediction score
2050,30213303,score de prédiction
2051,30213303,épigénétique
2054,31562615,multinodular goiter
2055,31562615,nativity
2056,31562615,wooden little shepherds
2057,31143336,graves´ disease
2058,31143336,onycholysis
2059,31143336,hyperthyroidism
2060,31143336,hypothyroidism
2061,31143336,plummer´s nails
2062,31143336,thyroid disease cois
2064,29452583,drugs
2065,29452583,eye lids
2066,29452583,inflammation
2067,29452583,orbit
2068,29452583,vision cois publication: not applicable. competing interests: the authors state that there is no competing interests regarding the publication of this paper. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
2069,29325833,antithyroid drugs
2070,29325833,encuesta
2071,29325833,enfermedad de graves
2072,29325833,fármaco antitiroideo
2073,29325833,graves’ disease
2074,29325833,hipertiroidismo
2075,29325833,hyperthyroidism
2076,29325833,pediatric
2077,29325833,pediátrico
2078,29325833,survey
2086,29353393,autoimmunity
2087,29353393,graves’ disease
2088,29353393,hyperthyroidism
2089,29353393,iodine induced
2090,29353393,trab
2091,29353393,toxic goitre
2092,29909393,general practice / family medicine
2093,29909393,hyperthyroidism
2094,29909393,liver disease
2095,29909393,thyroid disease
2096,29909393,thyroiditis cois
2097,32461007,evaluation of results of therapeutic interventions
2098,32461007,myxedema
2099,32461007,steroids
2100,32461007,therapeutics
2101,29525760,malignant and benign haematology
2102,29525760,thyroid disease cois
2103,29721730,goitre
2104,29721730,medical diagnosis
2105,29721730,painting
2106,29721730,raphael
2108,28450378,*decompression
2109,28450378,*diplopia
2110,28450378,*graves ophthalmopathy
2111,28450378,*orbital fat
2112,28450378,*proptosis cois
2113,30949910,*biomarker
2114,30949910,*graves’ disease
2115,30949910,*microrna
2116,30949910,*plasma
2117,31424978,etiopathogenesis
2118,31424978,graves’ disease
2119,31424978,genetic factors
2120,31424978,thyroid-associated orbitopathy
2121,31424978,vitamin d receptor
2123,31132076,igf-1
2124,31132076,igf-1r
2125,31132076,thyroid cancer
2126,31637658,*differentiated thyroid carcinoma
2127,31637658,*graves’ disease
2128,31637658,*mortality
2129,31637658,*recurrence
2130,31268129,*goiter
2131,31268129,*iodine deficiency
2132,31268129,*iodine status
2133,31268129,*thyroid-stimulating hormone concentration
2134,31268129,*urinary iodine concentration
2135,30996065,respiratory medicine
2136,30996065,thyroid disease cois
2139,31292360,graves disease
2140,31292360,marine-lenhart syndrome
2141,31292360,plummer disease
2142,31144509,thyroid
2143,31144509,graves
2144,31144509,orbitopathy
2145,30504400,graves' disease
2146,30504400,ki-67
2147,30504400,metallothionein
2148,30504400,nodular goiter
2149,30504400,thyroid
2150,31496266,graves’ ophthalmopathy
2151,31496266,quantitative analysis
2152,31496266,radiation therapy
2153,31496266,thyroid eye disease
2154,31496266,volumetric analysis
2160,29027675,airway management
2161,29027675,anesthesia
2162,29027675,head and neck
2163,29027675,neck neoplasm
2164,29027675,tracheostomy
2165,29027675,ultrasound
2166,32180887,anicteric cholestasis
2167,32180887,graves’ disease
2168,32180887,hyperthyroidism cois
2169,29108474,*oncogene testing
2170,29108474,*pediatric thyroid cancer cois of the other authors have any conflicts of interest to declare.
2171,29728450,pre-tibial myxoedema
2172,29728450,thyroid acropachy
2173,29728450,thyroid associated ophthalmopathy
2174,29728450,vitiligo cois
2175,31713721,antithyroid drugs
2176,31713721,children
2177,31713721,graves’ disease
2178,31713721,hyperthyroidism
2179,31713721,“block-and-replace” method
2180,29962351,graves` associated ophthalmopathy
2181,29962351,il-6
2182,29962351,thyroid-associated ophthalmopathy
2183,29962351,extrathyroidal manifestation
2184,29962351,infiltrating cytokines
2185,29962351,tocilizumab.
2186,30935806,internal carotid artery thrombosis
2187,30935806,thromboembolic stroke
2188,30935806,thyroid goitre
2189,30257972,anaesthesia
2190,30257972,cardiovascular medicine
2191,30257972,"ear, nose and throat/otolaryngology"
2192,30257972,resuscitation
2193,30257972,thyroid disease cois
2194,32476968,graves’ disease
2195,32476968,eosinophil
2196,32476968,sarcoidosis
2197,30307028,graves’ disease
2198,30307028,depressive symptoms
2199,30307028,hyperthyroidism
2200,30307028,sexual functioning
2201,30307028,thyroid nodules
2202,29574428,emergency medicine
2203,29574428,endocrinology
2204,29574428,paediatrics
2205,29574428,thyroid disease cois
2206,29791909,fetal goiter
2207,29791909,fetal hypothyroidism
2208,29791909,intra-amniotic treatment
2209,29791909,iodine
2210,29791909,wolff-chaikoff effect
2212,30351170,fam167a-blk
2213,30351170,graves' disease (gd)
2214,30351170,hashimoto's thyroiditis (ht)
2215,30351170,autoimmune thyroid disease (aitd)
2216,30351170,polymorphism
2218,30311856,*pakistan
2219,30311856,*goiter prevalence
2220,30311856,*iodine deficiency disorder
2221,30311856,*iodized salt
2222,30311856,*pregnancy
2223,30509783,anestesia general
2224,30509783,general anaesthesia
2225,30509783,glucogenosis
2226,30509783,glycogenosis
2227,30509783,hipertermia maligna
2228,30509783,hipoglucemia
2229,30509783,hypoglycaemia
2230,30509783,malignant hyperthermia
2231,30509783,mcardle's syndrome
2232,30509783,mioglobinuria
2233,30509783,miopatía
2234,30509783,myoglobinuria
2235,30509783,myopathy
2236,30509783,síndrome de mcardle
2237,31383679,asthma
2238,31383679,"ear, nose and throat"
2239,31383679,pregnancy
2240,31383679,thyroid disease cois
2241,31450040,*graves' disease
2242,31450040,*hyperthyroidism
2243,31450040,*toxic multinodular goiter
2244,31450040,*toxic solitary nodule
2245,30455812,graves
2246,30455812,child
2247,30455812,treatment
2248,30541519,graves’ disease
2249,30541519,graves’ disease treatment.
2250,30541519,i131.
2251,30541519,radioiodine. cois metro south human research ethics committee (reference number: lnr/qms/43580). all necessary permissions to access medical records from the princess alexandra hospital were obtained. consent to participate was not a requirement. competing interests: the authors declare they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
2252,30626069,*graves’ orbitopathy
2253,30626069,*corticosteroids
2254,30626069,*hyperthyroidism
2255,30626069,*ophthalmopathy
2256,30626069,*prednisone cois
2259,31869260,* tnfsf15
2260,31869260,*graves’ disease
2261,31869260,*graves’ ophthalmopathy
2262,31869260,*tl1a
2263,31869260,*single nucleotide polymorphism
2264,31827052,aequorin
2265,31827052,graves’ ophthalmopathy
2266,31827052,thyroid-stimulating antibody
2267,31827052,thyrotropin receptor antibody
2268,31408196,*dicer1 syndrome
2269,31408196,*childhood
2270,31408196,*genetic counselling
2271,31408196,*multinodular goitre
2272,31408196,*thyroid pathologies
2278,30537006,*graves' disease
2279,30537006,*rln injury
2280,30537006,*complications
2281,30537006,*hypoparathyroidism
2282,30537006,*thyroidectomy
2283,31155292,*crispr/cas9
2284,31155292,*hearing loss
2285,31155292,*mouse model
2286,31155292,*pendred syndrome
2287,31155292,*slc26a4
2288,31155292,*vestibular dysfunction
2291,31377715,"ear, nose and throat/otolaryngology"
2292,31377715,hyperthyroidism
2293,31377715,otolaryngology/ent
2294,31377715,thyroid disease
2295,31377715,thyrotoxicosis cois
2298,31252621,ebv
2299,31252621,graves’ disease
2300,31252621,autoimmune thyroid disease
2301,31252621,hyperthyroidism
2302,31252621,viruses cois as prejudicing the impartiality of the research.
2303,31762351,receptive language outcomes
2304,31762351,non-syndromic enlarged vestibular aqueduct
2305,31762351,peabody picture vocabulary test
2306,31762351,pediatric cohort
2307,31762351,pendred syndrome
2309,30654201,depression
2310,30654201,hyperthyroidism
2311,30654201,thyroid disease
2312,30654201,women’s health
2313,31633822,*dfnb4
2314,31633822,*eva
2315,31633822,*pendred syndrome
2316,31633822,*slc26a4
2317,31633822,*genotype vs. phenotype
2318,31633822,*inner ear morphology
2319,31633822,*nonsyndromic enlarged vestibular aqueduct
2323,31749116,*antithyroid drug
2324,31749116,*graves’ disease
2325,31749116,*lymphocyte
2326,31749116,*neutrophil
2327,31749116,*relapse
2329,30955175,*fine-needle aspiration
2330,30955175,*goiter
2331,30955175,*hyperthyroidism
2332,30955175,*hypothyroidism
2333,30955175,*thyroid cancer
2334,30955175,*thyroid nodule
2335,30955175,*thyroid ultrasound
2336,29053044,graves’ ophthalmopathy
2337,29053044,graves’ orbitopathy
2338,29053044,thyroid eye disease
2339,29053044,superior ophthalmic vein thrombosis
2341,31290382,fluorescence microscopy
2342,31290382,thyroid nodule
2343,31372509,*cell biology
2344,31372509,*endocrinology
2345,31372509,*genetics
2346,31372509,*pathogenesis cois
2349,31187663,*hearing loss
2350,31187663,*iran
2351,31187663,*missense variant
2352,31187663,*next-generation sequencing
2355,27773627,bocio multinodular
2356,27773627,horner
2357,27773627,multinodular goiter
2358,27773627,oculosympathetic pathway
2359,27773627,thyroid
2360,27773627,tiroides
2361,27773627,vía oculosimpática
2362,31407208,autoimmune poliglandular syndromes
2363,31407208,graves’ disease
2364,31407208,hyperthyroidism
2365,31407208,thyroid
2366,30513035,dyshormonogenesis
2367,30513035,graves disease
2368,30513035,trab
2369,30513035,fetal goiter
2370,30513035,hyperthyroidism
2371,30513035,hypothyroidism
2372,31222404,corvis st
2373,31222404,goldmann applanation tonometry
2374,31222404,intraocular pressure
2375,31222404,ora
2376,31222404,thyroid-associated orbitopathy
2377,31222404,icare
2378,30862149,*graves’ disease
2379,30862149,*hyperthyroidism
2380,30862149,*antithyroid drugs cois
2381,31217394,adenovirus
2382,31217394,graves disease
2383,31217394,model
2385,30688164,*graves' disease
2386,30688164,*graves' ophthalmopathy
2387,30688164,*graves' orbitopathy
2388,30688164,*patient knowledge
2389,30688164,*thyroid eye disease
2390,30173328,*cognitive function
2391,30173328,*graves’ disease
2392,30173328,*graves’ ophthalmopathy
2393,30173328,*hyperthyroidism
2394,30173328,*quality of life
2395,30924917,*cancer
2396,30924917,*inflammation
2397,30924917,*neutrophil to lymphocyte ratio
2398,30924917,*thyroid nodule
2399,30263008,*dgge
2400,30263008,*gd
2401,30263008,*gut microbiota
2402,30263008,*high-throughput sequencing
2403,30263008,*hyperthyroidism
2404,30263008,*ophthalmopathy cois
2405,29281760,*complications
2406,29281760,*epidemiology biochemistry
2407,29281760,*hypoparathyroidism
2408,29281760,*mortality
2409,30955162,*graves’ disease
2410,30955162,*hyperthyroidism
2411,30955162,*leg tremor
2412,30955162,*postural tremor
2413,29923059,cholesterol
2414,29923059,graves
2415,29923059,ophthalmopathy
2416,29923059,orbitopathy
2417,29923059,statins
2418,29043478,goiter
2419,29043478,growth
2420,29043478,mri
2421,29043478,observer agreement
2422,29043478,quality of life
2423,29043478,thyroid function
2424,29043478,thyroidectomy
2425,30057393,graves orbitopathy
2426,30057393,deppression
2427,30057393,quality of life
2429,31184263,*external branch of the superior laryngeal nerve
2430,31184263,*goiter
2431,31184263,*quality of life
2432,31184263,*recurrent laryngeal nerve
2433,31184263,*thyroidectomy
2434,31184263,*voice
2435,31849168,graves' disease
2436,31849168,antithyroid drug
2437,31849168,children
2438,31849168,remission
2439,31849168,thyroid-stimulating hormone receptor antibodies
2440,30390961,benign/goiter
2441,30390961,preoperative workup
2442,30390961,thyroid
2443,30390961,thyroid surgery
2444,30390961,ultrasound/imaging
2445,30409157,gitelman syndrome
2446,30409157,graves’ disease
2447,30409157,"hypokalemia cois ethics approval and consent to participate: this study was performed according to the helsinki declaration. written informed consent to participate in the study was obtained from the patient and his mother. the patient’s son was 17 years old, and written informed consent was obtained from him and his parents as legal guardians. consent for publication: written informed consent was obtained from the patient and his mother for publication of the details of the case report. the patient’s son was 17 years old, and written informed consent was obtained from him and his parents as legal guardians. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
2448,31758881,*hashimoto’s thyroiditis
2449,31758881,*hypothyroidism
2450,31758881,*precocious puberty
2451,31758881,*stature cois
2452,30457413,biotherapies
2453,30457413,eugogo
2454,30457413,graves’ ophthalmopathy
2455,30457413,proptosis
2456,30457413,tocilizumab
2457,30339291,*cornea
2458,30339291,*dysthyroid optic neuropathy
2459,30339291,*orbital decompression
2460,30339291,*sight-threatening graves’ orbitopathy
2462,30760283,*myotonic dystrophy
2463,30760283,*papillary thyroid carcinoma
2464,30760283,*thyroid goiter
2465,30760283,*thyroid nodule
2466,30760283,"*ultrasound scan cois person (cpp), iorg 0009553 – institutional review board for the university hospital of lille. ethical committee under number: hp 1821 (benhamou_ethics_ojrd.pdf). consent for publication: na competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
2467,31655515,*lymphocyte
2468,31655515,*monocyte
2469,31655515,*neutrophil
2470,31655515,*platelet
2471,31655515,*ratio
2472,31655515,*thyrotoxicosis cois
2473,31323889,goiter
2474,31323889,hypothyroidism
2475,31323889,iodine deficiency
2476,31323889,iodine deficiency disorders
2477,31323889,iodine prophylaxis
2478,31323889,pregnancy
2479,31323889,schoolchildren cois as prejudicing the impartiality of the research reported.
2481,30880636,*graves' disease
2482,30880636,*autoimmune disease
2483,30880636,*balance
2484,30880636,*muscle strength
2485,30880636,*thyroid
2486,31715677,clinical protocols
2487,31715677,glaucoma
2488,31715677,graves ophthalmopathy
2489,31715677,ocular hypertension
2490,29306930,adolescents
2491,29306930,antithyroid drugs
2492,29306930,children
2493,29306930,hyperthyroidism
2494,29306930,management
2495,29306930,radioiodine
2496,29306930,thyrotoxicosis
2499,28569050,graves’ disease
2500,28569050,mir-146a
2501,28569050,mir-155
2502,28569050,mir-210
2503,28569050,regulatory t cells
2505,30302663,nodular recurrence
2506,30302663,thyroid lobectomy
2507,30302663,thyroid nodules
2508,32397019,disease attribute
2509,32397019,"lymphoma, non-hodgkin"
2510,32397019,prognosis
2511,32397019,thyroid neoplasms
2512,29595868,*goitre
2513,29595868,*hypocalcaemia
2514,29595868,*hypoparathyroidism
2515,29595868,*retrosternal goitre
2516,29595868,*thyroid gland
2517,29595868,*thyroidectomy
2518,29450866,diplopia
2519,29450866,graves’ orbitopathy
2520,29450866,orbital decompression
2521,29450866,proptosis
2522,29450866,quality of life
2523,29771881,endocrine ophthalmopathy
2524,29771881,multidimensional linear regression modeling
2525,29771881,prognostication
2526,29771881,risk factors
2527,29771881,toxic diffuse goiter
2529,30485487,*graves’ disease treatment
2530,30485487,*thyrotrophin receptor antibodies
2533,30540214,pulsed ivmp
2534,30540214,active ted
2535,30540214,efficacy and safety
2536,30540214,medical management
2537,30540214,steroid sparing agents
2540,31646433,*exophthalmos
2541,31646433,*graves’ disease
2542,31646433,*orbital decompression
2543,31646433,*orbital radiotherapy
2544,31646433,*orbitopathy
2545,31586293,*endogenous thyrotropin
2546,31586293,*methimazole
2547,31586293,*multinodular goitre
2548,31586293,*radioiodine cois
2549,30334140,*+49a/g polymorphism of the ctla4 gene
2550,30334140,*graves’ hyperthyroidism
2551,30334140,*graves’ orbitopathy
2552,30334140,*methimazole
2553,30334140,*predictors of remission
2555,31849350,cervical oesophageal perforation
2556,31849350,oesophageal injury
2557,31849350,oesophagogastroscopy
2558,31849350,oesophagus dilation
2559,31849350,thyroidectomy
2564,30369298,*ecological momentary assessments
2565,30369298,*patient-reported outcomes
2566,30369298,*thyroid diseases
2567,30369298,*thyroid-related quality of life
2569,30194634,graves’ ophthalmopathy
2570,30194634,tbii
2571,30194634,trab
2572,30194634,tsab
2574,31536167,afirma
2575,31536167,cytology
2576,31536167,fine-needle aspiration (fna)
2577,31536167,gene expression classifier (gec)
2578,31536167,genomic sequencing classifier (gsc)
2579,31536167,molecular
2580,31536167,thyroid
2583,29759035,*nis
2584,29759035,*slc5a5
2585,29759035,*congenital hypothyroidism
2586,29759035,*goiter
2587,29759035,*novel mutation
2588,29759035,*sodium–iodide symporter cois
2590,30135996,graves’ disease
2591,30135996,lipidomic analysis
2592,30135996,ophthalmopathy
2593,30135996,plasma
2594,30135996,urine
2595,30135996,nuplc-esi-ms/ms
2596,29332250,dysfunctional tear syndrome
2597,29332250,hyperthyroidism
2598,29332250,ocular surface inflammation
2599,29332250,tear cytokines
2600,29332250,thyroid-associated orbitopathy
2604,30696398,*acute airway obstruction
2605,30696398,*goitre
2606,30696398,*pregnancy
2607,30696398,*respiratory arrest cois publication: written informed consent for publication of the clinical details and clinical images was obtained from the patient. written informed consent for publication of the clinical details and clinical images was obtained from patient. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
2608,31727496,children
2609,31727496,iodized salt
2610,31727496,thyroid abnormalities
2611,31727496,urinary iodine
2612,31727496,water iodine
2613,31727496,water replacement
2614,28766837,dicer1
2615,28766837,cystic nephroma
2616,28766837,multinodular goiter
2617,28766837,mutation
2618,28766837,neuroblastoma
2619,28766837,syndrome
2622,30387079,benign thyroid disease
2623,30387079,meta-analysis
2624,30387079,prospective study
2625,30387079,thyroid cancer
2627,31237847,intraocular pressure
2628,31237847,thyroid-associated orbitopathy
2629,31201593,extraocular muscle
2630,31201593,graves’ ophthalmopathy
2631,31201593,magnetic resonance imaging
2632,31201593,radiation therapy
2633,31201593,steroids
2638,30217613,basedow
2639,30217613,graves
2640,30217613,quality of life
2641,30217613,qualité de vie
2642,30217613,questionnaire
2643,30217613,strabisme
2644,30217613,strabismus
2645,30217613,thyroid
2646,30217613,thyroïde
2647,30217607,chirurgie de strabisme
2648,30217607,diplopia
2649,30217607,diplopie
2650,30217607,dysthyroid orbitopathy
2651,30217607,graves’ disease
2652,30217607,maladie de basedow
2653,30217607,orbitopathie dysthyroïdienne
2654,30217607,strabismus surgery
2655,31340806,bleeding
2656,31340806,hematoma
2657,31340806,risk factor
2658,31340806,thyroid surgery
2659,31340806,thyroidectomy cois
2660,31641884,computed tomography
2661,31641884,deep lateral orbital wall decompression
2662,31641884,fat removal
2663,31641884,graves’ orbitopathy
2664,31641884,prediction
2665,31641884,the greater wing of the sphenoid
2666,30862763,graves’ disease
2667,30862763,children
2668,30862763,long-term outcome
2669,30862763,methimazole treatment
2670,30862763,remission
2671,31023276,bioassay
2672,31023276,graves’ disease
2673,31023276,trab
2674,31023276,"thyroid cois involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 helsinki declaration and its later amendments or comparable ethical standards. the study protocol was approved by the local ethics committee (ethikkommission nordwest und zentralschweiz (eknz) project no. 2015/227). need for informed consent was waived by the local ethics committee due retrospective nature of analysis with no impact on health outcome. consent for publication: not applicable. competing interests: bm and ps received research support by thermo fisher scientific, roche diagnostics, abbott and siemens unrelated to this study. all authors confirm that they do not have a conflict of interest associated with this manuscript. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
2675,30132285,autoimmune thyroiditis
2676,30132285,graves’ disease
2677,30132285,graves’ ophthalmopathy
2678,30132285,graves’ orbitopathy
2679,30132285,insulin-like growth factor-1 receptor
2680,30132285,thyroid
2681,30132285,thyroid autoimmunity
2682,30132285,thyroid eye disease
2683,30049435,*graves' disease
2684,30049435,*thyroid cancer
2685,30049435,*thyroid nodules
2686,30696370,*children
2687,30696370,*goiter
2688,30696370,*sufficient iodine intake
2689,30696370,*thyroid volume
2690,31622299,"thyroidectomy, complications, hypocalcaemia, recurrent laryngeal nerve injury,  haemorrhage. (jpma 69: 1470; 2019).doi:10.5455/jpma.301233"
2693,30767621,*graves' disease
2694,30767621,*ciliogenesis
2695,30767621,*nodular hyperplasia
2696,30767621,*primary cilia
2697,30767621,*thyrocytes
2699,29649988,lipid layer thickness
2700,29649988,meibomian gland dysfunction
2701,29649988,"thyroid eye diseases cois (irb)/ethics committee approval was obtained from the committee of medical ethics and human experiments of chang gung memorial hospital (cgmh), taiwan. informed consent was obtained from each subject in the cgmh. consent for publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
2703,31309667,fukushima
2704,31309667,japanese black
2705,31309667,cattle
2706,31309667,goiter
2707,31309667,thyroid gland
2710,31094460,hormones
2711,31094460,immunological
2712,31094460,liquidators of the chernobyl accident
2713,31094460,non-hospital pneumonia
2714,30197184,*autoimmune disease
2715,30197184,*celiac disease
2716,30197184,*graves’ disease
2717,30197184,*myotonic dystrophy type 2
2718,29183262,*sds
2719,29183262,*globus symptoms
2720,29183262,*quality of life
2721,29183262,*thyroid surgery
2722,30719623,cyclosporine
2723,30719623,graves’ orbitopathy
2724,30719623,intravenous glucocorticoids
2725,30719623,methotrexate
2726,30737677,*hashimoto’s thyroiditis
2727,30737677,*iodothyronine deiodinase
2728,30737677,*thyroid gland
2729,30737677,*thyroid hormone metabolism
2730,31170960,destructive thyrotoxicosis
2731,31170960,diagnostic meta-analysis
2732,31170960,differential diagnosis
2733,31170960,graves’ disease
2734,31170960,peak systolic velocity of superior thyroid artery
2735,31170960,thyrotoxicosis cois
2736,31933295,focus harmonic scalpel
2737,31933295,hypocalcaemia
2738,31933295,hypoparathyroidism
2739,31933295,thyroidectomy
2740,31514388,diagnosis
2741,31514388,exosomes
2742,31514388,goiter
2743,31514388,heat shock proteins (hsp)
2744,31514388,molecular chaperones
2745,31514388,papillary carcinoma
2746,31514388,thyroid gland cois
2747,30110704,congenital hypothyroidism
2748,30110704,duoxa2
2749,30110704,fetal goiter
2750,30110704,mutation
2751,30110704,polyhydramnios
2752,29354016,*computed tomography
2753,29354016,*euthyroidism
2754,29354016,*graves' disease
2755,29354016,*methimazole
2756,29354016,*single-photon emission computed tomography
2757,29943563,graves disease
2758,29943563,hepatitis a virus
2759,29943563,triggering factor
2762,30092670,*go-qol
2763,30092670,*graves’ ophthalmopathy (go)
2764,30092670,*thyroid eye disease (ted)
2765,30092670,*adults
2766,30092670,*psychometrics
2767,30092670,*reliability
2768,30092670,*validity
2769,30783963,*diabetes
2770,30783963,*graves’ disease
2771,30783963,*islet autoantibodies
2772,30783963,*thyroid autoantibodies cois ethical approval: all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 helsinki declaration and its later amendments or comparable ethical standards. informed consent: informed consent was obtained from all individual participants included in the study.
2773,30690623,*endemic
2774,30690623,*goitre
2775,30690623,*iodine
2776,30690623,*urinary iodine excretion
2777,27659020,goiter
2778,27659020,subtotal resection
2779,27659020,thyroidectomy
2781,29032778,*iodine-deficiency disorders
2782,29032778,*iodized salt
2783,29032778,*iran
2784,29032778,*school-aged children
2785,31411490,arhi
2786,31411490,fine-needle aspiration cytology
2787,31411490,imprinted gene
2788,31411490,thyroid nodule cois
2789,31028051,"ear, nose and throat"
2790,31028051,respiratory system
2791,31028051,venous thromboembolism cois
2793,30621642,hashimoto’s thyroiditis
2794,30621642,magnetic resonance
2795,30621642,ophthalmopathy
2796,30621642,"orbitopathy cois accordance with the ethical standards of the institutional and/or national research committee and with the 1964 helsinki declaration and its later amendments or comparable ethical standards. this is a case report, retrospectively describing the course of the diagnostics and therapy, thus does not require the local bioethical committee approval. consent for publication: written informed consent was obtained from the patient for the publication of this report and any accompanying images. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
2797,31347001,euthyroid
2798,31347001,in vitro fertilization
2799,31347001,intra-cytoplasmic sperm injection
2800,31347001,pregnancy outcomes
2802,31696306,*epoprostenol
2803,31696306,*hyperthyroidism
2804,31696306,*prostanoids
2805,31696306,*pulmonary hypertension
2806,31696306,*selexipag
2808,30369343,*pps method
2809,30369343,*thyroid volume
2810,30369343,*urinary iodine concentration
2811,30710486,goiter
2812,30710486,iodine deficiency disorders
2813,30710486,urinary iodine
2814,30710486,urinary thiocyanate
2818,30431723,graves’ disease
2819,30431723,graves’ ophthalmopathy
2820,30431723,optic nerve diseases
2821,30431723,optic nerve injuries
2822,30431723,"ultrasonography, doppler, color"
2823,31420436,materno-fetal medicine
2824,31420436,pregnancy
2825,31420436,thyroid disease cois
2826,30515705,bihar
2827,30515705,intelligence quotient (iq)
2828,30515705,iodized salt consumption
2829,30515705,total goitre rate
2831,30484383,*cochlear implantation
2832,30484383,*enlarged endolymphatic sacs
2833,30484383,*enlarged vestibular aqueduct
2834,30484383,*pendred syndrome
2835,30484383,*slc26a4
2836,30484383,*temporal bone
2838,31565879,*autoantibodies
2839,31565879,*graves disease
2840,31565879,*recurrence
2841,31565879,*thyroid peroxidase antibody cois
2843,30667296,*graves' disease
2844,30667296,*qol
2845,30667296,*sf-36
2846,30667296,*thypro
2847,30667296,*long-term
2848,30667296,*radioiodine
2849,30392997,hipocalcemia
2850,30392997,hipoparatiroidismo
2851,30392997,hypocalcemia
2852,30392997,hypoparathyroidism
2853,30392997,parathormone
2854,30392997,paratohormona
2855,30392997,thyroidectomy
2856,30392997,tiroidectomía
2857,31677639,*goiter
2858,31677639,*salt iodine concentration
2859,31677639,*shanghai
2860,31677639,*thyroid volume
2861,31677639,*urinary iodine concentration cois
2863,31860407,*graves'
2864,31860407,"*disease, graves'"
2865,31860407,"*orbitopathy, radioiodine, glucocorticoids, tsh receptor antibodies"
2866,30814438,graves’ disease
2867,30814438,hashimoto’s thyroiditis
2868,30814438,interleukin-17
2869,30814438,interleukin-1β
2870,30814438,interleukin-23
2873,29198022,*glaucoma
2874,29198022,*graves' disease
2875,29198022,*register study
2876,29198022,*toxic nodular goiter
2877,30890403,fna
2878,30890403,ptc
2879,30890403,mir-137
2880,30890403,mir-181b
2881,30890403,mir-214
2882,30890403,mir-222
2885,30577987,thyroid surgery
2886,30577987,transcutaneous laryngeal ultrasound
2887,30577987,vocal cord mobility
2888,30593716,blinking
2889,30593716,dry eye
2890,30593716,meibomian gland dysfunction
2891,30593716,thyroid eye disease
2892,31691654,mechanical high-speed bone removal
2893,31691654,orbital bone decompression
2894,31691654,osteodestruction
2895,31691654,scanning electron microscopy
2896,31691654,thyroid eye disease
2897,31691654,ultrasonic bone removal
2900,30701793,graves’ disease
2901,30701793,endocrine ophthalmopathy
2902,30701793,polymorphic genetic markers
2903,29446011,iodine
2904,29446011,iodine deficiency
2905,29446011,iodized salt
2906,29446011,iran
2907,29446011,uic cois ethical approval: the local ethics committee approved the study protocol. informed consent: informed consent was obtained from all individual participants included in the study.
2910,29946800,antithyroid drugs
2911,29946800,goiter
2912,29946800,graves’ disease
2913,29946800,graves’ orbitopathy
2914,29946800,hyperthyroidism
2915,29946800,predictive models
2916,29946800,recurrence
2917,29946800,tsh-receptor antibody
2918,31841476,accident at chnpp
2919,31841476,breast cancer
2920,31841476,functional parameters
2921,31841476,malignant tumors
2922,31841476,mammary gland
2923,31841476,structural parameters
2924,31841476,thyroid gland
2925,29937466,dysthyroid eye disease
2926,29937466,glucocortoid-resistant
2927,29937466,graves’ orbitopathy
2928,29937466,rituximab
2929,29940879,goiter
2930,29940879,iodine deficiency
2931,29940879,iodized salt
2932,29940879,pregnant women
2933,29940879,urinary iodine cois the institutional review board of hawassa university (irb 065-06). the local authorities were informed about the study objectives. after the study purpose was explained to the pregnant women informed written consent was obtained. confidentiality of the data obtained from participants was strictly secured and maintained. consent for publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
2934,29334119,elastography
2935,29334119,nodular goitre
2936,29334119,thyroid
2937,29334119,thyroid imaging reporting and data system
2938,29334119,ultrasound
2940,31660895,hmga2
2941,31660895,thyroid carcinoma
2942,31660895,microrna
2943,31660895,molecular markers
2944,31660895,preoperative diagnosis cois
2945,31810448,goitre
2946,31810448,iodine
2947,31810448,thyroid
2948,31810448,uic
2949,31810448,wic
2950,31810448,water cois
2951,29556769,ablation techniques
2952,29556769,high-intensity focused ultrasound ablation
2953,29556769,interventional ultrasonography
2954,29556769,nodular goitre
2955,29556769,ultrasound imaging
2957,30219088,antithyroid drugs
2958,30219088,cascore
2959,30219088,graves’ disease
2960,30219088,graves’ ophthalmopathy
2961,30219088,hyperthyroidism
2962,30219088,muscle index
2963,30219088,nospecs
2964,30219088,superonasal index
2965,30219088,"thyroidectomy cois medical university vienna gave a positive vote on the protocol and consent to participate. (protocol record 1839/2015). the trial was registered at the european clinical trials database (eudra-ct: 2015–003515-38). consent for publication: in consenting to participate in the clinical trial, all patients also consent to publication, as is stated in their consent form. competing interests: the author(s) declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
2967,31312298,graves´ disease
2968,31312298,hashimoto´s thyroiditis
2969,31312298,south africa
2970,31312298,autoimmune thyroid disease
2971,31312298,hyperthyroidism
2972,31312298,hypothyroidism cois
2973,31171533,acute renal failure
2974,31171533,liver disease
2975,31171533,thyroid disease cois
2976,30885146,cyclin d1
2977,30885146,cytology
2978,30885146,diagnosis
2979,30885146,ngs
2980,30885146,"thyroid nodule cois the patients, and the ethical committee of the national cancer center hospital, tokyo, japan, approved the procedures (approval #2010–077). the informed consent will be written or verbal from participants. the research poses no more than minimal risk to patients and includes appropriate safeguards to protect the patients’ rights, safety and privacy. consent for publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
2981,28656526,antioxidant
2982,28656526,fibroblast
2983,28656526,graves’
2984,28656526,melatonin
2985,28656526,n-acetyl-l-cysteine
2986,28656526,ophthalmopathy
2987,28656526,orbitopathy
2988,28656526,vitamin c
2989,29026936,*eyelid retraction
2990,29026936,*graves’ orbitopathy
2991,29026936,*lid surgery
2992,29026936,*upper eyelid retraction
2993,29983514,goitre
2994,29983514,difficult intubation
2995,29983514,modified intubation difficulty score
2996,29983514,predictive factors
2997,29983514,thyroidectomy
2998,30572375,cohort study
2999,30572375,school-aged children
3000,30572375,thyroid
3001,30572375,volume
3002,28832090,*aortic grafting
3003,28832090,*goitre
3004,28832090,*retrotracheal
3005,28832090,*thoracotomy
3006,28832090,*thyroidectomy
3007,29764405,excessive iodine intake
3008,29764405,goitre
3009,29764405,iodine deficiency
3010,29764405,pregnant women
3011,29764405,"thyroid volume cois approved by the committee on human research, publications and ethics, knust, school of medical sciences and komfo anokye teaching hospital. the ethical approval reference number is chrpe/rc/058/16. permission to undertake the study at the hospitals was also sought from the hospital management. written informed consent was obtained from all participants recruited into the study. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
3012,29319381,dwi
3013,29319381,grave’s orbitopathy
3014,29319381,mri
3015,29319381,head and neck
3016,29319381,orbit
3017,29319381,thyroid eye disease
3018,29787340,cd8+ t cells
3019,29787340,cd8+ t-regulatory cells
3020,29787340,graves’ ophthalmopathy
3021,29787340,thyroid autoimmunity
3026,29708883,graves’ disease
3027,29708883,allogenic hematopoietic stem cell transplantation
3028,29708883,hyperthyroidism; severe aplastic anemia
3030,30458118,*rthβ
3031,30458118,*thrb gene
3032,30458118,*novel mutation
3033,28992728,intrapartum treatment
3034,28992728,cesarean section
3035,28992728,congenital high airway obstruction
3036,28992728,fetal neck tumors
3037,28992728,trachea
3039,30224619,graves’ disease
3040,30224619,glucose intolerance
3041,30224619,glycosuria
3042,30224619,hyperthyroidism
3043,30224619,urine glucose screening program
3044,29409479,dysthyroid optic neuropathy
3045,29409479,orbital radiotherapy
3046,29409479,three-wall decompression
3047,29409479,thyroid eye disease cois this case report was approved by the ethics committee of shanghai ninth people’s hospital (no. [2016]-29). the report was in compliance with the tenets of the declaration of helsinki for clinical research. consent for publication: written informed consent was obtained from the patient for publication of this case report and any accompanying images. a copy of the consent is available for review by the editor of this journal. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
3048,29307098,hybrid procedure
3049,29307098,lung tumor
3050,29307098,mediastinal tumor
3051,29307098,robotic surgery
3052,29307098,single incision
3053,29307098,thyroid tumor
3055,29786585,pesticides
3056,29786585,morbidity
3057,29786585,thyroid gland
3058,29786585,application rate
3063,30413358,(99m)tc-pertechnetate uptake
3064,30413358,calculated-dose
3065,30413358,captación de (99m)tc-pertecnetato
3066,30413358,clinical outcomes
3067,30413358,cálculo de dosis
3068,30413358,enfermedad de graves
3069,30413358,graves’ disease
3070,30413358,radioiodine
3071,30413358,resultados clínicos
3072,30413358,yodo radiactivo
3073,31670633,postoperativehypocalcemia
3074,31670633,recurrentlaryngealnervepalsy
3075,31670633,totalthyroidectomy
3076,31670633,tubercleofzuckekandl
3080,30610492,antithyroid antibodies
3081,30610492,antithyroid drugs
3082,30610492,graves’ disease
3083,30610492,hyperthyroidism
3084,30610492,type 2 deiodinase
3085,29096966,*calcificaciones
3086,29096966,*calcifications
3087,29096966,*carcinoma tiroideo
3088,29096966,*doppler
3089,29096966,*ecografía
3090,29096966,*elastografía
3091,29096966,*elastography
3092,29096966,*malignancy
3093,29096966,*malignidad
3094,29096966,*nódulo tiroideo
3095,29096966,*thyroid carcinoma
3096,29096966,*thyroid nodule
3097,29096966,*ultrasound
3098,30426886,*graves' disease
3099,30426886,*tsh receptor antibody
3100,30426886,*incidence
3101,30426886,*neonatal hyperthyroidism
3102,30426886,*radioiodine therapy
3103,29633307,*graves’ disease
3104,29633307,*thypro
3105,29633307,*thyrotoxicosis
3106,29633307,*treatment choice
3107,29633307,*treatment satisfaction
3108,29023978,body mass index
3109,29023978,levothyroxine
3110,29023978,radioactive iodine ablation
3111,31369161,*grave's
3112,31369161,*cancer
3113,31369161,*nodules
3114,31369161,*thyroid
3115,31124148,*immunology
3116,31124148,*immunosuppression
3117,31124148,*thyroid diseases
3118,31124148,*vasculitis
3119,31079052,*cosmesis
3120,31079052,*eye lids
3121,31079052,*orbit cois
3122,30658624,99mtc-dtpa
3123,30658624,graves’ orbitopathy
3124,30658624,mri
3125,30658624,"spect/ct cois involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964. helsinki declaration and its later amendments or comparable ethical standards. the study was approved by the bioethical commission of medical university of bialystok, poland. all participants provided written informed consent to participate. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
3126,30628510,clinical activity score
3127,30628510,color doppler imaging
3128,30628510,thyroid eye disease
3129,30616573,*diagnosis
3130,30616573,*graves’ disease
3131,30616573,*hashimoto’s thyroiditis
3132,30616573,*model
3133,29959506,computed tomography
3134,29959506,eyelid retraction
3135,29959506,graves’ orbitopathy
3136,29959506,inferior rectus muscle
3137,29959506,levator palpebrae superioris muscle
3138,29959506,margin reflex distance
3139,29959506,superior rectus muscle
3141,28738723,*thyroid eye disease
3142,28738723,*patient expectations
3143,28738723,*psychosocial adjustment
3144,28738723,*reconstructive surgery
3145,28738723,*treatment satisfaction
3148,29469200,*dicer1
3149,29469200,*cryptic exon
3150,29469200,*deep intronic mutation
3151,29469200,*lung cyst
3152,29469200,*multinodular goiter
3153,29469200,*ovarian sertoli-leydig cell tumor
3154,30761931,graves’ disease
3155,30761931,movement disorders
3156,30761931,autoimmune
3157,30761931,chorea
3158,30761931,hyperthyroidism
3159,30761931,myoclonus
3160,30761931,tremor
3161,30721670,*bone morphogenic protein 4
3162,30721670,*orbit
3163,30721670,*pathology
3164,30721670,*site-specific adipogenesis
3168,31784912,embryopathy
3169,31784912,graves’ diseases
3170,31784912,methimazole
3171,31784912,pancreatitis
3172,31784912,pregnancy
3173,31784912,propylthiouracil
3175,28568286,gpr174
3176,28568286,ptpn22
3177,28568286,rnaset2
3178,28568286,gene polymorphism
3179,28568286,liver damage
3180,29521049,graves’ disease
3181,29521049,matrix metalloproteinases
3182,29521049,orbithopathy
3183,29521049,tissue inhibitors of metalloproteinases
3184,30918165,antithyroid drug
3185,30918165,graves’ disease
3186,30918165,hyperthyroidism
3187,30918165,tsh receptor antibody
3188,30918165,thyroid
3191,30151919,*3d
3192,30151919,*thyroid-associated orbitopathy
3193,30151919,*eye-tracking
3194,30151919,*facial deformity
3195,30151919,*scanpath
3196,29739340,*brazil
3197,29739340,*hereditary deafness
3198,29739340,*pendrin gene
3199,29739340,"*slc26a4 cois written informed consent was obtained from all individuals or their legal guardians (if patients were under 18). the project was approved by the ethics committee, instituto de biociências, universidade de são paulo (protocol n(o) 109/2010). consent for publication: all subjects have approved the submission of the manuscript by written informed consent. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
3202,29096933,graves’ orbitopathy
3203,29096933,balanced decompression
3204,29096933,deep lateral decompression
3205,29096933,intact rim
3206,29096933,proptosis
3207,29096933,rim removal
3210,30167837,graves’ orbitopathy
3211,30167837,nasal airflow
3212,30167837,olfactory performance
3213,30167837,orbital decompression
3214,30167837,surgical outcome
3219,32202741,*igg4-associated disease
3220,32202741,*autoimmune thyroiditis
3221,32202741,*case report
3222,32202741,*inflammatory orbital disease
3223,32202741,*orbital involvement
3224,32202741,*thyroid eye disease
3228,30442552,graves’ orbitopathy
3229,30442552,deep lateral decompression
3230,30442552,proptosis
3231,30442552,rim-sparing
3232,32476690,"cholesterol, hdl"
3233,32476690,"igf1 protein, human"
3234,32476690,"igf2 protein, human"
3235,32476690,insulin
3236,32476690,insulin-like growth factor i
3237,32476690,insulin-like growth factor ii
3238,32476690,iodine
3239,32476690,"obesity, abdominal"
3240,32476690,thyroid nodule
3241,32476690,case-control studies
3242,32476690,insulin resistance
3243,32476690,metabolic syndrome
3244,30223781,*cd40
3245,30223781,*ctla-4
3246,30223781,*genetic polymorphism
3247,30223781,*graves’ disease cois the medical ethics committee of the affiliated hospital of guangdong medical university. the approval number was: pj2012029. all the above enrolled patients signed an informed consent document. consent for publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
3248,31188037,*bézier curves
3249,31188037,*graves orbitopathy
3250,31188037,*contour analysis
3251,31188037,*lower eyelid
3252,31188037,*lower eyelid retraction
3255,29627743,chronic autoimmune thyroiditis
3256,29627743,diffuse thyroid disease
3257,29627743,swe
3258,29627743,ft3/ft4 ratio
3259,31474503,graves’ orbitopathy
3260,31474503,endocrine ophthalmopathy
3261,31474503,fat removal
3262,31474503,orbital decompression
3263,30543152,*mapk/erk pathway
3264,30543152,*pi3k/akt pathway
3265,30543152,*tbx1
3266,30543152,*epithelial–mesenchymal transition
3267,30543152,*thyroid cancer
3268,30954956,endocrine system
3269,30954956,thyroid disease cois
3270,30084099,*craniosynostosis
3271,30084099,*graves’ orbitopathy
3272,31831041,graves disease
3273,31831041,thrombotic thrombocytopenic purpura cois
3275,30142011,color doppler imaging
3276,30142011,orbital decompression
3277,30142011,thyroid eye disease
3278,29937157,extraocular muscles
3279,29937157,graves’ ophthalmopathy
3280,29937157,grosor muscular
3281,29937157,muscle thickness
3282,29937157,músculos extraoculares
3283,29937157,oftalmopatía de graves
3284,29937157,optical coherence tomography
3285,29937157,orbitopatía tiroidea
3286,29937157,thyroid orbitopathy
3287,29937157,tocilizumab
3288,29937157,tomografía de coherencia óptica
3289,31056988,extraocular muscle
3290,31056988,graves’ eye disease
3291,31056988,superior recuts
3292,31056988,thyroid eye disease
3293,30009641,*human extraocular muscle
3294,30009641,*human extraocular muscle myoblasts
3295,30009641,*myogenesis
3296,30009641,*thyroid-associated ophthalmopathy
3297,30009641,*thyroid-stimulating hormone receptor
3299,30941511,anterior blepharotomy
3300,30941511,esthetic outcome
3301,30941511,graves’ ophthalmopathy
3302,30941511,tarsal platform show
3303,30941511,upper eyelid retraction
3309,31365979,graves orbitopathy
3310,31365979,graves orbitopathy guality of life questionnaire
3311,31365979,quality of life
3312,31059842,cxcl10
3313,31059842,cxcl8
3314,31059842,fibroblasts
3315,31059842,graves' disease
3316,31059842,graves' ophthalmopathy
3317,31059842,thyrocytes
3320,29319400,graves’
3321,29319400,orbital decompression
3322,29319400,strabismus
3323,29166180,*corvis-st
3324,29166180,*dynamic scheimpflug analyzer
3325,29166180,*biomechanics
3326,29166180,*thyroid orbitopathy
3327,29166180,*whole eye movement
3328,28177666,graves’ disease
3329,28177666,graves’ ophthalmopathy
3330,28177666,cytokine
3331,28177666,gene
3332,28177666,genetic polymorphism
3333,28177666,maladie de graves
3334,28177666,ophtalmopathie de graves
3335,28177666,poly (adp-ribose) polymerase-1
3336,28177666,poly (adp-ribose) polymérase-1
3337,28177666,polymorphism
3338,28177666,polymorphisme
3339,28177666,polymorphisme génétique
3341,30535759,autoimmune thyroid diseases
3342,30535759,graves’ disease
3343,30535759,hashimoto’s thyroiditis
3344,30535759,magi2
3345,30535759,single-nucleotide polymorphisms
3346,30513237,graves’ orbitopathy
3347,30513237,orbital decompression
3348,30513237,diplopia
3349,30513237,piezosurgery
3350,30513237,proptosis reduction
3352,29190000,autoimmune
3353,29190000,dna methylation
3354,29190000,genome-wide
3355,29190000,graves’ orbitopathy
3356,30937820,hypoparathyroidism
3357,30937820,recurrent nerve injury
3358,30937820,reoperative thyroid surgery
3359,30937820,total thyroidectomy
3360,31604721,calcium and bone
3361,31604721,thyroid disease cois
3362,30801749,*calcium
3363,30801749,*hypoparathyroidism
3364,30801749,*dyspepsia
3365,30801749,*hospitalization
3366,30801749,*patient survey
3367,30801749,*vitamin d
3368,30176063,*chinese cohort
3369,30176063,*graves' disease
3370,30176063,*genome-wide association study
3371,30176063,*susceptibility loci
3372,29336220,*graves'
3373,29336220,*cholesterol
3374,29336220,*ophthalmopathy
3375,29336220,*orbitopathy
3376,29336220,*statins
3377,29273685,*igf receptor
3378,29273685,*immune system
3379,29273685,*signal transduction
3380,29273685,"*thyroid cois member at the ucla school of medicine covering the diagnostic methods for monitoring anti-igf-ir antibodies and the therapeutic targeting of igf-ir in graves’ disease and other autoimmune diseases. i have requested that my current employer, the university of michigan medical school, adjudicate any conflicts of interest."
3381,31271716,*graves’ disease
3382,31271716,*pretibial myxedema
3383,31271716,*thyroid dermopathy
3386,31884304,autoantibodies
3387,31884304,graves' disease
3388,31884304,smoking
3389,31884304,vitamin 25(oh)d3 cois
3391,30092570,childhood onset
3392,30092570,graves’ disease
3393,30092570,papillary thyroid carcinoma
3394,30092570,slc5a5
3395,30092570,tfg/ntrk1
3396,30092570,tshr
3398,31685507,*graves' disease
3399,31685507,*cognitive impairment
3400,31685507,*functional near-infrared spectroscopy
3401,31685507,*hippocampus
3402,31685507,*magnetic resonance volumetry
3403,31685507,*quality of life cois and bristol-myers squibb.
3404,31338585,dexamethasone
3405,31338585,interleukin 6
3406,31338585,interleukin 6 receptor
3407,31338585,thyroid eye disease
3408,31338585,tocilizumab
3411,31462328,aggressive carcinoma
3412,31462328,graves’ disease
3413,31462328,matched cohort
3414,31462328,outcomes
3415,31462328,papillary thyroid carcinoma cois
3416,31304517,graves’ disease
3417,31304517,mig
3418,30825882,champagne bottle neck sign
3419,30825882,graves’ disease
3420,30825882,moyamoya vasculopathy
3421,30825882,recurrence
3422,30825882,vasculitis cois publication: written informed consent was obtained from the patient for publication of this case report. a copy of the written consent is available for review by the editor of this journal. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
3424,29742012,eyelid
3425,29742012,recession
3426,29742012,retraction
3427,29742012,spacer graft
3428,29742012,thyroid
3432,28822031,thyroid eye disease
3433,28822031,thyroid ophthalmopathy
3434,28822031,visa
3436,31482765,*graves' disease
3437,31482765,*antithyroid drugs
3438,31482765,*hyperthyroidism
3439,31482765,*long-term follow-up
3440,31482765,*radioiodine
3441,31482765,*recurrence
3442,31482765,*remission
3443,31482765,*thyroidectomy
3446,31057005,compressive optic neuropathy
3447,31057005,dysthyroid optic neuropathy
3448,31057005,extra-ocular muscles
3449,31057005,orbital computed tomography
3450,31057005,thyroid eye disease
3451,31057005,visual field
3453,30803176,orbital fibroblast
3454,30803176,pirfenidone
3455,30803176,thyroid
3456,30803176,transforming growth factor
3459,29439614,*131i
3460,29439614,*graves' disease
3461,29439614,*thyroglobulin autoantibodies
3462,29439614,*thyroglobulin measurement
3463,29439614,*thyroglobulin metabolic clearance
3464,29439614,*thyroid cancer
3465,28776731,*+49a/g
3466,28776731,*131i
3467,28776731,*graves' disease
3468,28776731,*cytotoxic t lymphocyte antigen 4
3469,28776731,*polymorphism
3470,28776731,*radionuclide
3471,28776731,*−318c/t
3474,28944477,*endoscopy
3475,28944477,*graves disease
3476,28944477,*orbit
3477,28944477,*paranasal sinus
3478,28944477,*quality of life
3479,28944477,*surgical decompression
3480,31152536,graves’ orbitopathy
3481,31152536,orbit decompression
3482,31152536,thyroid-associated orbitopathy
3485,31595798,*graves’ ophthalmopathy
3486,31595798,*retina
3487,31595798,*density
3488,31595798,*microvasculature
3489,31595798,*optical coherence tomography angiography
3491,29784035,american thyroid association guidelines
3492,29784035,graves’ disease
3493,29784035,hyperthyroid
3494,29784035,thyroid hormones
3495,29784035,thyroid storm
3496,29784035,thyroidectomy cois obtained through our review ethics board committee prior to the study. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
3497,29648895,autoimmune thyroid disease
3498,29648895,d1
3499,29648895,d2
3500,29648895,severity
3501,29648895,single nucleotide polymorphism
3502,29421653,*fibroblast proliferation
3503,29421653,*hyaluronan
3504,29421653,*igf-1
3505,29421653,*membrane potential
3506,29421653,*molecular weight
3507,29421653,*ph20
3509,31025590,b cells
3510,31025590,graves’ disease
3511,31025590,graves’ orbitopathy
3512,31025590,rituximab
3513,31025590,thyroid eye disease
3514,31025590,anti-cd20
3515,31025590,proptosis
3517,30354697,*graves’ disease
3518,30354697,*thyroid stimulating hormone receptor antagonist
3519,30354697,*antithyroid drugs
3520,30354697,*hyperthyroidism
3521,30354697,*immunosuppressive treatment
3522,30354697,*radioiodine
3523,30354697,*thyroid receptor antagonists
3524,30354697,*thyroid stimulating hormone
3525,30354697,*thyrotoxicosis
3526,30229982,*intravenous methylprednisolone
3527,30229982,*thyroid-associated ophthalmopathy
3528,30229982,*triglycerides
3530,29448964,exophthalmos
3531,29448964,myxedema
3532,29448964,primary hyperthyroidism
3533,29448964,rituximab cois case to the institutional ethics committee. consent for publication: written informed consent was obtained from the patient for publication of this case report and any accompanying images. copies of the written consent are available for review by the editor-in-chief of this journal. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
3536,30924084,*gene
3537,30924084,*graves’ disease
3538,30924084,*polymorphisms
3539,30924084,*vdr
3540,30924084,*vitamin d receptor
3541,30173330,*i-ionm
3542,30173330,*neuromonitoring
3543,30173330,*recurrent laryngeal nerve stimulation
3544,30173330,*staged thyroidectomy
3545,30173330,*thyroid
3547,31530446,*dunhill procedure
3548,31530446,*graves' disease
3549,31530446,*graves' ophthalmopathy
3550,31530446,*bilateral subtotal thyroidectomy
3551,31530446,*subtotal thyroidectomy
3552,31530446,*total thyroidectomy
3553,28388869,graves’ disease
3554,28388869,s-trabs
3555,28388869,hyperthyroidism
3556,29343299,graves’ disease
3557,29343299,hashimoto’s thyroiditis
3558,29343299,metamorphic autoimmunity
3559,29343299,natural history
3560,29343299,thyroid status cois publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
3561,30912336,*antithyroid agents
3562,30912336,*cure
3563,30912336,*graves hyperthyroidism
3564,30912336,*long term outcome
3565,30912336,*radioactive iodine
3566,30912336,*remission
3567,30912336,*thyroidectomy cois
3568,31169822,arteriovenous fistula
3569,31169822,false aneurysm
3570,31169822,goiter
3571,31169822,thyroidectomy
3572,31391354,graves’ disease
3573,31391354,hyperthyroidism
3574,31391354,iodine-131 radioactive iodine uptake
3575,31391354,radioiodine therapy
3576,31379878,*graves' disease
3577,31379878,*tshr
3578,31379878,*next-generation sequencing
3579,31379878,*splicing isoforms
3580,31379878,*thymus
3581,31379878,*thyroid
3582,31379878,*tolerance
3586,30256028,autografts
3587,30256028,dermis-fat graft
3588,30256028,eyelids – surgery
3589,30256028,graves ophthalmopathy – surgery
3590,30256028,reconstructive surgical procedures – methods
3591,30256028,skin transplantation
3592,31146635,*jordan
3593,31146635,*hyperthyroidism
3594,31146635,*hypothyroidism
3595,31146635,*prevalence
3596,31146635,*thyroid dysfunction
3597,31665858,hypercholesterolemia
3598,31665858,thyroid associated ophthalmopathy
3600,29562915,extra-thyroidal autoimmunity
3601,29562915,graves’ disease
3602,29562915,hashimoto’s thyroiditis
3603,29562915,metamorphic autoimmunity
3604,29562915,thyroid status cois publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
3605,31636036,ent surgery
3606,31636036,endocrine surgery
3607,31636036,gbi
3608,31636036,glasgow benefit inventory
3609,31636036,graves' disease
3610,31636036,patient recorded outcome measure
3611,31636036,patient satisfaction score
3612,31636036,thyroid
3613,31636036,total thyroidectomy cois
3615,30506346,gender
3616,30506346,graves’ disease (gd)
3617,30506346,hyperthyroidism
3618,30506346,hyperuricemia
3619,30506346,serum uric acid (sua)
3621,30170970,diplopia
3622,30170970,dysthyroid optic neuropathy
3623,30170970,exophthalmos
3624,30170970,grave's disease
3625,30170970,orbital decompression
3626,30170970,vision loss
3630,29996609,"decompression, surgical"
3631,29996609,graves ophthalmopathy
3632,29996609,optic nerve diseases
3633,29996609,orbit
3634,31021263,lower eyelid retraction
3635,31021263,orbital decompression
3636,31021263,proptosis
3637,31021263,surgical technique
3638,31021263,thyroid eye disease
3641,29367360,"ear, nose and throat/otolaryngology"
3642,29367360,head and neck surgery
3643,29367360,otolaryngology / ent
3644,29367360,thyroid disease cois
3647,31418705,*haemoglobin a2
3648,31418705,*hyperthyroidism
3649,31418705,*β-thalassemia trait
3651,30220185,choroid
3652,30220185,graves ophthalmopathy
3653,30220185,"tomography, optical coherence"
3654,29996608,"decompression, surgical"
3655,29996608,endoscopy
3656,29996608,graves ophthalmopathy
3657,29996608,orbit
3659,29890310,forkhead box p3 (foxp3)
3660,29890310,graves' disease
3661,29890310,regulatory t cells
3662,29890310,restriction fragment length polymorphism
3663,29890310,single nucleotide polymorphism
3666,29027055,deficiency disorder
3667,29027055,iodine in soil and plants
3668,29027055,people’s perception
3669,29027055,socio-economic determinants
3670,29027055,wheat crop
3673,30099999,*autoimmune disorders
3674,30099999,*crohn disease
3675,30099999,*graves disease
3676,30099999,*hashimoto thyroiditis
3677,30099999,*inflammatory bowel disease
3678,30099999,*multiple sclerosis
3679,30099999,*systemic lupus erythematosus
3680,30099999,*ulcerative colitis
3681,29406005,*fetal
3682,29406005,*graves disease
3683,29406005,*hyperthyroidism
3684,29406005,*neonatal
3685,29406005,*thyrotoxicosis
3686,31742747,*hyperthyroidism
3687,31742747,*thyroid scintigraphy
3688,31742747,*thyroid ultrasonography
3689,31742747,*thyroid-stimulating immunoglobulins (tsi)
3690,31742747,*thyrotropin receptor antibodies (trab)
3691,30244229,cardiovascular medicine
3692,30244229,thyroid disease cois
3693,30670519,*clinical trials
3694,30670519,*immunology
3695,30670519,*paediatric endocrinology
3696,30670519,*thyroid disease cois
3699,31460819,endocrine ophthalmopathy
3700,31460819,endoscopic sinus surgery
3701,31460819,orbital complication
3702,31460819,rhinosinusitis
3703,31460819,vision loss
3705,29510406,autoimmune thyroid disease (aitd)
3706,29510406,graves’ disease (gd)
3707,29510406,hashimoto’s thyroiditis (ht)
3708,29510406,ikaros family of zinc finger3 (ikzf3)
3709,29510406,single nucleotide polymorphism (snp)
3711,28598035,graves’ disease
3712,28598035,association analysis
3713,28598035,early-onset
3714,28598035,heterogeneity analysis
3715,28598035,single nucleotide polymorphisms
3717,30226207,graves’ disease
3718,30226207,membranoproliferative glomerulonephritis
3719,30226207,proteinuria
3720,29310665,*graves’ disease
3721,29310665,*hyperthyroidism
3722,29310665,*methimazole
3723,29310665,"*thyroid receptor antibodies cois analysis of de-identified data collected for another purpose. all data are retrospective and presented in an aggregated fashion. so, no irb approval was required. patient numbers used in the model validation section of the article are spreadsheet numbers from data, which can not be used to identify the patients name, family name or other specific details. consent for publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
3724,31280470,*arterial stiffness
3725,31280470,*blood pressure
3726,31280470,*graves’ disease
3727,31280470,*pulse wave analysis
3730,31899052,*igf-1
3731,31899052,*orbital fibroblasts
3732,31899052,*thyroid-associated ophthalmopathy
3733,31899052,*thyroid-stimulating hormone receptor cois conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.
3734,31827051,autoimmune thyroid diseases
3735,31827051,graves’ disease
3736,31827051,hashimoto’s thyroiditis
3737,31827051,meta-analysis
3738,31827051,regulatory t cells
3739,31617239,graves' disease
3740,31617239,autoantibody
3741,31617239,catalase
3742,31617239,hydrogen peroxide
3743,31617239,malondialdehyde
3744,31617239,oxidative stress
3746,29976201,*circulating mirnas
3747,29976201,*graves’ disease
3748,29976201,*let-7b
3749,29976201,*thyrotropin receptor antibody
3752,29549672,autoantibodies
3753,29549672,autoimmune thyroid diseases
3754,29549672,blood platelets
3755,29549672,chronic inflammation
3756,29549672,lymphocytes
3757,28343872,*balanced decompression
3758,28343872,*dysthyroid optic neuropathy
3759,28343872,*fat decompression
3760,28343872,*lateral decompression
3761,28343872,*medial decompression
3762,28343872,*orbital decompression
3763,28343872,*surgical technique
3764,28343872,*thyroid eye disease
3769,30369529,graves’ disease
3770,30369529,cerebral venous thrombosis
3771,30369529,factor viii procoagulant protein
3772,30369529,hyperthyroidism
3773,29319130,anaplastic thyroid carcinoma
3774,29319130,thyrotoxicosis
3777,31932147,*autoimmune thyroid diseases
3778,31932147,*chemokines
3779,31932147,*cytokines
3780,31932147,*dermatological autoimmune diseases
3781,31932147,*systemic autoimmune diseases cois
3782,30843111,*anti-pla2r
3783,30843111,*children
3784,30843111,*graves’ disease
3785,30843111,*membranous nephropathy
3786,30843111,*rituximab
3791,29266775,*bmpr2
3792,29266775,*epstein-barr virus
3793,29266775,*graves’ disease
3794,29266775,*tgf-β/bmp
3795,29266775,*expression assay
3796,29266775,*functional analysis
3797,29266775,*lymphoblastoid cell lines
3798,29266775,*pulmonary arterial hypertension
3800,31279175,*autoimmune thyroid disease
3801,31279175,*development
3802,31279175,*ifng
3803,31279175,*methylation
3804,31279175,*prognosis
3805,30880626,*graves'
3806,30880626,*bimatoprost
3807,30880626,*fat atrophy
3808,30880626,*orbitopathy
3809,30880626,*prostaglandin f
3810,30880626,*thyroid eye disease
3811,30565709,*graves ophthalmopathy
3812,30565709,*inactive phase
3813,30565709,*interleukin-15
3814,30565709,*interleukin-17
3815,30057255,anca
3816,30057255,antineutrophil cytoplasmic antibodies
3817,30057255,methimazole
3818,30057255,metimazol
3819,30057255,vasculite
3820,30057255,vasculitis
3821,29517388,blood vessel density
3822,29517388,graves’ orbitopathy
3823,29517388,oct angiography
3824,29517388,decompression
3825,29517388,dysthyroid optic neuropathy
3826,29325496,*graves' disease
3827,29325496,*trab
3828,29325496,*neonatal thyrotoxicosis
3829,29325496,*pregnancy
3830,29325496,*thyroid
3831,30452877,calprotectin
3832,30452877,graves’ orbitopathy
3833,30452877,inflammation
3834,30452877,orbital fibroblast
3835,30452877,thyroid eye disease
3836,29174550,decompression
3837,29174550,endocrine orbitopathy
3838,29174550,scleral show
3839,31792849,graves’ ophthalmopathy
3840,31792849,spect/ct
3841,31792849,triamcinolone
3844,30044728,*graves’ disease
3845,30044728,*autoimmune
3846,30044728,*monoclonal antibody
3847,30044728,"*signaling cois antibody-mediated inflammatory auto-immune disorders (us 6936426), the diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders (us 7998681 and us 8153121), and diagnostic methods related to graves’ disease and other autoimmune disorders (us 8178304). he was previously a paid consultant for river vision."
3848,29601105,*graves' ophthalmopathy
3849,29601105,*graves' orbitopathy
3850,29601105,*glucocorticoids
3851,29601105,*rituximab
3852,29601105,*thyroid eye disease
3856,31223030,graves' disease
3857,31223030,inflammation
3858,31223030,neutrophils platelet count.
3860,30187962,corticosteroid
3861,30187962,endocrine disorders
3862,30187962,topical
3864,30358895,*graves' disease
3865,30358895,*hcp5
3866,30358895,*autoimmunity
3867,30358895,*children
3868,30358895,*genetics
3869,30358895,*single nucleotide polymorphism
3870,30358895,*thyroid
3875,30854863,iodine radioisotopes
3876,30854863,neck dissection
3877,30854863,thyroid neoplasms
3878,30854863,thyrotoxicosis
3879,30814442,anti-thyroid drugs
3880,30814442,autotaxin
3881,30814442,graves’ disease
3882,30814442,lysophosphatidic acids
3883,30814442,thyroid hormones
3884,30488266,asymmetric enlargement
3885,30488266,lacrimal gland
3886,30488266,malignancy
3887,30488266,thyroid eye disease
3888,30463536,8-ohdg
3889,30463536,graves’ orbitopathy
3890,30463536,mda
3891,30463536,oxidative stress
3892,30463536,"tear cois all patients, and the study was conducted with approval from the institutional review board at chonnam national university hospital. consent for publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
3893,30148416,graves disease
3894,30148416,lasik
3895,30148416,salzmann’s nodular degeneration
3896,30148416,thyroid eye disease
3898,29949121,coagulation
3899,29949121,graves’ orbitopathy
3900,29949121,methylprednisolone
3901,29949121,pulmonary embolism
3902,29949121,venous thromboembolic event cois ethical approval: all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 helsinki declaration and its later amendments or comparable ethical standards. informed consent: informed consent was obtained from all individual participants included in the study.
3904,29507013,adrenal disorders
3905,29507013,endocrine system
3906,29507013,thyroid disease cois
3908,30568070,graves’ disease
3909,30568070,surgical complications
3910,30568070,total thyroidectomy
3911,29482520,case report
3912,29482520,graves’ ophthalmopathy
3913,29482520,graves’ disease
3914,29482520,loss of vision
3915,29482520,orbital decompression
3916,29482520,strabismus cois publication: written informed consent was obtained from the patient for publication of this case report and any accompanying images. a copy of the written consent is available for review by the editor of this journal. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
3917,30325581,99mtc-anti-tnf
3918,30325581,graves disease
3919,30325581,graves ophthalmopathy
3920,30325581,diagnosis
3921,30325581,nuclear medicine
3922,30188609,*aggregation
3923,30188609,*autoimmune thyroid diseases
3924,30188609,*blood platelets
3925,30188609,*platelet-derived microparticles
3927,31257166,*graves’ disease
3928,31257166,*hashimoto’s thyroiditis
3929,31257166,*autoimmune disease
3930,31257166,*dysbiosis
3931,31257166,*enterohepatic cycling of thyroid hormones
3932,31257166,*probiotics
3933,30302684,*hyperthyreodism
3934,30302684,*antithyroid drug
3935,30302684,*radioiodine therapy
3936,30302684,*thermoablation
3937,30302684,*thyroid surgery
3939,31240859,slco1b1
3940,31240859,grave's disease
3941,31240859,drug-induced liver injury
3942,31240859,methimazole
3943,31240859,polymorphisms
3944,31715678,acellular dermis
3945,31715678,eyelids
3946,31715678,graves ophthalmopathy
3947,31715678,reconstructive surgical procedures
3948,31715678,"transplantation, heterologous"
3950,29440561,*graves’ disease
3951,29440561,*polymorphism
3952,29440561,*tumor necrosis factor-α cois manuscript.
3956,28856610,ablation
3957,28856610,autoimmunity
3958,28856610,graves’ disease
3959,28856610,graves’ orbitopathy
3960,28856610,radioiodine
3961,28856610,thyroid
3962,31691261,graves’ disease
3963,31691261,graves’ orbitopathy
3964,31691261,idiopathic orbital inflammation
3965,31691261,orbital lymphoma
3966,31691261,pseudotumor
3967,31453725,graves’ disease
3968,31453725,thyrotropin
3969,31453725,hyperthyroidism
3970,31453725,immunoassay
3971,31453725,thyroid-stimulating antibody
3974,29571699,apparent diffusion coefficient
3975,29571699,diffusion-weighted imaging
3976,29571699,graves’ disease
3977,29571699,orbit
3978,29571699,thyroid associated ophthalmopathy
3979,29147850,*active
3980,29147850,*cytokines
3981,29147850,*eye
3982,29147850,*graves’
3983,29147850,*specificity
3984,29147850,*tears
3985,31834613,adverse events
3986,31834613,graves’ orbitopathy
3987,31834613,mycophenolate
3988,31834613,safety
3989,31782290,*thyroid hormone
3990,31782290,*thyroid volume
3991,31782290,*graves’ disease
3992,31782290,*soluble cd40 ligand (scd40l)
3993,31705858,graves' orbitopathy
3994,31705858,nrf2
3995,31705858,oxidative stress
3996,31705858,polydatin cois competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
3997,31612195,cxcr3
3998,31612195,graves’ophthalmoapthy
3999,31612195,mig
4000,31612195,thyroid eye disease
4002,31316787,*aih
4003,31316787,*graves' ophthalmopathy
4004,31316787,*methylprednisolone-induced liver injury
4005,31316787,*multiple sclerosis
4006,31316787,*steroid pulses
4007,30261581,graves’ disease
4008,30261581,nt-probnp
4009,30261581,ambulatory blood pressure monitoring
4010,30261581,blood pressure
4011,30261581,glucocorticoids
4012,30261581,graves’ orbitopathy
4013,30261581,hypertension
4014,30261581,methylprednisolone
4015,30261581,pulse therapy cois
4016,30222206,graves’ disease
4017,30222206,hashimoto thyroiditis
4018,30222206,alopecia areata
4019,30222206,autoimmune disease
4020,30222206,autoimmune thyroid disease
4021,29457989,"*aav, anti-neutrophil cytoplasmic antibody-associated vasculitis"
4022,29457989,"*anca, anti-neutrophil cytoplasmic antibody"
4023,29457989,"*dress, drug reaction with eosinophilia and systemic symptoms"
4024,29457989,"*ivig, intravenous ɤ-globulin"
4025,29457989,"*kd, kawasaki disease"
4026,29457989,*kawasaki disease
4027,29457989,"*mmi, methimazole"
4028,29457989,"*mpo, myeloperoxidase"
4029,29457989,"*ptu, propylthiouracil"
4030,29457989,*propylthiouracil
4031,29457989,*anti-neutrophil cytoplasmic antibody
4032,29457989,*general paediatrics
4033,29457989,*immunology
4034,29457989,*intravenous ɤ-globulin
4035,31393984,*basedow disease
4036,31393984,*dysthyroid optic neuropathy
4037,31393984,*endoscopic endonasal surgery
4038,31393984,*graves disease
4039,31393984,*optic nerve decompression
4040,31393984,*orbital apex
4041,31393984,*thyroid eye disease
4042,31296093,extraocular muscle
4043,31296093,graves’ ophthalmopathy
4044,31296093,real-time ultrasound elastography
4045,31236779,*antithyroid drug
4046,31236779,*graves’ disease
4047,31236779,*relapse
4048,31236779,*remission
4050,30179522,graves' disease
4051,30179522,autopsy
4052,30179522,high-altitude cerebral edema
4053,30179522,high-altitude pulmonary edema
4054,30179522,hyperthyroidism
4055,30179522,sudden death
4058,31255731,*autoimmune thyroid disease (aitd)
4059,31255731,*fas
4060,31255731,*hla-dr
4061,31255731,*hypothyroidism
4062,31255731,*il-1β
4063,31255731,*uterus globulin associated protein 1 (ugrp1)
4064,31176495,estrabismo
4065,31176495,fistula
4066,31176495,fístula
4067,31176495,hipertiroidismo
4068,31176495,hyperthyroidism
4069,31176495,orbit
4070,31176495,orbitopatía tiroidea
4071,31176495,strabismus
4072,31176495,thyroid orbitopathy
4073,31176495,órbita
4075,29866676,stroke
4076,29866676,thyroid disease cois
4077,29371709,"grave's disease, pcr-rflp, snps, cd 28, cd 40."
4078,31672295,cytology
4079,31672295,false-negative diagnoses
4080,31672295,false-positive diagnoses
4081,31672295,fine-needle aspiration
4082,31672295,thyroid cancer
4083,31672295,thyroid nodule cois this work did not receive any specific grant funding.
4084,31587179,adverse events
4085,31587179,graves’ disease
4086,31587179,graves’ orbitopathy
4087,31587179,oral prednisone
4088,31587179,radioiodine
4089,31587179,steroid prophylaxis
4090,31207925,graves’ disease
4091,31207925,oxidative stress
4092,31207925,thiol/disulphide homeostasis cois
4093,31091045,*graves’ disease
4094,31091045,*alpha-2-macroglobulin
4095,31091045,*cytokines
4096,31091045,*lactoferrin
4097,30618332,*graves' disease
4098,30618332,*autoimmunity
4099,30618332,*peptides
4100,30618332,*thyroid
4103,29383806,*hla
4104,29383806,*association study
4105,29383806,*autoimmunity
4106,29383806,*haplotype
4107,29383806,*type 1 diabetes
4109,30474825,acute pancreatitis
4110,30474825,drug-induced pancreatitis
4111,30474825,methimazole
4114,29566435,*graves’ disease
4115,29566435,*anaemia
4116,29566435,*haemoglobin
4117,29566435,*hyperthyroidism
4118,29566435,*thyroid function tests
4119,29566435,*thyroid hormones
4120,29566435,*thyrotoxicosis
4121,29412482,*3d reconstruction
4122,29412482,*orbital soft tissue volume
4123,29412482,*thyroid associated ophthalmopathy
4124,31301652,mutation
4125,31301652,polymorphism
4126,31301652,thyroid digenesis
4127,31301652,thyroid gland
4128,31301652,thyroid hormones
4129,31612654,decompression
4130,31612654,extraocular muscles
4131,31612654,graves ophthalmopathy
4132,31612654,optic nerve
4133,31612654,optical coherence tomogrphy cois
4134,31538314,cytokine
4135,31538314,graves’ orbitopathy
4136,31538314,human leukocyte antigen
4137,31538314,immunohistochemistry
4138,31538314,orbital tissue
4139,31538314,tsh receptor
4140,31202168,drug-induced liver injury
4141,31202168,human leukocyte antigens
4142,31202168,methimazole
4143,31202168,molecular docking
4147,30086864,*graves' disease
4148,30086864,*childhood
4149,30086864,*fetus
4150,30086864,*hyperthyroidism
4151,30086864,*neonates
4153,30414981,*biomarkers
4154,30414981,*fibrosis
4155,30414981,*graves' disease
4156,30414981,*inflammatory cytokines
4157,30414981,*orbitopathy
4158,30414981,*pai-1
4159,30414981,*plasmin cascade
4160,30414981,*serpins
4161,30414981,*tgf-β
4162,30414981,*tissue remodeling cois
4163,31446546,131i therapy
4164,31446546,hyperthyroidism
4165,31446546,hypothyroidism
4166,31446546,ku-70
4167,31446546,radiosensitivity
4168,29101123,*experimental laboratory cois
4169,31023005,*graves’ disease
4170,31023005,*methimazole
4171,31023005,*selenium
4172,31023005,*trab
4173,31023005,*tpoab
4174,31023005,*tgab cois
4176,29256262,*ago
4177,29256262,*autoimmune thyroid disease
4178,29256262,*intractability
4179,29256262,*polymorphism
4180,29256262,*severity
4182,29300515,b-cell lymphoma
4183,29300515,graves’ orbitopathy
4184,29300515,r-chop
4185,29300515,rituximab
4186,29300515,immunochemotherapy
4187,29300515,thyroid orbitopathy
4191,29308951,alexis retractor
4192,29308951,retractor
4193,29308951,lateral orbit
4194,29308951,thyroid eye disease
4196,31162982,eyelid retraction
4197,31162982,hering’s phenomenon
4198,31162982,mueller’s muscle-conjunctiva resection
4199,31162982,marginal reflex distance
4200,31162982,phenylephrine test
4201,31162982,thyroid eye disease
4202,30012381,anemarrhena bunge
4203,30012381,case report
4204,30012381,graves’ disease
4205,30012381,herbal decoction
4206,30012381,tsh binding inhibitory immunoglobulins
4207,30012381,thyroid stimulating hormone
4215,31740989,*grave’s disease
4216,31740989,*hepatotoxicity
4217,31740989,*mao-a
4218,31740989,*metabolomics
4219,31740989,*methimazole
4220,31740989,*ugt1a1*6
4223,30913888,adjustable sutures
4224,30913888,congenital fibrosis of the extraocular muscles
4225,30913888,double elevator palsy
4226,30913888,thyroid eye disease
4227,30913888,transposition procedure sec. knapp
4228,30913888,vertical strabismus
4229,30103255,*graves’ orbitopathy
4230,30103255,*methotrexate
4231,30103255,*methylprednisolone
4232,30103255,*steroid-sparing agents
4233,30103255,*thyroid eye disease
4234,29652204,corticoresistant
4235,29652204,graves’ orbitopathy
4236,29652204,low-dose
4237,29652204,rituximab
4238,29652204,treatment
4239,29491282,graves' disease
4240,29491282,central diabetes insipidus
4241,29491282,hyperthyroidism
4242,29491282,lymphocytic infundibulo-neurohypophysitis and thyroid crisis
4243,31194638,*graves' disease
4244,31194638,*autoimmune thyroid disease
4245,31194638,*desensitization
4246,31194638,*immunomodulation
4247,31194638,*peptide immunotherapy
4248,31194638,"*thyroid stimulating hormone receptor cois attending study meetings and for ad hoc advice. s.h.s.p. has received speaker fees from sanofi, quidel, and berlin-chemie. c.d. has consulted for apitope, has received speaker fees, and has consulted for sanofi-genzyme. d.c.w. serves as chief scientific officer for apitope technology (bristol) ltd. and apitope international nv on a consultative basis; is on the scientific advisory board for apitope international nv and has sat on scientific advisory boards for actelion pharma and zealand pharma; received travel funding from apitope international nv; is a senior editor for immunotherapy; holds patents for peptides, tolerization-inducing composition, fviii peptides, and their use in tolerizing hemophiliacs, composition, disease markers, tolerogenic peptides from mbp, peptide selection method, and improvements relating to influenza vaccine; has consulted for peptide therapeutics ltd., teva, gsk bio, hoffmann-la roche, novartis, dti, and the food standards agency; received research support within the past three years from apitope international nv, ucb celltech, mrc, the immune tolerance network, and the wellcome trust; holds stock and stock options with apitope international nv; and was an expert witness for geron. k.b. is employed by apitope technology (bristol) ltd. n.o. was a contractor to apitope technology (bristol) ltd., a subsidiary of apitope international nv. l.j. is an employee of apitope international nv. t.w.-s. was an employee of apitope technology (bristol) ltd., a subsidiary of apitope international nv. c.c. serves as chief medical officer for apitope technology (bristol) ltd. and apitope international nv on a consultative basis. k.f.m. was an executive director of apitope international nv and its subsidiary, apitope technology (bristol) ltd. he was an employee of apitope technology (bristol) ltd. he is currently a non-executive director of and shareholder in apitope international nv. p.p. consults for ibsa. b.v. has received speaker fees from berlin-chemie. s.r. has received speaker fees from merck plc and abbott india ltd. g.j.k. consults for apitope and quidel and has received speaker fees from merck and berlin-chemie. k.b., j.g., c.e.h., i.m., r.d.m., and f.w. report no disclosures."
4250,30562606,ampk/mtor signaling pathway
4251,30562606,orbital preadipocyte
4252,30562606,sf1
4253,30562606,thyroid-associated ophthalmopathy
4255,29037117,*graves'
4256,29037117,"*disease, relapse, predictive biomarker, siglec1, ifn signature"
4259,29397435,aldehyde dehydrogenase 2
4260,29397435,autoantigen
4261,29397435,graves’ orbitopathy
4262,29397435,orbital fat
4263,29397435,proteomic analysis
4265,31271712,*graves’ disease
4266,31271712,*acromegaly
4267,31271712,*case report
4268,31271712,*panhypopituitarism
4269,31271712,*radiosurgical treatment
4270,31271712,*secondary hypothyroidism
4271,31271712,*thyrotoxicosis
4273,30674011,16s rrna gene
4274,30674011,graves’ orbitopathy (go)
4275,30674011,gut microbiota
4276,30674011,thyrotropin receptor antibody (trab)
4278,30269213,graves’ disease
4279,30269213,hyperthyroidism
4280,30269213,robotic-assisted surgery
4281,30269213,surgical outcomes
4282,29848886,th2
4283,29848886,autoimmune thyroid disease
4284,29848886,intractability
4285,29848886,polymorphism
4286,29848886,severity
4288,30938833,cd4+p35+ebi3+t cell
4289,30938833,graves’ disease
4290,30938833,immunology
4291,30938833,interleukin 35
4297,29058517,thyroid eye disease
4298,29058517,abducens nerve
4299,29058517,orbital decompression
4300,30777066,corneal dynamic scheimpflug analyser
4301,30777066,corvis st
4302,30777066,graves ophthalmopathy
4303,30777066,orbital soft tissue
4304,30777066,whole eye movement cois the tenets of the declaration of helsinki and received institutional review board (irb) approval from seoul st. mary’s hospital for the analysis of their medical records. the need for consent was waived by irb (name of irb: cmc irb). consent for publication: not applicable. competing interests: hhs is a member of the editorial board (associate editor) of bmc ophthalmology. the other authors declare that they have no competing interests. the authors declare that they have no financial competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
4305,30297028,*dry eye disease
4306,30297028,*graves' ophthalmopathy
4307,30297028,*tear break up time
4308,30297028,*tear osmolarity
4309,30297028,*thyroid eye disease
4310,30232923,*graves' disease
4311,30232923,*x chromosome
4312,30232923,*association analysis
4313,30232923,*dosage compensation
4314,30232923,*genetic model
4315,29875930,graves´ disease
4316,29875930,hyperthyroidism
4317,29875930,nuclear medicine
4318,29875930,thyroid neoplasms
4319,29377729,*ct
4320,29377729,*thyroid eye disease
4321,29377729,*exophthalmometer
4322,29377729,*exophthalmos
4323,30470210,intraoperative relaxed muscle positioning
4324,30470210,restrictive strabismus
4325,30470210,thyroid orbitopathy cois approval from the local ethical committee (cerrahpasa ethics committee) was received. informed consent was obtained from the patients for the participation in the study. consent for publication: additional consent was obtained from the patients whose preoperative and postoperative photos were used in the manuscript. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
4326,31705696,graves disease
4327,31705696,hashimoto thyroiditis
4328,31705696,superb microvascular imaging
4329,31705696,chronic autoimmune thyroiditis
4330,31705696,color doppler
4331,31705696,vascularity index
4332,31310160,*graves' disease
4333,31310160,*long-term
4334,31310160,*methimazole
4335,31310160,*remission rates
4337,30384566,*shear wave elastography
4338,30384566,*virtual touch tissue imaging quantification
4339,30384566,*thyroid
4340,30384566,*hashimoto’s thyroiditis
4341,30384566,*graves’ disease
4342,30281845,*b-lymphocytes
4343,30281845,*b-cell activating factor
4344,30281845,*graves
4345,30281845,*autoimmune
4346,30281845,*disease
4347,30281845,*genotyping
4348,30281845,*polymorphism
4349,30281845,*thyroid
4350,29478847,breast cancer
4351,29478847,cancer du sein
4352,29478847,graves’ disease
4353,29478847,hyperthyroidism
4354,29478847,hyperthyroïdie
4355,29478847,maladie de basedow
4356,29478847,thyroxine
4357,29478847,triiodothyronine
4358,31690110,graves’ orbitopathy
4359,31690110,endoscopic orbital decompression
4360,31690110,feasibility
4361,31690110,robotic endoscope guiding system
4362,31690110,robotic surgery
4363,31209622,ablation techniques
4364,31209622,graves’ disease
4365,31209622,high-intensity focused ultrasound ablation
4366,31209622,interventional ultrasonography
4367,31209622,thyrotoxicosis
4368,31203506,cosmesis
4369,31203506,endoscopic surgery
4370,31203506,graves’ ophthalmopathy
4371,31203506,optic nerve
4372,31203506,orbital decompression
4375,28181061,amsterdam declaration
4376,28181061,graves’ disease
4377,28181061,joint thyroid eye clinic
4378,28181061,ophthalmopathy
4379,28181061,thyroid
4380,31552761,*il-6
4381,31552761,*autoimmune thyroid disease
4382,31552761,*intractability
4383,31552761,*methylation
4384,31552761,*severity
4385,31308303,abo
4386,31308303,blood groups
4387,31308303,hashimoto
4388,31308303,thyroid
4389,31184281,*graves' disease
4390,31184281,*thyroglobulin antibody
4391,31184281,*thyroid peroxidase antibody
4392,31184281,*thyroiditis
4393,31184281,*thyrotropin receptor
4394,31184281,*transgenics cois
4395,31111437,pd-1 inhibitor
4396,31111437,pdl-1 inhibitor
4397,31111437,pembrolizumab
4398,31111437,small cell carcinoma of ovary
4399,31111437,thyroid
4400,31111437,thyroiditis
4401,31111437,thyrotoxicosis
4403,29319128,graves’ disease
4404,29319128,hif-1α
4405,29319128,pdgf-bb
4406,29319128,immunology
4407,29319128,macrophages
4410,28548552,biomarker
4411,28548552,ccn1
4412,28548552,cyr61
4413,28548552,inflammation
4414,28548552,thyroid ophthalmopathy
4415,31473202,biotin
4416,31473202,biotin interference
4417,31473202,biotin supplements
4418,31473202,immunoassay
4420,31554206,b lymphocytes
4421,31554206,graves’ disease
4422,31554206,t lymphocytes
4423,31554206,toll-like receptor 2
4424,31554206,toll-like receptor 4
4425,31554206,cytokines cois
4426,31134819,*graves’ disease
4427,31134819,*treg-th17-related immunosuppressive cytokines
4428,31134819,*dihydrotestosterone
4429,31134819,*mice
4430,31134819,*oxidative stress
4432,29372654,*functional tsh receptor antibodies
4433,29372654,*autoimmune thyroid diseases
4434,29372654,*bioassays
4435,29372654,*children
4436,29372654,*drug delivery
4437,29372654,*thyroid associated orbitopathy
4438,29372654,*thyroid blocking antibodies
4439,29372654,*thyroid stimulating antibodies
4440,29199443,inferior laryngeal nerve
4441,29199443,nonrecurrent laryngeal nerve
4442,29199443,thyroid surgery
4443,29336230,*dnmt
4444,29336230,*graves' disease
4445,29336230,*autoimmune thyroid disease
4446,29336230,*global dna methylation
4447,29336230,*lymphocyte
4448,31387688,hipocalcemia
4449,31387688,hipoparatiroidismo
4450,31387688,hormona paratiroidea
4451,31387688,hypocalcemia
4452,31387688,hypoparathyroidism
4453,31387688,parathyroid hormone
4454,31387688,thyroidectomy
4455,31387688,tiroidectomía
4456,31407938,*graves’ orbitopathy
4457,31407938,*thyroid eye disease
4458,31407938,*ocular ductions
4459,31407938,*recession
4460,31407938,*resection
4461,31407938,*squint surgery
4463,30927115,autoimmune thyroid disease
4464,30927115,chronic widespread pain
4465,30927115,fibromyalgia
4466,30927115,hashimoto thyroiditis
4467,30927115,osteoarthritis
4468,30927115,spinal degenerative disc disease
4470,29960265,ct
4471,29960265,graves' orbitopathy
4472,29960265,iterative model reconstruction
4473,29420104,decompression
4474,29420104,graves’ orbitopathy
4475,29420104,dysthyroid optic neuropathy
4476,29420104,steroids
4477,29420104,tocilizumab
4479,29098964,biotin
4480,29098964,graves’ hyperthyroidism
4481,29098964,tsh receptor antibodies
4482,29098964,false laboratory results
4483,29098964,immunoassay
4484,31505972,cd58
4485,31505972,autoimmune thyroid disease
4486,31505972,severity
4487,31505972,single nucleotide polymorphism
4488,31034694,choroid
4489,31034694,optical coherence tomography
4490,31034694,thickness
4491,31034694,thyroid-associated orbitopathy
4492,30270655,diplopia
4493,30270655,graves ophthalmopathy
4494,30270655,inferior oblique muscle
4495,30270655,orbital decompression
4497,29614339,*co-expression modules
4498,29614339,*functional pathways
4499,29614339,*graves' disease
4500,29614339,*pathogenesis
4501,29614339,*weighted gene co-expression network analysis
4502,29463244,duration of eye symptoms
4503,29463244,intravenous glucocorticoid therapy
4504,29463244,pretreatment clinical activity score
4505,29463244,restoration of euthyroidism
4506,29463244,thyroid-associated ophthalmopathy cois by the ethics committee of shanghai ninth people’s hospital. the written informed consents were obtained from all participants. this study was in compliance with the tenets of the declaration of helsinki for clinical research. consent for publication: not applicable competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
4507,29360077,graves' disease
4508,29360077,hyperthyroidism
4509,29360077,struma ovarii
4513,30646996,decompression
4514,30646996,graves ophthalmopathy
4515,30646996,strabismus
4516,30646996,surgical
4517,31674156,cytology
4518,31674156,fine-needle aspiration biopsy
4519,31674156,histopathology
4520,31674156,hyperthyroidism
4521,31674156,radioactive iodine
4522,30850507,*graves’ disease
4523,30850507,*hemoglobin
4524,30850507,*multispectral optoacoustic tomography (msot)
4525,30850507,*thyroid nodule
4526,30257816,graves’ disease
4527,30257816,hashimoto thyroiditis
4528,30257816,mrc 65/93
4529,30257816,antithyroglobulin antibodies
4530,30257816,immunoassays
4531,30257816,thyroglobulin
4532,30204589,*graves’ disease
4533,30204589,*biotin
4534,30204589,*multiple sclerosis
4535,30204589,*thyroid
4537,31755324,cd80
4538,31755324,cd86
4539,31755324,intractability
4540,31755324,polymorphism
4541,31755324,severity
4542,31657648,adipogenesis
4543,31657648,graves’ orbitopathy
4544,31657648,fibroblast growth factor receptors
4545,31657648,fibroblast growth factors
4546,31657648,myofibroblast
4547,31494956,*graves' disease
4548,31494956,*hashimoto's thyroiditis
4549,31494956,*autoimmune thyroid disease
4550,31494956,*interferon regulatory factor 3
4551,31494956,*interferon regulatory factor 7
4552,31055979,graves’ disease
4553,31055979,il-21
4554,31055979,th17 cells
4555,31055979,treg cells
4556,31055979,immune
4557,31488432,*graves’ orbitopathy
4558,31488432,*orbital adipose tissue
4559,31488432,*orbital fibroblast cois
4560,29361886,*antiretroviral therapy
4561,29361886,*graves’ disease
4562,29361886,*hiv
4563,29361886,*iris
4564,29361886,*immune thrombocytopenic purpura
4565,31707189,*3d anatomical modeling
4566,31707189,*biomechanical simulation
4567,31707189,*computer-assisted surgery planning
4568,31707189,*endocrine orbitopathy
4569,31707189,*fibrosis
4570,31707189,*retrospective cohort study
4572,30560705,graves’ ophthalmopathy
4573,30560705,oxidative stress
4574,30560705,thiol-disulfide homeostasis
4575,30351237,*graves’
4576,30351237,*antagonist
4577,30351237,*disease
4578,30351237,*hyperthyroidism
4579,30351237,*orbitopathy
4580,30351237,*small molecule
4581,30351237,*thyrotropin receptor
4584,29053038,igg4-related orbital disease
4585,29053038,thyroid eye disease
4586,29053038,rituximab
4587,29023175,orbital
4588,29023175,autologous
4589,29023175,cosmetic
4590,29023175,decompression
4591,29023175,fat
4592,29023175,graft
4594,31366254,*cd4+cd8+
4595,31366254,*graves’ disease
4596,31366254,*rtes
4597,31366254,*trab
4598,31366254,*effector memory cd8
4599,31366254,*lymphocyte subpopulations
4601,31036428,cigarette
4602,31036428,cigarro
4603,31036428,dejar de fumar
4604,31036428,graves orbitopathy
4605,31036428,orbitopatía de graves
4606,31036428,orbitopatía tiroidea
4607,31036428,smoke cessation
4608,31036428,tabaco
4609,31036428,thyroid orbitopathy
4610,31036428,tobacco
4611,30182361,cd-20
4612,30182361,graves’ disease
4613,30182361,graves’ ophthalmopathy
4614,30182361,graves’ orbitopathy
4615,30182361,lymphocytes
4616,30182361,thyroid
4617,30182361,thyroid eye disease
4618,29987165,*graves’ disease
4619,29987165,*hla
4620,29987165,*mhc
4621,29987165,*amino acid position
4622,29987165,*genome-wide association studies cois
4624,29103088,diastolic function
4625,29103088,echocardiography
4626,29103088,graves’ disease
4627,29103088,left ventricular function
4628,29103088,left ventricular mass index
4629,29103088,myocardial performance index
4630,29103088,tissue doppler imaging
4631,31739945,*arteriovenous malformations
4632,31739945,*benign disease
4633,31739945,*desmoid tumor
4634,31739945,*dupuytren contracture
4635,31739945,*graves ophthalmopathy
4636,31739945,*gynecomastia
4637,31739945,*heterotopic ossification
4638,31739945,*histiocytosis
4639,31739945,*radiation therapy
4640,30814476,*antithyroid drug-induced agranulocytosis
4641,30814476,*antithyroid drug-induced neutropenia
4642,30814476,*association
4643,30814476,*flavin-containing monooxygenase 3
4644,30814476,*graves’ disease
4648,30335539,ocular pulse amplitude
4649,30335539,choroidal perfusion in thyroid eye disease
4650,30335539,choroidal thickness in thyroid eye disease
4651,30335539,dynamic contour tonometry
4652,30335539,thyroid eye disease
4655,29973096,*children
4656,29973096,*graves’ disease
4657,29973096,*hashimoto’s disease
4658,29973096,*ifih1 gene
4659,29973096,*ptpn gene
4660,29973096,*tshr gene
4661,29973096,*single nucleotide polymorphisms
4662,29058307,*graves' disease
4663,29058307,*graves' orbitopathy
4664,29058307,*autoimmunity
4665,29058307,*self-antigen mouse model
4666,29058307,*thyroid disease
4668,31266487,*dfnb4
4669,31266487,*deafness
4670,31266487,*haplotype
4671,31266487,*hearing
4672,31266487,*noncoding
4673,31266487,*pendred syndrome
4674,31266487,*slc26a4 cois
4675,31327128,graves’ disease
4676,31327128,graves’ orbitopathy
4677,31327128,outcome
4678,31327128,radioiodine
4679,31327128,tsh-receptor antibody
4680,31327128,thyroid carcinoma
4681,31327128,thyroidectomy
4682,31267667,hyperthyroidism
4683,31267667,obesity
4684,31267667,treatment
4685,31267667,weight changes
4687,31444554,macular vasculature
4688,31444554,peripapillary vasculature
4689,31444554,thyroid eye disease
4690,30372544,*graves’ disease
4691,30372544,*trab
4692,30372544,*tshr
4693,30372544,*hyperthyroidism
4694,30372544,*thyroid scintigraphy
4695,30197231,*adderall
4696,30197231,*attention deficit hyperactivity disorder
4697,30197231,*etomidate
4698,30197231,*fentanyl
4699,30197231,*graves disease
4700,30197231,*hyperthyroidism
4701,30197231,*midazalom
4702,30197231,*moderate sedation
4703,30197231,*procedural sedation
4704,30197231,*propofol
4705,30197231,*rapid sequence intubation
4706,30197231,*rocuronium
4707,30197231,*thyroid storm
4709,29329570,case report
4710,29329570,graves’ disease
4711,29329570,graves’ orbitopathy
4712,29329570,igg4-related disease
4713,29329570,igg4-related orbitopathy cois of the declaration of helsinki. approval by the institutional ethics comittee was not required as this was a single case report. consent for publication: written informed consent was obtained from the patient for publication of this case report and any accompanying images. a copy of written consent is available for review by the editor of this journal. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
4715,29288501,*graves’ disease
4716,29288501,*iodine
4717,29288501,*iodine restricted
4718,29288501,*iodine supplemented
4719,29288501,*recurrence rate
4720,31669312,autoimmune hypothyroidism
4721,31669312,cribado neonatal tiroideo
4722,31669312,enfermedad de graves
4723,31669312,graves disease
4724,31669312,hipertirotropinemia
4725,31669312,hipotiroidismo autoinmune
4726,31669312,hyperthyrotropinemia
4727,31669312,neonatal thyroid screening
4728,31669312,thyroiditis
4729,31669312,tiroiditis
4730,31108563,*agranulocytosis
4731,31108563,*antithyroid drug
4732,31108563,*human leucocyte antigen
4733,31108563,*meta-analysis cois
4734,30528501,national health insurance research database
4735,30528501,cohort study
4736,30528501,hyperthyroidism
4737,30528501,hypothyroidism
4738,30528501,psoriasis
4739,30528501,psoriatic arthritis
4740,30528501,thyroid diseases
4741,29485308,*diplopia
4742,29485308,*resection
4743,29485308,*thyroid eye disease
4744,29485308,*vertical strabismus
4745,30900216,angptl8
4746,30900216,graves’ disease cois
4747,30673921,*autoantigen
4748,30673921,*autoimmune
4749,30673921,*flow cytometry
4750,30673921,*immune
4751,30673921,*interleukin 2
4752,30673921,*lupus
4753,30673921,*metformin
4754,30673921,*multiple sclerosis
4755,30673921,*orbitopathy
4756,30673921,*pcsk9
4757,30673921,*rheumatoid arthritis
4758,30673921,*somatostatin
4759,30673921,*statin
4760,30673921,*testosterone
4761,30673921,*thyroid
4762,30291728,*graves’ disease
4763,30291728,*graves’ ophthalmopathy
4764,30291728,*hypothyroidism
4765,30291728,*iodine radioisotopes
4766,30291728,*thyroid function tests
4767,30291728,*thyrotoxicosis
4768,30291728,*treatment failure
4769,30291728,*weight gain
4771,31580214,*epstein-barr virus
4772,31580214,*graves' disease
4773,31580214,*asymptomatic infection
4774,31580214,*autoantibody
4775,31580214,*thyrotropin receptor autoantibody (trab)
4776,31580214,*viral reactivation cois
4777,30911279,biomarker
4778,30911279,diagnostics
4779,30911279,genetic signature
4780,30911279,molecular alteration
4781,30911279,papillary thyroid cancer cois
4782,31708111,*ctla4
4783,31708111,*graves’ disease
4784,31708111,*restriction fragment length polymorphism
4785,31708111,*single nucleotide polymorphism
4786,31033004,cd32b
4787,31033004,fcγr
4788,31033004,fcγrii
4789,31033004,graves' disease
4790,31033004,autoimmunity
4792,29974826,*cd4+ helper t cells
4793,29974826,*graves’ disease
4794,29974826,*t cell immunoglobulin domain and mucin domain 3
4795,29974826,*thyroid-associated ophthalmopathy
4796,29974826,*autoimmune thyroid disease
4797,29974826,*immune tolerance.
4798,31733941,*graves’ disease
4799,31733941,*ifih1 gene
4800,31733941,*lada diabetes
4801,31733941,*multiple sclerosis
4802,31733941,*polymorphism cois
4803,31557136,graves’ ophthalmopathy
4804,31557136,graves’ orbitopathy
4805,31557136,calcium
4806,31557136,methylprednisolone
4807,31557136,phosphate
4809,31272958,*graves’ ophthalmopathy
4810,31272958,*glucocorticoid
4811,31272958,*network meta-analysis cois
4812,30549306,*graves' orbitopathy
4813,30549306,*immunosuppression
4814,30549306,*methotrexate
4815,30549306,*methylprednsolone
4816,30549306,*rituximab
4819,31833078,graves' disease
4820,31833078,hyperthyroidism
4821,31833078,tissue doppler imaging
4822,31833078,two-dimensional speckle tracking echocardiography
4824,30771152,*autoimmune thyroid disease
4825,30771152,*ctla-4
4826,30771152,*foxp3
4827,30771152,*graves’ disease
4828,30771152,*hashimoto’s thyroiditis
4829,30771152,*polymorphism
4831,29589999,*graves'
4832,29589999,*adipogenesis
4833,29589999,*extracellular-regulated kinase (erk)
4834,29589999,*hyaluronan production
4835,29589999,"*orbitopathy, biguanides, amp-activated protein kinase"
4836,29526990,false-positive
4837,29526990,lithium-heparin plasma
4838,29526990,tsh receptor antibody (trab)
4839,29526990,third-generation
4841,30979639,dysthyroid optic neuropathy
4842,30979639,medial orbital wall decompression
4843,30979639,transcaruncular approach
4844,30979639,transnasal endoscopic approach
4845,30979639,vision
4847,30111225,graves' disease
4848,30111225,acute kidney injury
4849,30111225,hyperthyroidism
4850,30111225,methimazole
4851,30111225,nephrotoxicity
4852,30616690,*graves disease
4853,30616690,*hashimoto thyroiditis
4854,30616690,*macrophage-nk cells cross talk
4855,30616690,*thyroid cancer
4856,30616690,*tumor immunity cois competing interests: the authors declare that they have no conflict of interest. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
4857,30335556,graves’ disease
4858,30335556,orbital decompression
4859,30335556,infraorbital anaesthesia
4860,30335556,piezoelectric surgery
4861,30335556,thyroid eye disease
4862,29631510,*graves' ophthalmopathy immunoglobulins
4863,29631510,*igf-1 receptor
4864,29631510,*tsh receptor
4865,29631510,*pakt
4866,29631510,*perk1/2 cois
4867,30246383,*t follicular helper cells (tfh)
4868,30246383,*t helper 17 (th17)
4869,30246383,*t helper 22 (th22)
4870,30246383,*autoimmune thyroid diseases (aitds)
4871,30246383,*cytokines
4872,30246383,*immune tolerance
4873,30246383,*interleukin 17 (il-17)
4874,30246383,*interleukin 21 (il-21)
4875,29941778,autoimmune thyroid disease
4876,29941778,celiac disease
4877,29941778,glandular autoimmunity
4878,29941778,polyglandular autoimmune syndrome
4879,29941778,type 1 diabetes cois
4885,30973094,*graves' orbitopathy
4886,30973094,*toll-like receptor 2
4887,30973094,*high mobility group box 1
4888,30973094,*inflammation
4889,30973094,*receptor for advanced glycation end products
4890,30391932,*foxp3 acetylation
4891,30391932,*graves’ disease (gd)
4892,30391932,*treg function defect
4893,30391932,*mir-23a-3p
4896,30519958,bone mineral density
4897,30519958,bone turnover markers
4898,30519958,glucocorticoid
4899,29174716,autoimmune thyroid disease
4900,29174716,ctla4
4901,29174716,drb1*
4902,29174716,graves' disease
4903,29174716,hashimoto's thyroiditis
4904,29174716,human leukocyte antigen
4905,29021480,continuous glucose monitoring
4906,29021480,methylprednisolone pulse therapy
4907,29021480,mitiglinide
4908,29021480,rapid-acting insulin secretagogue
4909,29021480,repaglinide
4910,29021480,steroid-induced diabetes
4911,29256181,antioxidant
4912,29256181,fibroblast
4913,29256181,graves’
4914,29256181,ophthalmopathy
4915,29256181,orbitopathy
4916,29256181,retinol
4917,29256181,vitamin e
4918,29256181,β-carotene
4919,30284412,donor sclera
4920,30284412,ocular deviations
4921,30284412,strabismus
4922,30284412,surgical technique
4923,30515677,*continuous glucose monitoring
4924,30515677,*glycemic variation
4925,30515677,*graves’ disease
4926,30515677,*mean amplitude of glycemic excursions cois
4927,29804271,*durvalumab
4928,29804271,*graves’ orbitopathy
4929,29804271,*tremelimumab
4934,29549956,*graves' disease
4935,29549956,*autoantibodies
4936,29549956,*breast milk
4937,29549956,*methimazole
4938,29549956,*propylthiouracil
4939,29549956,*thyroid hormones
4940,30196781,*ophthalmoplegia
4941,30196781,*carotid-cavernous sinus fistula
4942,30196781,*cranial neuropathy
4943,30196781,*diplopia
4944,30196781,*hypoglobus
4945,30196781,*proptosis
4946,29482415,inter-ethnic
4947,29482415,orbit
4948,29482415,orbital decompression
4949,29482415,trigone
4950,31062662,*graves’ disease
4951,31062662,*autoantibody
4952,31062662,*decoy effect
4953,31062662,*exosome
4954,31062662,*thyrotropin receptor
4955,31809586,*b10 cells
4956,31809586,*graves’ disease
4957,31809586,*ilc2s
4958,31809586,*autoantibodies
4959,29656212,autoimmune thyroid disease
4960,29656212,calgranulins
4961,29656212,mrp14
4962,29656212,mrp6
4963,29656212,mrp8
4964,29656212,oxidative stress
4966,30222515,*epstein–barr virus
4967,30222515,*epstein–barr virus reactivation
4968,30222515,*epstein–barr virus-encoded small rna1
4969,30222515,*graves' disease
4970,30222515,*igg4-related disease cois
4971,29141453,*nodular thyroid diseases
4972,29141453,*goitre
4973,29141453,*insulin resistance
4974,29141453,*metabolic syndrome
4975,29141453,*thyroid volume
4977,30503299,*coronary artery vasospasm
4978,30503299,*graves’ disease
4979,30503299,*interleukin-6
4980,30503299,*silent myocardial infarction
4981,29557700,*decompression
4982,29557700,*graves’ orbitopathy
4983,29557700,*dose-effect
4984,29557700,*eye muscle surgery
4985,29557700,*tendon elongation of medial rectus muscle
4986,29233566,*anergy
4987,29233566,*autoimmune thyroid disease
4988,29233566,*b lymphocytes
4989,29233566,*flow cytometry
4992,30938100,*graves' disease
4993,30938100,*ptpn22 gene
4994,30938100,*gene polymorphism cois
4996,30724135,*graves' orbitopathy
4997,30724135,*pdgf-bb
4998,30724135,*adipogenesis
4999,30724135,*basic-fgf
5000,30724135,*tyrosine kinase inhibitor
5002,29780146,anca-related vasculitis
5003,29780146,mpo-anca
5004,29780146,omaav
5005,29780146,propylthiouracil
5007,30679116,autologous fat
5008,30679116,esthetic
5009,30679116,hyaluronic acid
5010,30679116,lateral orbital wall decompression
5011,30679116,temporal hollowing
5012,30679116,thyroid eye disease
5014,29800560,*graves' opthalmopathy
5015,29800560,*lfa-1/icam-1/gsk-3β pathway
5016,29800560,*logistic regression
5017,29800560,*mdr model
5018,29800560,*single nucleotide polymorphism
5019,29800560,*smoking
5020,29454070,graves’ disease
5021,29454070,interleukin-1 receptor antagonist
5022,29454070,interleukin-1-β
5023,29454070,restriction fragment length polymorphism
5024,29454070,single nucleotide polymorphism
5026,31328557,*circadian rhythm
5027,31328557,*graves’ disease
5028,31328557,*hashimoto’s thyroiditis
5029,31328557,*polymorphism
5030,31264142,anti-gastric parietal cell antibodies
5031,31264142,autoimmune gastritis
5032,31264142,autoimmune thyroid disease
5033,31264142,children
5034,31264142,screening
5035,29970608,endocrine system
5036,29970608,thyroid disease cois
5037,29269558,*endocrinology
5038,29269558,*pharmacology cois
5039,31411123,*graves' disease
5040,31411123,*levothyroxine
5041,31411123,*radioiodine treatment
5042,31411123,*thyrotropin
5043,31411123,*triiodothyronine cois
5044,31088643,abhormone
5045,31088643,colloid antigen 2
5046,31088643,graves’ disease
5047,31088643,thyroid blocking antibody
5048,31088643,thyroid stimulating antibody
5049,29666119,*experimental – laboratory
5050,29666119,*inflammation
5051,29666119,*orbit
5052,29666119,*pathology
5053,29666119,*stem cells cois
5054,29729713,autoimmune diseases
5055,29729713,meta-analysis.
5056,29729713,ptpn22
5057,31399042,*adipogenesis
5058,31399042,*go animal model
5059,31399042,*graves’ disease
5060,31399042,*graves’ ophthalmopathy
5061,31399042,*thyroid disease
5062,31399042,*hpmscs cois
5063,31034586,b cell-activating factor
5064,31034586,graves' disease
5065,31034586,hashimoto's thyroiditis
5066,31034586,autoimmune thyroid disease
5067,31034586,osteopontin
5068,30208979,* aitd autoimmune thyroid disease
5069,30208979,* dio deiodinases
5070,30208979,* gd graves’ disease
5071,30208979,* gpx glutathione peroxidases
5072,30208979,* ht hashimoto's thyroiditis
5073,30208979,* id iron deficiency
5074,30208979,* l-t4 levothyroxine
5075,30208979,* rct randomised controlled trial
5076,30208979,* t3 tri-iodothyronine; t4
5077,30208979,* tpo thyroid peroxidase
5078,30208979,* tsh thyroid-stimulating hormone
5079,30208979,* tg thyroglobulin
5080,30208979,* thyroxine
5081,30208979,*autoimmune thyroid disease
5082,30208979,*autoimmune thyroiditis
5083,30208979,*iodine
5084,30208979,*iron
5085,30208979,*nutrition
5086,30208979,*selenium
5088,28960748,hashimoto's
5089,28960748,autoimmune
5090,28960748,goiter
5091,28960748,hypothyroidism
5092,28960748,iodine
5093,28960748,vitiligo
5095,31091046,*graves’ ophthalmopathy
5096,31091046,*fibrosis
5097,31091046,*glycosaminoglycans
5098,31091046,*matrix metalloproteinases
5099,31091046,*pathogenesis
5100,31091046,*tissue inhibitor of metalloproteinases
5101,30684216,*autoantibodies
5102,30684216,*graves’ disease
5103,30684216,*hashimoto’s thyroiditis
5104,30684216,*tsh receptor
5105,30684216,*thyroid
5106,31439560,dermatology
5107,31439560,meningitis
5108,31439560,paediatrics cois
5109,31384956,fibroblast growth factor 23
5110,31384956,graves’ disease
5111,31384956,osteoporosis
5112,31384956,phosphorus
5113,30725486,*graves’ disease
5114,30725486,*hashimoto’ s thyroiditis
5115,30725486,*autoimmune thyroid disease
5116,30725486,*metabolomics
5117,30725486,*polyamine metabolites
5118,30725486,*serum
5119,30725486,*spermine
5120,29709954,carcinoembryonic antigen
5121,29709954,hypothyroidism
5122,31527321,denosumab
5123,31527321,fibroblast growth factor 23 (fgf-23)
5124,31527321,hypercalcemia
5125,31527321,hyperthyroidism
5126,31527321,zoledronic acid
5127,30506426,*bone mineral density
5128,30506426,*graves’ ophthalmopathy
5129,30506426,*graves’ orbitopathy
5130,30506426,*gucocorticoid-induced osteoporosis
5131,30506426,*methylprednisolone
5132,30506426,*trabecular bone score cois
5133,29526119,*graves’ disease
5134,29526119,*hashimoto’s disease
5135,29526119,*tnf-α
5136,29526119,*methylation
5137,29526119,*polymorphism
5139,31750736,4q21.1
5140,31750736,cxcl9
5141,31750736,hashimoto's thyroiditis
5142,31750736,naaa
5143,31750736,single nucleotide polymorphisms
5145,29864750,*autoimmunity
5146,29864750,*rheumatic diseases
5147,29864750,*thyroiditis
5148,31359380,autoimmune thyroid diseases
5149,31359380,dna methylation
5150,31359380,graves’ disease
5151,31359380,hashimoto thyroiditis
5152,31359380,icam-1
5154,30589937,b lymphocyte kinase
5155,30589937,graves' disease
5156,30589937,hashimoto’s thyroiditis
5157,30589937,autoimmune thyroid disease
5158,30589937,secreted phosphoprotein 1
5159,30133352,*ebv reactivation
5160,30133352,*graves’ disease
5161,30133352,*ig production
5162,30133352,*estradiol cois
5163,29791034,cd10
5164,29791034,adenomatous goitre
5165,29791034,anaplastic thyroid carcinoma
5166,29791034,immunohistochemistry
5167,29791034,thyroid tumour
5169,28725932,alzheimer’s disease
5170,28725932,chronological age
5171,28725932,dna methylation
5172,28725932,graves’ disease
5173,28725932,neural networks
5174,28725932,prediction accuracy
5175,30067105,antibody
5176,30067105,antithyroid drugs
5177,30067105,autoimmunity
5178,30067105,cutaneous reactions
5179,30067105,hepatotoxicity
5180,31573408,*antithyroid drugs
5181,31573408,*drug-induced hepatotoxicity
5182,31573408,*drug-induced liver injury
5183,31573408,*metimazole
5184,31573408,*propylthiouracil
5186,30417843,goitre
5187,30417843,incidence
5188,30417843,pyramidal lobe
5189,30417843,thyroidectomy cois
5191,31793246,highly differentiated follicular carcinoma of ovary
5192,31793246,imprint cytology
5193,31793246,monodermal teratoma
5194,31793246,struma ovarii
5195,31105122,gitelman syndrome
5196,31105122,slc12a3 gene
5197,31105122,eplerenone
5198,31105122,hypokalemia
5199,31105122,thyrotoxic hypokalemic periodic paralysis
5200,30201436,*autoimmunity
5201,30201436,*immune regulation
5202,30201436,*t cells
5203,30201436,*microrna-183
5204,30201436,*microrna-96
5205,31434818,graves’ disease
5206,31434818,hashimoto’s thyroiditis
5207,31434818,immune-checkpoint inhibitors
5208,31434818,immunoglobulin g4
5209,31434818,riedel’s thyroiditis
5210,30599051,*benign thyroid disease
5211,30599051,*radioiodine therapy
5212,30599051,*radioiodine uptake test
5213,30599051,*thyroid
5214,30599051,*thyroid stunning
5215,31301659,autopsy
5216,31301659,goiter
5217,31301659,malignancy
5218,31301659,metastatic disease
5219,31301659,thyroid
5220,31301659,thyroid nodule
5221,29956299,l-thyroxine in utero treatment
5222,29956299,dyshormonogenesis
5223,29956299,foetal goitre
5224,30936024,*biological therapy
5225,30936024,*disease progression
5226,30936024,*prognosis
5227,30936024,*treatment
5228,31387553,diagnostic criteria
5229,31387553,metastasis
5230,31387553,painful goiter
5231,31387553,subacute thyroiditis
5232,31387553,thyroid cancer cois
5233,29398296,*goitre
5234,29398296,*myasthenia gravis
5235,29398296,*ophthalmoplgia
5236,29398296,*thyrotoxicosis
5237,29923170,ancient greece
5238,29923170,endocrinology
5239,29923170,galen
5240,29923170,goitre
5241,29923170,hippocrates
5242,29923170,history
5243,29923170,thyroid
5244,30589040,nodular goiters
5245,30589040,ultrasound grayscale ratio (usgr)
5246,30589040,papillary carcinoma
5247,30589040,thyroid nodules cois
5248,28693960,backdoor
5249,28693960,lateral approach
5250,28693960,open throidectomy
5251,28693960,sternomastoid
5252,29396842,age-related changes
5253,29396842,chemical elements
5254,29396842,inductively coupled plasma mass spectrometry
5255,29396842,neutron activation analysis
5256,29396842,thyroid
5257,30175973,casc2
5258,30175973,long non-coding rna
5259,30175973,lymph node metastasis
5260,30175973,papillary thyroid cancer
5261,29724875,diabetes
5262,29724875,thyroid disease cois
5265,30860079,*endoscopic thyroidectomy using vestibular approach
5266,30860079,*scar.free thyroidectomy
5267,30860079,*transoral endoscopic thyroidectomy cois
5268,30939883,* thyroid nodules
5269,30939883,*fnab of thyroid gland
5270,30939883,*the bethesda 2017 revised classification of thyroid fnab
5271,30939883,*the bethesda system for reporting thyroid cytology 2010
5272,30939883,*goitre
5273,30939883,*thyroid cancer
5274,31691509,*echogenicity
5275,31691509,*nodular goiters
5276,31691509,*papillary thyroid carcinoma
5277,31691509,*ultrasonic diagnosis
5278,31691509,*ultrasound gray scale ratio cois
5281,31155540,deiodinase
5282,31155540,ft3/ft4 ratio
5283,31155540,hashimoto thyroiditis
5284,31155540,thyroid hormone
5285,31155540,thyroid volume
5286,29197093,*fndc5 gene
5287,29197093,*hyperthyroidism
5288,29197093,*hypothyroidism
5289,29197093,*irisin
5290,29996756,*thyroid diseases
5291,28627279,graves’ disease
5292,28627279,maternal autoantibodies
5293,28627279,anti-ro and anti-la antibodies
5294,28627279,athrogryposis multiplex congenital
5295,28627279,autoimmune thrombocytopenia
5296,28627279,fetal brain hemorrhage
5297,28627279,fetal heart block
5298,28627279,fetal thyroid goiter
5299,28627279,myasthenia gravis
5300,31670631,calciumsupliments
5301,31670631,calciumvalue
5302,31670631,thyroidectomy
5303,29626393,fnac
5304,29626393,children
5305,29626393,thyroid
5306,29409458,*breast cancer
5307,29409458,*goitre
5308,29409458,*lobular breast cancer
5309,29409458,*metastases to thyroid cois publication: written informed consent was obtained from the patient for the publication of this case report and any accompanying images. a copy of the written consent is available for review by the editor-in-chief of this journal. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
5310,31580203,neuromonitoring
5311,31580203,goiter
5312,31580203,recurrent laryngeal nerve palsy
5313,31580203,thyroid
5314,31580203,vocal cords
5315,31178475,congenital hypothyroidism
5316,31178475,gene mutation
5317,31178475,goiter
5318,31178475,thyroglobulin cois
5319,31292912,c cell hyperplasia
5320,31292912,c cells
5321,31292912,papillary carcinoma
5322,31292912,thyroid
5323,31292912,thyroidectomy
5324,31127647,*dnmt1
5325,31127647,*mgmt
5326,31127647,*ms-hrm
5327,31127647,*ctdna
5328,31127647,*methylation
5329,31127647,*papillary thyroid cancer
5330,31255196,autoimmune thyroiditis
5331,31255196,graves’ disease
5332,31255196,hashimoto's thyroiditis
5333,31255196,surgical management
5334,29724805,spect/ct
5335,29724805,parallax error
5336,29724805,parathyroid scintigraphy
5337,29724805,pinhole collimator
5338,29724805,thyroid scintigraphy
5339,30927996,history of thymectomy
5340,30927996,myasthenia gravis
5341,30927996,myasthenic
5342,30927996,surgical management of myasthenia gravis
5343,30927996,thymoma
5344,30927996,thymus
5345,30927996,transcervical
5346,30884127,cep78
5347,30884127,wdr62
5348,30884127,lateral lymph node metastasis
5349,30884127,thyroid cancer
5350,30739612,*deficiency
5351,30739612,*excess
5352,30739612,*iodine
5353,30739612,*sub-saharan africa
5354,29459090,cancer thyroïdien
5355,29459090,goitre ovarien
5356,29459090,ovarian teratoma
5357,29459090,struma ovarii
5358,29459090,thyroid carcinoma
5359,29459090,tératome ovarien
5360,31430255,tpo gene
5361,31430255,congenital goiter
5362,31430255,congenital hypothyroidism
5363,31430255,thyroid carcinoma
5364,31430255,thyroid dyshormonogenesis
5365,29313120,ablation techniques
5366,29313120,high-intensity focused ultrasound ablation
5367,29313120,induced hyperthermia
5368,29313120,interventional ultrasonography
5369,29313120,nodular goitre
5370,29503241,atrial fibrillation
5371,29503241,congestive heart failure
5372,29503241,graves’ disease
5373,29503241,hyperthyroidism
5374,29503241,toxic multinodular goitre
5377,29845469,*family health
5378,29845469,*health promotion
5379,29845469,*screening cois
5380,31267862,*nrf2
5381,31267862,*personalized nutrition
5382,31267862,*flavonoid
5383,31267862,*goiter
5384,31267862,*hyperthyroidism
5385,31267862,*hypothyroidism
5386,31267862,*phytochemical
5387,31267862,*thyroid.
5388,29676344,histopathology
5389,29676344,retrospective
5390,29676344,thyroid diseases cois
5391,31297898,*bipolar disorders
5392,31297898,*lithium
5393,31297898,*thyroid hormones
5394,31297898,*thyroid structure
5396,30665612,*hypocalcemia
5397,30665612,*indocyanine green
5398,30665612,*multinodular goiter
5399,30665612,*parathyroid
5400,30665612,*parathyroid hormone
5401,30665612,*thyroidectomy
5403,29354015,*benign thyroid nodule
5404,29354015,*laser
5405,29354015,*laser ablation
5406,29354015,*quality of life
5407,29354015,*thyroid
5408,29354015,*thyroid nodule
5409,29330630,ablation techniques
5410,29330630,high-intensity focused ultrasound ablation
5411,29330630,interventional ultrasonography
5412,29330630,nodular goitre
5413,29330630,pain management
5414,30009365,galen
5415,30009365,thomas wharton
5416,30009365,botium
5417,30009365,thyroid foramen
5418,30949714,autonomous thyroid function
5419,30949714,hyperthyroidism
5420,30949714,hypothyroidism
5421,30949714,iodine exposure
5422,30949714,nodular goiter
5425,30717458,diet
5426,30717458,gestational diabetes mellitus
5427,30717458,microbiota
5428,30717458,"pregnancy cois design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results."
5429,30903785,children
5430,30903785,morbidity
5431,30903785,pesticides
5432,30903785,thyroid gland
5433,31670642,crp
5434,31670642,anaplastic
5435,31670642,cancer
5436,31670642,ferritin
5437,31670642,inflammatorymarkers
5438,31670642,thyroid
5439,30732901,congenital hypothyroidism
5440,30732901,goiter
5441,30732901,idd
5442,30732901,iran
5443,30732901,salt iodisation
5445,30358496,*goiter
5446,30358496,*iodine deficiency
5447,30358496,*iodine in salt
5448,30358496,*thyroid volume
5449,30358496,*urinary iodine
5450,30378716,*foxq1
5451,30378716,*papillary thyroid carcinoma
5452,30378716,*poor prognosis
5453,30568076,infertility
5454,30568076,negative thyroid antibody
5455,30568076,nongoitrous
5456,30568076,subclinical hypothyroidism
5457,30568076,thyroid autoimmunity
5458,28952819,ebsln
5459,28952819,ionm
5460,28952819,rln
5461,28952819,goiter
5462,28952819,surgery
5463,28952819,thyroid
5464,28940588,ectopic thyroid
5465,28940588,endobronchial ultrasonography
5466,28940588,transbrochial needle aspiration
5467,29770856,benign thyroid disease
5468,29770856,mixed follicular-papillary variant
5469,29770856,multifocality
5470,29770856,papillary thyroid microcarcinoma
5471,29770856,risk factors
5472,29770856,thyroid weight
5473,29770856,tumour size
5474,31237859,vegf-a
5475,31237859,angiogenic factor
5476,31237859,histopathological factors
5477,31237859,immunohistochemistry
5478,31237859,papillary thyroid carcinoma
5479,31237859,thyroid carcinoma
5481,28224254,eastern mediterranean region (emr)
5482,28224254,goiter
5483,28224254,iodine
5484,28224254,iodine deficiency disorders (idds)
5485,28224254,who
5486,31445060,environmental chemicals
5487,31445060,pesticides
5488,31445060,thyroid diseases
5489,31445060,case–control study
5490,30521675,*goiter
5491,30521675,*health insurance
5492,30521675,*socioeconomic disparities
5493,30521675,*thyroid disease
5494,30521675,*thyroid volume
5496,30773379,*fusion imaging
5497,30773379,*hybrid imaging
5498,30773379,*single-photon emission computed tomography/ultrasound
5499,30773379,*thyroid
5500,30773379,*ultrasound
5502,31074384,follicular proliferation
5503,31074384,lobectomy
5504,31074384,malignancy
5505,31074384,surgery
5506,31074384,tir3b
5507,31074384,thyroid cancer
5508,31074384,total thyroidectomy cois
5509,30734891,dysgenesis
5510,30734891,dyshormonogenesis
5511,30734891,hashimoto thyroiditis
5512,30734891,hypothyroidism
5513,30734891,iodine deficiency
5514,30734891,levothyroxine
5515,30734891,mental retardation
5516,30734891,stunted growth
5519,32312925,benign thyroidectomy
5520,32312925,cervical thyroid remnant
5521,32312925,papillary thyroid carcinoma
5526,31142293,hashimoto’s thyroiditis
5527,31142293,papillary thyroid carcinoma cois
5528,29544745,adults
5529,29544745,influences
5530,29544745,prevalence
5531,29544745,thyroid nodules
5534,30371103,neuromonitoring
5535,30371103,nonrecurrent laryngeal nerve
5536,30371103,palsy
5537,30371103,recurrent laryngeal nerve
5538,30371103,thyroidectomy
5539,29573939,*shear wave
5540,29573939,*cancer
5541,29573939,*elastography
5542,29573939,*thyroid nodules
5543,29573939,"*ultrasound cois device or technology referenced in this paper. ag, mb, vk, bhk, jw, ddm, mr, jmk, mf, and aa have no competing financial interests in the technology described in this study. the content is solely the responsibility of the authors and does not necessarily represent the official views of the national institutes of health."
5544,30829140,*benign/goiter
5545,30829140,*endocrine
5546,30829140,*thyroid
5547,30829140,*thyroid cancer
5548,30829140,*thyroid/parathyroid
5549,30829140,*thyroidectomy
5550,30086865,*complication prevention
5551,30086865,*congenital hypothyroidism
5552,30086865,*goiter
5553,30086865,*next generation sequencing
5554,30086865,*systemic disease complications
5555,30086865,*thyroid
5556,30637454,hypocalcemia
5557,30637454,postoperative hypoparathyroidism
5558,30637454,thyroid surgery
5559,30637454,thyroidectomy
5560,30637454,vitamin d deficiency
5561,29695560,*bad
5562,29695560,*bax
5563,29695560,*bcl-2
5564,29695560,*benign thyroid nodules
5565,29695560,*apoptosis
5566,29695560,*gene expression
5567,29720101,*congenital hypothyroidism
5568,29720101,*goiter
5569,29720101,*novel mutations
5570,29720101,*tg
5571,29720101,"*thyroglobulin cois performed in miami has been approved by the human subject research office of the university of miami (irb number: 20140632). written informed consent for participating in the study has been obtained from all study participants and in the case of subjects under the age of 18 assent was obtained from the child and consent from their parents. consent for publication: written informed consent for publishing all data of the study, such as medical data, images and genetic results has been obtained from all study participants or in the case of subjects under the age of 18 assent was obtained from the child and consent from their parent. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
5572,31326901,genetics
5573,31326901,pituitary disorders
5574,31326901,thyroid disease cois
5576,30666977,iccidd
5577,30666977,iodine deficiency disorder
5578,30666977,iodized salt
5579,30666977,last mile
5580,30666977,public health nutrition
5581,30666977,success story
5582,30666977,way forward cois
5583,31169246,anaplastic thyroid carcinoma
5584,31169246,giant cells
5585,31169246,osteoclasts cois
5588,30610567,collision
5589,30610567,double tumor
5590,30610567,pit-1
5591,30610567,pituitary tumor
5592,30610567,plurihormonal
5593,30610567,sf-1
5594,30610567,stem cell
5595,29717097,*complication
5596,29717097,*elderly
5597,29717097,*morbidity
5598,29717097,*mortality
5599,29717097,*tracheostomy cois
5600,30707410,early diagnosis of rth β
5601,30707410,rth β management
5602,30707410,resistance to thyroid hormones
5603,30707410,spanish cohort
5604,30707410,thrb gene
5607,31250039,billing diagnosis
5608,31250039,coding quality
5609,31250039,prevalence of thyroid disorders
5610,31250039,primary data
5611,31250039,validation
5612,30700956,cardiovascular disease
5613,30700956,hyperthyroidism
5614,30700956,pattern
5615,30700956,presentation
5616,30700956,thyro-cardiac disease
5617,31489070,sarcoidosis
5618,31489070,endoscopy
5619,31489070,hypothalamus
5620,31489070,neurosarcoidosis
5621,31489070,pituitary gland
5622,31489070,sella turcica cois
5623,30450534,congenital hypothyroidism
5624,30450534,screening
5625,30450534,thyroid dysgenesis
5626,30450534,thyroid scintigraphy
5627,29409365,*percutaneous laser ablation
5628,29409365,*hyperthyroidism
5629,29409365,*toxic nodules
5630,31243250,igg4
5631,31243250,hypertrophic pachymeningitis
5632,31243250,non-caseating granuloma
5633,31243250,sarcoidosis
5635,30236136,conventional
5636,30236136,hypocalcemia
5637,30236136,ligasure® small jaw
5638,30236136,recurrent laryngeal nerve
5639,30236136,"thyroidectomy cois chancellor of research and development, tabriz university of medical sciences (committee reference number: 92170), and registered in iranian registry of clinical trials (www.irct.com), trial registration: irct2014010516077n1, registered: 23 may 2014). all patients provided written consent form in order to participate in the study and the procedures followed were in accordance with the ethical standards of the ethics committee of the tabriz university of medical sciences. consent for publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
5640,29039144,*endoscopic thyroidectomy
5641,29039144,*natural orifice transluminal endoscopic surgery
5642,29039144,*robotic thyroidectomy
5643,29039144,*transoral thyroidectomy
5644,30919068,ablation techniques
5645,30919068,high-intensity focused ultrasound ablation
5646,30919068,interventional ultrasonography
5647,30919068,nodular goiter
5648,30919068,pain management
5649,30778718,ablation techniques
5650,30778718,high-intensity focused ultrasound ablation
5651,30778718,interventional ultrasonography
5652,30778718,nodular goiter
5653,30778718,ultrasound imaging
5654,32202723,*cancer
5655,32202723,*cytology
5656,32202723,*nodular goiter
5657,32202723,*stratification
5658,32202723,*thyroid gland
5659,32202723,*ultrasonography
5660,30105949,*tirads
5661,30105949,*imaging
5662,30105949,*multinodular goiter
5663,30105949,*scoring system
5664,30105949,*ultrasonography
5665,30039748,*graves' disease
5666,30039748,*hashimoto's thyroiditis
5667,30039748,*quality of life
5668,30039748,*sexual dysfunction
5669,30039748,*thyroid autoimmunity
5670,31741093,adolescent
5671,31741093,child
5672,31741093,thyroid neoplasm
5673,31741093,thyroid nodule
5674,31741093,ultrasonography
5675,30833205,e-learning
5676,30833205,personalized learning environment
5677,30833205,practice-based learning and improvement
5678,30833205,professionalism
5679,30833205,systems-based practice
5680,30833205,vodcast vs. lecture
5682,30666981,anaemia
5683,30666981,diagnosis
5684,30666981,hypertension
5685,30666981,interventions
5686,30666981,recovery
5687,30666981,status fluorosis
5688,30666981,stillbirth cois
5689,29239041,familial adenomatous polyposis
5690,29239041,familial medullary thyroid carcinoma
5691,29239041,familial non-medullary thyroid carcinoma
5692,29239041,familial thyroid carcinoma
5693,29239041,multiple endocrine neoplasia
5694,29683529,*braf mutation
5695,29683529,*immunocytochemistry
5696,29683529,*molecular testing
5697,29683529,*plump cells
5698,29683529,*thyroid malignancies
5699,29683529,*thyroid nodules
5700,29529424,*goiter
5701,29529424,*iodine deficiency disorders
5702,29529424,*iodine supplementation
5703,29529424,*pregnancy
5704,29529424,*thyroid hormones
5705,31752761,bilateral cataract
5706,31752761,hypocalcemia
5707,31752761,hypoparathyroidism
5708,31752761,serum calcium and ethiopia
5709,31752761,tetany
5710,31752761,total thyroidectomy cois authors have any proprietary interests or conflicts of interest related to this submission.
5711,30595314,autopsy
5712,30595314,hypothyroidism
5713,30595314,ischemic heart disease
5714,30595314,thyroid
5715,31396854,ezh2
5716,31396854,h3k27me3
5717,31396854,immunohistochemistry
5718,31396854,thyroid cancer
5719,31074392,cancer
5720,31074392,fine needle aspiration citology
5721,31074392,follicular
5722,31074392,goiter
5723,31074392,kidney transplantation
5724,31074392,papillary
5725,31074392,thyroid
5726,31074392,thyroid nodule cois
5728,30197365,carcinoma thyroid
5729,30197365,poorly differentiated
5730,30197365,thyroglobulin cois
5731,31254103,"chronic hypocalcaemia, permanent hypoparathyroidism, operative volume"
5732,31254103,endocrine surgery
5733,31254103,surgeon volume
5734,31254103,thyroidectomy
5735,31254103,volume-outcome
5736,29637242,notes
5737,29637242,parathyroid gland
5738,29637242,toetva
5739,29637242,thyroid gland
5740,30252648,adolescent
5741,30252648,anthropometry
5742,30252648,blood pressure
5743,30252648,child
5744,30252648,glucose metabolism
5745,30252648,lipid metabolism
5746,30252648,subclinical hypothyroidism
5747,29885011,*biobanking
5748,29885011,*fine needle aspiration cytology
5749,29885011,*preanalytical procedures
5750,29885011,*thyroid
5751,28771678,sjögren syndrome
5752,28771678,annular erythema
5753,28771678,eccrine gland
5754,28771678,hidradenitis
5755,28771678,lymphocyte
5759,31565844,*intraoperative neuromonitoring
5760,31565844,*nerves at risk
5761,31565844,*phonosurgical therapy
5762,31565844,*recurrent laryngeal nerve
5763,31565844,*vocal fold paralysis
5764,31565844,*vocal function
5765,31133065,children
5766,31133065,deficiency
5767,31133065,excess
5768,31133065,nepal
5769,31133065,salt iodine
5770,31133065,thyroid
5771,31133065,urinary iodine cois
5772,31502218,acromegaly
5773,31502218,complications
5774,31502218,doppler
5775,31502218,ultrasound
5776,31502218,visceromegaly
5778,29319359,hyperthyroidism
5779,29319359,hypothyroidism
5780,29319359,pregnancy and thyroid
5781,29319359,prevention
5782,29319359,screening
5783,29319359,thyroid cancer
5784,29319359,thyroid disease
5785,31820353,iodine
5786,31820353,kombu
5787,31820353,risk assessment
5788,31820353,seaweeds
5789,31820353,toxic risk
5790,31820353,wakame
5791,31671395,choriocarcinoma
5792,31671395,germ cell tumors
5793,31671395,human chorionic gonadotropin
5794,31671395,hyperthyroidism
5796,29886838,anaplastic thyroid carcinoma
5797,29886838,aetiology
5798,29886838,new approaches
5799,29886838,prognostic factors
5800,29886838,risk factors
5801,29886838,treatment.
5802,31409088,dicer1
5803,31409088,cystic nephroma
5804,31409088,genetic testing
5805,31409088,hereditary cancer syndromes
5806,31409088,pleuropulmonary blastoma
5807,31238185,carotid body tumor
5808,31238185,ectopic thyroid
5809,31238185,in-111 pentetreotide
5810,31238185,paraganglioma
5811,29444549,body weight
5812,29444549,endocrine surgery
5813,29444549,general surgery
5814,29444549,thyroidectomy
5815,30259504,calcifediol
5816,30259504,sunlight
5817,30259504,thyroid disease
5818,30259504,ultraviolet rays
5819,30259504,vitamin d deficiency
5820,31400012,*epidemiology
5821,31400012,*hyperthyroidism
5822,31400012,*hypothyroidism
5823,31400012,*incidence
5824,31400012,*iodine
5825,31400012,*myxoedema
5826,31400012,*thyrotoxicosis
5827,29851122,*epidemiology
5828,29851122,*hyperthyroidism
5829,29851122,*incidence
5830,29851122,*iodine
5831,29851122,*thyrotoxicosis
5832,31468286,anaplastic thyroid carcinoma
5833,31468286,ham-1
5834,31468286,in situ hybridization
5835,31468286,long non-coding rna
5836,31468286,pca3
5837,31468286,pcr array
5838,31468286,papillary thyroid carcinoma
5839,31468286,rt-pcr
5840,31468286,thyroid carcinoma
5841,30413933,aggressiveness
5842,30413933,id genes
5843,30413933,thyroid cancer
5844,30413933,bhlh
5846,30681972,hashimoto’s thyroiditis
5847,30681972,thrβ gene mutation
5848,30681972,resistance to thyroid hormone
5849,29798143,collagen triple helix repeat containing 1
5850,29798143,epithelial-mesenchymal transition
5851,29798143,immunohistochemistry
5852,29798143,thyroid neoplasms cois relevant financial relationships with commercial interests to disclose.
5853,29333819,autoimmune thyroiditis
5854,29333819,child
5855,29333819,hashimoto's disease
5856,29333819,hypothyroidism
5860,31610911,children
5861,31610911,conseil génétique
5862,31610911,dicer1
5863,31610911,dépistage
5864,31610911,enfant
5865,31610911,genetic counseling
5866,31610911,ovarian sertoli-leydig tumor
5867,31610911,pleuropneumoblastoma
5868,31610911,pleuropneumoblastomes
5869,31610911,rare tumors
5870,31610911,screening
5871,31610911,surveillance
5872,31610911,tumeur ovarienne de sertoli-leydig
5873,31610911,tumeurs rares
5874,31375535,cancer
5875,31375535,cytopathology
5876,31375535,endocrine pathology
5877,31375535,thyroid cancer cois
5878,30074074,benign thyroid surgery
5879,30074074,head and neck surgery
5880,30074074,postoperative complications
5881,30074074,thyroid surgery
5882,30074074,vocal fold palsy
5884,30387163,*rct
5885,30387163,*cholecalciferol
5886,30387163,*hypocalcaemia
5887,30387163,*thyroidectomy
5888,30387163,*vitamin d
5889,30306604,adolescents
5890,30306604,autoimmune thyroiditis
5891,30306604,children
5892,30306604,l-selenomethionine
5893,30306604,organic selenium
5895,30902382,*carcinoma de células renales
5896,30902382,*neoplasia metastásica
5897,30902382,*neoplasm metástasis
5898,30902382,*renal cell carcinoma
5899,30902382,*thyroid
5900,30902382,*tiroides
5901,29466241,graves’ disease
5902,29466241,amiodarone-induced thyrotoxicosis
5903,29466241,hyperthyroidism
5905,32372175,c cell
5906,32372175,cancer
5907,32372175,diagnosis
5908,32372175,foxa1
5909,32372175,thyroid
5911,30891786,*iodine
5912,30891786,*iodine excess
5913,30891786,*iodized salt
5914,30891786,*thyroglobulin
5915,30891786,*thyroid autoimmunity
5917,29459556,autoimmune polyglandular syndrome
5918,29459556,hashimoto’s thyroiditis
5919,29459556,pulmonary hypertension
5920,29459556,type 1 diabetes
5921,31770674,iodine
5922,31770674,adolescents
5923,31770674,children
5924,31770674,deficiency
5925,31770674,dietary intake
5926,31770674,pre-schoolers
5928,31835129,copper
5929,31835129,iodine
5930,31835129,selenium
5931,31835129,thyroiditis
5932,31835129,zinc
5935,28717869,endoscopic thyroidectomy
5936,28717869,toetva
5937,28717869,thyroidectomy
5938,28717869,transoral
5939,28717869,transoral endoscopic thyroidectomy
5940,28717869,transoral neck surgery
5941,30953492,epidemiology
5942,30953492,hepatitis c infection
5943,30953492,interferon
5944,30953492,morbidity
5945,30953492,ribavirin
5946,30953492,"thyroid dysfunction cois database. according to the regulation of ministry of health and welfare, taiwan, all of the nhir datasets are only available from the information center, ministry of health and welfare, taiwan. the study was approved by the institute review board of the show chwan memorial hospital, taiwan (no. 1051201). informed consent from the subjects was not obtained because there was no personal contact between the patients and the data collectors. consent for publication: not applicable. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
5947,30168266,inguinal hernia
5948,30168266,uroflowmetry
5949,30168266,visual analog scale
5950,30168266,voiding dysfunction
5952,31881874,acdf
5953,31881874,anterior cervical discectomy and fusion
5954,31881874,c7/t1 anterior discectomy
5955,31881874,cervicothoracic junction
5956,31881874,hemithyroidectomy cois
5957,29079441,graves’ disease
5958,29079441,ompf porin
5959,29079441,serological cross-reactivity
5960,29079441,thyroid-stimulating hormone receptor
5961,29079441,yersinia pseudotuberculosis
5962,30955264,"carcinoma, papillary"
5963,30955264,prognosis
5964,30955264,thyroid neoplasms
5965,29993215,color doppler
5966,29993215,neoplasms
5967,29993215,thyroid nodule
5968,29993215,ultrasonography
5971,30784009,acoustic respiratory rate monitoring
5972,30784009,airway obstruction
5973,30784009,postoperative hemorrhage
5974,30784009,tachypnea
5975,30784009,thyroidectomy
5976,30298217,cross-sectional studies
5977,30298217,epidemiology
5978,30298217,general practice
5979,30298217,health services research
5980,30298217,otolaryngologists
5981,30298217,thyroid gland
5982,30272298,*co-morbidities
5983,30272298,*endometriosis
5984,30272298,*whole exome sequencing
5985,30272298,*autoimmune diseases
5986,30272298,*family history
5987,29730784,*neuromonitoring
5988,29730784,*quality of life
5989,29730784,*surgery
5990,29730784,*thyroid
5991,29730784,*voice cois ethical approval: all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 helsinki declaration and its later amendments or comparable ethical standards. informed consent: informed consent was obtained from all individual participants included in the study.
5992,31248397,3d printing
5993,31248397,airway pathology
5994,31248397,bronchial tree
5995,31248397,bronchoscopy
5996,31248397,multi-material
5997,31248397,simulation cois
5999,30264384,choline
6000,30264384,parathyroid adenoma
6001,30264384,positron emission tomography computed tomography
6002,30264384,primary hyperparathyroidism
6003,29380231,*diagnose
6004,29380231,*glucocorticoid treatment
6005,29380231,*igg4
6006,29380231,*inflammation
6007,29380231,*riedel cois ethical approval: for this type of retrospective study formal consent was not required.
6009,31821747,*braf mutation
6010,31821747,*fine-needle aspiration cytology
6011,31821747,*personalized medicine
6012,31821747,*programmed death-ligand 1 (pd-l1)
6013,31821747,*thyroid cancer
6014,31751626,*congenital hypothyroidism
6015,31751626,*erad
6016,31751626,*protein folding
6017,31751626,*thyroid genes
6019,30260174,gh
6020,30260174,igf-1
6021,30260174,acromegaly
6022,30260174,cancer
6023,30260174,neoplasms
6024,30260174,registry
6025,29504626,rdw
6026,29504626,heart failure
6027,29504626,hypothyroidism
6028,29504626,radioiodine therapy
6029,29317181,extramedullary hematopoiesis
6030,29317181,fine needle aspiration
6031,29317181,thyroid
6032,31914295,lymphatic metastasis
6033,31914295,melatonin
6034,31914295,melatonin receptor
6035,31914295,papillary thyroid cancer cois relevant financial relationships with commercial interests to disclose.
6038,30691690,"abordaje biaxilo-biareolar, ba-ba"
6039,30691690,abordaje extracervical
6040,30691690,baba endoscopic thyroidectomy
6041,30691690,bilateral axillo-breast approach
6042,30691690,endoscopic thyroidectomy
6043,30691690,scarless thyroidectomy
6044,30691690,tiroidectomía endoscópica
6045,30691690,tiroidectomía sin cicatriz cervical
6046,30406929,autoimmune
6047,30406929,empty sella
6048,30406929,pituitary adenoma
6049,30406929,prolactin
6050,30406929,thyroid
6051,30218312,iodine
6052,30218312,iodine deficiency disorder
6053,30218312,pregnancy
6054,30218312,thyroid
6055,29582344,hypothyroidism
6056,29582344,levothyroxine formulation
6057,29582344,liquid levothyroxine
6058,29582344,tsh
6059,29022276,central hyperthyroidism
6060,29022276,hyperthyroidism
6061,29022276,pituitary tumors
6062,29022276,tsh-secreting pituitary adenoma
6063,29022276,thyrotropinoma
6064,30740757,*18f-fdg pet/ct
6065,30740757,*eu-tirads
6066,30740757,*diagnosis
6067,30740757,*thyroid cancer
6068,30740757,*ultrasound
6069,31703968,*contrast-enhanced ultrasonography
6070,31703968,*papillary thyroid microcarcinoma
6071,31703968,*tumor size stratification
6072,31918249,braf(v600e)
6073,31918249,hbme-1
6074,31918249,lymph node metastasis
6075,31918249,papillary thyroid carcinoma
6076,31918249,ultrasound
6077,30443896,difficulty scale
6078,30443896,operative time
6079,30443896,total thyroidectomy
6080,30267376,autoimmune thyroid disease
6081,30267376,greece
6082,30267376,iodine
6083,30267376,thyroid
6084,30267376,thyroiditis
6085,30182360,incidence
6086,30182360,recurrence
6087,30182360,risk factors
6088,30182360,thyroid lobectomy
6089,30182360,thyroid nodules
6090,29774590,*anatomy handbook
6091,29774590,*pathogenesis and classification of neoplasms
6092,29774590,*prostatic hyperplasia
6093,30058426,electrophoresis
6094,30058426,mass spectrometry
6095,30058426,proteomics
6096,30058426,serum
6097,30058426,thyroid cancer
6098,29698806,14q32 deletion
6099,29698806,cancer
6100,29698806,dicer1 syndrome
6101,29536247,indocyanine green
6102,29536247,mivat
6103,29536247,near-infrared fluorescence
6104,29536247,parathyroid
6105,29536247,video-assisted thyroidectomy
6106,29164514,iodine
6107,29164514,microcarcinoma
6108,29164514,papillary thyroid cancer
6109,29164514,risk factors
6110,29164514,thyroid thyroglobulin antibody
6111,29164514,thyroid-stimulating hormone
6113,29438906,*fgf19
6114,29438906,*fgfr4
6115,29438906,*serum concentration
6116,29438906,*thyroid cancer
6117,29438906,*βklotho
6118,29273943,children
6119,29273943,pten hamartoma tumor syndrome (phts)
6120,29273943,screening
6121,29273943,thyroid cancer
6122,29273943,thyroid disease
6123,31841457,131і
6124,31841457,chornobyl disaster
6125,31841457,late endocrine and neuropsychiatric effects
6126,31841457,pathogenesis
6127,31841457,prenatal irradiation
6128,29968224,*apheresis
6129,29968224,*therapeutic plasma exchange
6130,29968224,*thyroid hormones
6131,29968224,*thyrotoxicosis
6132,29340973,age
6133,29340973,iodine status
6134,29340973,reference intervals
6135,29340973,thyroid dysfunction
6136,29340973,thyrotropin
6137,31190472,cold nodule
6138,31190472,cytology
6139,31190472,histopathology
6140,31190472,hot nodule
6141,31190472,warm nodule
6143,30639646,autoimmune thyroid diseases
6144,30639646,autoimmune thyroiditis
6145,30639646,celiac disease
6146,30639646,chronic autoimmune gastritis
6147,30639646,graves' diseases
6148,30639646,graves' ophthalmopathy
6149,30639646,multiple sclerosis
6150,30639646,polymyalgia rheumatica
6151,30639646,rheumatoid arthritis
6152,30639646,sarcoidosis
6153,30639646,sjogren disease
6154,30639646,systemic lupus erythematosus
6155,30639646,type 1 diabetes (type 1)
6156,30639646,vitiligo
6157,29949024,cytology
6158,29949024,diagnosis
6159,29949024,fine-needle aspiration
6160,29949024,niftp
6161,29949024,negative
6162,29949024,thyroid
6164,31383578,hypocalcemia
6165,31383578,hypoparathyroidism
6166,31383578,pediatric population
6167,31383578,total thyroidectomy
6168,31365889,etiology
6169,31365889,thyroid disease
6170,31365889,thyroid tissue
6171,31365889,toxic/essential trace metals
6172,30953130,*brain tumor
6173,30953130,*cns sarcoma
6174,30953130,*ciliary body medulloepithelioma
6175,30953130,*dicer1
6176,30953130,*dicer1-associated cns sarcoma
6177,30953130,*etmr
6178,30953130,*pineoblastoma
6179,30953130,*pituitary blastoma
6181,29703200,classification and regression tree method (cart)
6182,29703200,low transmission
6183,29703200,malaria exposure
6184,29703200,plasmodium falciparum
6185,29703200,plasmodium vivax
6186,29703200,reservoir of infection
6187,29703200,sero-epidemiology
6188,29703200,vietnam
6189,30410095,*diagnostic evaluation
6190,30410095,*etiology
6191,30410095,*genetic
6192,30410095,*hydrops fetalis
6193,30410095,"*nonimmune cois through the ucsf center for maternal-fetal precision medicine. m.e.n. is a consultant to invitae and has received research funding from natera, but this funding was not applied to this study. the other authors declare no conflicts of interest."
6194,31699952,congenital
6195,31699952,hypothyroidism
6196,31699952,young adult
6198,31621051,autoregulation
6199,31621051,cognition
6200,31621051,primary hyperparathyroidism
6201,31621051,vascular stiffness
6202,31621051,vasomotor reactivity cois
6203,30997493,*developing countries
6204,30997493,*effectiveness
6205,30997493,*folic acid
6206,30997493,*fortification
6207,30997493,*functional outcomes
6208,30997493,*iodine
6209,30997493,*iron
6210,30997493,*micronutrient status
6211,30997493,*systematic review
6212,30997493,*vitamin a
6214,31323353,hypocalcemia
6215,31323353,intact parathyroid hormone (pth)
6216,31323353,pediatric thyroidectomy
6217,30973063,*tbab
6218,30973063,*trab
6219,30973063,*tsab
6220,30973063,*fetal hyperthyroidism
6221,30973063,*fetal malformation
6222,30973063,*maternal hashimoto's disease
6223,30772970,tyumen region
6224,30772970,iodine deficiency
6225,30772970,iodized salt
6226,30772970,nutrition
6227,30772970,prevention cois publication of this article.
6228,30963819,*s1pr1
6229,30963819,*sphingosine 1 phosphate
6230,30963819,*sphingosine kinase 1
6231,30963819,*thyroiditis
6232,29650436,concentración urinaria de yodo
6233,29650436,epidemiological survey
6234,29650436,escolares
6235,29650436,estudio epidemiológico
6236,29650436,schoolchildren
6237,29650436,tsh en sangre capilar
6238,29650436,tsh in capillary blood
6239,29650436,urinary iodine concentration
6240,29030129,acoustic analysis
6241,29030129,análise acústica
6242,29030129,disfonia
6243,29030129,dysphonia
6244,29030129,hoarseness
6245,29030129,laryngeal paralysis
6246,29030129,paralisia laríngea
6247,29030129,rouquidão
6248,29030129,thyroidectomy
6249,29030129,tireoidectomia
6250,30891966,*classification
6251,30891966,*convolutional neural network
6252,30891966,*deep learning
6253,30891966,*head and neck cancer
6254,30891966,*hyperspectral imaging
6255,30891966,*optical biopsy
6256,30891966,*squamous cell carcinoma
6257,30472362,carbon nanoparticles
6258,30472362,parathyroid glands
6259,30472362,recurrent laryngeal nerve
6260,30472362,total thyroidectomy
6261,30443770,foxp3
6262,30443770,garp
6263,30443770,papillary thyroid carcinoma
6264,30443770,thyroid cancer
6265,29848235,*central neck
6266,29848235,*hypocalcemia
6267,29848235,*hypoparathyroidism
6268,29848235,*parathyroid hormone
6269,29848235,*paresthesia
6270,29848235,*thyroidectomy
6271,28875268,hashimoto’s thyroiditis
6272,28875268,papillary thyroid carcinoma
6273,28875268,tsh
6274,28875268,thyroid cytology
6275,28875268,thyroid nodules
6276,29170092,*adaptive redox homeostasis
6277,29170092,*antioxidant defense
6278,29170092,*argpyrimidine-modified heat-shock proteins
6279,29170092,*ccm1/krit1
6280,29170092,*cerebral cavernous malformations
6281,29170092,*cerebrovascular disease
6282,29170092,*glyoxalase 1 (glo1)
6283,29170092,*heme oxygenase-1 (ho-1)
6284,29170092,*nuclear factor erythroid 2-related factor 2 (nrf2)
6285,29170092,*oxidative dna damage and apoptosis
6286,29170092,*oxidative stress
6287,29170092,*redox signaling
6288,29170092,*c-jun
6290,31619220,calcitonin
6291,31619220,carcinoembryogenic antigen
6292,31619220,medullary thyroid carcinoma
6293,31619220,thyroid cancer cois
6294,31135104,*braf mutation
6295,31135104,*hyalinizing trabecular tumor
6296,31135104,*immunocytochemistry
6297,31135104,*molecular testing
6298,31135104,*personalized medicine
6299,31135104,*thyroid malignancy
6300,31135104,*thyroid nodule
6301,29043574,autoimmunity
6302,29043574,ctla4
6303,29043574,immune checkpoint inhibitors
6304,29043574,melanoma
6305,29043574,pd1
6306,29043574,thyroid diseases
6308,30684524,diagnostic marker
6309,30684524,ptc
6310,30684524,plasma microrna
6311,30684524,qrt-pcr
6312,30509240,braf v600e
6313,30509240,matrix metalloproteinase-9
6314,30509240,"papillary thyroid cancer cois institutional review board and ethics committee of the research institute for endocrine sciences, shahid beheshti university of medical sciences, tehran, iran (25ecries93/10/23); and was conducted in accordance with the declaration of helsinki guidelines a written informed consent was obtained from all participants. consent for publication: not applicable. competing interests: the authors do not report any relevant conflict of interest. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
6315,31784815,comparison between germany and switzerland
6316,31784815,degs1
6317,31784815,iodine
6318,31784815,iodine-containing foods
6319,31784815,iodized salt
6320,31784815,salt
6322,30909759,*statement
6323,30909759,*minimally invasive treatments
6324,30909759,*percutaneous thermal ablation
6325,30909759,*thyroid gland
6326,30909759,*thyroid nodule
6327,30909759,*ultrasonography
6328,31182340,*autoimmunity
6329,31182340,*graves' disease
6330,31182340,*ifnγ
6331,31182340,*immune checkpoints
6332,31182340,*pd-1
6333,31182340,*pd-l1
6334,31182340,*pd-l2
6335,31182340,*t-lymphocytes
6336,31182340,*tolerances
6339,35288841,anaplastic thyroid carcinoma
6340,35288841,cribriform-morular thyroid carcinoma
6341,35288841,follicular nodular disease
6342,35288841,follicular thyroid carcinoma
6343,35288841,high-grade thyroid carcinoma
6344,35288841,hyalinizing trabecular tumor
6345,35288841,medullary thyroid carcinoma
6346,35288841,papillary thyroid carcinoma
6347,35288841,poorly differentiated thyroid carcinoma
6348,35288841,thyroblastoma
6349,35288841,who classification of thyroid tumors
6350,34506000,compression syndrome
6351,34506000,goiter
6352,34506000,ischemic stroke
6353,34506000,thrombosis
6354,34417736,autoimmune
6355,34417736,fibrocyte
6356,34417736,graves’ ophthalmopathy
6357,34417736,insulin-like growth factor receptor
6358,34417736,orbit
6360,35657195,basedow
6361,35657195,hashimoto
6362,35657195,inflammation
6363,35657195,thyroiditis
6364,35657195,auto
6365,35657195,immunity
6366,34792795,autoimmune/inflammatory syndrome induced by adjuvants (asia)
6367,34792795,covid-19
6368,34792795,graves’ disease
6369,34792795,sars-cov2 vaccination
6370,34792795,thyroiditis cois
6371,34670889,hyperthyroidism
6372,34670889,multinodular goiter
6373,34670889,thyroglobulin
6374,34670889,tracheal compression
6375,34670889,tracheal deviation cois
6376,35685217,*massive goiter
6377,35685217,*multinodular goiter
6378,35685217,*retrosternal extension
6379,35685217,*sternotomy
6380,35685217,*thyroidectomy cois commercial or financial relationships that could be construed as a potential conflict of interest.
6381,34342859,covid
6382,34342859,graves’ disease
6383,34342859,sars-cov-2 rna vaccination
6384,34342859,thyroid cois employment by an organization that may gain or lose financially from publication of the article. there are also no other competing interests regarding the manuscript.
6387,35538703,giant goiter
6388,35538703,hashimoto’s thyroiditis
6389,35538703,case report
6390,35538703,en bloc excision
6391,35538703,hyperthyroidism
6392,35538703,thyroid
6393,35567330,complication
6394,35567330,large intrathoracic goiter
6395,35567330,minimally invasive surgery
6396,35567330,robot-assisted thoracoscopic surgery
6397,35567330,tracheal stenosis cois
6398,34272677,fine arts
6399,34272677,giovanni martino spanzotti
6400,34272677,goiter
6401,34272677,history
6402,34272677,renaissance
6404,34688699,*long-term
6405,34688699,*proptosis
6406,34688699,*re-treatment
6407,34688699,*teprotumumab
6408,34688699,*thyroid eye disease
6410,34915750,*adaptor protein
6411,34915750,*aging
6412,34915750,*cytoskeleton
6413,34915750,*hypothyroidism
6414,34915750,*iodide organification cois
6415,34476761,fermo stella
6416,34476761,fine arts
6417,34476761,goiter
6418,34476761,history
6419,34476761,renaissance
6421,35331216,micronodular goiter
6422,35331216,papillary thyroid microcarcinoma
6423,35331216,ultrasound grayscale ratio cois
6426,34405392,autonomous multinodular goiter
6427,34405392,gene expression
6428,34405392,thyroid nodule cois
6429,35221176,*airway stenosis
6430,35221176,*ecmo
6431,35221176,*nodular goiter cois authors were disclosed.
6433,34448414,audiometry
6434,34448414,graves ophthalmopathy
6435,34448414,hearing loss
6436,34448414,miscellaneous
6437,34448414,otolaryngology
6438,34448414,otology
6439,34448414,ototoxicity
6440,34448414,teprotumumab
6441,35186140,alt – alanine aminotransferase
6442,35186140,ap – alkaline phosphatase
6443,35186140,ast – aspartate aminotransferase
6444,35186140,arttg – antibodies to thyroid-stimulating hormone receptors
6445,35186140,cdld – chronic diffuse liver diseases
6446,35186140,dtg – diffuse toxic goiter
6447,35186140,swv – shear wave velocity
6448,35186140,t3f – free triiodothyronine
6449,35186140,t4f – thyroxine free
6450,35186140,tg – thyroid gland
6451,35186140,tsh – thyroid-stimulating hormone
6452,35186140,diffuse toxic goiter
6453,35186140,shear wave elastography
6454,35186140,ultrasound examination
6455,34980104,*iodine
6456,34980104,*nodular goiter
6457,34980104,*perchlorate
6458,34980104,*thyroid cancer
6459,34980104,*thyroid function cois
6460,35469855,bkmr analysis
6461,35469855,ng
6462,35469855,pbdes
6463,35469855,risk factor
6464,35436270,diffuse non-toxic goiter
6465,35436270,mathematical model
6466,35436270,risk
6467,35436270,type 2 diabetes mellitus
6468,35390148,benign multinodular goiter
6469,35390148,postoperative morbidity
6470,35390148,total thyroidectomy
6471,35390148,vocal cord palsy
6472,35390148,weight of specimen
6475,33218789,extra-adrenal paraganglioma
6476,33218789,paraganglioma
6477,33218789,subclavian paraganglia
6478,33218789,superior mediastinum
6482,34874796,graves’ ophthalmopathy
6483,34874796,thyroid-associated orbitopathy
6484,34874796,thyroid eye disease
6485,34874796,thyroid ophthalmopathy
6489,34928376,*graves’ disease
6490,34928376,*adolescents
6491,34928376,*children
6492,34928376,*rituximab
6493,34928376,*thionamide
6494,34928376,*thyrotoxicosis
6496,35037871,hypercalcemia
6497,35037871,lithium
6498,35037871,nephrogenic diabetes insipidus
6499,35037871,thyroid disorders
6500,34787691,environment
6501,34787691,genetic codes
6502,34787691,graves’ ophthalmopathy
6503,34787691,human organism
6504,34787691,risk factor
6505,33832185,*congenital goiter
6506,33832185,*hypothyroidism
6507,33832185,*thyroglobulin
6508,33832185,*novel mutation
6509,33832185,*case report
6513,33226264,bactericide
6514,33226264,intestinal microbiota
6515,33226264,iodine
6516,33226264,nutrition
6517,33226264,thyroid diseases
6518,33226264,thyroid hormones
6521,35264385,immunology
6522,35264385,materno-fetal medicine
6523,35264385,neonatal intensive care
6524,35264385,thyrotoxicosis cois
6525,35574000,epidemiology
6526,35574000,evaluation
6527,35574000,graves orbitopathy
6528,35574000,novel therapeutic approach
6529,35574000,pathogenesis cois commercial or financial relationships that could be construed as a potential conflict of interest.
6530,33349089,*elephantiasis
6531,33349089,*graves dermopathy
6532,33349089,*graves disease
6533,33349089,*thyroid eye disease
6534,35307540,*covid-19
6535,35307540,*graves' disease
6536,35307540,*hashimoto's thyroiditis
6537,35307540,*thyroid cois
6538,35226548,coronavirus disease 2019
6539,35226548,hyperthyroidism
6540,35226548,hypothyroidism
6541,35226548,non-thyroidal illness
6542,35226548,thyroid
6543,35226548,thyroid cancer
6544,35226548,thyroiditis cois conflict of interest.
6545,35334525,cervicotomy
6546,35334525,intrathoracic goitre
6547,35334525,morbidity
6548,35334525,sternotomy
6549,35334525,thyroid surgery cois
6550,32975863,graves ophthalmopathy
6551,32975863,thyroid eye disease
6553,35167950,*dry eye
6554,35167950,*exposure keratopathy
6555,35167950,*ocular surface disease
6556,35167950,*thyroid eye disease
6559,35226748,*graves disease
6560,35226748,*autoimmune addison disease
6561,35226748,*autoimmune hypothyroidism
6562,35226748,*autoimmune polyendocrine syndromes
6563,34334562,emo syndrome
6564,34334562,graves' disease
6565,34334562,musculoskeletal ultrasound
6566,34334562,osteoarthropathy cois
6567,33525898,teprotumumab
6568,33525898,compressive optic neuropathy
6569,33525898,dysthyroid optic neuropathy
6570,33525898,graves’ ophthalmopathy
6571,33525898,thyroid eye disease
6572,35684009,cancer
6573,35684009,iodine
6574,35684009,iodine deficiency
6575,35684009,iodine supplementation
6576,35684009,prevalence
6577,35684009,thyroid dysfunction cois
6579,35614620,"graves, orbital fibroblasts, autoimmunity."
6580,35230257,graves‘ disease
6581,35230257,iceland
6582,35230257,pediatric
6583,35230257,treatment
6584,35422184,autoimmune eye diseases
6585,35422184,graves’ orbitopathy
6586,35422184,anti-il6-receptor antibodies
6587,35422184,neuromyelitis optica spectrum disorders
6588,35422184,noninfectious uveitis
6589,35422184,optic neuropathy
6590,35422184,peripheral ulcerative keratitis
6591,35422184,tocilizumab
6593,35287535,*graves’ disease
6594,35287535,*graves’ orbitopathy
6595,35287535,*k1-70
6596,35287535,*antithyroid drugs
6597,35287535,*hyperthyroidism
6598,35287535,*iscalimab
6599,35287535,*methimazole
6600,35287535,*propylthiouracil
6601,35287535,*radioactive iodine
6602,35287535,*rituximab
6603,35287535,*thyroidectomy
6604,35287535,*thyrotropin receptor
6605,33908335,graves disease
6606,33908335,antithyroid agents
6607,33908335,hemodynamics
6608,33908335,hyperthyroidism
6609,33908335,thyroidectomy
6610,33908335,thyrotropin
6611,33775197,entropion
6612,33775197,eyelid retraction
6613,33775197,orbital decompression
6614,33775197,thyroid eye disease
6615,33775197,ultrasound biomicroscopy
6616,34487995,diplopia
6617,34487995,endoscopic
6618,34487995,eye
6619,34487995,graves'
6620,34487995,oculoplastic
6621,34487995,orbital decompression
6622,34487995,proptosis
6623,34487995,revision
6624,34487995,rhinology
6625,34487995,sinus
6626,34487995,thyroid
6627,34954838,graves' disease
6628,34954838,head and neck
6629,34954838,hyperthyroidism
6630,34954838,surgery
6631,35738449,molecular mechanism
6632,35738449,receptor mutations
6633,35738449,structure-activity relationship
6634,35738449,therapeutic development
6635,35738449,thyroid hormone receptor
6636,35738449,thyroid hormone resistance
6637,34663089,*graves'
6638,34663089,*disease
6639,34663089,*patient-reported outcomes
6640,34663089,*quality of life
6641,34663089,*thyroidectomy cois
6642,35534869,*autoimmune thyroid disease
6643,35534869,*human leucocyte antigen
6644,35534869,*relapsing polychondritis cois
6646,35315985,graves' ophthalmopathy
6647,35315985,proptosis
6648,35315985,thiol-disulfide
6649,35658138,parathyroidectomy
6650,35658138,prevention of damage
6651,35658138,recurrent laryngeal nerve
6652,35658138,thyroidectomy
6653,34291428,*art
6654,34291428,*exophthalmos
6655,34291428,*graves’ disease
6656,34291428,*history
6657,33579690,*eye (globe)
6658,33579690,*eye lids
6659,33579690,*immunology
6660,33579690,*orbit
6661,33579690,*pathology cois medical centre has received research-associated funding from horizon therapeutics.
6662,34687316,*graves disease
6663,34687316,*adolescents
6664,34687316,*children
6665,34687316,*rituximab
6666,34687316,*thionamide
6667,34687316,*thyrotoxicosis
6668,35379490,hypoparathyroidism
6669,35379490,paediatrics
6670,35379490,postoperative complications
6671,35379490,thyroidectomy
6672,35379490,"vocal cord palsy cois hy chung, and kenneth ky wong have no conflicts of interest or financial ties to disclose."
6674,35600602,graves’ disease
6675,35600602,central hypothyroidism
6676,35600602,maternal trab
6677,35600602,neonatal hyperthyroidism
6678,35600602,neonates cois commercial or financial relationships that could be construed as a potential conflict of interest.
6680,35015288,adjuvants
6681,35015288,autoimmune syndrome
6682,35015288,graves’ disease
6683,35015288,sars-cov-2 vaccination
6684,35015288,subacute painful thyroiditis
6685,35015288,thyrotoxicosis cois
6687,35381100,graves’ disease
6688,35381100,antithyroid agents
6689,35381100,pericarditis
6690,35381100,pleurisy
6692,35100622,*covid-19
6693,35100622,*graves’ disease
6694,35100622,*sars-cov-2
6695,35100622,*revaccination
6696,35100622,*subacute thyroiditis
6697,35100622,*vaccine
6698,35504153,multinodular goiter
6699,35504153,neck hematoma
6700,35504153,recurrent laryngeal nerve injury
6701,35504153,substernal thyroid goiter
6702,35504153,thyroidectomy
6703,35303084,graves’ orbitopathy
6704,35303084,cystine deprivation
6705,35303084,ferroptosis
6706,35303084,glycolysis
6707,35303084,orbital fibroblast
6708,34996091,*addison disease
6709,34996091,*autoantibodies
6710,34996091,*graves
6711,34996091,*hashimoto thyroiditis
6712,34996091,*disease
6713,34996091,*insulin-dependent diabetes mellitus
6715,35580958,gynecological cancer
6716,35580958,obstetrics and gynaecology cois
6717,32912014,myositis
6718,32912014,whipple’s disease
6719,32912014,orbitopathy
6720,32912014,tropheryma whipplei
6722,35662442,antithyroid drugs
6723,35662442,graves disease
6724,35662442,hyperthyroidism
6725,35662442,radioiodine therapy
6726,35662442,thyroid eye disease
6727,35662442,thyroidectomy cois
6728,35069441,*dna methylation
6729,35069441,*graves’ ophthalmopathy
6730,35069441,*epigenetics
6731,35069441,*gut microbiome
6732,35069441,*histone modification
6733,35069441,*noncoding rnas cois commercial or financial relationships that could be construed as a potential conflict of interest.
6736,35734334,compressive goitre
6737,35734334,case report
6738,35734334,dyspnea
6739,35734334,thyroidectomy cois
6740,35039921,central neck tumour
6741,35039921,hypercalcaemia
6742,35039921,hyperparathyroidism
6743,35039921,parathyroid adenoma
6744,35039921,parathyroid cancer
6745,35039921,parathyroid neoplasms
6746,34642808,dysthyroid optic neuropathy
6747,34642808,graves orbitopathy
6748,34642808,magnetic resonance imaging
6749,34642808,muscle index
6750,34642808,optic neuropathy
6751,34250837,choroidal vascularity
6752,34250837,graves’ disease
6753,34250837,binarization
6754,34250837,choroidal thickness
6755,34250837,thyroid
6756,33884704,graves' disease
6757,33884704,tsh receptor antibody
6758,33884704,antithyroid drug
6759,33884704,remission
6760,34515780,graves’ disease
6761,34515780,juvenile dermatomyositis
6762,34515780,anti-melanoma differentiation antigen 5
6763,34515780,soluble interleukin-2 receptor
6764,35418378,contraindications and precautions
6765,35418378,"ear, nose and throat/otolaryngology"
6766,35418378,eye
6767,35418378,ophthalmology
6768,35418378,thyroid disease cois
6769,35413468,covid-19
6770,35413468,graves' disease
6771,35413468,graves' ophthalmopathy
6772,35413468,sars-cov-2
6773,35413468,vaccine cois personal relationships that could have appeared to influence the work reported in this paper.
6775,35562686,multinodular goitre
6776,35562686,rln trifurcations
6777,35562686,recurrent laryngeal nerve variations
6778,35562686,thyroidectomy cois
6780,35504602,*graves disease
6781,35504602,*hashimoto disease
6782,35504602,*immunoglobulin g4
6783,35504602,*riedel thyroiditis
6784,35504602,*thyroid diseases cois was reported.
6786,35168232,benign intracranial hypertension
6787,35168232,child
6788,35168232,graves’ disease
6789,35168232,idiopathic intracranial hypertension
6790,35168232,pseudotumor cerebri
6791,34365588,asthenia
6792,34365588,parathyroidectomy
6793,34365588,quality of life
6794,34365588,thyroidectomy
6795,35791115,dysthyroid optic neuropathy
6796,35791115,graves' ophthalmopathy
6797,35791115,oculoplastics
6798,35791115,orbital inflammation
6799,35791115,strabismus
6800,35791115,teprotumumab
6801,35791115,thyroid eye disease cois
6804,34895729,*graves hyperthyroidism
6805,34895729,*endocrine ophthalmopathy
6806,34895729,*orbital irradiation
6807,34895729,*radiotherapy
6808,34895729,*thyroid eye disease
6809,34895729,*thyroid-associated orbitopathy
6810,35119087,18f-fch pet/ct
6811,35119087,fluorocholine
6812,35119087,hyperparathyroidism
6813,35119087,parathyroid imaging
6814,35651979,*graves’ disease (gd)
6815,35651979,*autoimmune disease (aid)
6816,35651979,*autoimmune thyroid disease (aitd)
6817,35651979,*inactivated sars-cov-2 vaccine
6818,35651979,*thyrotropin receptor antibody (trab) cois commercial or financial relationships that could be construed as a potential conflict of interest.
6819,35627231,graves’ disease
6820,35627231,x chromosome
6821,35627231,covariates
6822,35627231,logistic regression
6823,35627231,robust cois
6824,35403994,*amyloid encephalopathy
6825,35403994,*graves’ orbitopathy
6826,35403994,*hearing loss
6827,35403994,*inflammatory bowel disease
6828,35403994,*teprotumumab
6829,35403994,*thyroid-eye disease
6831,35734176,*graves’ disease
6832,35734176,*auto-immune thyroiditis
6833,35734176,*kidney biopsy
6834,35734176,*membranous nephropathy
6835,35734176,*renal pathology cois commercial or financial relationships that could be construed as a potential conflict of interest.
6836,35320248,"graves, thyroid associated orbitopathy, immunomodulation"
6837,35614367,*compressive optic neuropathy (con)
6838,35614367,*diplopia
6839,35614367,*dysthyroid optic neuropathy (don)
6840,35614367,*graves ophthalmopathy (go)
6841,35614367,*teprotumumab
6842,35614367,*thyroid eye disease (ted)
6843,35112273,*atrial fibrillation
6844,35112273,*hypothyroidism
6845,35112273,*subclinical thyroid disease
6846,35112273,*thyroid disease
6847,35548945,graves disease
6848,35548945,hyperthyroidism
6849,35548945,newborn
6850,35548945,pregnancy
6851,35548945,thyroid-stimulating hormone receptor antibodies
6852,35615845,clinical activity score; intraocular pressure; orbitopathy; thyroid dysfunction.
6853,35707463,graves orbitopathy
6854,35707463,adipogenesis
6855,35707463,fibroblasts
6856,35707463,fibrosis
6857,35707463,inflammation
6858,35707463,periostin cois commercial or financial relationships that could be construed as a potential conflict of interest.
6859,35331947,decompression
6860,35331947,endonasal
6861,35331947,endoscopic
6862,35331947,nonthyroid
6863,35331947,orbital
6867,34752624,*graves disease
6868,34752624,*amygdala
6869,34752624,*cognition
6870,34752624,*depression
6871,34752624,*hippocampus
6872,34752624,*longitudinal
6874,35022743,*graves disease
6875,35022743,*pittsburgh sleep quality index
6876,35022743,*hyperthyroidism
6877,35022743,*subjective sleep disorders
6878,35022743,*sympathetic tone
6879,35606042,endocrine cancer
6880,35606042,hyperthyroidism
6881,35606042,thyroid disease
6882,35606042,thyrotoxicosis cois
6883,32017356,*iodine deficiency
6884,32017356,*nepal
6885,32017356,*micronutrients
6886,32017356,"*salt iodization cois unicef, support the government of nepal's effort toward universal salt iodization but have no conflict of interest in developing this summary. the opinions and statements in this article are those of the authors and may not reflect official unicef policies. kedar parajuli, in his capacity working for government of nepal to prevent and control iodine deficiency in nepal, has no conflict of interest in developing this summary. robin houston, chandra pandav, macha raja maharjan, and jonathan gorstein have all both undertaken consultancies with various agencies working in nepal on nutrition issues, including in support of the usi program, but have no conflict of interest related to this paper."
6888,35182078,c-reactive protein
6889,35182078,graves' disease
6890,35182078,hashimoto's thyroiditis
6891,35182078,interleukin-39
6892,35182078,white blood cell cois
6893,33865565,graves’ disease
6894,33865565,iodine therapy
6895,33865565,meta-analysis
6896,33865565,radioactive iodine
6897,33865565,thyroid diseases
6898,34347269,*antiquity
6899,34347269,*endocrinology
6900,34347269,*etruscan
6901,34347269,*goitre
6902,34347269,*palaeopathology
6903,34347269,*thyroid
6904,33910662,*copper deficiency
6905,33910662,*hematological disease
6906,33910662,*mri
6907,33910662,*myeloneuropathy
6908,34487739,*graves’ orbitopathy
6909,34487739,*thyroid eye disease
6910,34487739,*fibroblast
6911,34487739,*insulin-like growth factor 1 receptor
6912,34487739,*microrna
6913,34487739,*orbital fibroblast
6914,34487739,*teprotumumab
6915,34487739,"*therapeutics, targeted therapy cois"
6916,35432203,*22q11.2 deletion syndrome
6917,35432203,*digeorge syndrome
6918,35432203,*growth disorders
6919,35432203,*hypoparathyroidism
6920,35432203,*thyroid disorders cois commercial or financial relationships that could be construed as a potential conflict of interest.
6922,33059514,epiblepharon
6923,33059514,singapore
6924,33059514,graves’ ophthalmopathy
6925,33059514,pediatric
6926,33059514,thyroid eye disease
6927,35528009,hashimoto thyroiditis
6928,35528009,anti-parietal cell antibodies
6929,35528009,gastric malignancies
6930,35528009,organ-specific autoimmunity
6931,35528009,systemic autoimmunity cois commercial or financial relationships that could be construed as a potential conflict of interest.
6932,35628410,smad
6933,35628410,tgfβ
6934,35628410,adipogenesis
6935,35628410,hpmscs
6936,35628410,thyroid disease
6937,35628410,thyroid-associated ophthalmopathy cois
6939,34970859,*graves' disease
6940,34970859,*metabolomics
6941,34970859,*myopathy
6942,34970859,*senescence
6943,34970859,*t cells cois
6944,33172865,*anatomy
6945,33172865,*orbit
6946,33172865,"*treatment medical cois ak—employer, horizon therapeutics."
6947,34920294,cyclind1
6948,34920294,d2–40
6949,34920294,follicular neoplasm
6950,34920294,multinodular goiter with dominant nodules
6951,34920294,oncocytic cell tumors
6952,34920294,poorly differentiated thyroid carcinoma
6954,35489725,gapdh
6955,35489725,papillary thyroid carcinoma
6956,35489725,cfdna integrity index
6957,35489725,circulating cell-free dna
6958,35489725,β-actin
6960,35675824,graves’ disease
6961,35675824,hashimoto’s thyroiditis
6962,35675824,autoimmune thyroid disease
6963,35675824,gut microbiota
6964,34374618,graves’ hyperthyroidism
6965,34374618,anti-ttg
6966,34374618,celiac disease
6967,34374618,false-positivity
6970,32965148,graves’s orbitopathy
6971,32965148,tocilizumab
6972,32965148,outcome
6973,32965148,rituximab
6975,35429598,*autoimmune thyroid diseases
6976,35429598,*high-throughput sequencing
6977,35429598,*immune repertoires
6978,35429598,*t cells receptor
6979,34782167,*nodular goiter
6980,34782167,*operated recurrent goiter
6981,34782167,*shear-wave velocity
6982,34782167,*thyroid sonoelastography cois
6984,35108585,"*botox-a (btx-a, botulinum toxin type a)"
6985,35108585,*orbital fibroblast
6986,35108585,*tgf-β/smad signaling
6987,35108585,*thyroid-associated ophthalmopathy (tao)
6988,35672057,"ear, nose and throat/otolaryngology"
6989,35672057,oncology
6990,35672057,thyroid disease cois
6991,35459655,cardiothoracic surgery
6992,35459655,surgical oncology
6993,35459655,thyroid disease cois
6995,34799942,c-reactive protein
6996,34799942,graves’ disease
6997,34799942,hashimoto's thyroiditis
6998,34799942,autoimmune thyroid disease
6999,34799942,interleukin-38 cois
7000,35338690,*childhood cancer survivors
7001,35338690,*head and neck radiation
7002,35338690,*hypoparathyroidism
7003,35338690,*pediatric thyroidectomy
7004,35338690,*recurrent laryngeal nerve paralysis
7005,34193409,experimental and laboratory
7006,34193409,orbit cois
7007,34291345,diplopia
7008,34291345,exophthalmos
7009,34291345,graves’ orbitopathy
7010,34291345,orbital decompression
7011,34291345,surgical outcome cois paper and did not receive any financial support toward the completion of this work.
7012,34933777,b cell subsets
7013,34933777,cd32b
7014,34933777,graves’ disease
7015,34933777,inhibitory receptors cois competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
7016,35018816,*italy
7017,35018816,*age-standardized rates
7018,35018816,*thyroid surgery
7019,35018816,*thyroidectomies
7020,35018816,*time trends
7021,35522861,autoimmune thyroiditis
7022,35522861,ctla
7023,35522861,graves’ disease
7024,35522861,hashimoto’s thyroiditis (ht)
7025,35522861,il-17
7026,35522861,il-23
7028,35235663,*graves’ disease
7029,35235663,*sars-cov-2 vaccine
7030,35235663,*hyperthyroidism
7031,35145479,*b lymphocytes
7032,35145479,*graves’ disease
7033,35145479,*graves’ orbitopathy
7034,35145479,*rituximab
7035,35145479,*tsh-receptor antibodies cois commercial or financial relationships that could be construed as a potential conflict of interest.
7036,35237808,cervicotomy
7037,35237808,hemi-clamshell
7038,35237808,plunging goitre
7039,35135806,general surgery
7040,35135806,head and neck surgery
7041,35135806,otolaryngology / ent
7042,35135806,thyroid disease
7043,35135806,thyrotoxicosis cois
7044,35024887,computed tomography
7045,35024887,correlations
7046,35024887,itmig classification
7047,35024887,lymphadenopathy
7048,35024887,thoracic radiography
7049,35285929,graves disease
7050,35285929,endocrinology
7051,35285929,hyperthyroidism
7052,35285929,thyroid function
7053,35285929,thyroid-stimulating antibody
7054,35285929,thyrotropin receptor antibody
7055,32878536,ct imaging
7056,32878536,extraocular muscle
7057,32878536,fatty infiltration
7058,32878536,thyroid eye disease
7060,35381687,*antithyroid agents
7061,35381687,*epidemiology
7062,35381687,*graves disease
7063,35381687,"*kidney failure, chronic cois was reported."
7064,35624535,graves’ disease
7065,35624535,hyperthyroidism
7066,35624535,hypercalcemia
7067,35624535,liver damage
7068,35624535,palpitation
7069,35624535,vomiting cois non-financial interests to disclose.
7070,34788857,*m22 (a monoclonal tsab)
7071,34788857,*tsh receptor (tshr)
7072,34788857,*tshr stimulating antibody (tsab)
7073,34788857,*crosstalk
7074,34788857,*insulin-like growth factor receptor 1 (igf1r)
7075,34788857,*teprotumumab
7076,34788857,*thyroid eye disease (ted)
7077,35273577,*il-11
7078,35273577,*clinical activity score
7079,35273577,*fibrosis
7080,35273577,*orbital fibroblast
7081,35273577,*thyroid-associated ophthalmopathy cois commercial or financial relationships that could be construed as a potential conflict of interest.
7082,35728893,oculoplastics
7083,35728893,orbital and lacrimal disorders
7084,35728893,thyroid disease cois
7085,35018442,*individual participant data
7086,35018442,*meta-analysis
7087,35018442,*muscle strength
7088,35018442,*quality of life
7089,35018442,*vitamin d
7090,35663306,erk
7091,35663306,graves’ ophthalmopathy
7092,35663306,stat3
7093,35663306,dihydroartemisinin
7094,35663306,fibrosis
7095,35663306,inflammation
7096,35663306,orbital fibroblast cois commercial or financial relationships that could be construed as a potential conflict of interest.
7098,34324163,autoimmune thyroid diseases
7099,34324163,bioassay
7100,34324163,disease
7101,34324163,functional thyrotropin receptor antibodies
7102,34324163,graves
7103,34324163,orbitopathy
7104,34324163,stimulatory antibodies
7105,35119800,drug reaction with eosinophilia and systemic symptoms (dress)
7106,35119800,severe cutaneous adverse drug reactions (scars)
7107,35119800,thyroid dysfunction
7108,35119800,thyroiditis
7109,35066781,*blood markers
7110,35066781,*clinical biomarkers
7111,35066781,*graves’ ophthalmopathy
7112,35066781,*orbital imaging
7113,35066781,*tear cytokines
7114,35610583,bayesian method
7115,35610583,graves’ disease data
7116,35610583,minnesota center for twin and family research data
7117,35610583,penalized fieller’s method
7118,35610583,skewed x chromosome inactivation cois
7119,35184917,*decompression surgery
7120,35184917,*endocrine orbitopathy
7121,35184917,*fully digital analysis
7122,35184917,*navigated surgery
7123,35244288,99mtechnetium uptake
7124,35244288,grave's disease
7125,35244288,trab
7126,35244288,nonuniform uptake
7127,35220164,*autoimmune thyroid diseases
7128,35220164,*graves' disease
7129,35220164,*hyperthyroidism
7130,35220164,*inactivated covid-19 vaccine
7131,35220164,*sars-cov-2
7132,35220164,*mrna vaccine cois
7133,35563653,graves’ orbitopathy
7134,35563653,disulfiram
7135,35563653,fibrosis
7136,35563653,myofibroblasts
7137,35563653,perimysial orbital fibroblasts cois
7138,35307774,dicer1
7139,35307774,multinodular goiter
7140,35307774,pediatric poorly differentiated thyroid carcinoma
7141,35307774,thyroblastoma cois
7142,35088381,antithyroid drug
7143,35088381,graves’ disease
7144,35088381,long-term
7145,35088381,methimazole
7146,35088381,remission
7147,35088381,thionamides
7148,35295987,*cancer diagnosis
7149,35295987,*cancer risk
7150,35295987,*familial non-medullary thyroid carcinoma
7151,35295987,*familial thyroid cancer
7152,35295987,*papillary thyroid carcinoma
7153,35295987,*susceptibility genes cois commercial or financial relationships that could be construed as a potential conflict of interest.
7154,35398834,dysthyroid optic neuropathy
7155,35398834,fat decompression
7156,35398834,grave’s disease
7157,35398834,orbital decompression
7158,35398834,thyroid eye disease
7159,35189399,*cd4(+) t cells
7160,35189399,*graves’ disease (gd)
7161,35189399,*immune
7162,35189399,*regulatory t cells
7163,35189399,*t helper cells 17
7164,34861792,*graves' disease
7165,34861792,*mica
7166,34861792,*mendelian randomization
7167,34861792,*nkg2d
7168,34861792,*community-based cohort
7169,34861792,*phenome-wide association
7170,35241008,*adpkd
7171,35241008,*polycystic kidney disease
7172,35241008,*thyroid nodules
7173,35241008,*ultrasonography cois commercial or financial relationships that could be construed as a potential conflict of interest.
7174,34532987,graves’ eye disease
7175,34532987,graves’ ophthalmopathy
7176,34532987,graves’ orbitopathy
7177,34532987,diplopia
7178,34532987,outcomes
7179,34532987,strabismus surgery
7180,34532987,thyroid eye disease
7181,34532987,topical anaesthesia
7182,35565939,graves’ disease
7183,35565939,antithyroid drugs
7184,35565939,neonate
7185,35565939,thyroid volume
7186,35565939,ultrasound cois
7187,35300630,intraocular pressure
7188,35300630,strabismus
7189,35300630,surgery
7190,35300630,thyroid eye disease cois
7192,34549377,extra-cellular volume fraction
7193,34549377,extraocular muscle
7194,34549377,fibrosis
7195,34549377,t1 mapping
7196,34549377,thyroid-associated ophthalmopathy
7197,35615718,graves’ disease
7198,35615718,graves’ orbitopathy
7199,35615718,antithymocyte globulin
7200,35615718,proptosis
7201,35615718,thyroid eye disease cois commercial or financial relationships that could be construed as a potential conflict of interest.
7202,35508893,graves' disease
7203,35508893,dosimetry
7204,35508893,hyperthyroidism
7205,35508893,multinodular goitre
7206,35508893,radioiodine
7207,35508893,theranostics
7208,35508893,toxic adenoma
7209,34988642,benign goitre
7210,34988642,quality of life
7211,34988642,thypro 39 questionnaire
7212,34988642,thyroidectomy
7213,33103521,graves’ disease
7214,33103521,hashimoto’s thyroiditis
7215,33103521,autoimmune thyroid diseases
7216,33103521,polymorphism
7217,33103521,protein tyrosine phosphatase nonreceptor 22
7218,34347224,blepharoptosis
7219,34347224,graves' disease
7220,34347224,myasthenic ptosis
7221,34347224,myogenic ptosis
7222,34347224,thyroid eye disease
7223,33390059,exophthalmos
7224,33390059,eyelid retraction
7225,33390059,orbital decompression
7226,33390059,thyroid-associated orbitopathy
7227,33390059,vertical diplopia
7229,34850456,autoimmune thyroid disease
7230,34850456,interference
7231,34850456,nonthyroid autoimmune diseases
7232,34850456,thyroid hormone autoantibody
7233,34605662,*graves'
7234,34605662,*adipogenesis
7235,34605662,*antifibrotic
7236,34605662,*disulfiram
7237,34605662,*orbital fibroblast
7238,34605662,*orbitopathy
7240,34871593,*autoimmune thyroid disease
7241,34871593,*homogeneous camp biosensor
7242,34871593,*thyroid blocking immunoglobulins or antibodies
7243,34871593,*thyroid stimulating immunoglobulins or antibodies
7244,34871593,*thyroid-stimulating hormone receptor
7245,35386700,*cd11c+ b cells
7246,35386700,*cxcr3-cxcl10
7247,35386700,*graves’ disease
7248,35386700,*trab
7249,35386700,*cytokines cois commercial or financial relationships that could be construed as a potential conflict of interest.
7252,34773561,clinical features
7253,34773561,cytokines
7254,34773561,graves’ disease
7255,34773561,igg4-related diseases
7256,34773561,serum igg4
7257,34928110,pediatric age.
7258,34928110,thyroid cancer
7259,34928110,grave's disease
7260,34877883,*go-qol
7261,34877883,*graves' orbitopathy
7262,34877883,*decompression
7263,34877883,*lid
7264,34877883,*quality of life
7265,34877883,*strabismus surgery
7266,34877883,*systematic review
7267,35458147,sarawak
7268,35458147,usi
7269,35458147,goitre
7270,35458147,school children
7271,35458147,urinary iodine concentration cois
7275,35405683,inflammatory myofibroblastic tumor
7276,35405683,surgery
7277,35405683,thyroid cancer
7278,35405683,ultrasonic examination
7279,35459658,endocrine system
7280,35459658,hyperthyroidism
7281,35459658,thyroid disease cois
7284,35402292,*16 rrna gene sequencing
7285,35402292,*graves’ disease
7286,35402292,*th17 & treg axis
7287,35402292,*intestinal flora
7288,35402292,*short chain fatty acids cois commercial or financial relationships that could be construed as a potential conflict of interest.
7290,35064543,bone mineral density
7291,35064543,graves’ disease
7292,35064543,muscle mass
7293,35064543,thyroid hormone
7294,33637620,experimental – laboratory
7295,33637620,inflammation
7296,33637620,"orbit cois coinvestigator on a study funded by genentech to evaluate the use of rituximab for orbital inflammatory diseases. jtr, rad, bsk, dok, and gjh are consultants to horizon pharmaceuticals which manufactures teprotumumab. jtr receives research support from horizon pharmaceuticals."
7297,34489313,*cardiomyopathies
7298,34489313,*diastolic
7299,34489313,*heart failure
7300,34489313,*systolic cois
7301,34060342,graves’ disease
7302,34060342,hematoma
7303,34060342,hypocalcemia
7304,34060342,recurrent laryngeal nerve injury
7305,34060342,"thyroidectomy cois conflicts of interest with respect to the research, authorship, and/or publication of this article."
7306,35187713,elisa
7307,35187713,graves’ disease
7308,35187713,tsh-receptor antibody
7309,35187713,diagnostic performance
7310,35187713,dot blot assay cois
7311,34778997,*hirata disease
7312,34778997,*human leukocyte antigen
7313,34778997,*hyperinsulinaemic hypoglycaemia
7314,34778997,*insulin autoantibody
7315,34778997,*insulin autoimmune syndrome
7316,34778997,*sulfhydryl group
7317,35713042,"multinodular goitre, complications of total thyroidectomy, surgeons' experience  in thyroid surgery."
7319,35220890,graves’ disease
7320,35220890,nrcam
7321,35220890,th1 cells
7322,35220890,lncrna runx1-it1 cois
7323,35569928,graves' disease
7324,35569928,coronavirus disease 2019
7325,35569928,type 1 diabetes
7326,35569928,vaccination cois
7328,35568525,*puberty
7329,35568525,*fetal programming
7330,35568525,*goiter
7331,35568525,*hyperthyroidism
7332,35568525,*hypothyroidism
7335,34671950,b cells
7336,34671950,graves' ophthalmopathy
7337,34671950,graves' orbitopathy
7338,34671950,lymphocytes
7339,34671950,plasmacells
7340,34671950,t-cells
7341,34671950,thyroid eye disease
7342,34545512,collagen1
7343,34545512,fibrocytes
7344,34545512,graves orbitopathy
7345,34545512,tshr
7346,34545512,peripheral blood mononuclear cells
7348,35439657,dysthyroid optic neuropathy
7349,35439657,graves' disease
7350,35439657,orbital decompression surgery
7351,35439657,orbital surgery
7352,35439657,visual acuity
7353,34613563,graves’ orbitopathy
7354,34613563,immunoassay
7355,34613563,thyroid stimulating immunoglobulin
7356,34613563,thyroid-associated orbitopathy
7358,34714163,*graves' disease
7359,34714163,*trab assay
7360,34714163,*thyroid autoimmunity-clinical
7361,34714163,*thyroid eye disease
7362,34714163,*thyroid stimulating immunoglobulins
7363,34927457,*graves' orbitopathy
7364,34927457,*igf-1r
7365,34927457,*tshr antibody
7366,34927457,*teprotumumab cois
7367,35320246,"sub acute thyroiditis, nuclear scan, pyrexia of unknown origin, thyroid  antibodies."
7370,34544941,graves’ disease
7371,34544941,graves’ ophthalmopathy
7372,34544941,hyperthyroidism
7373,34544941,internal ophthalmoplegia
7374,34544941,tonic pupil
7376,35555881,fat-suppression
7377,35555881,intravenous glucocorticoid therapy
7378,35555881,magnetic resonance imaging
7379,35555881,t2 mapping
7380,35555881,thyroid-associated ophthalmopathy
7381,35555881,treatment response cois
7382,35278055,abuja
7383,35278055,goitres
7384,35278055,management outcome
7385,35278055,pattern cois
7386,34781042,graves ophthalmopathy
7387,34781042,diabetes
7388,34781042,extraocular muscles
7389,34781042,optic neuropathy
7390,34781042,severity
7391,34781042,thyroid eye disease
7392,34241830,autoimmunity
7393,34241830,goiter
7394,34241830,lupus
7395,34241830,malar
7396,34241830,pregnancy
7397,34241830,rash
7398,34241830,sle
7399,34241830,thyroid cois
7400,35734310,bahirdar
7401,35734310,ethiopia
7402,35734310,salt iodization
7403,35734310,households
7404,35734310,iodine deficiency cois
7406,35698219,case report
7407,35698219,graves' disease
7408,35698219,guillain-barré syndrome
7409,35698219,hashimoto's disease
7410,35698219,transition cois
7412,35082799,*graves’ disease
7413,35082799,*berberine
7414,35082799,*methimazole
7415,35082799,*microbiome
7416,35082799,*prebiotics cois commercial or financial relationships that could be construed as a potential conflict of interest.
7417,35396078,ethanol
7418,35396078,radiofrequency
7419,35396078,thermal ablation
7420,35396078,thyroid cancer
7421,35396078,thyroid nodule
7423,34743487,*eyelids
7424,34743487,*inflammation
7425,34743487,*orbit
7426,34743487,*selenium cois was reported.
7427,35592782,*diffusion tensor imaging
7428,35592782,*dysthyroid optic neuropathy
7429,35592782,*magnetic resonance imaging
7430,35592782,*optic nerve
7431,35592782,*thyroid-associated ophthalmopathy cois commercial or financial relationships that could be construed as a potential conflict of interest.
7432,34714162,*graves' disease
7433,34714162,*graves' orbitopathy
7434,34714162,*orbital cell stimulation
7435,34714162,*thyroid stimulation
7436,34714162,"*thyrotropin receptor stimulatory autoantibodies cois germany, has received research-associated funding from the jgu medical faculty, advancecor (germany), apitope (united kingdom), berlin-chemie (germany), byondis (the netherlands), horizon therapeutics (usa), immunovant (usa), isar (germany), mediomics (usa), merck (germany), novartis (usa), quidel (usa), river vision (usa), and roche (switzerland). g.j.k. consults for glycoera (switzerland), immunovant, mediomics, merck, novartis, roivant (usa), quidel, and vasaragen (usa)."
7438,34330200,dry eye
7439,34330200,graves’ ophthalmopathy
7440,34330200,meibography
7441,34330200,meibomian glands
7442,34330200,ocular surface
7443,35413779,*blood flow velocity
7444,35413779,*graves disease
7445,35413779,"*receptors, thyrotropin"
7446,35413779,*thyroiditis
7447,35413779,*thyrotoxicosis
7448,35413779,"*ultrasonography, doppler, color cois samsung medison co., ltd. (seoul, korea). the sponsor had no role in the writing of the manuscript or in the decision to submit the manuscript for publication."
7449,35144579,extraocular muscles
7450,35144579,graves’ disease
7451,35144579,lacrimal gland
7452,35144579,magnetic resonance imaging
7453,35144579,prolapse
7454,35144579,proptosis
7455,35144579,thyroid-associated ophthalmopathy cois
7456,34774300,*drinking water
7457,34774300,*goiter
7458,34774300,*nitrate
7459,34774300,*perchlorate
7460,34774300,*sodium iodide symporter
7461,34774300,*thiocyanate
7462,34979862,central choroidal thickness
7463,34979862,choroidal vascularity index
7464,34979862,clinical activity score
7465,34979862,non-inflammatory active ted
7466,34979862,thyroid eye disease
7467,34637060,dysthyroid optic neuropathy
7468,34637060,octa
7469,34637060,peripapillary vessel density
7470,34637060,retinal nerve fiber layer thickness
7471,34637060,thyroid-associated ophthalmopathy cois
7472,35405579,clinical activity score prediction
7473,35405579,disease activity differentiation
7474,35405579,magnetic resonance imaging
7475,35405579,magnetization transfer
7476,35405579,thyroid-associated ophthalmopathy
7477,35235144,angptl3
7478,35235144,graves’ disease
7479,35235144,hdl subfractions
7480,35235144,hyperthyroidsim
7481,35235144,hypothyroidism
7482,35235144,pre-β1 hdl
7483,35370997,*graves’ disease (gd)
7484,35370997,*hashimoto’s thyroiditis (ht)
7485,35370997,*n-glycosylation
7486,35370997,*immunoglobulin g (igg)
7487,35370997,*immunosuppressive therapy
7488,35370997,*ultraperformance liquid chromatography  cois commercial or financial relationships that could be construed as a potential conflict of interest.
7492,34325607,autoimmune thyroid disease
7493,34325607,graves’ disease
7494,34325607,hashimoto’s thyroiditis
7495,34325607,psors1c1
7496,34325607,single nucleotide polymorphism
7498,34645767,autoimmune polyglandular syndrome
7499,34645767,superior mesenteric artery syndrome
7500,34645767,type 1 diabetes cois
7501,35094312,*antithyroid drugs
7502,35094312,*efficacy
7503,35094312,*graves
7504,35094312,*hyperthyroidism
7505,35094312,*therapeutic plasma exchange
7507,34536118,medial orbital wall decompression
7508,34536118,medial rectus muscle expansion
7509,34536118,medial rectus muscle misalignment
7510,34536118,periosteal flap
7511,34536118,thyroid eye disease
7513,34822305,atf4
7514,34822305,pct
7515,34822305,ret mutation
7516,34822305,cancer médullaire de la thyroïde
7517,34822305,medullary thyroid carcinoma
7518,34822305,mutation de ret
7519,34822305,recurrence
7520,34822305,récidive
7521,34822305,survie
7522,34822305,survival
7524,35069439,*graves’ disease
7525,35069439,*autoimmune thyroid disease
7526,35069439,*hyperthyroidism
7527,35069439,*pulmonary hypertension
7528,35069439,*thyroid hormone cois commercial or financial relationships that could be construed as a potential conflict of interest.
7529,35061094,mibi
7530,35061094,parathyroidectomy
7531,35061094,primary hyperparathyroidism
7532,35061094,surgery
7533,35061094,thyroid nodule cois
7534,35429846,graves' disease
7535,35429846,incidentally discovered
7536,35429846,medullary thyroid carcinoma
7537,35429846,thyroid
7538,35619700,*cd40
7539,35619700,*pd-l1
7540,35619700,*t cell
7541,35619700,*orbital fibroblast
7542,35619700,*thyroid associated ophthalmopathy cois commercial or financial relationships that could be construed as a potential conflict of interest.
7543,34779257,*graves'
7544,34779257,*autoimmunity
7545,34779257,*disease
7546,34779257,*orbitopathy
7547,34779257,*preclinical mouse model
7548,35720300,*graves’ disease
7549,35720300,*hashimoto’s thyroiditis
7550,35720300,*cell communication
7551,35720300,*immune dysregulation
7552,35720300,*thyroid tissue cois commercial or financial relationships that could be construed as a potential conflict of interest.
7553,35265076,*akt/nfκb signaling pathway
7554,35265076,*graves ophthalmopathy
7555,35265076,*glucocorticoid sensitivity
7556,35265076,*mir-885-3p
7557,35265076,*plasma exosomes cois commercial or financial relationships that could be construed as a potential conflict of interest.
7559,35321340,*graves’ disease (gd)
7560,35321340,*electronic medical record (emr)
7561,35321340,*genome-wide association study (gwas)
7562,35321340,*human leukocyte antigen (hla)
7563,35321340,*phenome-wide association studies (phewas) cois commercial or financial relationships that could be construed as a potential conflict of interest.
7565,35667695,"*ear, nose and throat"
7566,35667695,*genetics
7567,35667695,*thyroid disease cois
7570,33198545,octa
7571,33198545,ted
7572,33198545,thyroid eye disease
7573,33198545,optical coherence tomography angiography
7574,33198545,retinal vascularity
7575,35784564,graves’ disease
7576,35784564,hyperthyroidism treatment
7577,35784564,quality of life
7578,35784564,selenium
7579,35784564,vitamin d cois commercial or financial relationships that could be construed as a potential conflict of interest.
7580,34859391,anti-tg
7581,34859391,anti-tpo
7582,34859391,ctla-4
7583,34859391,graves´ disease
7584,34859391,radioiodine
7585,34859391,trab cois
7586,35489145,biomedical informatics
7587,35489145,computer-aided diagnosis (cad)
7588,35489145,convolutional neural network (cnn)
7589,35489145,deep learning
7590,35489145,multi-class classification
7591,35489145,thyroid disease diagnosis
7593,34477926,computed tomography
7594,34477926,extraocular muscles
7595,34477926,graves’ orbitopathy
7596,34477926,quantitative analysis
7597,34477926,thyroid eye disease
7601,34851466,bell’s phenomenon
7602,34851466,graves
7603,34851466,ophthalmopathy
7604,34851466,orbital wall decompression
7605,34851466,thyroid-associated ophthalmopathy
7606,34544076,16s ribosomal rna
7607,34544076,25(oh)d
7608,34544076,graves’ disease
7609,34544076,il-17
7610,34544076,intestinal flora
7611,35637045,multiple autoimmunity
7612,35637045,pediatrics
7613,35637045,type 1 diabetes cois potential conflicts of interest to disclose.
7614,35784325,graves’ disease
7615,35784325,graves’ orbitopathy
7616,35784325,ted
7617,35784325,estrogen
7618,35784325,estrogen receptor
7619,35784325,sex steroids
7620,35784325,steroid homeostasis
7621,35784325,thyroid eye disease cois commercial or financial relationships that could be construed as a potential conflict of interest.
7623,35721705,*graves’ disease
7624,35721705,*biomedical modeling
7625,35721705,*computer-aided treatment
7626,35721705,*hyperthyroidism
7627,35721705,*mathematical thyroid model cois commercial or financial relationships that could be construed as a potential conflict of interest.
7629,35698208,biomechanical simulation
7630,35698208,computer tomography data
7631,35698208,decompression surgery
7632,35698208,endocrine orbitopathy cois
7633,35413827,antithyroid drug
7634,35413827,maternal subtotal thyroidectomy
7635,35413827,neonatal hyperthyroidism
7636,35413827,thyroid function
7637,35413827,thyroid-stimulating hormone receptor antibody cois
7639,35229626,*graves' disease
7640,35229626,*autoimmune thyroid disease
7641,35229626,*primary thyroid lymphoma
7642,34468829,octa
7643,34468829,pulse therapy
7644,34468829,thyroid-associated orbitopathy cois
7645,35088429,graves' disease
7646,35088429,graves' ophthalmopathy
7647,35088429,autoimmune diseases
7648,35088429,hyperthyroidism
7649,35088429,thyroid diseases
7651,35566351,graves orbitopathy (go)
7652,35566351,alternative tobacco products
7653,35566351,cigarette smoke extract
7654,35566351,real time cell electronic sensing (rt ces)
7655,35566351,retrobulbar fibroblast cois
7657,33913798,graves’ disease
7658,33913798,medullary thyroid carcinoma
7659,33913798,carcinogenesis
7660,33913798,endothelin
7661,34580763,dicer1
7662,34580763,papillary thyroid carcinoma
7663,34580763,poorly differentiated thyroid carcinoma
7664,34580763,thyroid carcinoma
7666,35370990,*graves’ disease
7667,35370990,*iodine radioisotopes
7668,35370990,*radiopharmaceuticals
7669,35370990,*subclinical thyrotoxicosis
7670,35370990,*toxic multinodular goitre
7671,35370990,*toxic nodule
7672,35370990,*treatment outcome cois commercial or financial relationships that could be construed as a potential conflict of interest.
7674,35145480,*lymph node metastasis
7675,35145480,*papillary thyroid carcinoma
7676,35145480,*postoperative radioactive iodine
7677,35145480,*treatment strategy
7678,35145480,*tumor location cois commercial or financial relationships that could be construed as a potential conflict of interest.
7679,35465762,*goiter
7680,35465762,*thyroid
7681,35465762,*thyroid nodule
7682,35465762,*thyroiditis
7683,35465762,"*ultrasound cois conflicts of interest with respect to the research, authorship, and/or publication of this article."
7685,35538553,intraocular pressure
7686,35538553,lateral gaze
7687,35538553,primary gaze
7688,35538553,teprotumumab
7689,35538553,thyroid eye disease
7690,35538553,upgaze cois
7691,33443352,*activating variant of tshr gene
7692,33443352,*non-autoimmune hyperthyroidism
7693,33443352,*neonatal hyperthyroidism
7694,35144533,case report
7695,35144533,glucocorticoids
7696,35144533,graves’ disease
7697,35144533,hepatitis b virus
7698,35144533,methimazole cois
7699,35441746,benign thyroid nodule
7700,35441746,papillary thyroid carcinoma
7701,35441746,platelet count
7702,35441746,platelet distribution width
7703,35441746,thyroglobulin cois
7704,34854944,*fibrous dysplasia
7705,34854944,*gnas
7706,34854944,*intramuscular myxoma
7707,34854944,*mazabraud’s syndrome
7708,34854944,*mccune-albright syndrome
7709,35579208,aneurysmal bone cyst
7710,35579208,graves’ disease
7711,35579208,moyamoya disease
7712,35579208,case report
7713,35579208,ischemic cerebral infarction
7714,35579208,proximal femur cois conflict of interest.
7715,35443720,case report
7716,35443720,germ cell tumor
7717,35443720,human chorionic gonadotropin
7718,35443720,hyperthyroidism
7719,35443720,paraneoplastic syndrome cois
7720,35091101,graves' disease
7721,35091101,trab
7722,35091101,bioassay
7723,35091101,diagnosis
7724,35091101,thyroid-stimulating immunoglobulin
7725,35091101,thyrotoxicosis
7726,35090420,acute transient thyroid swelling
7727,35090420,adenomatous goiter
7728,35090420,airway obstruction
7729,35090420,aortic regurgitation
7730,35090420,fine-needle aspiration
7731,35090420,nodular goiter
7732,35090420,thyroid gland
7733,35090420,tracheal intubation cois
7737,35562642,machine learning
7738,35562642,mass spectrometry imaging
7739,35562642,papillary thyroid carcinoma
7740,35562642,probe electrospray ionization mass
7741,35562642,rapid diagnosis
7742,35659565,acute inflammation
7743,35659565,fucoidan
7744,35659565,neutrophil adhesion
7745,35659565,p-selectin
7746,35659565,sargassum fusiforme
7747,34751793,laser therapy
7748,34751793,nodular goiter
7749,34751793,radiofrequency ablation
7750,34751793,thyroid nodule
7751,35039349,immunological products and vaccines
7752,35039349,lung cancer (oncology)
7753,35039349,safety
7754,35039349,therapeutic indications
7755,35039349,thyroid disease cois
7757,34050454,dental fluorosis
7758,34050454,ptpn22
7759,34050454,polymorphisms
7760,34050454,tshr
7761,34050454,thyroid
7762,34780050,congenital hypothyroidism
7763,34780050,goiter
7764,34780050,next-generation sequencing
7765,34780050,tpo
7766,34780050,thyroid dyshormonogenesis
7767,34861221,euthyroidism
7768,34861221,euthyroïdie
7769,34861221,french endocrine society
7770,34861221,hypothyroidism
7771,34861221,hypothyroïdie
7772,34861221,levothyroxine
7773,34861221,liothyronine
7774,34861221,lévothyroxine
7775,34861221,société française d’endocrinologie
7776,34861221,survey
7777,34861221,sondage
7778,34755283,autoimmune thyroiditis
7779,34755283,hypothyroidism
7780,34755283,survey
7781,34755283,thyroid
7782,34755283,thyroid hormones
7783,35593680,l-thyroxine
7784,35593680,active follow-up
7785,35593680,active surveillance
7786,35593680,fine-needle aspiration biopsy
7787,35593680,indications for hemithyroidectomy
7788,35593680,nodular goiter
7789,35593680,papillary thyroid microcarcinoma
7790,35593680,radioiodine treatment
7791,35593680, thyroid cancer
7793,34416585,france
7794,34416585,goiter cause
7795,34416585,hair analysis
7796,34416585,historical samples
7797,34416585,lead contamination
7798,34416585,savoy
7799,35382047,graves’ disease
7800,35382047,case report
7801,35382047,type 1 diabetes mellitus
7802,35638259,2dct
7803,35638259,bolus tracking
7804,35638259,percentage arterial enhancement
7805,35638259,primary hyperparathyroidism
7806,35638259,prospective validation
7811,28668317,goiter
7812,28668317,retrograde dissection of the inferior laryngeal nerve
7813,28668317,sternotomy
7814,27701774,graves’ ophthalmopathy
7815,27701774,graves’ orbitopathy
7816,27701774,thyroid eye disease
7818,28648509,*pendred syndrome
7819,28648509,*congenital hypothyroidism
7820,28648509,*goiter
7821,28648509,*iodide
7822,28648509,*sensorineural deafness
7823,28648509,*thyroid hormone
7824,27221572,*substernal goiter
7825,27221572,*thyroid disease
7826,27221572,*thyroid neoplasm
7827,27221572,*thyroid nodule
7828,27221572,*thyroidectomy
7829,28572231,grave’s disease
7830,28572231,radioiodine
7831,28572231,thionamides
7832,28572231,thyroidectomy
7833,28572231,thyrotoxicosis
7838,26392367,clinical evaluation
7839,26392367,multinodular goiter
7840,26392367,physiopathology
7841,26392367,treatment
7842,27480576,*goiter
7843,27480576,*rhtsh
7844,26708850,benign multinodular goiter
7845,26708850,dunhill procedure
7846,26708850,goiter recurrence
7847,26708850,post-operative complications
7848,26708850,subtotal thyroidectomy
7849,26708850,total thyroidectomy
7850,26433162,arrhythmias
7851,26433162,carlos chagas
7852,26433162,goiter
7853,26433162,history
7854,26433162,myxedema
7855,26433162,thyroid
7856,28516755,dietary iodine intake
7857,28516755,goiter
7858,28516755,iodine
7859,28516755,japanese
7860,28516755,kombu
7861,28516755,seaweed
7862,28516755,thyroid function
7866,26520480,ct
7867,26520480,fiberoptic endoscopy
7868,26520480,goiter
7869,26520480,substernal
7870,26520480,surgery
7871,27687679,anatomy
7872,27687679,intrathoracic goiter
7873,27687679,multinodular goiter
7874,27687679,thoracic inlet
7875,27687679,thyroid gland
7876,27687679,thyroidectomy
7877,28749783,children
7878,28749783,goiter
7879,28749783,l thyroxine
7880,28749783,nodular
7881,28749783,recurrence
7882,28749783,thyroidectomy
7885,29172409,ethiopia
7886,29172409,goiter
7887,29172409,prevalence
7888,29172409,risk factors cois
7889,27173499,*clinical images
7890,27173499,*endocrinology
7891,27173499,*surgery cois
7896,28271464,goiter
7897,28271464,medical diagnosis
7898,28271464,painting
7899,28271464,rubens
7901,27059986,graves’ disease
7902,27059986,graves’ orbitopathy
7903,27059986,immunmodulatory therapy
7904,27059986,reconstructive surgical procedures
7905,27059986,thyroid-stimulating hormone receptor
7906,28551882,acid sulfate soils
7907,28551882,iodide
7908,28551882,laterite
7909,28551882,salt iodization
7910,28551882,selenium
7911,28551882,soil organic matter
7913,28395497,"goiter, substernal"
7914,28395497,harmonic scalpel
7915,28395497,"surgical procedures, operative"
7916,26995097,cervical approach
7917,26995097,ectopic goiter
7918,26995097,ectopic thyroid
7919,26995097,intrathoracic goiter
7920,26995097,substernal goiter
7921,26995097,thyroidectomy
7923,26472934,asthma
7924,26472934,goiter
7925,26472934,mediastinum
7926,26472934,sternotomy
7927,26472934,thyroidectomy
7928,26472934,substernal
7929,28331628,*china
7930,28331628,*iodine deficiency disorders (idd)
7931,28331628,*iodized salt
7933,28258641,amyloid goiter
7934,28258641,familial mediterranean fever
7935,28258641,head and neck ultrasound
7936,28258641,thyroid
7942,26742784,*creutzfeldt-jacob disease
7943,26742784,*heidenhain variant
7944,26742784,*compressive optic neuropathy
7945,26742784,*higher visual processing
7946,26742784,*proptosis
7947,26742784,*spongiform encephalopathy
7948,26742784,*thyroid eye disease
7949,26742784,*visual fields
7955,28612896,*complications
7956,28612896,*recurrent goiter
7957,28612896,*surgery
7958,28612896,*thyroidectomy
7965,28648505,*digeorge syndrome
7966,28648505,*hypoparathyroidism
7967,28648505,*parathyroid
7968,28648505,*pseudohypoparathyroidism
7969,28648505,*thyroid
7972,27005286,*areola approach
7973,27005286,*laparoscope
7974,27005286,*silk thread
7975,27005286,*strategies
7976,27005286,*substernal goiter
7977,27005286,*thyroidectomy
7978,26403613,body surface area
7979,26403613,drinking water
7980,26403613,goiter
7981,26403613,iodized salt
7982,26403613,prevalence
7983,28606271,"antigens, cd40"
7984,28606271,bone marrow cells
7985,28606271,fibroblasts
7986,28606271,graves ophthalmopathy
7987,28606271,insulin-like growth factor ⅰ
7988,28606271,"receptors, thyrotropin"
7990,28535654,clinicopathological characteristics
7991,28535654,nuclear factor erythroid 2-related factor 2
7992,28535654,thyroid neoplasms
7993,26708863,cervical approach
7994,26708863,mediastinal goiter
7995,26708863,sternotomy
7996,26708863,thoracotomy
7997,26708863,thyroidectomy
7998,26721191,cervico-mediastinal goiter
7999,26721191,cervicosternotomy
8000,26721191,cervicotomy
8001,26721191,goiter
8002,26721191,intrathoracic thyroid mass
8003,26721191,total thyroidectomy
8006,28471268,*graves' disease
8007,28471268,*cardiovascular risk
8008,28471268,*hyperthyroidism
8009,28471268,*morbidity
8010,28471268,*mortality
8011,28471268,*toxic nodular goiter
8012,28190186,iodine
8013,28190186,nis
8014,28190186,nodular goiter
8015,28190186,tshr
8017,28292346,*endemic goiter
8018,28292346,*high iodine
8019,28292346,*iodine deficiency
8022,27779276,adolescents
8023,27779276,children
8024,27779276,overt hypothyroidism
8025,27779276,pregnancy
8026,27779276,subclinical hypothyroidism
8028,28805773,diffuse toxic goiter
8029,28805773,long-term results
8030,28805773,subtotal resection of the thyroid gland
8031,28805773,surgical treatment
8032,28805773,thyroidectomy
8033,29265071,angiogenesis
8034,29265071,apoptosis
8035,29265071,diffuse toxic goiter
8036,29265071,thyroid cell proliferation
8038,28835334,fine needle aspiration and biopsy
8039,28835334,nodules
8040,28835334,thyroid
8041,28835334,ultrasound
8042,26900630,*autoimmune thyroiditis
8043,26900630,*cxcl10
8044,26900630,*cxcr3
8045,26900630,*graves ophthalmopathy
8046,26900630,*graves disease
8047,26900630,*chemokines
8048,26900630,*corticosteroids
8049,26900630,*rituximab
8050,26900630,*teprotumumab
8051,26900630,*tocilizumab
8052,28215480,goiter prevalence
8053,28215480,iodine deficiency disorder
8054,28215480,iodine nutritional status
8055,28215480,pakistan
8056,28215480,salt iodization
8059,27106540,boron
8060,27106540,goiter
8061,27106540,iodine
8062,27106540,schoolchildren
8063,27106540,silicon
8064,27106540,thyroid
8065,28841887,intravascular lymphoma
8066,28841887,large b-cell
8067,28841887,nodular goiter
8068,28841887,"thyroid cois waived by the institutional ethics committee of the central hospital of wuhan, china. consent for publication: written informed consent for the publication of clinical details and clinical images of the patient was obtained from a relative of the patient. a copy of the consent form is available for review by the editor of this journal. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
8072,28061776,*ethiopia
8073,28061776,*goiter
8074,28061776,*salt iodine content
8075,28061776,*school children
8077,28011236,dicer
8078,28011236,iodine metabolism-related genes
8079,28011236,microrna
8080,28011236,thyroid
8081,28011236,thyroid cell differentiation
8082,28011236,thyroid tumor
8084,28127991,*autoimmunity
8085,28127991,*graves’ disease
8086,28127991,*ophthalmopathy
8087,28127991,*tyrosine kinase
8088,26966785,*graves’ disease
8089,26966785,*graves’ ophthalmopathy
8090,26966785,*graves’ orbitopathy
8091,26966785,*antithyroid drugs
8092,26966785,*glucocorticoids
8093,26966785,*hyperthyroidism
8094,26966785,*radiotherapy
8095,26966785,*rituximab
8096,26966785,*selenium
8097,28872214,*thyroid-related quality-of-life patient-reported outcome (thypro)
8098,28872214,*goiter
8099,28872214,*quality of life
8100,28872214,*surgery
8101,28872214,*thyroid
8102,28580573,*ex-utero intrapartum treatment
8103,28580573,*airways obstruction
8104,28580573,*fetus
8105,28580573,*neck tumors
8106,28580573,*ultrasound
8109,27460951,congenital goiter
8110,27460951,endemic goiter
8111,27460951,fifteenth century
8112,27460951,fine arts
8113,27460951,hyperthyroidism
8114,28703113,intraoperative neuromonitoring
8115,28703113,recurrent goiter
8116,28703113,recurrent laryngeal nerve
8117,26750728,benign thyroid diseases
8118,26750728,changes of radioiodine therapy
8119,26750728,jóindulatú pajzsmirigybetegségek
8120,26750728,pajzsmirigyrák
8121,26750728,radiojódterápia változásai
8122,26750728,thyroid cancer
8125,27927635,*children
8126,27927635,*thyroid volume
8127,27927635,*total goiter rate
8128,27927635,*urine iodine concentration
8129,27927635,*urine iodine excretion
8130,26884295,doppler
8131,26884295,elasticity imaging techniques
8132,26884295,goiter
8133,26884295,nodular
8134,26884295,thyroid
8135,26884295,ultrasonography
8136,27153850,*hepatotoxicity
8137,27153850,*hyperthyroidism
8138,27153850,*methimazole
8139,27153850,*propylthiouracil
8140,27153850,*radioactive iodine
8141,27153850,*thyroid
8142,27153850,*thyroidectomy
8145,26298554,autoimmune thyroiditis
8146,26298554,child
8147,26298554,doppler
8148,26298554,goiter
8149,26298554,thyroid gland
8150,26298554,ultrasound
8151,28891673,lead
8152,28891673,nodular goiter
8153,28891673,papillary thyroid carcinoma
8154,28891673,thyroid adenoma
8155,28891673,thyroid hormones
8160,27673426,*goiter
8161,27673426,*hypothyroidism
8162,27673426,*respiratory function
8163,27673426,*sleep apnea syndrome
8164,27673426,*thyroid disease
8165,27673426,*upper airway obstruction
8170,27552913,bmn
8171,27552913,egipcios
8172,27552913,egyptian
8173,27552913,mng
8174,27552913,tsh
8175,27552913,vitamin d
8176,27552913,vitamina d
8178,28025831,*goiter
8179,28025831,*headache attributed to hypothyroidism
8180,28025831,*hyperthyroidism
8181,28025831,*migraine
8182,28025831,*new daily persistent headache
8184,28178662,han chinese
8185,28178662,snps
8186,28178662,vegfa
8187,28178662,nodular goiter
8188,28178662,papillary thyroid carcinoma cois
8192,27862717,*congenital hypothyroidism
8193,27862717,*fetal therapy
8194,27862717,*goiter
8195,28506088,leukocytes
8196,28506088,papillary thyroid carcinoma
8197,28506088,platelets
8198,28506088,thyroid cancer
8199,28506088,white blood cells
8200,28728986,benign multi-nodular goitre
8201,28728986,thyroidectomy
8202,26841373,i-131
8203,26841373,large goiter
8204,26841373,multinodular goiter
8205,26841373,radioiodine therapy
8206,26841373,radioiodine uptake
8207,26841373,rhtsh
8208,27931874,follicular thyroid cancer
8209,27931874,goiter
8210,27931874,papillary thyroid cancer
8211,27931874,raman spectroscopy
8212,27931874,thyroid
8216,29183897,paediatrics
8217,29183897,thyroid disease cois
8219,27828690,*graves disease
8220,27828690,*hashimoto’s thyroiditis
8221,27828690,*igg4 related disease
8222,27828690,*riedel’s thyroiditis
8223,27828690,*immunoglobulin
8228,26260217,antonello da messina
8229,26260217,goiter in holy images
8230,26260217,italian renaissance
8232,27029843,graves’ disease
8233,27029843,hyperthyroidism
8234,27029843,mediastinal mass
8235,27029843,thyroid remnant
8236,27029843,total thyroidectomy
8237,28578595,*graves’ disease
8238,28578595,*autoimmune
8239,28578595,*hyperplasia
8240,28578595,*thymic
8241,28578595,*thymic lymphoid hyperplasia
8242,28578595,*true thymic hyperplasia
8243,26850414,*goiter
8244,26850414,*medical diagnosis
8245,26850414,*painting
8246,26850414,*titian
8247,27385363,disparity
8248,27385363,graves’ ophthalmopathy
8249,27385363,orbitopathy
8250,27385363,socioeconomic status
8253,28533884,graves’ disease
8254,28533884,thyroid gland
8255,28533884,tuberculosis
8257,28606272,autoimmunity
8258,28606272,genetic predisposition to disease
8259,28606272,graves ophthalmopathy
8260,28606272,oxidative stress
8261,28606272,smoking
8268,27565137,*cretinism
8269,27565137,*goiter
8270,27565137,*iodine
8271,27565137,*thyroid
8273,28899873,endocrine system
8274,28899873,paediatrics (drugs and medicines)
8275,28899873,thyroid disease cois
8279,29075974,adjuvant treatment
8280,29075974,escape
8281,29075974,hyperthyroidism
8282,29075974,iodide
8283,29075974,thyroidectomy cois ethical approval: this article does not contain any studies with human participants or animals performed by any of the authors.
8284,28942732,*etiology
8285,28942732,*graves’ disease
8286,28942732,*pathophysiology
8287,28942732,*primary immunodeficiency
8288,28942732,*review cois publication: not applicable competing interests: all authors declare they have no competing interest.
8289,28770897,"thyroid associated orbitopathy, graves ophthalmopathy, hypothyroidism."
8306,27169853,dietary
8307,27169853,goitrogens
8308,27169853,nitrate
8309,27169853,perchlorate
8310,27169853,risk assessment
8311,27169853,thiocyanate
8314,27795799,*toxic goiter
8315,27795799,*thyroid abscess
8316,27795799,*thyroiditis cois
8318,27819113,ata
8319,27819113,graves’ disease
8320,27819113,igg4
8321,27819113,ophthalmopathy
8322,27819113,tpoab
8324,28493593,*recurrent laryngeal nerve
8325,28493593,*superior parathyroid
8326,28493593,*thyroid
8327,28493593,*thyroidectomy
8331,27481173,*thyroidectomy
8332,27481173,*graves
8333,27481173,*hematoma
8334,27481173,*malignancy
8335,27481173,*toxic nodular goitre
8337,27470116,drainage
8338,27470116,hematoma
8339,27470116,surgical outcomes
8340,27470116,thyroid surgery
8343,29138656,hyperthyroidism
8344,29138656,senegal
8345,29138656,child
8346,29138656,profile
8348,26994869,*graves' ophthalmopathy
8349,26994869,*chronic lymphocytic leukemia (cll)
8350,26994869,*lymphoproliferative disorder
8351,26994869,*orbital inflammation
8352,26994869,*orbital lymphoma
8353,26994869,*proptosis
8354,26994869,*small lymphocytic lymphoma (sll)
8355,26994869,*thyroid eye disease
8357,28450994,graves-basedow's disease
8358,28450994,child
8359,28450994,student abuse cois
8361,27933384,autoimmune thyroid disease
8362,27933384,papillary thyroid cancer
8363,27933384,thyroglobulin antibodies
8364,27933384,thyroid peroxidase antibodies
8366,29422752,goiter
8367,29422752,graves' disease
8368,29422752,ophthalmopathy
8369,29422752,thyroid
8370,29422752,thyroid-associated orbitopathy cois
8372,26477042,goiter
8373,26477042,iodine deficiency disorders
8374,26477042,salt iodization
8375,26477042,urinary iodine concentration
8377,28533836,thyroid
8378,28533836,pathology
8379,28533836,sarcoma
8380,28533836,treatment cois
8382,28363119,ct
8383,28363119,grave's disease
8384,28363119,pulmonary hypertension
8385,28755510,graves' disease
8386,28755510,graves' hyperthyroidism
8387,28755510,graves' orbitopathy
8388,28755510,thyroid eye disease
8389,28606263,"decompression, surgical"
8390,28606263,graves ophthalmopathy
8391,28606263,"imaging, three-dimensional"
8392,28606263,orbit
8393,28278511,graves ophthalmopathy
8394,28278511,il-6
8395,28278511,microrna-146a
8396,28278511,notch2
8397,28278511,orbital fibroblast reporter gene
8398,28278511,qrt-pcr
8399,27609530,diplopia
8400,27609530,intraocular pressure
8401,27609530,orbital decompression
8402,27609530,proptosis
8403,27609530,visual acuity
8404,27609530,visual field
8405,29890100,*thyroidectomy
8406,29890100,*thyroid nodule
8407,29890100,*recurrent laryngeal nerve palsy
8408,29890100,*hypoparathyroidism
8409,29890100,*postoperative pain
8414,28635216,"carcinoma, papillary"
8415,28635216,multifocal tumor
8416,28635216,ret/ ptcrearrangement
8417,28635216,thyroid neoplasms
8419,26927707,*graves' disease
8420,26927707,*thyroid surgery
8421,26927707,*hyperthyroidism
8422,26927707,*thyroid storm
8423,26927707,*thyroidectomy
8424,26927707,*thyrotoxicosis
8425,27375108,antithyroïdien de synthèse
8426,27375108,graves’ disease
8427,27375108,grossesse
8428,27375108,hyperthyroidism
8429,27375108,hyperthyroïdie
8430,27375108,maladie de basedow
8431,27375108,pregnancy
8432,27375108,synthetic antithyroid drug
8435,26466836,*graves’ disease
8436,26466836,*ophthalmopathy
8437,26466836,*radiotherapy
8439,27494076,*biomarkers
8440,27494076,*graves’ disease
8441,27494076,*hashimoto thyroiditis
8442,27494076,*vegf
8443,27494076,*splicing isoforms
8446,27555041,calcium oxalate
8447,27555041,colloid
8448,27555041,crystals
8449,27555041,cytology
8450,27555041,thyroid
8451,27402179,bocio endémico
8452,27402179,cirugía general
8453,27402179,cooperación sanitaria
8454,27402179,endemic goiter
8455,27402179,equipamiento quirúrgico
8456,27402179,general surgery
8457,27402179,nódulo tiroideo
8458,27402179,surgical aid program
8459,27402179,surgical equipment
8460,27402179,thyroid gland
8461,27402179,thyroid nodule
8462,27402179,thyroidectomy
8463,27402179,tiroidectomía
8464,27402179,tiroides
8465,28456099,goiter
8466,28456099,hashimoto thyroiditis
8467,28456099,hyperthyroidism
8468,28456099,hypothyroidisms
8469,28456099,mammographic density
8470,28456099,thyroid
8473,29871201,e-cadherin
8474,29871201,papillary thyroid carcinoma
8475,29871201,serum cois relevant financial relationships with commercial interests to disclose.
8483,26932403,hashimoto thyroiditis
8484,26932403,igg4-related disease
8485,26932403,immunoglobulin g cois
8489,26813846,disparity
8490,26813846,substernal goiter
8491,26813846,thyroidectomy
8492,27083552,art
8493,27083552,goitre
8494,27083552,renaissance
8497,28329777,graves’ disease
8498,28329777,children
8499,28329777,thyreostatics
8500,28606260,clinical protocols
8501,28606260,graves ophthalmopathy
8502,28606260,practice guidelines as topic
8503,27619197,*airflow
8504,27619197,*cfd
8505,27619197,*energy loss
8506,27619197,*goiters
8507,27619197,*trachea
8511,28420409,adolescent students
8512,28420409,ethiopia
8513,28420409,iodine deficiency
8514,28420409,wolaita and dawuro zone
8522,27222685,nodular goiter
8523,27222685,malignancy
8524,27222685,ultrasound
8527,29798067,hornor's symptoms
8528,29798067,lymph node dissection
8529,29798067,thyroid gland operation cois relevant financial relationships with commercial interests to disclose.
8530,26315305,goitrous children
8531,26315305,iodine
8532,26315305,selenium
8533,26315305,trace elements
8534,26315305,zinc
8537,25261415,*life cycle
8538,25261415,*minerals/trace elements
8539,25261415,*nutrition
8540,25261415,*parenteral nutrition
8541,25261415,*pediatrics
8544,28606261,clinical protocols
8545,28606261,glucocorticoids
8546,28606261,graves ophthalmopathy
8547,28606261,radiotherapy
8550,27383156,e-cadherin
8551,27383156,thyroid cancer
8552,27383156,β-catenin
8553,26669779,autoimmune thyroiditis
8554,26669779,fibrosing variant of hashimoto’s thyroiditis
8555,26669779,igg4-related disease
8556,26669779,riedel’s thyroiditis
8557,29541314,intubation
8558,29541314,cervical spine surgery
8559,29541314,thyroidectomy
8565,27809623,*hyperthyroidism
8566,27809623,*hypothyroidism
8567,27809623,*pregnancy
8569,28537560,tsh
8570,28537560,calcium
8571,28537560,hypocalcemia
8572,28537560,multinodular goiter
8573,28537560,thyroidectomy
8574,27687458,difficult airway
8575,27687458,difficult ventilation
8576,27687458,fiberoptic intubation
8577,27687458,general anesthesia
8580,28457178,*complications
8581,28457178,*hematoma
8582,28457178,*hypocalcemia
8583,28457178,*outcomes
8584,28457178,*safety
8585,28457178,*thyroidectomy
8586,28389359,aitd
8587,28389359,ps
8588,28389359,slc26a4
8589,28389359,splicing minigene assay
8590,28389809,computer-assisted
8591,28389809,diagnosis
8592,28389809,thyroid neoplasms
8593,28389809,ultrasonography
8595,27426718,cáncer de tiroides
8596,27426718,cáncer tiroideo incidental
8597,27426718,incidental thyroid cancer
8598,27426718,prognosis
8599,27426718,pronóstico
8600,27426718,thyroid cancer
8605,28699427,*t3
8606,28699427,*t4
8607,28699427,*hyperthyroidism
8608,28699427,*metabolomics
8610,27601286,methimazole
8611,27601286,mild graves' disease
8612,27601286,thyroid function
8613,27601286,thyroid volume
8614,29084476,*graves' disease
8615,29084476,*graves' orbitopathy
8616,29084476,*mortality
8617,29084476,*suicide
8618,29084476,*unnatural death
8626,26438397,autophagy
8627,26438397,graves’ orbitopathy
8628,26438397,statins
8629,28806880,*goiter
8630,28806880,*neck ultrasound
8631,28806880,*nodular goiter
8632,28806880,*thyroid gland
8633,28806880,*volume
8638,27882431,cervico-mediastinal goiters
8639,27882431,chest x-rays
8640,27882431,intrathoracic goiters
8641,27882431,mediastinal nodules
8642,27882431,thyroid surgery
8643,28255974,*acromegaly
8644,28255974,*meta-analysis
8645,28255974,*pituitary
8646,28255974,*thyroid
8647,28255974,*thyroid cancer
8649,26925783,*are
8650,26925783,*auf1
8651,26925783,*ftc.
8652,26925783,*hur
8653,26925783,*follicular adenoma
8654,26925783,*thyroid carcinoma
8656,28974848,i131 therapy
8657,28974848,hyperthyreoidism treatment
8658,28974848,"incidence of hypotihyeoidism cois sabrina licina participate in study design and acquisition, analysis and interpretation of data. authors equally participate in drafting the article and give final approval for the version which is submitted."
8659,27716078,*asystole
8660,27716078,*hyperextension
8661,27716078,*position
8662,27716078,*thyroidectomy
8664,29120123,*graves ophthalmopathy – diagnostic imaging
8665,29120123,*orbit – diagnostic imaging
8666,29120123,*multidetector computed tomography
8667,29120123,*exophthalmos – diagnosis
8668,29120123,*cross-sectional studies
8670,26337375,multinodular goiter
8671,26337375,thyroid autotransplantation
8672,26337375,thyroidectomy
8676,27438852,slovenia
8677,27438852,food supply
8678,27438852,iodine
8679,27438852,sales
8680,27438852,salt
8681,27438852,sodium
8684,26270564,gpx
8685,26270564,gsh
8686,26270564,hashimoto’s thyroiditis
8687,26270564,lpo
8688,26270564,oxidative stress
8689,26270564,catalase
8690,26270564,thyroid cancer
8691,26270564,thyroid goitre
8693,28619420,(131)i treatment
8694,28619420,bocio nodular
8695,28619420,fracaso de tratamiento
8696,28619420,hipertiroidismo
8697,28619420,hipotiroidismo
8698,28619420,hyperthyroidism
8699,28619420,hypothyroidism
8700,28619420,nodular goitre
8701,28619420,tratamiento (131)i
8702,28619420,treatment failure
8703,26969710,*imaging
8704,26969710,*muscles
8705,26969710,*orbit
8706,26969710,*treatment surgery
8707,29197845,materno-fetal medicine
8708,29197845,neonatal and paediatric intensive care
8709,29197845,neonatal health cois
8714,27693824,harmonic scalpel
8715,27693824,ligasure vessel sealing system
8716,27693824,substernal goitre
8717,27693824,thyroid surgery
8718,27693824,total thyroidectomy
8721,28025026,graves
8722,28025026,pulmonary hypertension
8723,28025026,right heart function
8724,28025026,strain
8725,28025026,tapse
8726,28025026,thyroid
8728,26936928,*dyshormonogenesis
8729,26936928,*goiter
8730,26936928,*hypothyroidism
8731,26936928,*pendred syndrome
8736,28771438,fetal goiter
8737,28771438,intra-amniotic levothyroxine administration
8738,28771438,maternal graves’ disease
8745,26272351,taiwan
8746,26272351,iodine
8747,26272351,iodized salt
8748,26272351,nutrition survey
8749,26272351,thyroid gland
8755,28737965,m22
8756,28737965,trab
8757,28737965,diagnosis
8758,28737965,hyperthyroidism
8762,26603660,graves' disease
8763,26603660,radioiodine therapy
8764,26603660,thyroid
8765,26603660,ultrasound
8766,26886211,autoimmune thyroid disease
8767,26886211,breast neoplasms
8768,26886211,trastuzumab cois
8769,28576912,endocrine cancer
8770,28576912,head and neck cancer
8771,28576912,head and neck surgery
8772,28576912,pathology
8773,28576912,thyroid disease cois
8775,28781316,graves' disease
8776,28781316,autoimmune hepatitis
8777,28781316,interface hepatitis
8778,28781316,liver histology
8779,28781316,pediatric case
8781,27586672,robotics
8782,27586672,thymectomy
8783,27586672,thymus
8784,27586672,thyroid
8785,27586672,transaxillary thyroidectomy
8790,26708845,fine needle cytology
8791,26708845,hurthle cells
8792,26708845,rapid on-site evaluation
8793,26708845,ultrasound
8796,26321232,case-control study
8797,26321232,disease
8798,26321232,fcrl3
8799,26321232,graves’
8800,26321232,single nucleotide polymorphisms
8801,26062519,graves’ orbitopathy
8802,26062519,hepatocyte growth factor
8803,26062519,interleukin-8
8804,26062519,methylprednisolone treatment
8805,26796368,recurrent laryngeal nerve injury
8806,26796368,substernal goitres
8807,26796368,surgical management
8808,28444621,criminal offense
8809,28444621,goiter
8810,28444621,major part
8811,28444621,metabolic disease
8812,28444621,public health
8813,28427469,*eugogo
8814,28427469,*epidemiology
8815,28427469,*graves’ orbitopathy
8816,28427469,*incidence
8817,28427469,*ophthalmopathy
8818,28427469,*prevalence
8819,28427469,*rare disease
8821,27206523,antiviral
8822,27206523,extrahepatic manifestation
8823,27206523,graves’ hyperthyroidism
8824,27206523,hbv infection
8826,27465670,*antithyroid drugs
8827,27465670,*goiter
8828,27465670,*graves’ disease
8829,27465670,*graves’ orbitopathy
8830,27465670,*hyperthyroidism
8831,27465670,*thyrotropin receptor antibody
8833,27422154,bocio multinodular
8834,27422154,bocio multinodular tóxico
8835,27422154,hipertiroidismo
8836,27422154,hyperthyroidism
8837,27422154,multinodular goitre
8838,27422154,radioiodine
8839,27422154,radioyodo
8840,27422154,toxic multinodular goitre
8841,27422154,rhtsh
8842,28215490,ectopic goitre
8843,28215490,horner's syndrome
8844,28215490,parapharyngeal space
8848,26626435,coagulación
8849,26626435,coagulation
8850,26626435,thyroid
8851,26626435,tiroides
8854,28389487,*surgery
8855,28389487,*cancer
8856,28389487,*overdiagnosis cois
8857,27531964,surgery
8858,28124062,papillon initiative
8859,28124062,diffuse goitre
8860,28124062,geriatric medicine
8861,28124062,nodular goitre
8862,28124062,thyroid dysfunction
8863,27358549,*coronary artery bypass grafting
8864,27358549,*subtotal thyroidectomy
8865,27358549,*surgery
8868,27241825,cochlear implantation
8869,27241825,pendred syndrome
8870,27241825,enlarged vestibular aqueduct
8871,27241825,gusher
8872,27241825,malformations
8873,27241825,surgical complications
8879,28458607,*computed tomography
8880,28458607,*euthyroidism
8881,28458607,*graves' disease
8882,28458607,*methimazole
8883,28458607,*single-photon emission computed tomography
8887,26066526,children
8888,26066526,endemic goitre
8889,26066526,iodine-deficiency goitre
8890,26066526,salt iodine
8891,28812921,dacryoadenitis
8892,28812921,idiopathic orbital inflammatory syndrome
8893,28812921,silent sinus syndrome
8894,28812921,thyroid eye disease
8895,26975391,autoimmunity
8896,26975391,hormone secretion
8897,26975391,nodular goiter
8898,26975391,thyroid
8899,27553050,graves’ disease
8900,27553050,marinelli’s formula
8901,27553050,thyroid iodine uptake
8902,27553050,thyroid technetium uptake cois
8904,28874217,hypocalcemia
8905,28874217,hypoparathyroidism
8906,28874217,parathyroid hormone
8907,28874217,thyroidectomy
8908,28874217,vitamin d
8911,27927064,*graves’ disease
8912,27927064,*cytokines
8913,27927064,*traditional chinese medicine
8914,27051255,computed tomography
8915,27051255,exophthalmos reduction
8916,27051255,graves ophthalmopathy
8917,27051255,orbital decompression cois was reported.
8918,26897110,iodine deficiency
8919,26897110,iodine prophylaxis
8920,26897110,iodized salt
8921,26897110,thyroid volume
8922,26897110,urinary iodine concentration
8926,28540810,*thyroid nodules
8927,28540810,*combined therapy
8928,28540810,*radiofrequency ablation (rfa)
8929,28540810,*radioiodine therapy (rit)
8932,26726836,hashimoto’s thyroiditis
8933,26726836,nodular goiter
8934,26726836,hepatocyte growth factor
8935,26726836,hypothyroidism
8937,28154699,*autoimmunity
8938,28154699,*dakar
8939,28154699,*hyperthyroidism cois
8940,27214836,berkeley drosophila genome project (bdgp)
8941,27214836,computerised tomography (ct)
8942,27214836,enlarged vestibular aqueduct (eva)
8943,27214836,hearing loss (hl)
8944,27214836,magnetic resonance imaging (mri)
8945,27214836,pendred syndrome (ps)
8946,27214836,videonystagmography (vng)
8947,27465319,*graves’ disease
8948,27465319,*graves’ ophthalmopathy
8949,27465319,*genetic polymorphism
8950,27465319,*meta-analysis
8953,28052261,*pendred syndrome
8954,28052261,*disease-specific ips cells
8955,28052261,*inner ear
8956,28052261,*outer sulcus cells
8962,27510038,*developmental delay
8963,27510038,*failure to thrive
8964,27510038,*spontaneous transient graves’ thyrotoxicosis
8974,28458304,basedow's disease
8975,28458304,igg4
8976,28458304,igg4 thyroiditis
8977,28458304,igg4-related disease
8978,27941044,*diagnostic tests/investigation
8979,27941044,*eye (globe)
8980,27941044,*imaging
8981,27941044,*orbit cois
8985,27906671,bethesda category iii
8986,27906671,acoustic radiation force impulse elastography
8987,27906671,fine-needle aspiration cytology
8988,27906671,thyroid nodules
8989,27906671,ultrasound cois
8991,26567024,immunology
8992,26567024,inflammation
8993,26567024,orbit
8994,26567024,treatment medical
8999,27157450,*hashimoto thyroiditis
9000,27157450,*autoimmune disease
9001,27157450,*autoimmune thyroid disease
9002,27157450,*hyperthyroidism
9003,27157450,*hypothyroidism
9004,27157450,*type 1 diabetes
9007,28688760,hypothyroidism
9008,28688760,hypothyroïdie
9009,28688760,l-thyroxine
9010,28688760,non adherence
9011,28688760,non-observance
9014,26801325,depression
9015,26801325,exophthalmos
9016,26801325,graves’ disease
9017,26801325,psychotherapy
9018,26801325,stress
9019,28074218,graves disease
9020,28074218,hashimoto disease
9021,28074218,hyperthyroidism
9022,28074218,hypothyroidism
9023,28074218,levothyroxine
9024,28050807,alternative first-line therapy
9025,28050807,graves ophthalmopathy
9026,28050807,orbital radiotherapy
9027,28050807,thyroid eye disease
9028,28001456,*graves’ ophthalmopathy
9029,28001456,*rasch analysis
9030,28001456,*quality of life
9031,28001456,*questionnaires
9032,28001456,*reliability
9033,28001456,*validation study
9034,28001456,*validity
9036,27106887,down's syndrome
9037,27106887,graves’ disease
9038,27106887,adolescent
9039,27106887,hemodialysis
9040,27106887,renal transplantation
9043,27350133,carcinoma
9044,27350133,diagnostic discrepancies
9045,27350133,histology
9046,27350133,sources of error
9047,27350133,thyroid cytology
9051,28861686,bell’s phenomenon
9052,28861686,inferior rectus muscle recession
9053,28861686,nasal transposition of the inferior rectus muscle
9054,28861686,thyroid-associated inferior rectus myopathy
9056,28296512,amsterdam declaration
9057,28296512,thyroid eye disease
9058,28296512,radioiodine
9059,28296512,smoking
9060,28296512,thyroid function
9061,26996584,thymus hyperplasia
9062,26996584,graves disease
9063,26996584,"immunoglobulins, thyroid-stimulating"
9064,26996584,receptors thyrotropin cois
9066,27651496,graves
9067,27651496,hyperthyroidism
9068,27651496,radioiodine
9069,27651496,thyroidectomy
9072,28755140,biomarker
9073,28755140,enzyme-linked immunosorbent assay
9074,28755140,klln protein
9075,28755140,pten protein
9076,28755140,papillary thyroid carcinoma
9081,28870952,*metallothioneins
9082,28870952,*papillary thyroid carcinoma
9083,28870952,*thyroid gland
9085,28882932,muscle disease
9086,28882932,thyroid disease cois
9087,28805160,*graves' disease
9088,28805160,*graves' ophthalmopathy
9089,28805160,*clinical activity score
9090,28805160,*immunoglobulin g4
9091,28805160,*thyroid autoantibody
9092,28675712,graves’ disease
9093,28675712,hashimoto’s disease
9094,28675712,thyroglobulin
9095,28675712,polymorphism
9096,28675712,severity
9097,28162094,graves’ disease
9098,28162094,human leukocyte antigen
9099,28162094,hyperthyroidism
9100,28162094,thiamazole
9101,28162094,thyroid scintigraphy
9102,28162094,thyroid-stimulating hormone-binding inhibitory immunoglobulin
9103,27664101,graves’ disease
9104,27664101,graves’ orbitopathy
9105,27664101,natural course
9107,26100786,cd69
9108,26100786,graves’ disease
9109,26100786,hashimoto thyroiditis
9110,26100786,il-10
9111,26100786,nkg2d
9112,26100786,treg cells
9115,28319410,*mean platelet volume
9116,28319410,*papillary thyroid cancer
9117,28319410,*platelet distribution width plateletcrit.
9119,28478488,anti-thyroid drugs
9120,28478488,graves’ disease
9121,28478488,hyperthyroidism
9122,28478488,radio-iodine
9123,28478488,surgery
9124,28478488,"thyroid cois currently in uk for observational studies. conflict of interest: the authors declare that they have no competing interests. ethical approval: no specific approval was obtained from an ethics committee. as this is an observational study of a current clinical pathway and no intervention was involved, permission was only obtained from the audit and service evaluation office of the sheffield teaching hospitals nhs foundation trust. as the data was anonymised and individual patients cannot be identified from the report, individual patient consent was not deemed to be necessary and was not obtained."
9128,28379055,diffusion
9129,28379055,graves
9130,28379055,magnetic resonance imaging
9131,28379055,orbit
9133,27804243,*graves’ disease
9134,27804243,*hyperthyroidism
9135,27804243,*pulmonary hypertension
9136,27804243,*pulmonary hypertensive crisis
9137,27804243,*thyroid storm
9138,27486810,dysthyroid optic neuropathy
9139,27486810,graves’ orbitopathy
9140,27486810,thyroid eye disease
9145,28500433,dysthyroid optic neuropathy
9146,28500433,orbital radiation therapy
9147,28500433,thyroid-associated orbitopathy
9148,28130596,angle kappa
9149,28130596,interpupillary distance
9150,28130596,orbital decompression
9151,28130596,thyroid-associated orbitopathy
9155,27638651,*graves’ disease
9156,27638651,*hyperthyroidism
9157,27638651,*mathematical modeling
9158,27638651,*relapse
9165,27319009,agranulocytosis
9166,27319009,alemtuzumab
9167,27319009,childhood
9168,27319009,graves’ disease
9169,27319009,graves’ orbitopathy
9170,27319009,hyperthyroidism
9171,27319009,methimazole
9172,27319009,pregnancy
9173,27319009,propylthiouracil
9174,27319009,radioiodine
9175,27319009,thionamides
9176,27319009,thyroidectomy
9179,26951052,autoimmunity
9180,26951052,graves’ disease
9181,26951052,hla
9182,26951052,stress
9183,27838267,*graves’ disease
9184,27838267,*coronary vasospasm
9185,27838267,*hyperthyroidism
9186,27838267,*methimazole
9187,27838267,*nitroglycerin
9188,27838267,*thyroid peroxidase antibody
9189,27838267,*thyroid-stimulating immunoglobulin
9190,28835054,graves′ disease
9191,28835054,hashimoto disease
9192,28835054,thyroid neoplasms
9193,28811719,cirrhosis
9194,28811719,cognitive impairment
9195,28811719,hepatic encephalopathy
9196,28811719,hypothyroidism
9197,28811719,magnetic resonance spectroscopy
9198,28811719,portosystemic shunt cois regarding funding or conflict of interest with respect to this manuscript.
9201,27560939,thyroid eye disease
9202,27560939,ptosis
9203,27560939,upper eyelid retraction
9206,26787873,cell engineering
9207,26787873,designer cells
9208,26787873,gene switch
9209,26787873,prosthetic networks
9210,26787873,synthetic biology cois
9211,28070771,*graves disease
9212,28070771,*clinical reasoning
9213,28070771,*dual process theory
9214,28070771,*framing cois interest. funding: none.
9215,27169807,compressive optic neuropathy
9216,27169807,dysthyroid optic neuropathy
9217,27169807,dysthyroid orbitopathy
9218,27169807,graves’ orbitopathy
9219,27169807,optical coherence tomography
9220,27169807,peripapillary retinal nerve fiber layer thickness
9223,27599688,graves ophthalmopathy
9224,27599688,quality of life
9225,27599688,thyroid eye disease
9226,27159575,graves’ ophthalmopathy
9227,27159575,long-term follow-up
9228,27159575,orbital decompression
9229,27159575,quality of life
9230,27159575,thyroid associated ophthalmopathy
9234,28222800,*autosomal recessive inheritance
9235,28222800,*childhood deafness
9236,28222800,*exome sequencing
9237,28222800,*pendred syndrome
9238,28222800,*syndromic hearing loss
9239,28347567,*art
9240,28347567,*exophthalmos
9241,28347567,*graves disease
9242,27086918,benign nodule
9243,27086918,programmed death-ligand 1
9244,27086918,protein biomarkers
9245,27086918,subcellular localization
9246,27086918,"thyroid cancer cois (sc, jv, fj, op, aa and cm) have nothing to disclose."
9247,27914141,children
9248,27914141,hashimoto disease
9249,27914141,hypothyroidism
9250,27914141,thyroid disease cois
9253,27220843,*antithyroid drugs
9254,27220843,*graves’ disease
9255,27220843,*graves’ ophthalmopathy
9256,27220843,*radioactive iodine
9257,27220843,*thyroidectomy
9261,28273705,congenital hypothyroidism
9262,28273705,gene
9263,28273705,mutation
9264,29270757,graves’ ophthalmopathy
9265,29270757,magnetic resonance
9266,29270757,methylprednisolone
9270,28715111,* hla-b*40:238
9271,28715111,*new allele
9272,28715111,*sequencing-based typing
9273,27715404,african descent
9274,27715404,graves orbitopathy
9275,27715404,pediatric
9276,27715404,optic neuropathy
9277,27709471,age
9278,27709471,glucocorticoids
9279,27709471,graves’ disease
9280,27709471,graves’ orbitopathy
9281,27709471,natural history
9282,27709471,radiotherapy
9283,27680576,echocardiography
9284,27680576,graves’ disease
9285,27680576,tissue doppler
9286,27170049,*graves’ ophthalmopathy
9287,27170049,*histamine
9288,27170049,*histamine receptor type-1
9289,27170049,*loratadine
9290,27170049,*mast cell
9291,27170049,*nf-κb controlled cytokine
9292,27170049,*nf-κb inhibitor
9293,27170049,*orbital fibroblast
9300,28941661,*anion transporters
9301,28941661,*homology modeling
9302,28941661,*membrane proteins
9303,28941661,*pathogenic mutations
9304,28941661,*slc26
9305,28941661,*solute carriers
9306,28941661,*trafficking
9307,28941661,*transport
9308,28063079,autoimmunity
9309,28063079,graves’ disease
9310,28063079,graves’ orbitopathy
9311,28063079,microbiota and dysbiosis
9312,26864507,*graves disease
9313,26864507,*hypothyroidism
9314,26864507,*radioiodine therapy
9315,26864507,*thyroid hormones
9316,26864507,*treatment outcome
9318,26686233,lateral rim repositioning
9319,26686233,orbital decompression
9320,26686233,proptosis
9321,26686233,thyroid eye disease
9322,26686233,thyroid related orbitopathy
9328,27762730,*tshr
9329,27762730,*autoimmune thyroid disease
9330,27762730,*intractability
9331,27762730,*polymorphism
9332,27762730,*severity
9333,27245701,col13a1
9334,27245701,thyroid-associated ophthalmopathy
9335,27245701,collagen xiii
9336,27245701,extraocular fat
9337,27245701,thyroid eye disease
9343,26799350,breastfeeding
9344,26799350,endocrinology
9345,26799350,pharmacology
9346,26799350,pregnancy
9347,26799350,thyroid
9348,26799350,women's health
9349,28463526,*overcorrection
9350,28463526,*strabismus surgery
9351,28463526,*thyroid eye disease
9352,28463526,*vertical strabismus
9354,27376649,ectopic (parasitic) goiter
9355,27376649,hashimoto’s autoimmune thyroiditis
9356,27376649,high plasma cell content
9357,27376649,hürthle cell
9358,27376649,lymph node metastasis
9359,29262478,genetic testing
9360,29262478,"receptors, thyroid hormone"
9361,29262478,thyroid hormone resistance syndrome
9362,28684549,*bisphenol a
9363,28684549,*endocrine disrupting chemical
9364,28684549,*iodine excess intake
9365,28684549,*nodular goiter
9366,28684549,*papillary thyroid carcinoma cois manuscript.
9374,27371612,histopathology
9375,27371612,molecular pathology
9376,27371612,thyroid cancer
9377,26876240,*graves’ orbitopathy
9378,26876240,*orbital radiation
9379,26876240,*systemic steroids
9380,26876240,*thyroid-associated orbitopathy
9383,29085976,grave’s orbitopathy
9384,29085976,increase of intraorbital pressure
9385,29085976,orbital diseases
9386,29085976,postoperative complications
9387,29085976,postoperative intraorbital hemorrhage
9389,26540014,intraoperative neuromonitoring (ionm)
9390,26540014,recurrent laryngeal nerve (rln)
9391,26540014,robotic thyroid surgery
9392,26540014,transaxillary robotic surgery
9393,26540014,vagal automatic periodic stimulation (aps)
9396,28392335,(131)i
9397,28392335,agranulocitosis
9398,28392335,agranulocytosis
9399,28392335,anti-thyroid drugs
9400,28392335,enfermedad de graves
9401,28392335,fármacos antitiroideos
9402,28392335,graves’ disease
9406,27848228,dna polymerase
9407,27848228,graves’ disease
9408,27848228,iodide peroxidase and mrnas
9409,29047240,exophthalmos
9410,29047240,korea
9411,29047240,sialyltransferases
9412,29047240,single nucleotide polymorphism
9413,29047240,thyroid-associated ophthalmopathy cois
9414,27792295,*graves' disease
9415,27792295,*hashimoto's thyroiditis
9416,27792295,*lymphocytic thyroiditis
9417,27792295,*papillary carcinoma
9418,27792295,*thyroid cancer
9420,27729751,*age group
9421,27729751,*computed tomography
9422,27729751,*computer communication network
9423,27729751,*lacrimal gland
9424,27729751,*thyroid-associated ophthalmopathy cois
9426,28195542,autoimmune thyroid diseases
9427,28195542,intractability
9428,28195542,intraindividual variation
9429,28195542,microrna
9430,28195542,severity
9432,27844093,diffusion tensor imaging
9433,27844093,extraocular muscle
9434,27844093,mri
9435,27844093,thyroid associated orbitopathy
9438,26860528,botulinum toxin
9439,26860528,restrictive strabismus
9440,26860528,strabismus surgery
9441,26860528,thyroid eye disease
9442,27449491,alternating diplopia
9443,27449491,alternating orthotropia
9444,27449491,cyclic vertical deviation
9445,27449491,dysthyroid ophthalmopathy
9447,27272160,*graves’ disease
9448,27272160,*adverse drug reactions
9449,27272160,*cutaneous figurate erythema
9450,27272160,"*methimazole cois conflicts of interest with respect to the research, authorship, and/or publication of this article."
9451,29030215,cost-effectiveness
9452,29030215,ionm
9453,29030215,nerve injury
9454,29030215,neural monitoring
9455,29030215,thyroid surgery
9458,27919794,*graves disease
9459,27919794,*ischemic stroke
9460,27919794,*magnetic resonance imaging
9461,27919794,*vasculitis
9462,27919794,*vessel wall imaging
9464,28845025,anti-thyroid peroxidase antibody
9465,28845025,graves’ disease
9466,28845025,hashimoto’s disease
9467,28845025,polymorphism
9468,28845025,severity
9475,27734978,complications
9476,27734978,different approaches
9477,27734978,graves’ orbitopathy
9478,27734978,orbital decompression
9480,29152991,esophageal carcinoma
9481,29152991,gastrointestinal stromal tumors
9482,29152991,non-small cell lung cancer
9483,29152991,thyroid papillary carcinoma
9484,29152991,multi-organ primary carcinoma
9485,28284988,*cd279
9486,28284988,*graves' disease
9487,28284988,*hyperthyroidism
9488,28284988,*lymphocytes
9489,28284988,*pd-1
9491,25835075,dythyroid optic neuropathy
9492,25835075,endoscopic transethomoid medial orbital wall decompression
9493,25835075,endoscopic transethomoid orbital fat decompression
9494,25835075,proptosis reduction
9495,25835051,dysthyroid optic neuropathy
9496,25835051,mean deviation
9497,25835051,pattern standard deviation
9498,25835051,three-wall orbital decompression
9499,25835051,two-wall orbital decompression
9501,26699948,brow fat hypertrophy
9502,26699948,premalar fat hypertrophy
9503,26699948,thyroid eye disease
9505,28606259,"decompression, surgical"
9506,28606259,graves ophthalmopathy
9507,28606259,orbit
9511,28547036,atrial fibrillation
9512,28547036,graves’ disease
9513,28547036,microrna
9514,28547036,thyroid hormone
9515,28768936,hashimoto’s thyroiditis
9516,28768936,thyroglobulin antibodies
9517,28768936,thyroid peroxidase antibodies
9519,27245255,*graves’ disease
9520,27245255,*hashimoto’s disease
9521,27245255,*sirt1
9522,27245255,*snp
9523,27245255,*intractability
9524,27245255,*severity
9525,27808570,*dicer
9526,27808570,*drosha
9527,27808570,*autoimmune thyroid disease
9528,27808570,*severity
9529,27808570,*single nucleotide polymorphism
9530,27387241,graves’ orbitiopathy
9531,27387241,anti-cel
9532,27387241,anti-cml
9533,27387241,methylprednisolone treatment
9534,28669056,autoimmune thyroiditis
9535,28669056,graves’ disease
9536,28669056,hashimoto’s thyroiditis
9537,28669056,th17 cells
9538,28669056,th22 cells
9539,25567342,laryngopharyngeal reflux
9540,25567342,local neck symptoms
9541,25567342,nodular goiter
9542,25567342,thyroidectomy
9546,26567020,*cosmesis
9547,26567020,*orbit
9548,26567020,*treatment surgery
9549,27422248,*gas inflation
9550,27422248,*single-incision endoscopic thyroidectomy
9551,27422248,*trans-axillary endoscopic thyroidectomy
9557,28742402,graves’ disease
9558,28742402,hashimoto’s disease
9559,28742402,il-10
9560,28742402,mirna
9561,28742402,polymorphism
9563,26666958,*cancer
9564,26666958,*coupling
9565,26666958,*metabolism
9566,26666958,*papillary
9567,26666958,*thyroid
9568,28243072,graves ophthalmopathy
9569,28243072,age-related
9570,28243072,autoimmune thyroidopathy
9571,28243072,elderly
9572,28243072,subconjunctival orbital fat prolapse
9573,28243072,thyroid associated orbitopathy cois
9575,26744121,pendred syndrome
9576,26744121,tp53
9577,26744121,thyroid carcinoma
9578,26683653,capsular dissection
9579,26683653,guidelines
9580,26683653,intraoperative
9581,26683653,neurophysiological monitoring
9582,26683653,nodular goiter
9583,27877085,*autophagy
9584,27877085,*age-related macular degeneration
9585,27877085,*cataracts
9586,27877085,*diabetic retinopathy
9587,27877085,*ocular tumours.
9588,27877085,*thyroid-associated ophthalmopathy cois
9590,28413173,autoimmune thyroid diseases
9591,28413173,graves’ disease
9592,28413173,hashimoto’s thyroiditis
9593,28413173,serum 25-hydroxyvitamin d
9594,28413173,vitamin d deficiency
9598,28219358,*graves’ disease
9599,28219358,*innate immunity
9600,28219358,*tlrs
9601,28883260,graves’ disease
9602,28883260,metastasis
9603,28883260,thyroid carcinoma
9604,28473357,arrhythmias
9605,28473357,paediatrics (drugs and medicines)
9606,28473357,thyroid disease cois
9609,28078992,*tobacco smoking
9610,28078992,*adults
9611,28078992,*children
9612,28078992,*ocular inflammation
9613,28078992,*optic neuropathy
9614,28078992,*orbitopathy
9615,28078992,*retinopathy
9620,27769543,*grave's disease
9621,27769543,*potassium iodide
9622,27769543,*thyroidectomy
9626,26884288,graves’ disease
9627,26884288,graves’ orbitopathy
9628,26884288,dysthyroid optic neuropathy
9629,26884288,endoscopic intranasal orbital decompression
9630,26884288,methylprednisolone
9631,26884288,orbital decompression
9639,28851197,graves ophthalmopathy
9640,28851197,psychometrics
9641,28851197,quality of life
9642,28851197,root cause analysis
9643,28741406,thyroid eye disease
9644,28741406,compressive optic neuropathy
9645,28741406,decompression
9646,28741406,diplopia
9647,28741406,orbit
9648,28741406,proptosis
9649,28699478,*graves' disease
9650,28699478,*antithyroid drugs
9651,28699478,*continuous therapy
9652,28699478,*long-term therapy
9653,28699478,*meta-analysis
9654,28699478,*methimazole
9655,28699478,*propylthiouracil
9657,27692684,*endocrine orbitopathy
9658,27692684,*navigated surgery
9659,27692684,*piezosurgery
9665,28341401,*hearing loss
9666,28341401,*localization
9667,28341401,*misfolding
9668,28341401,*molecular chaperone
9669,28341401,*morphological analysis
9670,28341401,*p123s mutant
9671,28341401,*pendrin
9673,26979769,*graves’ orbitopathy
9674,26979769,*pai-1
9675,26979769,*tgf-β
9676,26979769,*cell density
9677,26979769,*hyaluronan
9678,26979769,*orbital fibroblasts
9681,26701678,antithyroid drugs
9682,26701678,graves’ disease
9683,26701678,natural killer t cells
9684,26701678,radioactive iodine
9685,26701678,regulatory t cells
9687,28859864,decision making
9688,28859864,game of dice task
9689,28859864,graves’ disease
9690,28859864,hyperthyroidism
9691,28859864,thyroid hormones
9692,28235670,*comparative study
9693,28235670,*conventional open
9694,28235670,*endoscopy
9695,28235670,*graves' disease
9696,28235670,*meta-analysis
9697,28235670,*thyroidectomy
9698,27615550,*graves’ disease
9699,27615550,*hyperthyroidism
9700,27615550,*antithyroid drugs
9701,27615550,*carbimazole
9702,27615550,*methimazole
9703,27615550,*propylthiouracil
9704,28259878,cytopathology
9705,28259878,fine needle aspiration
9706,28259878,graves disease
9707,28259878,thyroid
9711,27771369,homology modeling
9712,27771369,mutation mapping
9713,27771369,non-syndromic hearing loss with enlarged vestibular aqueduct (ns-eva)
9714,27771369,pendred syndrome
9715,27771369,pendrin
9716,27771369,slc26a4
9717,27771369,transmembrane protein
9721,28515387,aitd
9722,28515387,il-12
9723,28515387,il-18
9724,28515387,polymorphism
9725,28515387,socs1
9733,27612658,*graves' disease
9734,27612658,*autoimmunity
9735,27612658,*fibrocyte
9736,27612658,*interleukin-12
9737,27612658,*thyroid-associated ophthalmopathy cois interest in any material discussed in this article.
9739,27543288,*biochemistry
9740,27543288,*experimental &#8211 laboratory
9741,27543288,*inflammation
9742,27543288,*orbit
9747,27160433,*diabetes mellitus
9748,27160433,*endocrine tumor
9749,27160433,*granulomatous insulitis
9750,27160433,*pancreas
9751,27580012,col13a1
9752,27580012,collagen xiii
9753,27580012,thyroid eye disease
9754,27580012,thyroid-associated ophthalmopathy
9756,28500376,graves’ disease
9757,28500376,ptpn22
9758,28500376,rheumatoid arthritis
9759,28500376,systemic lupus erythematosus
9760,27369733,convergence spasm
9761,27369733,cranial nerve palsy
9762,27369733,double vision
9763,27369733,graves’ disease
9764,27369733,strabismus
9769,26675405,adipocyte
9770,26675405,cytokine
9771,26675405,fibrocyte
9772,26675405,fibrosis
9773,26675405,graves' ophthalmopathy
9774,26675405,growth factor
9775,26675405,hyaluronan
9776,26675405,inflammation
9777,26675405,orbital fibroblast
9780,27987077,epstein–barr virus
9781,27987077,graves’ disease
9782,27987077,graves’ orbitopathy
9783,27987077,idiopathic inflammatory pseudotumor
9784,27987077,thyroid
9785,27637079,graves’ disease
9786,27637079,t3
9787,27637079,neutrophils
9788,27637079,resistin
9789,29093229,ctla-4 gene exon 1
9790,29093229,ctla-4 gene with promotor-318
9791,29093229,regulatory t cells
9792,29093229,tshr gene rs2268458 intron 1
9793,29093229,thyroid receptor antibody (trab)
9794,29093229,graves’ disease
9795,29093229,relapse
9798,27113266,pediatric graves' disease
9799,27113266,pediatric hyperthyroidism
9800,27113266,shared decision making
9801,27113266,thyroidectomy
9802,27793633,(177)lu-dotatate
9803,27793633,cáncer de tiroides
9804,27793633,peptide receptor radionuclide therapy
9805,27793633,radioactive iodine refractory
9806,27793633,refractario al yodo radiactivo
9807,27793633,thyroid neoplasms
9808,27793633,tratamiento con análogos de la somatostatina radiomarcados
9813,27130144,ck5/6
9814,27130144,cytokeratin
9815,27130144,lymphoepithelial complex
9816,27130144,p63
9817,27130144,squamous cell metaplasia
9818,27130144,thyroid
9819,27130144,thyroiditis
9822,28201927,graves’ disease
9823,28201927,cytological alteration
9824,28201927,histologic changes
9825,28201927,radioactive iodine treatment
9826,28201927,thyroid
9829,27700191,parathyroid autotransplantation
9830,27700191,hypocalcemia
9831,27700191,inadvertent parathyroidectomy
9832,27700191,parathormone
9833,27700191,thyroidectomy
9834,28336282,botulinum toxin type a
9835,28336282,dysthyroid orbitopathy
9836,28336282,grave's disease
9837,28336282,maladie de basedow
9838,28336282,ophtalmopathie dysthyroïdienne
9839,28336282,orbital inflammatory disease
9840,28336282,orbitopathie inflammatoire
9841,28336282,rétraction palpébrale supérieure
9842,28336282,toxine botulique a
9843,28336282,upper eyelid retraction
9844,27638540,cd28/ctla-4/icos
9845,27638540,gene polymorphism
9846,27638540,graves’ disease
9847,27638540,graves’ orbitopathy
9848,27638540,haplotype cois
9853,28825582,*immunosuppressive agents
9854,28825582,*multiple organ failure
9855,28825582,*plasmapheresis
9856,28825582,*thyroid crisis
9857,28825582,*thyroidectomy
9860,28895066,131i therapy
9861,28895066,graves’ hyperthyroidism
9862,28895066,lithium carbonate
9863,28895066,thyroid
9865,28185649,*anti-cd20
9866,28185649,*graves ophthalmopathy
9867,28185649,*neuropathie optique
9868,28185649,*optic neuropathy
9869,28185649,*orbitopathie basedowienne
9870,28185649,*rituximab
9873,28001121,*graves' disease
9874,28001121,*antithyroid agents
9875,28001121,*long-term prognosis
9876,27734319,autoimmunity
9877,27734319,graves’ disease
9878,27734319,hyperthyroidism
9879,27734319,selenium
9880,27734319,thyroid
9882,28705701,graves disease
9883,28705701,orbital decompression surgery
9884,28705701,piezosurgery
9885,28705701,thyroid-associated orbitopathy
9887,28176220,clinical activity score
9888,28176220,cyclosporine
9889,28176220,graves’ orbitopathy or ophthalmopathy
9890,28176220,intravenous glucocorticoids
9891,28176220,orbital radiotherapy
9892,28176220,shared decision-making
9893,26626367,graves' disease
9894,26626367,hyperthyroidism
9895,26626367,surgery
9896,26626367,thyroid carcinoma
9897,26626367,thyroid nodules
9900,27266815,aire
9901,27266815,apeced
9902,27266815,autoimmunity
9903,27266815,graves’ disease
9904,27266815,mutation
9905,27266815,polymorphism
9906,25855160,autoimmune thyroid disease
9907,25855160,instrumentation
9908,25855160,thyroid
9909,25855160,tissue characterization
9910,25855160,ultrasound
9913,29307154,graves
9914,29307154,interleukin-6
9915,29307154,meta-analysis
9916,29307154,polymorphism
9917,28223014,decompression
9918,28223014,endocrine orbitopathy
9919,28223014,navigated surgery
9922,27863461,*genome-wide association study
9923,27863461,*graves’ disease
9924,27863461,*pooled blood
9926,27618833,graves’ disease
9927,27618833,iodine radioisotopes
9928,27618833,pregnancy outcome
9929,27566407,calreticulin(calr)
9930,27566407,endoplasmic reticulum (er) stress
9931,27566407,graves' disease(gd)
9932,27566407,heat shock 70kda protein 5(hspa5)
9933,27566407,proteomics
9934,27419847,*choroidal thickness
9935,27419847,*graves’ disease
9936,27419847,*graves’ ophthalmopathy
9937,27419847,*clinical activity score
9938,27419847,*optical coherence tomography
9939,27163552,graves disease
9940,27163552,moyamoya
9941,27163552,stroke
9942,27163552,vasculopathy
9943,26932949,*graves’ disease
9944,26932949,*balanced decompression
9945,26932949,*endoscopic orbital decompression
9946,26932949,*orbital decompression
9947,26932949,*orbital sling
9948,26932949,*orbital strut
9951,28042648,*graves’ orbitopathy
9952,28042648,*intravenous steroids
9953,28042648,*orbital irradiation
9954,28042648,*radioiodine therapy
9956,26886940,graves’ orbitopathy
9957,26886940,ich guideline
9958,26886940,medical dictionary for regulatory activities (meddra)
9959,26886940,mycophenolate
9960,26886940,safety
9961,27206624,*graves’ disease
9962,27206624,*hashimoto’s thyroiditis
9963,27206624,*th17
9964,27206624,*tregs
9965,27206624,*anti-thyroid antibodies
9967,28506419,99m tc-mibi scintigraphy
9968,28506419,mibi uptake
9969,28506419,radioguided surgery
9970,28506419,thyroid cancer
9971,28506419,thyroid follicular neoplasm
9972,28506419,thyroidectomy
9977,27762178,endoscopic surgical procedure
9978,27762178,mri
9979,27762178,skull base
9981,27107937,*coexpression
9982,27107937,*graves' disease
9983,27107937,*ox40/ox40l
9984,27107937,*t cell activation
9985,29246597,*autoantibody
9986,29246597,*encephalitis
9987,29246597,*hashimoto's encephalopathy
9988,29246597,*intravenous immunoglobulin
9994,27143020,intraoperative neuromonitoring
9995,27143020,prognostic value
9996,27143020,recurrent laryngeal nerve
9997,27143020,staged thyroidectomy
9998,27143020,thyroid surgery cois interest: author małgorzata stopa declares that she has no conflict of interest. author marcin barczyński declares that he has no conflict of interest. ethical approval: all procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 helsinki declaration and its later amendments or comparable ethical standards. informed consent: informed consent was obtained from all individual participants included in the study.
10004,28119492,*antibody
10005,28119492,*gene polymorphism
10006,28119492,*hla-dq
10007,28119492,*ocular myasthenia gravis
10008,28119492,*tnf-α
10009,28119492,*thyroid associated ophthalmopathy cois manuscript.
10014,28236218,agranulocytosis
10015,28236218,antithyroid drug
10016,28236218,graves’ disease
10017,28236218,hyperthyroidism
10018,26850223,autoimmune thyroid diseases
10019,26850223,cytokines
10020,26850223,graves' disease
10021,26850223,hashimoto's disease
10022,26850223,single nucleotide polymorphisms
10023,26850223,thyroid-associated ophthalmopathy
10027,26735162,*in vivo confocal microscopy
10028,26735162,*langerhans cells
10029,26735162,*inflammation
10030,26735162,*ocular surface
10031,26735162,*thyroid-associated ophthalmopathy
10032,26559967,strabismus
10033,26559967,surgical outcomes
10034,26559967,thyroid eye disease
10035,28606262,"decompression, surgical"
10036,28606262,graves ophthalmopathy
10037,28606262,optic nerve diseases
10038,28606262,orbit
10039,28606262,treatment outcome
10041,28453366,thyroid eye disease
10042,28453366,compressive optic neuropathy
10043,28453366,visual field
10046,26775634,adjustable sutures
10047,26775634,endocrine orbitopathy
10048,26775634,orbital decompression
10049,26775634,restrictive strabismus
10050,26775634,strabismus surgery
10051,26775634,thyroid associated ophthalmopathy
10052,26635355,slc26
10053,26635355,stas domain
10054,26635355,anion transporters
10055,26635355,inherited diseases
10056,26635355,membrane protein folding
10057,28061802,endoscopy
10058,28061802,graves’ disease
10059,28061802,neurosurgery
10060,28061802,pituitary neoplasms
10061,28061802,tsh-producing tumor
10062,28061802,tshoma
10063,28061802,thyrotropin
10064,28502931,22q11.2 deletion syndrome
10065,28502931,graves' disease
10066,28502931,hla
10067,28502931,regulatory t-cell
10071,27824294,*graves'
10072,27824294,*fibroblast
10073,27824294,*ophthalmopathy
10074,27824294,*orbitopathy
10075,27824294,*selenium
10077,26795296,arylesterase
10078,26795296,autoimmune thyroid disease
10079,26795296,oxidative status
10080,26795296,paraoxonase cois that could be perceived as prejudicing the impartiality of the research reported.
10083,27838736,activity
10084,27838736,computed tomography
10085,27838736,hounsfield unit
10086,27838736,orbital volume
10087,27838736,thyroid-associated orbitopathy
10089,28070798,*addison’s disease
10090,28070798,*autoimmune polyendocrine syndromes
10091,28070798,*autoimmunity
10092,28070798,*environment
10093,28070798,*graves’ disease
10094,28070798,*hashimoto’s thyroiditis
10095,28070798,*lifestyle
10096,28070798,*type 1 diabetes mellitus
10097,28070798,*vitamin d
10098,29187926,basedow-graves ophthalmopathy
10099,29187926,corticosteroids
10100,29187926,exophthalmos decompression
10101,29187926,neuropathy
10103,28742400,autoimmune thyroid diseases
10104,28742400,cd40
10105,28742400,single nucleotide polymorphism
10110,27465669,*glucocorticoid
10111,27465669,*graves’ ophthalmopathy
10112,27465669,*hepatitis
10113,27465669,*statins
10116,26935935,autoimmunity
10117,26935935,graves’ disease
10118,26935935,primary biliary cirrhosis
10119,26864865,autoimmune thyroid diseases
10120,26864865,graves’ disease
10121,26864865,hashimoto thyroiditis
10122,26864865,cytokine
10123,26864865,interleukin-1β
10124,28209438,graves’ disease
10125,28209438,hypocretin
10126,28209438,myasthenia gravis
10127,28209438,myotonic dystrophy
10128,28081504,hashimoto's thyroiditis
10129,28081504,igg
10130,28081504,neonatal fc receptor
10131,28081504,tgab
10132,28081504,th1/th2 cytokines
10133,28630226,disturbances
10134,28630226,endocrinology
10135,28630226,fluid electrolyte and acid-base
10136,28630226,muscle
10137,28630226,thyroid disease cois
10138,27810496,alopecia areata
10139,27810496,graves’ disease
10140,27810496,non-hla genes
10141,27810496,trab
10142,27810496,type 1 diabetes
10143,26876268,graves’ orbitopathy
10144,26876268,igg4-asszociált betegség
10145,26876268,igg4-related disease
10146,26876268,endokrin orbitopathia
10147,26876268,idiopathic inflammatory orbitopathy
10148,26876268,idiopathiás inflammatorikus orbitopathia
10149,26876268,myasthenia gravis
10150,26876268,occularis lymphoma
10151,26876268,ocular lymphoma
10152,29196352,deaf awareness
10153,29196352,hearing impaired
10154,29196352,young people
10155,28238453,graves disease
10156,28238453,hashimoto thyroiditis
10157,28238453,autoimmune thyroiditis
10158,28238453,hyperthyroidism
10159,28238453,hypothyroidism
10160,28238453,thyroid cancer
10161,28238453,vitiligo
10164,26965896,endoscopic thyroidectomy
10165,26965896,graves’ disease
10166,26965896,hypocalcemia
10167,26965896,parathyroid preservation
10168,26204988,berke incision approach
10169,26204988,chemosis
10170,26204988,deep lateral orbital wall decompression
10171,26204988,swinging eyelid approach
10174,27116895,igg4-related disease
10175,27116895,lymphocyte/plasma cell infiltrations
10176,27116895,malt lymphomas
10177,27116895,orbital pseudotumors
10179,27273008,oscillopsia
10180,27273008,proptosis
10181,27273008,temporal hollowing
10182,27273008,thyroid eye disease
10183,27273008,visual acuity
10184,27259978,clpp
10185,27259978,slc26a4
10186,27259978,tbc1d24
10187,27259978,pendred syndrome
10188,27259978,perrault syndrome
10189,27259978,enlarged vestibular aqueduct
10190,27259978,hereditary deafness cois
10191,28665696,14q32.2
10192,28665696,ciqtnf6
10193,28665696,graves' disease
10194,28665696,rac2
10195,28665696,snp
10196,28665696,association
10197,28660988,graves' orbitopathy
10198,28660988,clinical activity score
10199,28660988,dysthyroid optic neuropathy
10200,28660988,rituximab
10201,28660988,thyroid gland
10203,28364200,graves’ orbitopathy
10204,28364200,inflammation
10205,28364200,orbital fibroblasts
10206,28364200,s1p receptor antagonist
10207,28364200,sphingosine-1-phosphate
10208,26955881,*genetics
10209,26955881,*graves’ disease
10210,26955881,*hashimoto thyroiditis
10211,26955881,*vegf
10212,26955881,*polymorphisms
10213,28689782,*bacteria
10214,28689782,*graves' disease
10215,28689782,*hashimotos's thyroiditis
10216,29180171,*graves' disease
10217,29180171,*hyperthyroidism
10218,29180171,*recurrence
10219,29180171,*subtotal thyroidectomy
10220,29088997,*graves' disease
10221,29088997,*antineutrophil cytoplasmic antibody
10222,29088997,*propylthiouracil
10223,29088997,*vasculitis
10224,29050489,*graves' ophthalmopathy
10225,29050489,*inflammation biomarker.
10226,29050489,*neutrophil-to-lymphocyte ratio
10227,29050489,*thyroid ophthalmopathy
10230,28260364,"decompression, surgical"
10231,28260364,graves ophthalmopathy
10232,28260364,orbit
10233,28260364,"surgical procedures, minimally invasive"
10234,28260364,treatment outcome
10235,26865797,diplopia
10236,26865797,exophthalmos
10237,26865797,eyelid retraction
10238,26865797,graves ophthalmopathy
10239,26865797,orbital decompression cois was reported.
10241,27247969,*grave’s disease
10242,27247969,*ted
10243,27247969,*ted treatment options
10244,27247969,*thyroid eye disease
10245,28606264,graves ophthalmopathy
10246,28606264,magnetic resonance imaging
10247,28606264,oculomotor muscles
10248,28388348,decompression
10249,28388348,graves’ disease
10250,28388348,geriatric
10251,28388348,strabismus
10252,28388348,thyroid eye disease cois alone are responsible for the content and writing of the paper.
10255,28439882,*graves' disease
10256,28439882,*hashimoto's thyroiditis
10257,28439882,*tsh-receptor blocking antibodies
10258,28439882,*tsh-receptor stimulating antibodies
10259,28439882,*bioassay
10260,28743746,*graves' disease
10261,28743746,*iodination
10262,28743746,*post-translational modification (ptm)
10263,28743746,*protein processing
10264,28743746,*protein secretion
10265,28743746,*thyroglobulin
10266,28743746,*thyroid
10267,28743746,*thyroid hormone cois this article
10269,27888002,*autoimmune thyroid diseases (aitd)
10270,27888002,*graves' disease (gd)
10271,27888002,*hashimoto's thyroiditis (ht)
10272,27888002,*micrornas
10273,27888002,*single nucleotide polymorphism (snp)
10276,26767650,graves’ disease
10277,26767650,graves’ ophthalmopathy
10278,26767650,graves’ orbitopathy
10279,26767650,nicotinamide phosphoribosyltransferase
10280,26767650,pre-b cell colony-enhancing factor
10281,26767650,visfatin
10283,29110673,clinical outcomes
10284,29110673,graves’ ophthalmopathy
10285,29110673,"imrt cois ethics committee of west china hospital, sichuan university. informed consent was obtained from all individual participants included in the study. consent for publication: the consent to publish the study and accompanying images was obtained. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations."
10289,28895880,graves’ disease
10290,28895880,hashimoto’s thyroiditis
10291,28895880,autoimmune thyroid disease
10292,28895880,thyroid cancer
10293,28895880,vitamin d cois
10294,28833367,graves’ hyperthyroidism
10295,28833367,ferritin
10296,28833367,hepcidin
10297,28833367,iron metabolism
10299,28133945,graves' orbitopathy
10300,28133945,field of binocular single vision
10301,28133945,quality of life
10302,28133945,strabismus surgery
10304,28521825,"*graves’ disease, susceptibility, single nucleotide polymorphisms, 4p14, 6q27"
10306,27003434,acute liver damage
10307,27003434,graves’ ophthalmopathy
10308,27003434,hepatotoxicity
10309,27003434,intravenous glucocorticoid therapy
10310,27003434,methylprednisolone
10312,29130665,hyaluronic acid
10313,29130665,insulin-like growth factor-1 receptor
10314,29130665,signal pathway
10315,29130665,thyroid associated ophthalmopathy
10316,28781323,sitsh
10317,28781323,familial dysalbuminemic hyperthyroxinemia (fdh)
10318,28781323,thiamazole
10321,27160786,enlarged
10322,27160786,fluctuation
10323,27160786,hearing loss
10324,27160786,large
10325,27160786,risk factor
10326,27160786,vertigo
10327,27160786,vestibular aqueduct
10328,28756232,*akt/nf-κb
10329,28756232,*galectin-9
10330,28756232,*inflammation
10331,28756232,*thyroid-associated ophthalmopathy
10332,28756232,*tim3
10333,27558389,*auto-immune thyroid dysfunction
10334,27558389,*chordoma
10335,27558389,*tyrosine kinase inhibitors
10336,27718482,graves’ disease
10337,27718482,analytical interference
10338,27718482,biotin
10339,27718482,hyperestrogenism
10340,27718482,immunoassay
10343,27234136,células t reguladoras (tregs)
10344,27234136,enfermedad de graves
10345,27234136,graves’ disease
10346,27234136,hashimoto's thyroiditis
10347,27234136,t helper
10348,27234136,t regulatory cells (treg)
10349,27234136,th17
10350,27234136,thyroid autoimmunity
10351,27234136,tiroideas autoinmunitarias
10352,27234136,tiroiditis de hashimoto
10354,26459776,dna methylation
10355,26459776,epigenetics
10356,26459776,graves' disease
10357,26459776,t cell signaling
10358,26459776,tshr
10361,27267669,*fibroblast growth factor
10362,27267669,*graves’ ophthalmopathy
10363,27267669,*hyaluronan
10364,27267669,*orbital fibroblast
10365,27267669,*platelet-derived growth factor-bb
10366,27267669,*vascular endothelial growth factor
10367,28450690,*basedow’s disease
10368,28450690,*sjogren’s syndrome
10369,28450690,*autoimmune diseases
10370,28450690,*chronic myopathic type
10371,28450690,*sarcoid myopathy
10372,28333576,*epstein–barr virus
10373,28333576,*graves' disease
10374,28333576,*activation-induced cytidine deaminase
10375,28333576,*autoreactive b cells
10376,28333576,*polyclonal b cell activation
10377,28333576,*reactivation cois
10380,26854256,autoimmune diseases
10381,26854256,coeliac disease
10382,26854256,comorbidity
10384,28636775,autoimmune thyroid disease
10385,28636775,cd163
10386,28636775,fn14
10387,28636775,tweak
10388,27986127,*graves' disease
10389,27986127,*hyperthyroidism
10390,27986127,*irisin
10391,27986127,*myostatin
10394,27458112,apoptosis
10395,27458112,autoimmune thyroid disease
10396,27458112,intractability
10397,27458112,polymorphism
10398,27458112,severity
10399,28049375,*graves' disease
10400,28049375,*antithyroid drugs (atds)
10401,28049375,*comparative effectiveness
10402,28049375,*hyperthyroidism
10403,28049375,*radioactive iodine (rai)
10404,28049375,*thyroidectomy cois
10407,29102101,graves disease
10408,29102101,cardiogenic shock
10409,29102101,iodinated contrast
10410,29102101,thyroid storm
10411,29235358,glioblastoma multiforme
10412,29235358,learning curve brain neoplasm
10413,29235358,multi-disciplinary team
10414,28187375,8-ohdg
10415,28187375,graves's disease
10416,28187375,hashimoto thyroiditis
10417,28187375,papillary thyroid carcinoma
10419,26791860,acute graft-versus-host disease
10420,26791860,dna typing
10421,26791860,epistatic interaction
10422,26791860,genome diversity
10423,26791860,graft-versus-leukemia effect
10424,26791860,graves’ disease
10425,26791860,hla allele
10426,26791860,hla class i and class ii gene and molecule
10427,26791860,hla haplotype
10428,26791860,hashimoto thyroiditis
10429,26791860,linkage disequilibrium
10430,26791860,next-generation sequencing
10431,26791860,polymorphism
10432,26791860,regulatory t cell
10433,26791860,thyroglobulin antibody and serum level
10434,26791860,thyroid peroxidase antibody and serum level
10435,26791860,thyroid stimulating hormone receptor antibody and serum level
10436,26791860,unrelated hematopoietic stem cell transplantation
10437,26997461,goitre ovarien
10438,26997461,kyste ovaire
10439,26997461,ovarian cyst
10440,26997461,struma ovarii
10441,26997461,thyroid
10442,26997461,thyroïde
10443,28087387,*a proliferation-inducing ligand (april)
10444,28087387,*b-cell activating factor (baff)
10445,28087387,*graves' orbitopathy
10446,28087387,*orbital fibroblasts
10448,27729026,*goitre in pregnancy
10449,27729026,*iodine status in pregnancy
10450,27729026,*thyroid stimulating hormone
10451,27729026,*thyroid volume
10452,27729026,*urinary iodine
10454,28099999,*graves' disease
10455,28099999,*tshr autoantibodies
10456,28099999,*autoimmunity
10457,28099999,*intrathymic transcription
10458,28099999,*thyroid autoantigens
10459,28099999,*tolerance
10461,27345036,graves’ disease
10462,27345036,tgfbeta1
10463,27345036,nodular goiter
10464,27345036,papillary cancer
10465,27345036,thyroid
10466,27345036,transforming growth factor beta 1
10467,26518171,alopecia areata
10468,26518171,associations
10469,26518171,autoimmune disease
10470,26518171,comorbidities
10471,26518171,prevalence
10472,26518171,thyroid disease
10473,26518171,vitiligo
10474,28604944,graves’ orbitopathy
10475,28604944,adrenal insufficiency
10476,28604944,cortisol
10477,28604944,glucocorticoids
10478,28604944,methylprednisolone
10480,27245471,*autoimmune thyroid disease
10481,27245471,*chemokine
10482,27245471,*intractability
10483,27245471,*severity
10484,27245471,*single nucleotide polymorphism
10485,28595789,goitre prevalence
10486,28595789,iodine intake
10487,28595789,saharawi refugee camps
10488,28595789,urinary iodine concentration
10489,28595789,water iodine concentration
10490,27888493,goitre
10491,27888493,medical diagnosis
10492,27888493,painting
10493,27888493,de ribera
10496,28420934,"goitre, hyperthyroidism, hypothyroidism, thyroid nodules."
10497,29169383,multinodular goitre
10498,29169383,saudi arabia
10499,29169383,solitary nodule
10500,29169383,thyroid fine needle aspiration cytology
10501,26996162,airway obstruction
10502,26996162,goitre
10503,26996162,intratracheal
10504,26996162,intubation
10505,28521312,children
10506,28521312,goitre
10507,28521312,iodine prophylaxis
10508,28521312,thyroid volume
10509,28521312,ultrasound examination
10510,25880137,*iodine
10511,25880137,*cognition
10512,25880137,*development
10513,25880137,*goitre
10514,25880137,*thyroid hormones
10516,27364542,*esrd
10517,27364542,*tsh
10518,27364542,*nodular goiter
10519,27364542,*thyroid gland
10520,27364542,*urinary iodine excretion
10521,28474274,*endoscopic thyroidectomy
10522,28474274,*goiter
10523,28474274,*mediastinal emphysema
10524,28474274,*robotic thyroidectomy
10525,28474274,*subcutaneous emphysema
10526,26612322,advanced spectral imaging
10527,26612322,duel-energy computed tomography
10528,26612322,intranodular hemorrhage
10529,26612322,material decomposition
10530,26612322,thyroid nodule
10531,28098046,* ht-us hypoechoic pattern at thyroid ultrasound
10532,28098046,* iqr interquartile range
10533,28098046,* tpoab thyroperoxidase antibodies
10534,28098046,* tsh thyroid-stimulating hormone
10535,28098046,* tgab thyroglobulin
10536,28098046,* uie urinary i excretion
10537,28098046,*goitre
10538,28098046,*iodine intake
10539,28098046,*thyroid antibodies
10540,28098046,*thyroid diseases
10541,28858843,methimazole
10542,28858843,plasma exchange
10543,28858843,thrombotic thrombocytopenic purpura
10544,28858843,thyrotoxicosis
10545,28858843,toxic multinodular goiter
10549,27421794,epidemiology
10550,27421794,iodine
10551,27421794,iodine deficiency disorders
10552,27421794,iodine fortification
10553,27421794,prophylaxis
10554,27421794,risk of iodine fortification
10557,25994301,all-trans retinoic acid
10558,25994301,autoantibodies
10559,25994301,hashimoto’s thyroiditis
10560,25994301,γδ t cells
10562,27852654,*cardiomyopathies
10563,27852654,*cobalt
10564,27852654,*heart failure
10565,27852654,*hip prosthesis
10566,27852654,*polycythemia
10568,28613043,congenital hypothyroidism with defective dehalogenation of iodotyrosines
10569,28613043,cretinism
10570,28613043,endemic goiter
10571,28613043,iodine deficiency
10572,28613043,thyroid hormones and mental development
10573,27119700,thyroid nodule
10574,27119700,benign adenoma
10575,27119700,multinodular goiter
10576,27119700,thyroid cancer
10577,26527084,fish bone
10578,26527084,foreign body
10579,26527084,neck radiograph
10580,26527084,retropharyngeal abscess
10581,26527084,retropharyngeal goiter
10582,26527084,tonsillitis
10583,28585680,radioactive iodine
10584,28585680,thyroid cancer
10585,28585680,toxic multinodular goitre
10586,29589552,antithyroid medication
10587,29589552,graves' disease
10588,29589552,hashitoxicosis
10589,29589552,hyperthyroidism
10590,29589552,radioactive iodine
10591,29589552,subacute granulomatous thyroiditis
10592,29589552,thyroidectomy
10593,29589552,toxic adenoma
10594,29589552,toxic multinodular goiter.
10596,29871272,langerhans cell histiocytosis
10597,29871272,thyroid cois relevant financial relationships with commercial interests to disclose.
10599,28297755,interleukin-17
10600,28297755,micrornas
10601,28297755,thyroid neoplasms
10602,28712235,total thyroidectomy
10603,28712235,recurrent laryngeal nerve injury
10604,28712235,subtotal thyroidectomy
10605,28690737,struma ovarii
10606,28690737,malignant ovarian goiter
10607,28690737,thyroid cois
10608,28262255,cowden syndrome
10609,28262255,hamartomatous tumour
10610,28262255,multinodular goiter
10611,28262255,pten
10612,28262255,pten hamartoma tumour syndrome
10615,29415534,*pegylated interferon alpha
10616,29415534,*chronic hepatitis c
10617,29415534,*thyroid dysfunction
10620,29798345,cn0
10621,29798345,lymph node metastasis
10622,29798345,papillary thyroid carcinoma
10623,29798345,risk factors cois relevant financial relationships with commercial interests to disclose.
10624,27263038,calcifications
10625,27263038,doppler
10626,27263038,malignancy
10627,27263038,thyroid carcinoma
10628,27263038,thyroid nodule
10629,27263038,ultrasound
10631,26526666,dicer1 syndrome
10632,26526666,hodgkin lymphoma
10633,26526666,t cell type
10634,28569114,children
10635,28569114,goiter
10636,28569114,iodine deficiency disorders
10637,28569114,thyroid volume
10638,28569114,urinary iodine
10640,28476227,*congenital hypothyroidism
10641,28476227,*deiodinase
10642,28476227,*dysgenesis
10643,28476227,*dyshormonogenesis
10644,28476227,*goiter
10645,28476227,*resistance to thyroid hormone
10646,28476227,*thyroid hormone receptors
10649,27922153,*graves’ disease
10650,27922153,*guideline
10651,27922153,*hyperthyroidism
10652,27922153,*radioiodine therapy
10653,27922153,*thyrotoxicosis
10654,27922153,*toxic goiter
10659,26686396,*airflow
10660,26686396,*cfd
10661,26686396,*energy
10662,26686396,*power
10663,26686396,*trachea
10664,26686396,*work of breathing
10668,27913858,fnac
10669,27913858,frozen section
10670,27913858,multinodular goiter
10671,27913858,papillary carcinoma
10672,27913858,thyroid cancer
10673,27913858,thyroid nodule
10676,26876062,*goiter
10677,26876062,*medullary
10678,26876062,*multiple endocrine neoplasia (men)
10679,26876062,*parathyroid
10680,26876062,*thyroidectomy
10683,26511970,cyclooxygenase-2
10684,26511970,ep4 receptor
10685,26511970,microsomal prostaglandin e synthase-1
10686,26511970,papillary thyroid carcinoma
10687,26511970,prostaglandin e2
10690,28042647,*core-needle aspiration biopsy
10691,28042647,*cytokeratin 17
10692,28042647,*fine-needle aspiration biopsy
10693,28042647,*nodular goiter
10694,28042647,*thyroid
10696,28103777,iodine
10697,28103777,iodine deficiency.
10698,28103777,iodine prophylaxis
10699,28103777,metabolic pathway
10700,28103777,synthesis
10701,28103777,thyroid hormones
10702,28085013,il-23
10703,28085013,papillary thyroid carcinoma
10704,28085013,mir-15a
10705,28085013,mir-16
10706,28085013,mir-940
10709,28756521,anticholinesterase pesticide
10710,28756521,hypothyroidism
10711,28756521,poisoning
10712,28954336,"goiter, nodular"
10713,28954336,thyroid neoplasms
10714,28954336,"tomography, x-ray computed"
10715,27259353,diffuse goiter
10716,27259353,iodine intake
10717,27259353,subclinical hypothyroidism
10718,27259353,thyroid nodule
10719,27259353,universal salt iodization (usi)
10720,27259353,urinary iodine concentration (uic)
10721,28405949,endoscopic thyroidectomy
10722,28405949,minimally invasive thyroidectomy
10723,28405949,thyroid surgery
10728,26537235,atrial fibrillation
10729,26537235,elderly
10730,26537235,hyperthyroidism
10731,26537235,iodine
10732,26537235,thyreostatic therapy
10735,27152602,thyroid diseases
10736,27152602,autoimmunity
10737,27152602,iodization
10738,27152602,study
10746,28867693,congenital hypothyroidism
10747,28867693,genetics
10748,28867693,mutation
10749,28867693,newborn screening
10750,28867693,thyroid peroxidase (tpo)
10751,27510155,benign goiter
10752,27510155,complications
10753,27510155,routine data
10754,27510155,thyroid surgery
10755,27510155,volume outcome
10762,26708844,chylous fistula
10763,26708844,thoracic duct
10764,26708844,thyroid-surgery
10766,27405595,*thyroid
10767,27405595,*laser
10768,27405595,*nodule
10769,27405595,*thermal ablation
10770,27405595,*ultrasound
10772,27344303,classification
10773,27344303,juan rosai
10774,27344303,poorly differentiated carcinoma
10775,27344303,thyroid
10780,26708858,inferior thyroid artery
10781,26708858,multinodular goiter
10782,26708858,thyroidectomy
10783,28845837,*mazabraud syndrome
10784,28845837,*mccune-albright syndrome
10785,28845837,"*fibrous dysplasia, malignant transformation."
10786,28845837,*myxoma
10789,26443708,general surgery
10790,26443708,minimally invasive surgery
10791,26443708,robotics
10792,28276222,*ataxia telengiectasia
10793,28276222,*papillary thyroid carcinoma
10795,26886166,dicer1
10796,26886166,laser capture microdissection
10797,26886166,mutation
10798,26886166,well-differentiated fetal adenocarcinoma
10799,26886166,β-catenin
10800,26884118,*68ga
10801,26884118,*cck2 receptor
10802,26884118,*pet/ct
10803,26884118,*medullary thyroid carcinoma
10804,26884118,*somatostatin receptor
10805,27094775,hashimotos
10806,27094775,hypothyroidism
10807,27094775,thyroiditis
10809,29050166,lymphoma
10810,29050166,pathology
10811,29050166,thyroid
10812,29050166,ultrasonography
10814,27784321,*case report
10815,27784321,*cervical sympathetic chain damage
10816,27784321,*horner’s syndrome
10817,27784321,*thyroidectomy
10819,27025990,*children
10820,27025990,*congenital hypothyroidism
10821,27025990,*cáncer de tiroides
10822,27025990,*hipotiroidismo congénito
10823,27025990,*ionising radiation
10824,27025990,*niños
10825,27025990,*radiación ionizante
10826,27025990,*thyroid cancer
10827,29038858,parathyroidectomy
10828,29038858,radiology
10829,29038858,synchronous thyroid pathology
10830,27530498,intra-operative
10831,27530498,pth
10832,27530498,post operative hypocalcemia
10833,27530498,thyroidectomy
10834,27121690,hyperthyroidism
10835,27121690,lithium
10836,27121690,radioactive iodine ablation
10837,27121690,thyroxine
10838,26884115,biopsy
10839,26884115,fine-needle biopsy
10840,26884115,thyroid cancer
10841,26884115,thyroid nodule
10842,26884115,thyroiditis
10848,26577641,basal cell carcinoma
10849,26577641,basal cell nevus syndrome
10850,26577641,dicer1 syndrome
10851,26577641,familial adenomatous polyposis
10852,26577641,pilomatrixoma
10853,26577641,pleuropulmonary blastoma
10855,28694722,acute illness
10856,28694722,guidelines
10857,28694722,thyroid tests cois
10858,28387096,diagnosis
10859,28387096,fnmtc
10860,28387096,genetic
10861,28387096,hereditary
10862,28387096,familial thyroid cancer
10865,28648507,*pax8
10866,28648507,*tshr
10867,28648507,*congenital hypothyroidism
10868,28648507,*hormone resistance
10869,28648507,*mutations
10870,28648507,*subclinical hypothyroidism
10871,28490006,adenoid cystic carcinoma
10872,28490006,cytopathology
10873,28490006,fine needle aspiration
10874,28490006,larynx
10875,28490006,thyroid
10876,27756965,*chlorpheniramine
10877,27756965,*drug-induced torsades de pointes
10878,27756965,*propranolol
10880,28276223,*kocher-debre-semelaigne syndrome
10881,28276223,*atrophic autoimmune thyroiditis
10882,28276223,*pituitary expansion
10883,28276223,*rickets
10884,27387245,*hypocalcemia
10885,27387245,*postoperative hypoparathyroidism
10886,27387245,*teriparatide
10888,29275552,hyperthyroidism
10889,29275552,blood chemical analysis
10890,29275552,case analysis
10891,29275552,"death, sudden, cardiac"
10892,29275552,forensic pathology cois relevant financial relationships with commercial interests to disclose.
10895,28479907,diagnostic accuracy
10896,28479907,cytology
10897,28479907,fine needle aspiration
10898,28479907,tertiary hospital
10899,28479907,thyroidectomy
10900,27162199,fnab
10901,27162199,immunohistochemistry
10902,27162199,neuroendocrine tumors
10903,27162199,thyroid paraganglioma
10906,27041628,fluorescence
10907,27041628,fluorescence-guided surgery
10908,27041628,indocyanine green
10909,27041628,near-infrared imaging
10910,27041628,parathyroid
10911,27041628,thyroidectomy
10913,28291538,anca anti-protéinase 3 (pr3-anca)
10914,28291538,anti-neutrophil cytoplasmic antibody (anca)
10915,28291538,anticorps anti-cytoplasme des neutrophiles (anca)
10916,28291538,propylthiouracil
10917,28291538,propylthiouracile
10918,28291538,proteinase3-anca (pr3-anca)
10919,28291538,pyoderma gangrenosum
10920,27520400,*c-reactive protein
10921,27520400,*resveratrol
10922,27520400,*resveratrol (pubchem cid: 445154)
10923,27520400,*type 2 diabetes mellitus
10924,27091372,laryngeal nerves
10925,27091372,prospective study
10926,27091372,recurrent laryngeal nerve
10927,27091372,recurrent laryngeal nerve injuries
10928,27091372,thyroidectomy
10931,28952196,c-cell
10932,28952196,ret mutation
10933,28952196,minute medullary thyroid carcinoma
10934,28952196,solid cell nests
10935,28025468,t1-weighted imaging
10936,28025468,fetus
10937,28025468,magnetic resonance imaging
10938,28025468,thyroid cois interest.
10939,27233786,diabetes mellitus
10940,27233786,hormone replacement therapy
10941,27233786,hypercalcemia
10942,27233786,hypertension
10943,27233786,osteoporosis
10944,29798949,carcinoma
10945,29798949,papillary
10946,29798949,thyroid cois
10947,28389458,drug interaction
10948,28389458,levothyroxine
10949,28389458,ritonavir
10951,28756810,high iodine
10952,28756810,iodine deficiency
10953,28756810,thyroglobulin
10954,28294052,cognition
10955,28294052,iodine deficiency
10956,28294052,iodine excess
10957,28294052,neurodevelopment
10958,28294052,pregnancy
10959,28294052,prophylaxis.
10961,29871097,"carcinoma, papillary"
10962,29871097,lymph node metastasis
10963,29871097,thyroid neoplasms cois relevant financial relationships with commercial interests to disclose.
10968,28688118,dicer1
10969,28688118,acute transient hepatitis
10970,28688118,monozygotic twins
10971,28688118,pleuropulmonary blastoma
10972,27105534,gene expression profile
10973,27105534,hypoxia
10974,27105534,microenvironment
10975,27105534,oncogenes
10976,27105534,thyroid cancer cois
10977,26193980,fnab
10978,26193980,nodule depth
10979,26193980,pain
10980,26193980,thyroid nodule
10981,26193980,vas score
10982,28196954,*metformin
10983,28196954,*thyroid cancer
10984,28196954,*thyroid disease
10985,28196954,*thyroid nodule
10986,28196954,*thyrotropin
10987,28188700,afirma
10988,28188700,fna
10989,28188700,cytology
10990,28188700,thyroid nodules
10992,28317625,*autoimmunity
10993,28317625,*hyperthyroidism
10994,28317625,*hypothyroidism
10995,28317625,*pulmonary hypertension
10996,28317625,*trab
10997,28229359,calcitonin
10998,28229359,pregnancy
10999,28229359,thyroid volume
11001,27461263,hyperthyroidism
11002,27461263,papillary thyroid cancer
11003,27461263,thyroid cancer
11004,27245300,*biokinetics
11005,27245300,*hyperthyroidism
11006,27245300,*internal dosimetry
11007,27245300,*radioiodine therapy
11008,27013327,ablation
11009,27013327,nodule
11010,27013327,radiofrequency
11011,27013327,thyroid
11012,26931517,patient safety
11013,26931517,resident involvement
11014,26931517,resident participation
11015,26931517,surgical education
11016,26931517,thyroid
11017,26744989,drinking water
11018,26744989,ion chromatography
11019,26744989,method development
11020,26744989,nis inhibitors
11021,29102947,*cancer
11022,29102947,*cardiovascular disease
11023,29102947,*end-stage renal disease
11024,29102947,*hypothyroidism
11025,29102947,*thyroid abnormalities
11026,29102947,*thyroid nodules
11027,29102947,*waiting list for renal transplant
11028,28432675,mini-invasive thyroidectomy
11029,28432675,thyroid
11030,28432675,thyroidectomy
11031,28432675,transoral thyroidectomy
11034,28684081,adherence to diet
11035,28684081,attitude towards diet
11036,28684081,body mass index
11037,28684081,meal plan
11038,28684081,type 2 diabetes mellitus
11039,28034775,*intra-operative neuro-monitoring
11040,28034775,*re-operation
11041,28034775,*recurrent laryngeal nerve palsy
11042,28034775,*thyroid cancer
11043,28034775,*thyroidectomy
11044,28238190,*pentraxin 3
11045,28238190,*resveratrol
11046,28238190,*total antioxidant status
11047,28238190,*type 2 diabetes mellitus
11048,27071746,all-cause mortality
11049,27071746,cardiovascular mortality
11050,27071746,cardiovascular risk
11051,27071746,mediterranean diet
11052,28982849,*thyroid
11053,28982849,*immunohistochemistry
11054,28982849,*lymph node metastasis
11055,28982849,*papillary thyroid carcinoma
11056,28982849,*sphingosine kinase 1
11057,28791817,binder syndrome
11058,28791817,bone graft
11059,28791817,cartilage graft
11060,28791817,maxillary underdevelopment
11061,28791817,resorption
11062,26932954,*4d ct
11063,26932954,*parathyroid adenoma
11064,26932954,*parathyroid hyperplasia
11065,26932954,*sestamibi scintigraphy
11066,26246426,hypothyroidism
11067,26246426,end-stage renal disease
11068,26246426,hemodialysis
11069,26246426,thyroid nodule
11070,28626131,congenital hypothyroidism
11071,28626131,duoxa2
11072,28626131,genetics
11073,28626131,mutation
11074,28626131,newborn screening
11075,28387647,thyroid nodule
11076,28387647,frozen section fine-needle aspiration biopsy.
11077,28387647,papillary carcinoma
11078,28387647,thyroidectomy
11079,28250870,*congenital hypothyroidism
11080,28250870,*growth retardation
11081,28250870,*mental retardation cois
11082,27488391,breast and endometrial cancer
11083,27488391,cowden syndrome
11084,27488391,multiple meningiomas
11085,27488391,pten hamartoma
11086,27488391,radiology
11087,26786663,tc99m sestamibi scintigraphy
11088,26786663,primary hyperparathyroidism
11089,26786663,thyroid disorder
11090,26786663,thyroid pathology
11091,26786663,ultrasonography
11093,28703115,completion lymphadenectomy
11094,28703115,tall-cell variant
11095,28703115,thyroid carcinoma
11096,26780986,hypocalcemia
11097,26780986,hypoparathyroidism
11098,26780986,parathyroid hormone
11099,26780986,thyroidectomy
11100,26780986,vitamin d
11101,26711165,assays
11102,26711165,biomarker
11103,26711165,differentiated thyroid cancers
11104,26711165,thyroglobulin
11110,29059259,*bone metabolism markers
11111,29059259,*hyperthyroidism
11112,29059259,*sclerostin
11113,28109483,global health
11114,28109483,haiti
11115,28109483,head and neck surgery
11116,28109483,otolaryngology
11117,27744598,99mtc-mibi
11118,27744598,autonomously functioning thyroid nodules
11119,27744598,parathyroid carcinoma
11120,27744598,parathyroid scintigraphy
11124,28604619,cancer
11125,28604619,flavonoid
11126,28604619,invasiveness
11127,28604619,iodide uptake
11128,28604619,phytochemical
11129,28604619,proliferation
11130,28604619,radioiodine therapy
11131,28604619,sodium iodide symporter (nis)
11132,28604619,thyroid cois
11133,26983701,dicer-1
11134,26983701,pleuropulmonary blastoma
11135,26983701,sertoli-leydig cell tumor
11136,26983701,thyroid carcinoma
11137,26983701,familial neoplasia
11139,28506409,bethesda classification
11140,28506409,guidelines
11141,28506409,lobectomy
11142,28506409,thyroid
11143,28506409,thyroid carcinoma
11144,28506409,thyroidectomy
11145,27639841,abtpo
11146,27639841,autoimmune thyroid diseases
11147,27639841,autoimmune thyroiditis
11148,27639841,hypothyroidism
11149,27639841,organ specific autoimmune diseases
11150,27639841,systemic rheumatological disorders
11152,28189449,hyperthyroidism
11153,28189449,lymphadenectomy
11154,28189449,pediatric thyroidectomy
11155,28189449,total thyroidectomy
11156,28189449,transient hypocalcemia
11157,27208531,computer-aided diagnosis
11158,27208531,medical imaging
11159,27208531,morphometry
11163,27809694,*us elastography
11164,27809694,*fibronectin-1
11165,27809694,*fibrosis
11166,27809694,*galectin-3
11167,27809694,*indeterminate cytology
11168,27809694,*thyroid nodules
11169,27833458,*epidemiology
11170,27833458,*monitoring
11171,27833458,*prevalence trend
11172,27833458,*thyroid disorders
11173,27288566,elderly
11174,27288566,harmonic
11175,27288566,ligasure
11176,27288566,thyroidectomy
11177,27288566,vessel sealing
11180,26838584,growth hormone deficiency
11181,26838584,hypothyroidism
11182,26838584,pituitary hyperplasia
11184,28025932,*global health
11185,28025932,*humanitarian
11186,28025932,*quality of life
11187,28025932,*resource limited
11188,28025932,*thyroid
11189,28025932,*thyroidectomy
11191,28039060,*calcium prophylaxis
11192,28039060,*hypocalcemia
11193,28039060,*oral calcium
11194,28039060,*parathyroid hormone
11195,28039060,*thyroidectomy
11200,28870235,barley young leaf
11201,28870235,chronic lymphocytic thyroiditis
11202,28870235,hypothyroidism
11203,28870235,isoflavones
11204,28870235,soybean
11205,28870235,thin-layer chromatography
11206,28870235,kale cois from the patient for publication of this case report and any accompanying images. a copy of the written consent is available for review by the editor-in-chief of this journal. competing interests: the authors declare that they have no competing interests. publisher’s note: springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
11207,28222777,*dicer1 mutations
11208,28222777,*dicer1 syndrome
11209,26970173,*27 kd heat-shock protein
11210,26970173,*antioxidants
11211,26970173,*oxidants
11212,26970173,*thyroid tumors
11213,26370671,diagnostic
11214,26370671,foxe1
11215,26370671,follicular thyroid lesion
11216,26370671,pax8
11217,26370671,ttf-1
11218,26370671,thyroid nodules
11220,26796150,24-h urine
11221,26796150,adults
11222,26796150,benin
11223,26796150,icp-ms
11224,26796150,iodine
11225,26289771,dicer1
11226,26289771,mirna
11227,26289771,ovarian cancer
11228,26289771,sarcoma
11229,26289771,sertoli-leydig cell tumor cois interest to disclose.
11231,28964290,hearing loss
11232,28964290,slc26a4
11233,28964290,whole exome sequencing cois to report.
11238,26795600,cerebral cavernous malformation (ccm)
11239,26795600,cerebrovascular disease
11240,26795600,cytochrome p450 (cyp)
11241,26795600,disease severity
11242,26795600,familial cerebral cavernous malformation type 1
11243,26795600,free radicals
11244,26795600,genetic markers set association study
11245,26795600,inter-individual variability in disease susceptibility and outcome
11246,26795600,intracerebral hemorrhage
11247,26795600,krit1/ccm1
11248,26795600,matrix metalloproteinase (mmp)
11249,26795600,oxidative stress
11250,26795600,reactive oxygen species (ros)
11251,26795600,vascular brain lesions
12866,20463839,complications
12867,20463839,retrosternal goitre
12868,20463839,sternotomy
12869,20463839,surgical treatment
12870,20463839,thyroid
12991,19270831,graves' disease
12992,19270831,hantaan virus
12993,19270831,hemorrhagic fever with renal syndrome
13267,19759882,biometry
13268,19759882,eye abnormalities
13269,19759882,graves’
13270,19759882,graves’ disease
13271,19759882,ophthalmopathy
13272,19759882,photography
13351,19568361,drug-induced hypersensitivity
13352,19568361,graves' disease
13353,19568361,hyperthyroidism
13354,19568361,iodine therapy
13355,19568361,vogt-koyanagi-harada disease
13437,19547630,graves’ disease
13438,19547630,endocrine orbitopathy
13439,19547630,impaired earning capacity
13440,19547630,occupational disability
13441,19547630,quality of life
13903,20463832,stem cells
13904,20463832,thyroid
13905,20463832,thyroid cancer
13906,20463832,tissue repair
14097,19606248,calcitonin
14098,19606248,false-positive test
14099,19606248,ret mutation
14100,19606248,total thyroidectomy
14111,32548696,compression symptoms
14112,32548696,fine needle aspiration cytology
14113,32548696,operative indications
14114,32548696,thyroid gland
14115,32548696,thyroid imaging reporting and data system
14116,32780357,goiter
14117,32780357,goiters
14118,32780357,intrathoracic goiter
14119,32780357,intrathoracic
14120,32780357,substernal
14122,33445947,retrosternal goiter – sternotomy – thoracotomy − thyroid gland disease − vocal  cord paresis
14123,34941205,retrosternal goiter
14124,34941205,simultaneous surgery
14125,34941205,sternotomy
14126,32929476,*graves disease
14127,32929476,*tsh receptor antibodies
14128,32929476,*antithyroid drugs
14129,32929476,*diagnosis
14130,32929476,*management
14131,32929476,*radioactive iodine
14132,32929476,*thyroidectomy
14133,32929476,*treatment
14135,34151940,american medicine
14136,34151940,benjamin smith barton
14137,34151940,goiter
14138,34151940,medical geography
14139,33069387,*enfermedad de graves-basedow
14140,33069387,*glucocorticoides
14141,33069387,*glucocorticoids
14142,33069387,*graves-basedow disease
14143,33069387,*graves’ ophthalmopathy
14144,33069387,*inflamación orbitaria
14145,33069387,*orbitopathy
14146,33069387,*orbitopatía
14147,33069387,*rituximab
14148,33069387,*teprotumumab
14149,33069387,*tocilizumab
14150,33835415,art and medicine
14151,33835415,epifania benintendi
14152,33835415,florence
14153,33835415,nodal goitre
14155,34288592,aspiration cytology
14156,34288592,dyshormonogenetic goiter
14157,34288592,thyroid
14158,33895978,dante alighieri
14159,33895978,goiter
14160,33895978,history
14161,33895978,middle ages
14167,32059832,*cxcl10
14168,32059832,*cxcr3
14169,32059832,*graves' disease
14170,32059832,*graves' ophthalmopathy
14171,32059832,*th1 immune response
14172,32059832,*teprotumumab cois
14174,33878810,*congenital hypothyroidism
14175,33878810,*literacy
14176,33878810,*cognitive dysfunction
14177,33878810,*indigenous population
14178,33878810,*prenatal care
14179,33878810,*chronic malnutrition
14180,33878810,*social vulnerability cois
14181,32472406,art
14182,32472406,drawing
14183,32472406,endemic
14184,32472406,endocrinology
14185,32472406,goiter
14186,33995810,goiter
14187,33995810,follicular carcinoma
14188,33995810,lymphoma
14189,33995810,malignancy
14190,33995810,papillary carcinoma cois
14191,32970371,rose
14192,32970371,us-fna
14193,32970371,amyloid
14194,32970371,amyloid goiter
14195,32970371,interventional pathologist
14196,34149612,*graves’ disease
14197,34149612,*autoimmune
14198,34149612,*goiter
14199,34149612,*growth factor
14200,34149612,*hormone
14201,34149612,*ophthalmopathy
14202,34149612,*thyroid cois autoimmune disease and consultancy for horizon therapeutics consultant immunovant.
14205,33507686,diet
14206,33507686,goiter
14207,33507686,helicobacter pylori
14208,33507686,gastric carcinoma
14209,33507686,stature
14210,33396042,endemic goiter
14211,33396042,hypo-and hyperthyroidism
14212,33396042,iodine nutrition
14213,33396042,thiocyanate
14214,33396042,thyroid echogenicity/cytomorphology
14217,33607721,cardiovascular diseases
14218,33607721,methylarginines
14219,33607721,multinodular goiter
14220,33607721,thyroid
14221,32500695,hypoparathyroidism
14222,32500695,laryngeal paresis
14223,32500695,polidocanol
14224,32500695,recurrent nodular goiter
14225,32500695,sclerotherapy
14227,32107168,*graves’ disease
14228,32107168,*th1 chemokines
14229,32107168,*epidemiology
14230,32107168,*hepatitis c virus
14231,32107168,*risk factors
14232,32107168,*viruses cois
14233,32893229,cardiopulmonary arrest
14234,32893229,intrathoracic goiter
14235,32893229,phrenic nerve paralysis cois
14236,33409915,multinodular goiter
14237,33409915,thyroid adenoma
14238,33409915,thyroid cancer
14239,33409915,trace elements
14240,34245984,goiter
14241,34245984,risk factors
14242,34245984,trace elements
14243,34707013,maximum density of ct
14244,34707013,nodular goiter
14245,34707013,parathyroid lesions
14246,34707013,single-photon emission computed tomography/computed tomography
14248,33574798,*graves’ hyperthyroidism
14249,33574798,*graves’ orbitopathy
14250,33574798,*oxidative stress
14251,33574798,*reactive oxygen species
14252,33574798,*selenium
14253,33574798,*selenocysteine
14254,33574798,*selenoproteins cois commercial or financial relationships that could be construed as a potential conflict of interest.
14255,32493403,antithyroid drug
14256,32493403,block-replace therapy
14257,32493403,case report
14258,32493403,fetal goiter
14259,32493403,perinatal management
14260,32493403,triiodothyronine-predominant graves’ disease cois
14262,33804853,goiter
14263,33804853,sternotomy
14264,33804853,thyroidectomy cois
14266,33396135,association
14267,33396135,case-control study
14268,33396135,mineral elements
14269,33396135,thyroid function
14270,33396135,thyroid tumor and goiter
14271,34628753,acupoint indications
14272,34628753,acupoints at the upper arms
14273,34628753,goiter
14274,34628753,scrofula
14275,34628753,specific effect
14278,32078117,*congenital hypothyroidism
14279,32078117,*gene mutation
14280,32078117,*tpo deficiency
14281,32078117,*thyroid dyshormonogenesis
14282,31907822,endemic
14283,31907822,goiter
14284,31907822,iconography
14285,31907822,surgery
14286,32474859,b-cell lymphoma
14287,32474859,hashimoto’s thyroiditis
14288,32474859,core needle biopsy
14289,32474859,fine needle aspiration cytology
14290,32474859,primary thyroid lymphoma
14292,32824922,*nf-e2-related factor 2
14293,32824922,*goiter
14294,32824922,*micrornas
14295,32824922,*thyroid neoplasms
14296,32824922,*vascular endothelial growth factor a cois commercial or financial relationships that could be construed as a potential conflict of interest.
14297,34244226,endocrine
14298,34244226,instrumentation
14299,34244226,radioactive iodine therapy
14300,34244226,radioactive iodine uptake
14301,34244226,radionuclide therapy
14302,34244226,substernal goiter
14305,33468112,*excessive iodine
14306,33468112,*goiter
14307,33468112,*iodization
14308,33468112,*school children
14309,33468112,*southern ethiopia cois
14310,31994506,aortic window
14311,31994506,ectopia
14312,31994506,hyperparathyroidism
14313,31994506,parathyroid adenoma
14314,31994506,thoracoscopy
14315,34167409,*intrathoracic goiter
14316,34167409,*ablation technique
14317,34167409,*ultrasound
14318,33579801,*diffuse and nodular goiter
14319,33579801,*lab tests for benign thyroid disorders
14320,33579801,*primary autoimmune hypothyroidism
14321,33579801,*radionuclide imaging
14322,33579801,"*subacute, destructive thyroiditis"
14323,33579801,*ultrasound imaging
14328,32341696,children
14329,32341696,dental pathology
14330,32341696,diffuse nontoxic goiter
14331,32341696,local protective mechanisms
14334,33837650,*anatomy
14335,33837650,*development
14336,33837650,*embryology
14337,33837650,*retrosternal goiter
14338,33837650,*thyroidectomy
14345,33310200,nodular goiter
14346,33310200,papillary thyroid carcinoma
14347,33310200,polycyclic aromatic hydrocarbon
14348,33310200,risk assessment cois competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
14349,32320467,*15 mci
14350,32320467,*fixed activity
14351,32320467,*hyperthyroidism
14352,32320467,*radioiodine
14353,32320467,*toxic multinodular goiter
14354,32320467,*volume reduction
14356,33980774,graves disease
14357,33980774,hyperthyroidism
14358,33980774,large goiter
14359,33980774,radioiodine therapy
14363,34220711,*congenital hypothyroidism
14364,34220711,*fetal goiter
14365,34220711,*growth
14366,34220711,*mutations
14367,34220711,*neuropsychological evaluation
14368,34220711,*thyroid peroxidase cois commercial or financial relationships that could be construed as a potential conflict of interest.
14369,33878943,retrosternal goiter
14370,33878943,acromegaly
14371,33878943,airway management
14372,33878943,anesthesia
14373,33878943,case report
14374,33878943,multidisciplinary strategy
14375,33878943,tracheal compression cois conflict of interest.
14377,33391188,*graves’ disease
14378,33391188,*asymmetry
14379,33391188,*exophthalmos
14380,33391188,*hyperthyroidism
14381,33391188,*unilateral cois commercial or financial relationships that could be construed as a potential conflict of interest.
14384,32812038,*15 mci
14385,32812038,*fixed activity
14386,32812038,*hyperthyroidism
14387,32812038,*radioiodine
14388,32812038,*toxic multinodular goiter
14389,32812038,*volume reduction
14390,33252592,*grave’s disease
14391,33252592,*trab
14392,33252592,*ft3:ft4 ratio
14394,31984866,*graves' disease
14395,31984866,*dementia
14396,31984866,*epidemiology
14397,31984866,*hyperthyroidism
14398,31984866,*toxic nodular goiter
14401,32633627,*anaplastic thyroid cancer
14402,32633627,*gene mutation
14403,32633627,*thyroglobulin
14404,32633627,*thyroid dyshormonogenesis
14406,31950881,*graves' disease
14407,31950881,*chronic lymphocytic thyroiditis
14408,31950881,*incidental thyroid microcarcinomas
14409,31950881,*multinodular goiter
14410,31950881,*papillary thyroid cancer
14411,31950881,*papillary thyroid microcarcinomas
14412,32495658,thyroid surgery
14413,32495658,anesthesia
14414,32495658,gastrointestinal intubation
14415,32495658,goiter
14416,32495658,intratracheal intubation
14417,32495658,nasogastric tube
14425,33619720,graves’ disease
14426,33619720,coronary artery spasm
14427,33619720,myocardial infarction
14428,33619720,thyrotoxicosis
14429,33735381,*graves orbitopathy
14430,33735381,*cholesterol
14431,33735381,*statins
14432,32729049,compressive optic neuropathy
14433,32729049,dysthyroid optic neuropathy
14434,32729049,graves orbitopathy
14435,32729049,orbital decompression
14436,32729049,stretch optic neuropathy
14437,32729049,thyroid eye disease
14438,32749654,graves’ orbitopathy
14439,32749654,pathogenesis
14440,32749654,thyrotropin receptor
14441,32749654,thyrotropin receptor antibodies cois
14442,33655885,graves' orbitopathy
14443,33655885,graves’ disease
14444,33655885,graves’ ophthalmopathy
14445,33655885,thyroid diseases
14447,32826306,*oesophageal varices cois
14448,34112358,biomarkers
14449,34112358,dietary reference values
14450,34112358,estimated average requirement cut-point method
14451,34112358,goiter
14452,34112358,goitrogens
14453,34112358,iodine
14454,34112358,iodine deficiency disorders
14455,34112358,"thyroid hormones, salt iodization"
14456,34112358,urinary iodine concentration
14458,34867996,*graves’ disease
14459,34867996,*hashimoto’s thyroiditis
14460,34867996,*autoimmune thyroid diseases (aitd)
14461,34867996,*exosomes
14462,34867996,*immune regulation cois commercial or financial relationships that could be construed as a potential conflict of interest.
14463,33484076,orbital disease
14464,33484076,thyroid eye disease
14465,33484076,thyroid ophthalmopathy
14466,32326785,chorioretinal folds
14467,32326785,grave’s ophthalmopathy
14468,32326785,choroidal folds
14469,32326785,thyroid eye disease
14470,32326785,thyroid orbitopathy
14471,32663624,autoimmunity
14472,32663624,hashimoto's thyroiditis
14473,32663624,helicobacter pylori
14474,32663624,hepatitis c
14475,32663624,mimicry
14476,32663624,thyroid cois declare. the authors did not recieve any funding from any institution for this article.
14477,33387353,art
14478,33387353,graves' disease
14479,33387353,thyroid swelling
14482,34680964,*pendred syndrome
14483,34680964,*whole-exome sequencing
14484,34680964,*genotype-phenotype correlation cois
14487,34362755,covid-19
14488,34362755,thyroid disease cois
14491,33011882,*chemiluminescence
14492,33011882,*cytochrome p450 reductase
14493,33011882,*cytochrome b5-reductase
14494,33011882,*nontoxic nodular goiter
14495,33011882,*papillary thyroid cancer
14496,33011882,*toxic goiter
14500,32880074,anterior
14501,32880074,computed tomography
14502,32880074,magnetic resonance imaging
14503,32880074,mediastinum
14510,34029917,cochlear implant
14511,34029917,deafness
14512,34029917,enlarged vestibular aqueduct
14513,34029917,hearing aid
14514,34029917,hearing loss
14515,34029917,incomplete partition
14516,34029917,pendred syndrome
14517,33619715,graves’ orbitopathy
14518,33619715,exophthalmos
14519,33619715,meningioma
14524,34410066,graves’ disease
14525,34410066,graves’ ophthalmopathy
14526,34410066,ted
14527,34410066,monoclonal antibodies
14528,34410066,thyroid eye disease
14530,32571507,benign
14531,32571507,goiter
14532,32571507,graves’ disease
14533,32571507,pediatric
14534,32571507,thyroid
14536,34033289,*implications
14537,34033289,*iodine deficiency
14538,34033289,*pregnancy
14540,35004341,*graves’ disease
14541,35004341,*graves’ orbitopathy (go)
14542,35004341,*lactobacillus
14543,35004341,*prevotella
14544,35004341,*tshr (thyroid-stimulating hormone receptor)
14545,35004341,*th17 and treg cells
14546,35004341,*veillonella
14547,35004341,*gut microbiota cois commercial or financial relationships that could be construed as a potential conflict of interest.
14548,34026662,*16s rrna
14549,34026662,*graves’ disease
14550,34026662,*clinical parameters
14551,34026662,*gut microbiota
14552,34026662,*next-generation sequencing cois commercial or financial relationships that could be construed as a potential conflict of interest.
14553,33449383,*graves' disease
14554,33449383,*hashimoto's thyroiditis
14555,33449383,*interferon lambda 1
14556,33449383,*interleukin-29
14557,33449383,*subacute thyroiditis
14558,34182968,dilated cardiomyopathy
14559,34182968,ethiopia
14560,34182968,methimazole
14561,34182968,propylthiouracil
14562,34182968,thyrotoxicosis
14563,34182968,β-blocker cois
14564,34855196,graves’ disease (gd)
14565,34855196,antithyroid drugs (atds)
14566,34855196,radioactive iodine (rai)
14567,34855196,total thyroidectomy (tt)
14568,30927742,*graves’ disease
14569,30927742,*factitious disorders
14570,30927742,*thyroxine
14571,33445994,graves’ disease
14572,33445994,intelligent diagnosis
14573,33445994,deep learning
14574,33445994,diagnostic performance
14575,33445994,nuclear medicine residents
14576,33445994,subacute thyroiditis
14577,33445994,thyroid disease
14578,33445994,thyroid scintigraphy cois conflict of interest.
14580,33515213,graves’ disease
14581,33515213,graves’ ophthalmopathy
14582,33515213,graves’ orbitopathy
14583,33515213,thyroglobulin cois as prejudicing the impartiality of the research reported.
14584,31919775,corticosteroids
14585,31919775,graves’ disease
14586,31919775,tshr
14587,31919775,thyroid eye disease
14588,32893226,cushing's syndrome
14589,32893226,graves' disease
14590,32893226,central hypothyroidism
14591,32893226,syndrome of inappropriate secretion of thyroid-stimulating hormone cois
14594,33487459,adipose tissue
14595,33487459,glande thyroïde
14596,33487459,thyroid gland
14597,33487459,thyrolipoma
14598,33487459,thyrolipomatose
14599,33487459,thyrolipomatosis
14600,33487459,thyrolipome
14601,33487459,tissu adipeux
14602,34965078,*graves’ disease
14603,34965078,*radioiodine therapy
14604,34965078,*thyroid eye disease
14605,34965078,*thyroidectomy
14610,34969797,ear
14611,34969797,nose and throat/otolaryngology
14612,34969797,vascular surgery cois
14613,34118212,cancer de la thyroïde
14614,34118212,goitre multinodulaire
14615,34118212,multinodular goiter
14616,34118212,mutation du gène pds
14617,34118212,pds gene mutation
14618,34118212,pendred syndrome
14619,34118212,syndrome de pendred
14620,34118212,thyroid cancer
14621,34195868,hypocalcemia
14622,34195868,hypoparathyroidism
14623,34195868,indocyanine green (icg)
14624,34195868,near-infrared autofluorescence (nir-af)
14625,34195868,near-infrared fluorescence imaging (nifi)
14626,34195868,parathyroid glands (pgs)
14627,34195868,thyroid surgery
14628,34195868,total thyroidectomy
14629,33112798,*graves’ orbitopathy
14630,33112798,*binding immunoglobulin protein
14631,33112798,*endoplasmic reticulum stress
14632,33112798,*thyroid eye disease
14633,33112798,*unfolded protein response
14635,32638234,graves’ disease
14636,32638234,pancytopenia
14637,32638234,review
14640,33685911,pericardial disease
14641,33685911,thyroid disease cois
14642,33462034,calcium and bone
14643,33462034,hyperthyroidism cois
14651,32765422,*graves' disease
14652,32765422,*autoimmunity
14653,32765422,*hyperthyroidism
14654,32765422,*inflammation
14655,32765422,*natural killer cells
14656,33557156,*22q11.2 deletion syndrome
14657,33557156,*down syndrome
14658,33557156,*graves’ disease
14659,33557156,*hashimoto’s thyroiditis
14660,33557156,*klinefelter syndrome
14661,33557156,*prader–willi syndrome
14662,33557156,*rasopathies
14663,33557156,*turner syndrome
14664,33557156,*williams syndrome
14665,33557156,*genetic syndromes cois
14666,33661574,antithyroid drugs
14667,33661574,hepatitis
14668,33661574,hyperthyroidism
14669,33661574,plasma exchange
14670,33661574,plasmapheresis
14673,34303550,basedow
14674,34303550,dysthyroidism
14675,34303550,dysthyroïdie
14676,34303550,glaucoma
14677,34303550,glaucome
14678,34303550,graves’ disease
14679,34303550,hypertonie intra-oculaire
14680,34303550,ocular hypertension
14681,34725062,cardiothoracic surgery
14682,34725062,otolaryngology / ent
14683,34725062,thyroid disease cois
14684,34753719,hepatitis other
14685,34753719,thyrotoxicosis cois
14687,32441005,antithyroid drugs
14688,32441005,covid-19
14689,32441005,glucocorticoids
14690,32441005,graves’ disease
14691,32441005,graves’ orbitopathy cois
14693,33789121,alkaloid
14694,33789121,cyanogenic glucoside
14695,33789121,flavonoid
14696,33789121,phytochemical
14697,33789121,polyphenol
14698,33789121,thyroid
14699,32157663,art
14700,32157663,history
14701,32157663,thyroid swelling
14705,31948703,*epidemiology
14706,31948703,*goiter
14707,31948703,*national inpatient sample
14708,31948703,*predictive factors
14709,31948703,*thyroid disease
14710,31948703,*thyroidectomy cois conflicts of interest to disclose.
14711,33420947,*lingual thyroid
14712,33420947,*oropharynx
14713,33420947,*robotic thyroidectomy
14714,33420947,*thyroidectomy
14716,32910410,art
14717,32910410,graves’ disease
14718,32910410,history
14723,33569041,*graves’ disease
14724,33569041,*hyperthyroidism
14725,33569041,*review
14726,33569041,*thyroxine
14727,33569041,*treatment cois commercial or financial relationships that could be construed as a potential conflict of interest.
14728,32173798,*benign thyroid disease
14729,32173798,*chris
14730,32173798,*radioiodine therapy
14731,32173798,*stunning
14732,32173798,*thyroid
14733,33367675,*graves’ disease
14734,33367675,*slit2
14735,33367675,*thyroid-associated ophthalmopathy
14737,34227705,*graves' disease
14738,34227705,*goiter
14739,34227705,*hyperthyroidism
14740,34227705,*pediatric
14741,34227705,*scintigraphy
14742,34969799,covid-19
14743,34969799,thyroid disease
14744,34969799,thyrotoxicosis
14745,34969799,unwanted effects/adverse reactions cois
14749,32477269,*graves' disease
14750,32477269,*anti-thyroid drug
14751,32477269,*carbimazole
14752,32477269,*dose
14753,32477269,*hyperthyroidism
14754,32797478,amyloidosis
14755,32797478,goitre
14756,32797478,hypothyroidism
14757,33431523,neonatal and paediatric intensive care
14758,33431523,pregnancy
14759,33431523,thyroid disease
14760,33431523,thyrotoxicosis cois
14761,33988300,*lepr
14762,33988300,*graves' disease
14763,33988300,*immune-related genes
14764,33988300,*leptin receptor
14765,33988300,*thyroid-associated ophthalmopathy
14766,33988300,*weighted gene co-expression network analysis cois
14767,32199035,*hyperthyroidism
14768,32199035,*postoperative complications
14769,32199035,*surgery
14770,32199035,*thyroid diseases
14771,32199035,*thyroidectomy
14774,33597052,*goiter prevalence
14775,33597052,*iodine nutrition
14776,33597052,*thyroid cancer
14777,33597052,*urine iodine
14778,33934566,*graves’ disease
14779,33934566,*myh11
14780,33934566,*itraq technique
14781,33934566,*inflammatory response
14782,33934566,*proteomics
14783,33934566,*thyroid-associated obitopathy cois
14784,33367747,*graves’ disease
14785,33367747,*igf-1r
14786,33367747,*thsr
14787,33367747,*autoimmunity
14788,33367747,*exosomes
14789,33914707,*endocrinology
14790,33914707,*thyroid disease cois exists.
14792,34192497,complications
14793,34192497,goitre
14794,34192497,thyroidectomy
14795,34192497,tracheomalacia
14798,33509724,excisional biopsy
14799,33509724,foot
14800,33509724,radiation therapy
14801,33509724,thyroid dermopathy
14802,33579884,*dfnb4
14803,33579884,*menière
14804,33579884,*hydrops
14805,33579884,*mouse
14806,33579884,*pendred
14808,33283314,*graves' disease
14809,33283314,*rai
14810,33283314,*long-term atd
14811,33283314,*surgery
14812,33283314,*treatment
14813,33863564,acuité visuelle
14814,33863564,antioxidant therapy
14815,33863564,cas score
14816,33863564,exophthalmos
14817,33863564,légère orbitopathie thyroïdienne
14818,33863564,mild graves’ orbitopathy
14819,33863564,ouverture palpébrale
14820,33863564,oxidative stress
14821,33863564,palpebral fissure
14822,33863564,placebo
14823,33863564,proptose
14824,33863564,selenium
14825,33863564,stress oxydatif
14826,33863564,sélenium
14827,33863564,traitement anti-oxydatif
14828,33863564,visual acuity
14829,32847459,dry eye disease
14830,32847459,grave’s disease
14831,32847459,grave’s eye disease
14832,32847459,ocular inflammation
14833,32847459,ocular surface
14834,32847459,thyroid eye disease
14835,34560868,*amhara region
14836,34560868,*dessie
14837,34560868,*ethiopia
14838,34560868,*iodine deficiency
14839,34560868,*urinary iodine concentration cois
14841,33994519,graves' disease
14842,33994519,antithyroid drug
14843,33994519,fetal goiter
14844,33994519,fetal hyperthyroidism
14845,33994519,tachycardia
14847,32553518,*graves’ disease
14848,32553518,*nsqip
14849,32553518,*racial disparities
14850,32553518,*thyroidectomy cois conflicts of interest to disclose.
14851,33530368,*graves’ disease
14852,33530368,*autoimmunity
14853,33530368,*dendritic cells
14854,33530368,*methimazole cois
14855,32968816,*graves disease
14856,32968816,*cytokine
14857,32968816,*fibroblasts
14858,32968816,*hyaluronan
14859,32968816,*ophthalmopathy
14860,32968816,*orbit
14861,33532627,*graves' disease
14862,33532627,*trab
14863,33532627,*multivariable analysis
14864,33532627,*thyroid surgery cois
14865,32709792,*dysthyroid optic neuropathy
14866,32709792,*indian
14867,32709792,*thyroid eye disease cois
14868,32130689,graves’ disease
14869,32130689,multiple sclerosis
14870,32130689,personalized medicine
14871,32130689,thyroidectomy
14872,32130689,thyroiditis
14873,33380646,immunohistochemistry
14874,33380646,molecular genetics
14875,33380646,thyroid paraganglioma
14876,33380646,thyroid tumor
14877,33380646,total thyroidectomy cois
14879,32691849,*graves’ disease
14880,32691849,*graves’ ophthalmopathy
14881,32691849,*eye diseases
14882,32691849,*geographical locations
14883,32691849,*meta-analysis
14884,32691849,*prevalence
14885,32691849,*thyroid diseases
14886,33146848,application test
14887,33146848,artificial intelligence
14888,33146848,clinical trials
14889,33146848,thyroid-associated ophthalmopathy
14890,34774035,extraocular muscle
14891,34774035,magnetic resonance imaging
14892,34774035,short-tau inversion recovery
14893,34774035,thyroid-associated ophthalmopathy cois
14894,33617351,dna methylation
14895,33617351,graves' disease
14896,33617351,bioinformatic analysis
14897,33617351,genome-wide
14898,33658136,graves’ ophthalmopathy
14899,33658136,diffusion magnetic resonance imaging
14900,33658136,extraocular muscles
14901,33658136,magnetic resonance imaging
14902,33593429,*graves’ disease
14903,33593429,*graves’ orbitopathy
14904,33593429,*gut microbiota
14905,33593429,*human fecal microbiota transplant
14906,33593429,*microbiome modulation
14907,33593429,*murine model
14908,33593429,*probiotics
14909,33593429,*vancomycin cois other collaborative projects with cultech ltd. the other authors declare that they have no competing interests.
14910,33675208,graves’ disease
14911,33675208,antithyroid treatment
14912,33675208,pediatric thyroidology
14913,33675208,thyroidectomy
14914,33675208,thyrotoxicosis
14915,32034469,endocrine orbitopathy
14916,32034469,epidemiology
14917,32034469,graves’ disease
14918,32034469,healthcare research
14919,32034469,interdisciplinary orbit center
14921,34497059,endocrine system
14922,34497059,respiratory system
14923,34497059,thyroid disease cois
14924,32924380,graves’ disease
14925,32924380,graves’ orbitopathy
14926,32924380,children
14927,32924380,hepatic dysfunction
14928,32924380,lymphocyte subsets
14929,34647611,complications
14930,34647611,hypoparathyroidism
14931,34647611,nodular goitre
14932,34647611,surgical treatment
14933,34647611,thyroid cancer
14934,34518175,genetics
14935,34518175,hyperthyroidism
14936,34518175,thyroid disease cois
14937,34725068,general practice / family medicine
14938,34725068,otolaryngology / ent
14939,34725068,thyroid disease
14940,34725068,thyrotoxicosis cois
14943,34448404,airway obstruction
14944,34448404,asthma
14945,34448404,goitre
14946,34448404,pre-eclampsia
14947,34448404,pregnancy
14948,33779950,hypocalcemia
14949,33779950,intrathoracic goiter
14950,33779950,morbidity
14951,33779950,nerve paralysis
14952,33779950,sternotomy
14953,33779950,surgery
14954,33779950,thyroid cois
14955,32727336,graves’ disease
14956,32727336,thyrotoxicosis
14957,32727336,anti-thyroid therapy
14958,32727336,arrhythmia
14959,32727336,electrocardiogram
14960,32727336,hyperthyroidism
14961,32705333,alopecia areata
14962,32705333,cohort study
14963,32705333,epidemiology
14964,32705333,taiwan’s national health insurance research database
14965,32705333,thyroid disease
14968,33481211,graves’ disease
14969,33481211,gut microbiota
14970,33481211,lactobacillus
14971,33481211,ruminococcus
14972,33481211,trab
14973,33169897,goiter
14974,33169897,imaging mass spectrometry
14975,33169897,obesity
14976,33169897,thyroglobulin
14977,33169897,thyroid disease
14978,33169897,thyroid tissue
14979,33926416,baff
14980,33926416,br3
14981,33926416,graves’ disease
14982,33926416,hashimoto’s thyroiditis
14983,33926416,taci cois
14985,32203974,*antibodies
14986,32203974,*autoimmune diseases
14987,32203974,*drug therapy
14988,32203974,*hyperthyroidism
14989,32203974,*hypothyroidism
14990,32203974,*placenta
14991,32203974,*research laboratories
14992,32203974,*therapeutic drug monitoring
14993,32203974,*thyroid
14994,32203974,*thyroid-stimulating hormone
14996,33563685,anxiety disorders (including ocd and ptsd)
14997,33563685,endocrinology
14998,33563685,psychiatry
14999,33563685,psychotic disorders (incl schizophrenia)
15000,33563685,thyroid disease cois
15001,33966669,*endemic goitre
15002,33966669,*iodine deficiency disorders
15003,33966669,*salt iodine content
15004,33966669,*total goitre rate
15005,33966669,*ultrasonography
15006,33966669,*universal salt iodisation
15007,33966669,*urinary iodine concentration
15008,32875953,thyroid stimulating hormone
15009,32875953,hyperthyroidism
15010,32875953,thyroid uptake and scan
15013,32705522,glucocorticoids
15014,32705522,graves’ orbithopathy
15015,32705522,radiotherapy
15018,33106982,extracellular matrix
15019,33106982,fbln1 gene
15020,33106982,fibulin-1
15021,33106982,multinodular goiter
15022,33106982,papillary thyroid cancer
15024,34689799,fine-needle aspiration
15025,34689799,midkine
15026,34689799,multinodular goiter
15027,34689799,thyroid cancer
15028,34689799,thyroid nodule cois
15029,34521015,epid dosimetry
15030,34521015,machine learning
15031,34521015,multifactorial error sources
15032,34521015,positioning error detection
15033,34521015,radiomics analysis
15034,34418335,graves’ disease
15035,34418335,hypothyroidism
15036,34418335,radioiodine therapy
15037,34418335,thyroid peroxidase antibody (tpoab)
15038,34418335,thyrotropin receptor antibody (trab)
15039,34194397,*graves’ disease
15040,34194397,*antithyroid drugs
15041,34194397,*children
15042,34194397,*hyperthyroidism
15043,34194397,*remission cois commercial or financial relationships that could be construed as a potential conflict of interest.
15044,34448415,fine-needle cytology
15045,34448415,goitre
15046,34448415,thyroid cancer
15047,34448415,thyroid nodules
15048,34448415,thyroidectomy
15049,34893568,*endocrine
15050,34893568,*exophthalmos
15051,34893568,*goiter
15052,34893568,*selfie
15053,34893568,*thyroid
15054,34893568,*thyroidectomy cois
15055,33128357,*c cell hyperplasia
15056,33128357,*medullary thyroid cancer
15057,33128357,*calcitonin
15058,33128357,*pentagastrin
15059,33128357,*cut-off cois
15060,34019179,cd73
15061,34019179,immunohistochemistry
15062,34019179,papillary thyroid carcinoma
15063,34019179,thyroid adenoma
15064,34019179,thyroid carcinoma cois
15066,34782518,goitre
15067,34782518,intrathoracic
15068,34782518,retrosternal
15069,34782518,sternotomy cois
15071,33193994,grave’s disease
15072,33193994,hyperthyroidism
15073,33193994,radioactive iodine disease cois
15074,33619717,genetic
15075,33619717,mutation
15076,33619717,thyroid disease
15077,34560890,graves’ disease
15078,34560890,r282s
15079,34560890,resistance to thyroid hormone
15080,34560890,syndrome of inappropriate secretion of tsh
15081,34560890,thyroid hormone receptor β cois
15084,33474918,bony orbital decompression
15085,33474918,dysthyroid optic neuropathy
15086,33474918,endoscopic orbital decompression
15087,33474918,surgical treatment
15088,33474918,thyroid eye disease
15089,34331946,diagnostic efficacy
15090,34331946,graves’ disease
15091,34331946,methimazole
15092,34331946,responsiveness
15093,34331946,thyroid-stimulating immunoglobulin
15094,32449092,16s rrna gene
15095,32449092,graves’ disease
15096,32449092,graves’ orbitopathy
15097,32449092,gut microbiota
15098,32449092,metabolic functions
15099,33345558,body composition
15100,33345558,hypocalcemia
15101,33345558,hypoparathyroidism
15102,33345558,thyroid
15103,33345558,total thyroidectomy
15106,32057544,goiter size
15107,32057544,graves' disease
15108,32057544,outcome
15109,32057544,radioiodine therapy cois declare.
15110,34552563,*dicer1 mutation
15111,34552563,*dicer1 syndrome
15112,34552563,*goiter
15113,34552563,*goitre
15114,34552563,*hereditary cancer
15115,34552563,*thyroidectomy cois commercial or financial relationships that could be construed as a potential conflict of interest. the reviewer kt declared a past collaboration with one of the authors kw to the handling editor.
15116,33528651,european group on graves’ orbitopathy
15117,33528651,graves’ orbitopathy
15118,33528651,quality of life
15119,33528651,thyroid eye disease
15121,32847889,ophthalmology
15122,32847889,pathology cois
15123,33346898,autoimmunity
15124,33346898,goiter
15125,33346898,graves’ disease
15126,33346898,graves’ orbitopathy
15127,33346898,hyperthyroidism cois
15128,31980413,*adolescents
15129,31980413,*antithyroid drugs
15130,31980413,*children
15131,31980413,*graves disease cois
15134,34630829,ectopic thyroid tissue
15135,34630829,case report
15136,34630829,submandibular mass
15137,34630829,thyroid goiter cois
15138,33026541,hyperthyroidism
15139,33026541,hypothyroidism
15140,33026541,iodine
15141,33026541,spa
15142,33026541,thyroid gland
15144,31982255,auto-immunité
15145,31982255,autoimmunity
15146,31982255,chest pain
15147,31982255,douleur thoracique
15148,31982255,graves’ disease
15149,31982255,maladie de basedow
15150,31982255,myocardite
15151,31982255,myocarditis
15154,34256242,graves' disease
15155,34256242,graves' orbitopathy
15156,34256242,interleukin 17
15157,34256242,interleukin 23
15158,34256242,thyrotropin receptor cois
15159,34823306,*aggression
15160,34823306,*graves disease
15161,34823306,*prevalence
15162,34823306,*prognosis
15163,34823306,*thyroid neoplasms cois was reported.
15164,34164724,deep lateral orbital wall decompression
15165,34164724,extraocular muscle expansion
15166,34164724,greater wing of sphenoid bone
15167,34164724,orbital fat removal
15168,33728674,graves' disease
15169,33728674,catalytic activity
15170,33728674,thyroid proteomics
15171,33728674,thyrotoxicosis
15172,33728674,toxic multinodular goitre
15173,34090378,non-specific orbital inflammation
15174,34090378,comorbidity
15175,34090378,orbital mass
15176,34090378,prednisolone
15177,34090378,thyroid eye disease cois
15178,32527309,case report
15179,32527309,lipoma
15180,32527309,minor salivary gland
15181,32527309,parotid gland
15182,32527309,sialolipoma cois
15183,33317492,case report
15184,33317492,graves’ disease
15185,33317492,orbitopathy
15186,33317492,pregnancy
15187,33317492,smoking
15188,33317492,tao cois
15189,34300095,*saudi arabia
15190,34300095,*iodine deficiency disorders
15191,34300095,*stunting cois
15192,34938274,*swedish endocrine society
15193,34938274,*desiccated thyroid extract (dte)
15194,34938274,*euthyroidism
15195,34938274,*hypothyroidism
15196,34938274,*levothyroxine
15197,34938274,*liothyronine
15198,34938274,"*survey cois authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. ibsa had no role in the design of the survey, data analysis, data presentation, data interpretation or writing the manuscript; the authors did not receive remuneration by ibsa."
15201,32279181,gender differences
15202,32279181,graves’ disease
15203,32279181,lymphocytic infiltration
15204,32279181,papillary thyroid cancer
15205,32279181,thyroidectomy
15206,32279181,thyroiditis and cancer
15207,34033290,*graves' disease
15208,34033290,*graves' orbitopathy
15209,34033290,*hyperthyroidism
15210,33544540,body surface area
15211,33544540,middle school students
15212,33544540,thyroid volume
15213,34252869,intravenous glucocorticoid
15214,34252869,t2 ideal
15215,34252869,t2 mapping
15216,34252869,therapeutic efficacy
15217,34252869,thyroid-associated ophthalmopathy
15218,32306294,*exophthalmos
15219,32306294,*graves’ disease
15220,32306294,*graves’ orbitopathy
15221,32306294,*igf-1 receptor
15222,32306294,*teprotumumab
15223,32306294,*thyroid eye disease
15224,32798996,*graves disease
15225,32798996,*outcomes
15226,32798996,*radioactive iodine ablation
15227,32798996,*thyroidectomy
15228,32166667,diabetes
15229,32166667,euthyroid hormones
15230,32166667,free thyroxine
15231,32166667,free triiodothyronine
15232,32166667,islet beta-cell function
15234,33860431,*antithyroid agents
15235,33860431,*grave’s disease
15236,33860431,*hyperthyroidism
15237,33860431,*recurrence
15238,33860431,*treatment outcome
15239,34381549,cameroon
15240,34381549,nodular goitre
15241,34381549,cancer
15242,34381549,thyroid cois
15243,32734611,*graves' disease
15244,32734611,*trabs
15245,32734611,*age
15246,32734611,*radioiodine
15247,32734611,*thyroid hormones cois
15248,34120661,complications
15249,34120661,recurrent laryngeal nerve
15250,34120661,surgery
15251,34120661,thyroid
15252,34120661,vagus nerve
15253,34120661,vocal fold palsy
15254,34806437,*iodine deficiency
15255,34806437,*iodine excess
15256,34806437,*iodized salt
15257,33993334,cerebrospinal fluid in the optic nerve sheath
15258,33993334,dysthyroid optic neuropathy
15259,33993334,magnetic resonance imaging
15260,33993334,optic nerve
15261,33993334,quantitative water-fat sequence
15262,32524368,antithyroid drugs
15263,32524368,graves’ disease treatment
15264,32524368,graves’ orbitopathy
15265,32524368,hyperthyroidism
15266,32461446,*diabetes mellitus
15267,32461446,*thyroid eye disease
15268,32461446,*thyroid-related orbitopathy
15269,32461446,*type-2 dm cois
15270,33439464,*effective half-life
15271,33439464,*graves’ disease
15272,33439464,*radioiodine therapy
15273,33439464,*radioiodine uptake test
15274,33439464,*thyroid cois
15275,31910731,graves’
15276,31910731,timp-1
15277,31910731,strain
15278,31910731,thyroid
15279,34659126,*n1b metastasis
15280,34659126,*nomogram
15281,34659126,*papillary thyroid cancer
15282,34659126,*predicting
15283,34659126,*skip metastasis cois commercial or financial relationships that could be construed as a potential conflict of interest.
15284,31927747,differentiated thyroid cancer
15285,31927747,pediatrics
15286,31927747,thyroid
15287,31927747,thyroid nodules
15288,32595602,*graves' hyperthyroidism
15289,32595602,*graves' ophthalmopathy
15290,32595602,*anti-thyroid drugs
15291,32595602,*corticosteroid pulse therapy
15292,32595602,*relapse of graves' hyperthyroidism
15293,34266819,head and neck surgery
15294,34266819,paediatric oncology
15295,34266819,radiotherapy
15296,34266819,thyroid disease cois
15299,32527127,prolonged endotracheal intubation
15300,32527127,retrosternal goitre (rsg)
15301,32527127,tracheomalacia
15302,32218623,point of care
15303,32218623,thyroid ultrasound cois
15304,33023116,endemic congenital hypothyroidism
15305,33023116,endemic goitre
15306,33023116,familial aggregation
15307,33023116,iodine deficiency
15308,33023116,thyroid metabolism cois
15309,32709788,*india
15310,32709788,*orbital decompression
15311,32709788,*survey
15312,32709788,*thyroid eye disease cois
15313,33947272,*graves'disease
15314,33947272,*radioactive iodine therapy
15315,33947272,*thyrotropin receptor antibody
15316,33947272,*thyrotropin-binding inhibitory immunoglobulins
15317,33947272,*total thyroidectomy cois
15318,32975031,*thypro
15319,32975031,*benign
15320,32975031,*quality of life
15321,32975031,*thyroid
15322,32975031,*thyroidectomy
15323,32358735,choroidal thickness
15324,32358735,ganglion cell layer thickness
15325,32358735,graves’ disease
15326,32358735,graves’ orbitopathy
15327,32358735,optic nerve head
15328,32358735,optical coherence tomography
15329,32358735,retinal thickness
15330,32173759,*graves disease
15331,32173759,*graves orbitopathy
15332,32173759,*th17.1 cell
15333,32173759,*effector t cell
15335,32602151,autofluorescence
15336,32602151,hypocalcemia
15337,32602151,parathyroid gland
15338,32602151,thyroidectomy
15339,34278816,*graves' disease
15340,34278816,*iodothyronine deiodinase
15341,34278816,*poorly differentiated thyroid carcinoma
15342,33080613,dicer1 syndrome
15343,33080613,multinodular goitre
15344,33080613,poorly differentiated thyroid cancer
15345,33080613,thyroid carcinoma
15346,33080613,thyroid nodule
15347,32944926,graves’ disease
15348,32944926,trab
15349,32944926,trab-negative
15350,32944926,hyperthyroidism
15351,32944926,smoking
15352,34028325,radioactive iodine
15353,34028325,graves’ disease
15354,34028325,hyperthyroidism
15355,34028325,lithium
15356,34028325,toxic nodule’ toxic multinodular goiter
15357,32037571,*dysthyroid optic neuropathy
15358,32037571,*optic nerve compression
15359,32037571,*thyroid eye disease
15361,32188795,graves’ disease
15362,32188795,graves’ hyperthyroidism
15363,32188795,potassium iodide
15364,32188795,wolff-chaikoff effect
15366,32451608,compressive optic neuropathy
15367,32451608,medial wall
15368,32451608,orbital floor
15369,32451608,spontaneous decompression
15370,32451608,thyroid eye disease
15371,32316214,goitre
15372,32316214,iodine pregnant women
15373,32316214,iodine schoolchildren
15374,32316214,iodised salt
15375,32316214,urine iodine
15376,32316214,water iodine cois the views of the institutions with which they are affiliated. the authors declare that there is no conflict of interest.
15381,32487052,131i−
15382,32487052,euthyreosis
15383,32487052,factors
15384,32487052,graves’ disease
15385,32487052,hyperthyroidism
15386,32487052,predictors
15387,32487052,radioiodine
15388,32487052,toxic multinodular goiter cois
15390,32532690,hepatitis
15391,32532690,methimazole
15392,32532690,plasmapheresis
15393,32532690,thyrotoxicosis
15395,32245343,*generalized additive model
15396,32245343,*salt iodine concentration
15397,32245343,*thyroid volume
15398,32245343,*urinary iodine concentration
15399,32504380,*magnetic resonance imaging
15400,32504380,*quantitative evaluation
15401,32504380,*thyroid-associated ophthalmopathy
15402,32504380,*treatment response
15403,32020533,iodine deficiency
15404,32020533,north macedonia
15405,32020533,schoolchildren
15406,32020533,thyroid gland ultrasonography
15407,32020533,thyroid volume
15408,31948188,*prevalence
15409,31948188,*school-age children
15410,31948188,*turkey
15411,31948188,*iodine deficiency
15412,32333320,energy vessel sealant device
15413,32333320,neck hematoma
15414,32333320,surgical complications
15415,32333320,thyroidectomy
15416,32139177,*graves' disease
15417,32139177,*antithyroid drugs
15418,32139177,*relapse
15419,32139177,*risk factors
15420,32253727,cognition
15421,32253727,diffusion tensor imaging
15422,32253727,thyroid-associated ophthalmopathy
15423,32253727,vision
15424,32253727,voxel-based morphometry
15425,31973681,*antithyroid medications
15426,31973681,*effectiveness of therapy
15427,31973681,*hyperthyroidism
15428,31973681,*radioactive iodine
15429,31973681,*thyroidectomy
15430,32758269,autoimmune antibody
15431,32758269,basedow’s disease
15432,32758269,hashimoto’s thyroiditis
15433,32758269,histopathological features cois
15434,32640447,*autoimmune diseases
15435,32640447,*costimulatory molecules
15436,32640447,*degranulation
15437,32640447,*mast cells
15438,32640447,*thyroid hormones
15440,32077044,anti-tsh receptor autoantibodies
15441,32077044,autoimmunity
15442,32077044,fine-needle aspiration biopsy
15443,32077044,graves’ disease
15444,32077044,graves’ orbitopathy
15445,32077044,hyperthyroidism
15446,32077044,thyroid
15447,32077044,thyroid nodules
15448,32658864,graves’ disease
15449,32658864,hashitoxicosis
15450,32658864,sudan
15451,32658864,adolescents
15452,32658864,childhood
15453,32474767,asymmetric
15454,32474767,graves’
15455,32474767,orbitopathy
15456,32474767,thyroid
15457,32474767,unilateral cois
15459,32174327,*generative adversarial network
15460,32174327,*orbital decompression
15461,32174327,*postoperative appearance
15462,32174327,*thyroid-associated ophthalmopathy cois declare.
15463,32593739,(131)i
15464,32593739,calculated dose
15465,32593739,dosimetry
15466,32593739,dosimetría
15467,32593739,dosis calculada
15468,32593739,dosis fija
15469,32593739,fixed dose
15470,32593739,hipertiroidismo
15471,32593739,hyperthyroidism
15472,32593739,radionuclide therapy
15473,32593739,radioterapia metabólica
15474,32847555,99mtc-pertechnetate scintigraphy
15475,32847555,graves’ disease
15476,32847555,immune checkpoint inhibitor
15477,32847555,nivolumab
15478,32847555,thyroid-stimulating hormone receptor antibody
15479,32847555,thyrotoxicosis cois
15480,32666542,pds
15481,32666542,slc26a4
15482,32666542,upd7
15483,32666542,growth retardation
15484,32709791,*graves orbitopathy
15485,32709791,*hindi
15486,32709791,*quality of life
15487,32709791,*questionnaire
15488,32709791,*validation cois
15489,31465286,131i
15490,31465286,goiter
15491,31465286,carbimazol
15492,31465286,chloride
15493,31465286,creatinine
15494,31465286,thyroid function tests
15495,31465286,thyrotoxicosis.
15496,33346473,21-oh-antibodies
15497,33346473,addison’s disease
15498,33346473,graves’ disease
15499,33346473,autoimmune polyglandular syndromes
15500,33346473,diabetes mellitus type 1
15501,33038927,autoimmune polyglandular syndrome
15502,33038927,chronic urticaria
15503,33038927,graves’ disease
15504,33038927,premature ovarian failure cois
15508,32154572,graves’ disease
15509,32154572,antithyroid drugs
15510,32154572,gender
15511,32154572,hyperthyroidism
15512,33256801,autoimmune disease
15513,33256801,basedow-graves’s disease
15514,33256801,nutritional assessment
15515,33256801,pediatric disability
15516,33256801,stickler syndrome cois
15517,32499464,*clinical impression
15518,32499464,*euthyroid
15519,32499464,*goiter
15520,32499464,*thyroid disorder
15521,32499464,*thyroid function test cois
15523,32295532,*case report
15524,32295532,*congenital chloride diarrhea
15525,32295532,*deafness
15526,32295532,*neonatal diarrhea
15527,32295532,*pendred syndrome cois
15528,34916318,*clinical trials
15529,34916318,*ophthalmology
15530,34916318,*thyroid disease cois
15533,34726857,bony orbital decompression
15534,34726857,corneal ulcer
15535,34726857,exophthalmos
15536,34726857,keratopathy
15537,34726857,lagophthalmos
15538,34726857,neurotrophic keratitis
15539,34726857,tarsorrhaphy
15540,34726857,thyroid eye disease
15541,33860819,exophthalmos
15542,33860819,graves’ ophthalmopathy
15543,33860819,low dose radiation therapy
15544,33860819,radiotherapy
15545,33860819,"thyroid eye disease cois o. ott, m. hecht, r. fietkau, b. frey, and f. putz declare that they have no competing interests."
15546,33517799,*lid flare
15547,33517799,*beziér lines
15548,33517799,*graves orbitopathy
15549,33517799,*lid contour
15550,33517799,*lid retraction
15551,33109498,autoimmune thyroid disease
15552,33109498,chinese herbal medicine
15553,33109498,graves’ disease
15557,33797646,*131i
15558,33797646,*effective half-life
15559,33797646,*graves’ disease
15560,33797646,*mird
15561,33797646,*tld measurements
15562,33049131,dio2 gene
15563,33049131,graves’ disease
15564,33049131,polymorphisms
15565,32844239,epidemiology
15566,32844239,graves’ ophthalmopathy
15567,32844239,proptosis
15568,32844239,thyroid eye disease
15570,31237218,cd40
15571,31237218,cd40 ligand
15572,31237218,graves’ ophthalmopathy
15573,31237218,cytokine
15574,31237218,protein microarray
15575,31237218,tear.
15576,34531272,*graves’ disease
15577,34531272,*hyperthyroidism
15578,34531272,*thyrotoxic periodic paralysis
15579,34531272,*weakness
15583,33247453,*graves disease
15584,33247453,*edrophonium testing
15585,33247453,*myasthenia gravis
15586,33247453,*ocular myasthenia gravis
15587,33247453,*repetitive nerve stimulation
15588,33247453,*thyroid eye disease
15589,34681884,inflammation
15590,34681884,orbital fibroblasts
15591,34681884,proopiomelanocortin (pomc)
15592,34681884,thyroid eye disease
15593,34681884,α-melanocyte stimulating hormone (α-msh) cois
15594,32057773,*extraocular muscle
15595,32057773,*gene microarray
15596,32057773,*proteomic profiling
15597,32057773,*thyroid-associated ophthalmopathy cois
15600,33676921,corticosteroid therapy
15601,33676921,corticothérapie
15602,33676921,graves’ orbitopathy
15603,33676921,mycophenolate mofetil
15604,33676921,mycophénolate mofetil
15605,33676921,orbitopathie basedowienne
15606,33676921,rituximab
15607,33676921,teprotumumab
15608,33676921,tocilizumab
15609,33367784,*graves disease
15610,33367784,*hla class i
15611,33367784,*stat1
15612,33367784,*autoimmune thyroid disease
15613,33367784,*enterovirus
15614,33367784,*viral infections
15615,32506060,*free triiodothyronine
15616,32506060,*free triiodothyronine to free thyroxine ratio
15617,32506060,*subcutaneous fat area
15618,32506060,*visceral fat area cois
15620,34185860,*basedow's disease
15621,34185860,*childhood onset
15622,34185860,*general anesthesia
15623,34185860,*graves' disease
15624,34185860,*hyperthyroidism
15625,34185860,*thyroid storm
15626,34185860,*thyrotoxicosis
15627,34033291,*graves' disease
15628,34033291,*il-27
15629,34033291,*il-35
15630,34033291,*anti-tpo
15631,34033291,*anti-tg
15632,35008579,graves’ disease
15633,35008579,graves’ orbitopathy
15634,35008579,vegf-a
15635,35008579,microrna-199a
15636,35008579,oxidative stress cois competing financial interests exist.
15640,34484118,*graves’ disease (gd)
15641,34484118,*mendelian randomization
15642,34484118,*autoimmune disease (ad)
15643,34484118,*causal relationship
15644,34484118,*rheumatoid arthritis cois commercial or financial relationships that could be construed as a potential conflict of interest.
15645,34078122,*thyroid-associated ophthalmopathy
15646,34078122,*adipogenesis
15647,34078122,*adipose/connective tissue
15648,34078122,*alternative splicing
15649,34078122,"*rmats cois of interest with respect to the research, authorship, and/or publication of this article."
15650,32529279,intraocular pressure
15651,32529279,neuropathy
15652,32529279,orbitopathy
15653,32529279,thyroid
15654,32529279,visual field defect
15655,33845801,fat decompression
15656,33845801,radiological
15657,33845801,"thyroid-associated ophthalmopathy cois presentation, financial support and proprietary interest statement."
15659,32854466,*graves’ ophthalmopathy
15660,32854466,*choroidal thickness
15661,32854466,*optical coherence tomography
15662,32854466,*proptosis cois
15663,32709794,*activity
15664,32709794,*eugogo
15665,32709794,*thyroid eye disease
15666,32709794,*visa
15667,32709794,*hyperthyroidism
15668,32709794,*severity cois
15669,31804961,hyperthyroidism
15670,31804961,radioactive iodine therapy
15671,31804961,sinusitis
15672,34647609,cd4+ t cell
15673,34647609,th lymphocytes
15674,34647609,treg lymphocytes
15675,34647609,autoimmune thyroid disease
15676,33400175,*anti-thyroid drugs
15677,33400175,*hyperthyroidism
15678,33400175,*outcome
15679,33400175,*radioactive iodine therapy
15680,32737644,laryngopharyngeal reflux
15681,32737644,local neck symptoms
15682,32737644,nodular goiter
15683,32737644,thyroidectomy cois
15684,34144327,*cyclic peptide
15685,34144327,*graves' orbitopathy
15686,34144327,*long-term graves' disease mouse model
15687,34144327,*orbital collagen
15688,34144327,*thyroid dysfunction
15689,34144327,*thyrotropin receptor antibodies
15690,32088116,*autoimmune
15691,32088116,*biological agents
15692,32088116,*graves' disease
15693,32088116,*insulin-like growth factor-i receptor
15694,32088116,*monoclonal antibodies
15695,32088116,*teprotumumab
15696,33086191,*pdk2
15697,33086191,*glycolysis
15698,33086191,*orbital fibroblasts
15699,33086191,*proliferation
15700,33086191,*thyroid-associated ophthalmopathy
15701,31345156,graves’ ophthalmopathy
15702,31345156,angiotensinconverting enzyme inhibitors
15703,31345156,enalapril
15704,31345156,hyperthyroidism
15705,31345156,mild ophthalmopathy
15706,31345156,palpebral fissure.
15707,34855199,csvt
15708,34855199,graves’ disease
15709,34855199,cerebral sinus venous thrombosis
15710,34855199,child
15711,34855199,hyperthyroidism
15712,32474766,gene polymorphisms
15713,32474766,graves' disease
15714,32474766,interleukin-1 (il-1)
15715,32474766,interleukin-6 (il-6)
15716,32474766,tumor necrosis factor-α (tnf-α)
15717,34147078,graves’ orbitopathy
15718,34147078,in vivo confocal microscopy
15719,34147078,meibomian glands
15720,34147078,microstructure cois
15722,33268601,graves’ ophthalmopathy
15723,33268601,anti-thyroid-stimulating hormone receptor antibodies
15724,33268601,clinical activity score
15725,33268601,pregnancy
15726,33268601,thyroid stimulating antibody
15728,32588167,decompression
15729,32588167,diplopia
15730,32588167,exophthalmos
15731,32588167,graves’ ophthalmopathy
15732,32588167,orbit
15733,32588167,proptosis cois
15735,31953667,graves ophthalmopathy
15736,31953667,lacrimal apparatus
15737,31953667,magnetic resonance imaging
15738,31953667,orbital diseases
15741,34156783,bony regrowth
15742,34156783,deep lateral orbital decompression
15743,34156783,thyroid eye disease
15744,34156783,ultrasonic osteodestruction
15745,33431733,graves' disease
15746,33431733,painless thyroiditis
15747,33431733,potassium iodide cois
15748,32727578,circular rna
15749,32727578,exosomes
15750,32727578,graves’ disease
15751,32727578,immune activation
15752,32727578,hsa_circrna_000102 cois
15753,34273482,benign thyroid disorders
15754,34273482,biologically effective dose
15755,34273482,dose-rate effects
15756,34273482,outcome probability
15757,34273482,proportional odds model
15758,34273482,radioiodine therapy
15759,33943012,*t helper 17 cells
15760,33943012,*autoimmune thyroid disease
15761,33943012,*selenium cois
15762,32810095,"postpartum thyroiditis, graves' disease, colour doppler ultrasound."
15764,34867823,*graves’ disease (gd)
15765,34867823,*hashimoto thyroiditis (ht)
15766,34867823,*autoimmune thyroid disease
15767,34867823,*gut microbiota
15768,34867823,*meta-analysis cois commercial or financial relationships that could be construed as a potential conflict of interest.
15769,33329408,*graves’ disease
15770,33329408,*graves’ orbitopathy
15771,33329408,*tsh receptor antibodies
15772,33329408,*hyperthyroidism
15773,33329408,*hypothyroidism
15774,33329408,*radioiodine (131i) treatment
15775,33329408,*smoking cois commercial or financial relationships that could be construed as a potential conflict of interest.
15776,34628889,hyperthyroidism
15777,34628889,hypercalcemia
15778,34628889,morbidity
15779,34628889,thyroid related antibodies
15780,34628889,vitamin d3
15781,32122631,computer-assisted surgery
15782,32122631,exophthalmos
15783,32122631,neuronavigation
15784,32122631,orbital decompression
15785,32122631,proptosis
15786,32122631,thyroid-associated ophthalmopathy
15788,33941360,complications
15789,33941360,graves’ disease
15790,33941360,lugol
15791,33941360,potassium iodide
15792,33941360,thyroidectomy
15793,33832456,autoimmune disease
15794,33832456,biomarker
15795,33832456,graves’ disease
15796,33832456,thyroid eye disease cois manuscript.
15798,35285441,graves disease
15799,35285441,tsi
15800,35285441,cancer
15801,35285441,papillary
15802,35285441,thyroid
15803,34844465,*covid-19
15804,34844465,*graves’ disease
15805,34844465,*sars-cov-2
15806,34844465,*thyroid storm
15807,34844465,"*thyrotoxicosis cois conflicts of interest with respect to the research, authorship, and/or publication of this article."
15808,31805011,*genetic diseases
15809,31805011,*genetics
15810,31805011,*oncology
15811,31805011,*rna processing
15812,31805011,*thyroid disease cois exists.
15816,32498091,*graves’ disease
15817,32498091,*hashimoto’s thyroiditis
15818,32498091,*irak1 polymorphism
15819,32498091,*x chromosome genetic analysis
15820,32498091,*autoimmune thyroid disease
15821,32498091,*thyroid-associated ophthalmopathy
15822,33568133,*graves’ disease
15823,33568133,*susceptibility genes
15824,33568133,*three generations
15825,33568133,*whole exome sequencing cois
15827,32845332,*graves’ disease
15828,32845332,*hyperthyroidism
15829,32845332,*immunomodulation
15830,32845332,*immunotherapy
15831,32845332,*thyroid hormone
15832,32845332,*thyroid-stimulating hormone receptor
15833,33858208,*graves'
15834,33858208,*sars-cov-2 vaccines
15835,33858208,*adverse vaccine reactions
15836,33858208,*autoimmune/inflammatory syndrome induced by adjuvants
15837,33858208,*disease
15838,33673340,*b cells
15839,33673340,*graves’ disease
15840,33673340,*igf-ir
15841,33673340,*igf-ir inhibitors
15842,33673340,*t cells
15843,33673340,*tshr
15844,33673340,*autoimmunity
15845,33673340,*proptosis
15846,33673340,*thyroid-associated ophthalmopathy cois inventions concerning the use of igf-ir inhibitors as therapy in graves’ disease. these patents are held by ucla school of medicine and los anglees biomedical research institute. he is a consultant for horizon therapeutics.
15847,32126013,graves
15848,32126013,hashimoto
15849,32126013,autoimmune thyroid
15852,32515628,corneal biomechanical properties
15853,32515628,corneal hysteresis
15854,32515628,ocular response analyzer
15855,32515628,thyroid associated ophthalmopathy
15858,33855963,thyroid eye disease
15859,33855963,tocilizumab
15860,33613458,*graves’ disease
15861,33613458,*hashimoto autoimmune thyroiditis
15862,33613458,*adolescents
15863,33613458,*autoimmune thyroid diseases
15864,33613458,*children cois commercial or financial relationships that could be construed as a potential conflict of interest.
15866,32930505,müllerectomy
15867,32930505,graves' orbitopathy
15868,32930505,levator disinsertion
15869,32930505,upper eyelid retraction
15870,32930505,upper eyelid surgery
15871,34020391,aitd
15872,34020391,il-10
15873,34020391,regulatory b cells
15875,34243868,graves disease
15876,34243868,hyperthyroidism
15877,34243868,thyroid
15878,34243868,thyroid cancer
15879,34243868,toxic nodule
15880,32785898,*cardiac output
15881,32785898,*echocardiography
15882,32785898,*n-terminal-pro-b-type natriuretic peptide
15883,32785898,*neonatal hyperthyroidism
15884,32785898,*thyroid-stimulating hormone receptor antibody
15885,34684053,creatine kinase
15886,34684053,graves’ disease
15887,34684053,methimazole
15888,34684053,myopathy cois
15890,32741892,graves' disease
15891,32741892,hyperthyroidism
15892,32741892,resting energy expenditure
15893,32741892,resting metabolic rate cois
15896,34742692,*eye proteins/*analysis
15897,34742692,*eye diseases/diagnosis/*metabolism
15898,34742692,*graves' ophthalmopathy
15899,34742692,*mesh
15900,34742692,*molecular diagnostic techniques/methods
15901,34742692,*orbital inflammatory diseases/diagnosis/*metabolism
15902,34742692,*proteome/*metabolism
15903,34742692,*proteomics/methods
15904,34742692,*tear biomarkers/*metabolism
15905,34742692,*tear proteomics
15906,34742692,"*tears/*metabolism cois eyevensys, santen, affibody, kyverna and covrus."
15907,33371640,cytochrome p450 system
15908,33371640,endocrine ophthalmopathy
15909,33371640,glucocorticoid receptor gene polymorphism
15910,33371640,glucocorticoid therapy
15911,33371640,resistance
15912,32507991,dynamic scheimpflug analyzer
15913,32507991,glucocorticoids
15914,32507991,graves’ orbitopathy
15915,32507991,ocular biomechanics
15916,32636230,drugs: endocrine system
15917,32636230,paediatrics (drugs and medicines)
15918,32636230,thyrotoxicosis cois
15921,32472423,*autoantibodies
15922,32472423,*graves’ disease
15923,32472423,*graves’ orbithopathy
15924,32472423,*tsh receptor
15925,32472423,*thyroid
15926,32472423,"*thyroid cancer cois a developer of medical diagnostics including kits for measuring tsh receptor antibodies. j.f., j.s. and b.r.s. are directors of av7 limited. av7 limited has no other competing interests to declare. k1-70 is currently in use as part of a phase i, single ascending intramuscular or single intravenous dose, safety, tolerability, pharmacokinetic and pharmacodynamic study in subjects with graves’ disease (iras id 199697, eudract number 2014-003815-12)."
15928,34130982,diabetes
15929,34130982,endocrinology
15930,34130982,thyroid disease
15931,34130982,thyrotoxicosis cois
15934,34037961,*antiphospholipid antibodies
15935,34037961,*apolipoproteins
15936,34037961,*autoimmune thyroid diseases
15937,34037961,*graves’ orbitopathy
15938,34037961,*interleukine 6
15941,34202024,graves’ ophthalmopathy
15942,34202024,curcumin
15943,34202024,orbital fibrosis
15944,34202024,thyroid eye disease cois
15945,33844165,ablation
15946,33844165,autoimmunity
15947,33844165,graves’ disease
15948,33844165,graves’ orbitopathy
15949,33844165,radioiodine
15950,33844165,thyroid cois
15951,33484567,*graves’ orbitopathy
15952,33484567,*genetics
15953,33484567,*thyroid eye disease
15954,33246456,case report
15955,33246456,hashimoto’s disease
15956,33246456,hashimoto’s thyroiditis
15957,33246456,ophtalmopathy
15958,33246456,orbitopathy cois
15959,32112702,graves’ disease
15960,32112702,adrenal crisis
15961,32112702,autoimmune polyglandular syndrome type ii
15964,33514849,*cd4+ cytotoxic t lymphocytes
15965,33514849,*graves’ orbitopathy
15966,33514849,*single-cell rna sequencing cois
15967,32991886,*fibroblasts
15968,32991886,*orbit
15969,32991886,*polysaccharides
15970,32991886,*prunella vulgaris
15971,32991886,*thyroid-associated ophthalmopathy
15972,32340849,cas
15973,32340849,graves orbitopathy
15974,32340849,graves’ disease
15975,32340849,maladie de basedow
15976,32340849,orbitopathie basedowienne
15977,32340849,anticorps aux récepteurs d’hormone thyréostimulante
15978,32340849,hyperthyroidism
15979,32340849,hyperthyroïdie
15980,32340849,thyroid-stimulating hormone receptor antibodies
15981,32340849,tocilizumab
15982,32293702,graves’ disease
15983,32293702,graves’ orbitopathy
15984,32293702,tsh-receptor antibodies
15985,32293702,radioiodine
15986,32293702,thyroidectomy
15987,32564766,graves' disease
15988,32564766,yersinia enterocolitica
15989,32564766,autoimmune thyroid diseases
15990,32564766,hashimoto's thyroiditis
15991,32564766,meta-analysis
15992,32564766,thyroid dysfunction
15993,34248849,*graves’ disease
15994,34248849,*children
15995,34248849,*environmental substances
15996,34248849,*metabolomics
15997,34248849,*single-nucleotide polymorphisms cois commercial or financial relationships that could be construed as a potential conflict of interest.
15998,32405700,anti-cd20 antibody
15999,32405700,basedow’s disease
16000,32405700,clinical activity score (cas)
16001,32405700,graves’ orbitopathy
16002,32405700,rituximab
16004,34616359,*graves’ disease (gd)
16005,34616359,*rna methyltransferase
16006,34616359,*rna modification
16007,34616359,*methyltransferase like 3 (mettl3)
16008,34616359,*suppressor of cytokine signaling (socs) cois commercial or financial relationships that could be construed as a potential conflict of interest.
16010,34130234,graves’ ophthalmopathy
16011,34130234,lacrimal gland
16012,34130234,magnetic resonance imaging
16013,34130234,t1 mapping
16014,34130234,t2 mapping
16017,34328251,*graves disease
16018,34328251,*hiv
16019,34328251,*immune reconstitution inflammatory syndrome
16020,34328251,*radioactive iodine treatment
16021,33746907,*clinical activity score
16022,33746907,*disease severity
16023,33746907,*ethnically diverse
16024,33746907,*immunosuppression
16025,33746907,*polyautoimmunity
16026,33746907,*psoriasis
16027,33746907,*rheumatoid arthritis
16028,33746907,*thyroid eye disease cois commercial or financial relationships that could be construed as a potential conflict of interest.
16029,33658982,*dna methylation
16030,33658982,*epigenetics
16031,33658982,*graves’ ophthalmopathy
16032,33658982,*orbital fibroblast
16033,33658982,*proteomics cois commercial or financial relationships that could be construed as a potential conflict of interest.
16034,33560351,*3-hydroxy-3-methylglutaryl-coenzyme reductase inhibitors
16035,33560351,*graves disease
16036,33560351,*graves orbitopathy
16037,33560351,*statins
16038,31927748,cytokines
16039,31927748,ocular surface
16040,31927748,tear
16041,31927748,thyroid eye disease
16042,34358537,*drug intervention
16043,34358537,*graves’ disease
16044,34358537,*hashimoto’s thyroiditis
16045,34358537,*mathematical model
16046,34358537,*thyroid hormone regulation cois competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
16047,33786753,exophthalmos
16048,33786753,figuration and abstraction
16049,33786753,graves’orbitopathy
16050,33786753,natalie frank
16051,33786753,post-modern american art
16053,32767605,graves disease
16054,32767605,free region of interest
16055,32767605,shear wave elastography
16056,32767605,ultrasound
16057,32107993,*graves disease
16058,32107993,*technetium (99mtc) pertechnetate thyroid scintigraphy
16059,32107993,*autoimmune disorder
16060,32107993,*color doppler ultrasonography
16061,32107993,*thyroid hormones
16062,32107993,*thyrotropin
16063,34281356,*autoimmune
16064,34281356,*comorbidities
16065,34281356,*thyroid
16066,33663404,*amiodarone
16067,33663404,*dilated thyrotoxic cardiomyopathy
16068,33663404,*heart failure
16069,33663404,*multifocal atrial tachycardia
16070,33663404,*thyroid storm cois
16074,34025584,*graves disease
16075,34025584,*graves ophthalmopathy
16076,34025584,*graves orbitopathy
16077,34025584,*optic neuropathy
16078,34025584,*thyroid eye disease
16079,34025584,*thyroid-associated ophthalmopathy cois thyroid eye disease amsterdam declaration implementation group). the remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
16080,32507887,*graves disease
16081,32507887,*epidemiology
16082,32507887,*hyperthyroidism
16083,32507887,*ulcerative colitis
16084,32315207,*graves’ disease
16085,32315207,*hyperthyroidism
16086,32315207,*antithyroid drugs
16087,32315207,*cardiovascular disease
16088,32315207,*mortality
16089,32315207,*pregnancy
16090,32315207,*radioactive iodine
16091,32315207,*thyroidectomy
16092,33941979,"carbimazole, graves's disease, hyperthyroidism, methimazole, prophylthiouracil,  thiomazole, thyrotoxicosis."
16095,33187482,child health
16096,33187482,iodine
16097,33187482,iodine deficiency
16098,33187482,iodine supplementation
16099,33187482,maternal health
16100,33187482,nutrition
16101,33187482,pregnancy
16102,33187482,psychomotor development
16103,33187482,public health intervention cois
16104,32949299,bovine pericardium
16105,32949299,strabismus surgery
16106,32949299,tendon elongation
16107,32949299,tutopatch® cois
16108,32771076,dexamethasone administration
16109,32771076,hypokalemia
16110,32771076,steroid-induced
16111,32771076,thyrotoxic periodic paralysis
16112,33711978,ocular duction
16113,33711978,orbital decompression
16114,33711978,strabismus
16115,33711978,thyroid eye disease cois
16117,32060570,chronic sinusitis
16118,32060570,eosinophilic angiocentric fibrosis
16119,32060570,igg4-related disease
16120,32060570,immunoglobulin g
16121,32060570,orbit
16122,34465342,biomarker
16123,34465342,hashimoto’s thyroiditis
16124,34465342,lymph node metastasis
16125,34465342,nodular goiter
16126,34465342,pd-1
16127,34465342,papillary thyroid carcinoma cois manuscript is approved by all authors for publication.
16129,33716970,*t2 relaxation time
16130,33716970,*extraocular muscle
16131,33716970,*intravenous methylprednisolone pulse
16132,33716970,*thyroid associated ophthalmopathy
16133,33716970,*treatment response cois commercial or financial relationships that could be construed as a potential conflict of interest.
16135,34144042,autoimmunity
16136,34144042,graves’ disease
16137,34144042,trab
16138,34144042,tsi
16139,34144042,thyroid stimulating hormone receptor autoantibodies
16140,34144042,thyroid stimulating immunoglobulin
16142,32146747,blood flow velocity
16143,32146747,graves disease
16144,32146747,"thyroiditis, autoimmune"
16145,32146747,thyrotoxicosis
16147,34232313,*akt1
16148,34232313,*egfr/pi3k/akt signaling
16149,34232313,*lncrna lpal2
16150,34232313,*mir-1287-5p
16151,34232313,*orbital fibroblast activation
16152,34232313,*thyroid eye disease
16153,33511522,*full-field electroretinography
16154,33511522,*isolated-check visual evoked potential
16155,33511522,*pattern visual evoked potential
16156,33511522,*thyroid-associated ophthalmopathy
16160,33198476,"anaesthesia, thyroid eye disease, thyroid-associated orbitopathy, graves'  ophthalmopathy"
16161,32744317,*cluster of differentiation 74
16162,32744317,*graves disease
16163,32744317,*graves ophthalmopathy
16164,32744317,*immunology & inflammation
16165,32744317,*molecular bases of health & disease
16166,32744317,*subject areas: endocrinology
16167,32744317,*single nucleotide polymorphisms cois manuscript.
16169,33613444,*graves’ ophthalmopathy
16170,33613444,*hub gene
16171,33613444,*lacrimal gland
16172,33613444,*microarray data
16173,33613444,*protein processing in endoplasmic reticulum cois remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
16174,33576183,graves’ orbitopathy
16175,33576183,deviation correction
16176,33576183,dose-effect
16177,33576183,success rates
16178,33576183,superior rectus recession
16179,33343507,*hashimoto autoimmune thyroiditis
16180,33343507,*autoimmunity
16181,33343507,*cancer
16182,33343507,*gut microbiota
16183,33343507,*thyroid cois commercial or financial relationships that could be construed as a potential conflict of interest.
16184,33130479,down syndrome
16185,33130479,graves' disease
16186,33130479,moyamoya disease
16187,33130479,quasi-moyamoya
16188,33130479,thyrotoxicosis
16189,33130479,trisomy 21 cois competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
16190,33000387,block and replace treatment
16191,33000387,hyperthyroidism
16192,33000387,titration regimen
16193,34102155,*graves ophthalmopathy
16194,34102155,*coefficient variation of cell area
16195,34102155,*corneal endothelium
16196,34102155,*diagnostic capacity
16197,34102155,*disease activity
16199,32684074,go treatment
16200,32684074,graves ophthalmopathy treatment
16201,32684074,ted treatment
16202,32684074,thyroid eye disease treatment
16203,32684074,teprotumumab
16204,32133893,*antithyroid
16205,32133893,*graves’ disease
16206,32133893,*carbimazole
16207,32133893,*methimazole
16208,32133893,*pediatric
16209,32133893,*propylthiouracil
16210,34243871,extraocular muscles
16211,34243871,graves disease
16212,34243871,graves eye disease (ged)
16213,34243871,lacrimal gland
16216,34235979,*graves' ophthalmopathy
16217,34235979,*extracellular matrix
16218,34235979,*histone deacetylases
16219,34235979,*orbital fibroblasts
16220,34235979,*platelet-derived growth factor-bb
16221,32739299,*cardiac arrest
16222,32739299,*coronary artery spasm
16223,32739299,*iodine contrast
16224,32739299,*thyrotoxicosis
16225,33468490,*optic nerve
16226,33468490,*orbit cois
16227,32562184,*graves’ disease
16228,32562184,*thyroid-stimulating immunoglobulin
16229,32562184,*thyroid-stimulating hormone receptor autoantibody
16230,32300961,count ivan viii drašković
16231,32300961,graves’ disease
16232,32300961,iodine
16233,32300961,orbitopathy
16234,32300961,spontaneous remission
16235,32300961,tobacco
16238,32858059,autoimmunity
16239,32858059,brahms
16240,32858059,biotin
16241,32858059,graves’ disease
16242,32858059,roche cobas
16243,32858059,trace
16244,32858059,trab
16245,32858059,tsh-receptor antibody
16246,32858059,thermo scientific kryptor
16247,32858059,thyroid stimulating antibody
16248,32134013,*channelopathies
16249,32134013,*tpp
16250,32134013,*hypokalaemia
16251,32134013,*paralysis
16252,32134013,*periodic palsy
16253,32134013,*thyroid hormones
16254,32134013,*thyrotoxicosis cois
16255,34855075,mir-155
16256,34855075,microrna
16257,34855075,rennin—angiotensin—aldosterone system
16258,34855075,thyrotoxic heart disease
16260,32666762,thyroid autoimmunity
16261,32666762,vitamin d
16262,32666762,vitamin d supplementation
16263,33349844,*maternal thyroid function
16264,33349844,*pregnancy
16265,33349844,*thyroid in pregnancy
16266,32249902,*graves’ orbitopathy
16267,32249902,*adipogenesis
16268,32249902,*autophagy
16269,32249902,*chloroquine
16270,32249902,*hydroxychloroquine
16271,32249902,*orbital fibroblasts
16273,31865369,*graves hyperthyroidism
16274,31865369,*tsh-r blocking antibodies
16275,31865369,*tsh-r stimulating antibodies
16276,31865369,*dilution analysis
16277,31865369,*prospective trial
16278,32693696,thyroid-associated ophthalmopathy
16279,32693696,dose response
16280,32693696,strabismus surgery
16281,32693696,torsion
16282,31756165,graves’ disease (gd)
16283,31756165,autoimmune polyglandular syndrome type 3 variant (aps3v)
16284,31756165,autoimmune thyroid disease (aitd)
16285,31756165,rheumatoid arthritis (ra)
16286,31756165,type 1 diabetes mellitus (t1d)
16287,31756165,type 2 diabetes mellitus (t2d)
16288,32804020,chronic sinus
16289,32804020,neck abscess
16290,32804020,polyglactin 910
16291,32804020,post thyroidectomy
16292,32804020,retained suture
16293,33880967,*adpla
16294,33880967,*rna interference
16295,33880967,*tao
16296,33880967,*adipocytes
16297,33880967,"*microneedles cois conflicts of interest with respect to the research, authorship, and/or publication of this article."
16299,32176314,*cd34
16300,32176314,*cd68
16301,32176314,*fgf-b
16302,32176314,*foxp-3
16303,32176314,*graves’ orbitopathy
16304,32176314,*igf-1r
16305,32176314,*ihc
16306,32176314,*ppar-g
16307,32176314,*tgf-b
16308,32176314,*autoimmunity
16309,32176314,*tissue remodeling
16311,31952487,dysthyroid optic neuropathy
16312,31952487,graves’ orbitopathy
16313,31952487,japanese
16314,31952487,orbital decompression
16315,31952487,visual outcome cois
16316,33972303,endocrinology
16317,33972303,neurology (drugs and medicines)
16318,33972303,ophthalmology
16319,33972303,thyroid disease cois
16322,32638278,elastography
16323,32638278,graves
16324,32638278,medial rectus muscle
16325,32638278,optic nerve
16326,32638278,shear wave
16328,31997590,*blood vessels
16329,31997590,*children
16330,31997590,*microvascular imaging
16331,31997590,*ultrasonography
16332,31997590,"*ultrasonography, doppler, color cois"
16333,33050937,graves’ disease
16334,33050937,papillary thyroid carcinoma
16335,33050937,prognosis
16336,33050937,recurrence cois
16338,32874077,cascade testing
16339,32874077,thyroid dysfunction
16340,32874077,thyroid stimulating hormone
16341,32321476,extraocular muscles
16342,32321476,histopathology
16343,32321476,ocular myasthenia gravis
16344,32321476,thyroid-associated ophthalmopathy cois
16348,33381085,*enalapril
16349,33381085,*graves’ orbitopathy (go)
16350,33381085,*n-acetyl-l-cysteine
16351,33381085,*quercetin
16352,33381085,*vitamin c
16353,33381085,*melatonin
16354,33381085,*oxidative stress
16355,33381085,*β-carotene cois commercial or financial relationships that could be construed as a potential conflict of interest.
16359,32447327,*drugs
16360,32447327,*orbit
16361,32447327,*treatment medical cois
16365,32297812,*graves’ disease (gd)
16366,32297812,*hyperlipidemia
16367,32297812,*polycystic ovary syndrome (pcos)
16368,32090526,*diffusion tensor imaging
16369,32090526,*extraocular muscle
16370,32090526,*optic nerve
16371,32090526,*readout-segmented echo-planar imaging
16372,32090526,*thyroid-associated orbitopathy cois
16373,34939881,*covid-19 vaccines
16374,34939881,*graves disease
16375,34939881,*sars-cov-2
16376,34939881,*case report
16377,34939881,*endocrinology
16378,34939881,*immunology
16379,34939881,"*pharmacovigilance cois conflicts of interest with respect to the research, authorship, and/or publication of this article."
16380,33158379,thyroid eye disease
16381,33158379,eyelid disease: eyelid malpositions/trichiasis/ptosis
16382,33158379,neuro ophthalmology
16383,33158379,optic neuropathy
16384,33158379,orbital disease
16385,33158379,strabismus
16386,32969067,131i
16387,32969067,dosimetry
16388,32969067,hyperthyroidism
16394,31915884,chronic sinusitis
16395,31915884,eosinophilic angiocentric fibrosis
16396,31915884,igg4-related disease
16397,31915884,immunoglobulin g
16398,31915884,orbit
16399,32712880,dicer1
16400,32712880,follicular thyroid carcinoma
16401,32712880,met
16402,32712880,macrofollicular variant
16403,32712880,mutation cois
16404,34704876,*graves’ ophthalmopathy
16405,34704876,*glucocorticoids
16406,34704876,*immunotherapy
16407,34704876,*therapy
16408,34704876,*tocilizumab
16409,34635084,bell’s phenomeon
16410,34635084,fibrosis
16411,34635084,inferior rectus muscle
16412,34635084,thryoid eye disease cois
16413,33543610,*tidm4 gene
16414,33543610,*functional mechanism
16415,33543610,*orbital adipose tissue
16416,33543610,*thyroid-associated ophthalmopathy
16420,34212219,histological confirmation
16421,34212219,idiopathic orbital inflammation
16422,34212219,lymphoid hyperplasia
16423,34212219,orbital lymphoma
16424,34212219,specific orbital inflammation
16425,33128233,*graves’ disease
16426,33128233,*hyperthyroidism
16427,33128233,*paediatric
16428,33128233,*quality of life
16429,33128233,*thyroid
16432,33121425,autoimmune hyperthyroidism
16433,33121425,gitelman syndrome
16434,33121425,endocrine
16435,33121425,gene mutation
16436,33121425,hypokalemia
16437,33121425,metabolic alkalosis.
16438,32643429,*b lymphocytes
16439,32643429,*cxcr5
16440,32643429,*cxcl13
16441,32643429,*graves’ orbitopathy
16442,32643429,*chemokine receptor
16443,32457697,*graves' disease
16444,32457697,*eosinophils
16445,32457697,*subacute thyroiditis
16446,32457697,*thyroxine
16447,32457697,*triiodothyronine
16448,34473251,*atp production
16449,34473251,*graves orbitopathy
16450,34473251,*adipogenesis
16451,34473251,*fatty acid uptake
16452,34473251,*mitochondria oxphos
16453,34473251,*orbital adipose tissue
16456,31928169,*escape
16457,31928169,*methimazole
16458,31928169,*potassium iodide
16459,31928169,*pregnancy
16460,31928169,*thyrotoxicosis
16462,33930408,*graves' disease
16463,33930408,*graves' orbitopathy
16464,33930408,*teprotumumab
16465,33930408,*translational science
16466,33930408,*biologics
16467,33930408,*clinical activity score
16468,33930408,*randomized clinical trial
16469,33930408,*review
16470,33930408,*thyroid eye disease
16471,33783712,graves’ ophthalmopathy
16472,33783712,meta-analysis
16473,33783712,rituximab
16474,33783712,treatment
16475,32908802,*graves’ ophthalmopathy
16476,32908802,*lincs
16477,32908802,*adipogenesis
16478,32908802,*orbital adipose stem cells
16479,32908802,*thyroid eye disease
16480,32908802,"*thyroid-associated orbitopathy cois d.t. tse, none; d. pelaez, none; s.t. wester, horizon therapeutics (c)"
16481,32738825,*graves´ disease
16482,32738825,*hashimoto thyroiditis
16483,32738825,*autoimmune thyroid disease
16484,32738825,*cluster analysis
16485,32738825,*polyautoimmunity
16487,34867951,*graves’ disease
16488,34867951,*hashimoto’s thyroiditis (ht)
16489,34867951,*autoimmune thyroid diseases (aitds)
16490,34867951,*exosome
16491,34867951,*proteomics cois commercial or financial relationships that could be construed as a potential conflict of interest.
16492,34412613,graves’ disease
16493,34412613,growth hormone
16494,34412613,insulin-like growth factor-i
16495,34412613,thyroid-related ophthalmopathy cois
16497,32785703,* bacteroides fragilis
16498,32785703,*graves’ disease
16499,32785703,*treg/th17
16500,32785703,*intestinal flora
16501,32785703,*propionic acid
16503,33603715,*graves’ orbitopathy
16504,33603715,*biomarker
16505,33603715,*functional thyrotropin receptor antibodies
16506,33603715,*stimulatory tsh receptor antibodies
16507,33603715,"*thyroid eye disease cois authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. the jgu medical center has received research-associated funding unrelated to this study from the jgu medical faculty, advancecor, germany, apitope, united kingdom; immunovant, usa, isar, germany, horizon, usa, mediomics, usa, merck, germany, novartis, usa, quidel, usa, river vision, usa, and roche, switzerland. this article was not specifically funded by a company. the funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article, or the decision to submit it for publication."
16508,33964007,autoimmunity
16509,33964007,covid-19
16510,33964007,graves’ disease
16511,33964007,graves’ orbitopathy
16512,33964007,sars-cov-2
16513,33964007,thyroid cois
16515,34602013,*graves’ orbitopathy
16516,34602013,*adipokines
16517,34602013,*methylprednisolone
16518,34051850,*go animal model
16519,34051850,*graves’ disease
16520,34051850,*graves’ ophthalmopathy
16521,34051850,*thyroid disease
16522,34051850,*adipogenesis
16523,34051850,*hpmscs cois paper.
16525,32567442,graves ophthalmopathy
16526,32567442,graves orbitopathy
16527,32567442,mri ted
16528,32567442,tendon sparing
16529,32567442,thyroid eye disease
16531,34117002,cardiovascular medicine
16532,34117002,emergency medicine
16533,34117002,endocrine system cois
16534,32968297,hyperthyroidism; pregnancy; pprom; thyrotoxicosis. cois
16535,32648002,clinical activity score
16536,32648002,graves’ disease
16537,32648002,graves’ ophthalmopathy
16538,32648002,graves’ orbitopathy
16539,32648002,tsh receptor autoantibodies
16540,32648002,thyroid eye disease
16541,32583374,autoimmune thyroiditis
16542,32583374,graves’ disease
16543,32583374,graves’ ophthalmopathy
16544,32583374,graves’ orbitopathy
16545,32583374,insulin-like growth factor-1 receptor
16546,32583374,thyroid
16547,32583374,thyroid autoimmunity
16548,32583374,thyroid eye disease
16549,32567373,*thyroid-associated ophthalmopathy
16550,32567373,*decompression surgery & interventional medicine
16551,32567373,*gene network analysis
16552,32567373,*graves’ ophthalmopathy
16553,32567373,*therapeutics
16554,34116129,*adipogenesis
16555,34116129,*graves' orbitopathy
16556,34116129,*orbital fibroblasts
16557,34116129,*stat3
16558,34116129,*signal transducer and activator of transcription 3
16559,34116129,*thyroid eye disease
16562,34406498,go
16563,34406498,imaging
16564,34406498,mri
16565,34406498,pet
16566,34406498,ted
16567,34406498,thyroid eye disease cois
16568,34344134,graves ophthalmopathy
16569,34344134,retinal diseases
16570,34344134,smoking cois was reported.
16571,32842335,eye injections
16572,32842335,eyelid diseases
16573,32842335,graves ophthalmopathy
16574,32842335,triamcinolone acetonide
16577,34077777,graves’ disease
16578,34077777,graves’ ophthalmopathy
16579,34077777,single nucleotide polymorphism
16580,34077777,vitamin d receptor
16581,33261249,*hyperthyroidism
16582,33261249,*agranulocytosis
16583,33261249,*methimazole
16584,33261249,*neutropenia
16585,33261249,*thionamides
16586,33866536,foxp3
16587,33866536,glucocorticosteroids
16588,33866536,orbitopathy
16589,33866536,rorγt
16590,33866536,th17
16591,33866536,treg
16592,34594339,*gnrh stimulation test
16593,34594339,*graves’ disease
16594,34594339,*autoimmune polyglandular syndrome type 3
16595,34594339,*isolated gonadotropin-releasing hormone deficiency
16596,34594339,*secondary amenorrhea
16597,34594339,*type 1 diabetes mellitus cois commercial or financial relationships that could be construed as a potential conflict of interest.
16598,34114495,*graves' ophthalmopathy
16599,34114495,*tsh receptor
16600,34114495,*antibody drugs
16601,34114495,*autoantibodies
16602,34114495,*thyroid cancer
16603,33148577,endocrine system
16604,33148577,endocrinology
16605,33148577,thyroid disease
16606,33148577,thyroiditis
16607,33148577,thyrotoxicosis cois
16609,33844898,covid-19
16610,33844898,thyroid disorders
16611,33844898,hyperthyroidism
16612,33844898,hypothyroidism
16613,33844898,subacute thyroiditis
16615,32339726,*adult
16616,32339726,*case report
16617,32339726,*magnetic resonance imaging
16618,32339726,*pathology
16619,32339726,*pituitary blastoma
16621,33882721,*graves'
16622,33882721,*age
16623,33882721,*disease
16624,33882721,*disease prognosis
16625,33882721,*hyperthyroidism
16626,33882721,*sex
16627,33505575,africa
16628,33505575,paralysis
16629,33505575,hyperthyroidism
16630,33505575,hypokalemia cois
16631,32669187,graves disease
16632,32669187,"infant, newborn"
16633,32669187,mothers
16634,32669187,pregnancy complications
16635,32669187,prenatal exposure delayed effects
16640,33409786,artifacts
16641,33409786,eye diseases
16642,33409786,magnetic resonance imaging
16643,33409786,thyroid diseases
16644,33081749,choroidal thickness
16645,33081749,optical coherence tomography angiography
16646,33081749,retinal nerve fiber layer
16647,33081749,thyroid-associated ophthalmopathy cois publication of this paper.
16648,32779176,ct
16649,32779176,mri
16650,32779176,ultrasonography
16651,32779176,ectopic thyroid
16652,32779176,multimodality
16653,32779176,thyroid scintigraphy
16655,32855872,*graves' disease
16656,32855872,*murine model
16657,32855872,*orbital inflammation
16658,32855872,"*thyroid eye disease cois none; l. ramos, none; s.k. freitag, none; d.r. bielenberg, none; l.a. kim, none; n.g. lee, none"
16659,32546346,*bone mineral density
16660,32546346,*graves’ disease
16661,32546346,*dual energy x-ray absorptiometry
16662,34526052,3d photography
16663,34526052,blepharoplasty surgery
16664,34526052,digital facial-analysis tool
16665,34526052,endocrine orbitopathy
16666,34526052,lid refinement
16667,34526052,lid repositioning
16668,34526052,ocular surface area cois
16670,32799342,*graves’ disease
16671,32799342,*hyperthyroidism
16672,32799342,*neutropenia
16673,32799342,*white blood cells
16674,33391187,*graves’ disease
16675,33391187,*autoimmune
16676,33391187,*connective tissue
16677,33391187,*insulin-like growth factor i receptor
16678,33391187,*monoclonal antibody
16679,33391187,*thyroid-associated ophthalmopathy cois inhibitors as therapy in graves’ disease. these patents are held by ucla school of medicine and los angeles biomedical research institute.
16680,33311000,grave’s disease
16681,33311000,hashimoto’s thyroiditis
16682,33311000,igg4 thyroiditis
16683,33311000,igg4-related thyroid disease
16684,33311000,riedel’s thyroiditis
16686,32919017,*long non-coding rna
16687,32919017,*orbital adipose/connective tissue
16688,32919017,*rna sequencing
16689,32919017,*thyroid-associated ophthalmopathy
16692,34106438,*ace2
16693,34106438,*autoimmune
16694,34106438,*covid-19
16695,34106438,*graves’ disease
16696,34106438,*hyperthyroidism
16697,34106438,*raas
16698,34106438,*sars-cov-2
16699,34106438,*thyroid cois
16700,34060524,compressive optic neuropathy
16701,34060524,nasal endoscopy
16702,34060524,orbital decompression
16703,34060524,thyroid eye disease cois
16704,33817897,*fractional amplitude of low-frequency fluctuation
16705,33817897,"*regional homogeneity, degree centrality"
16706,33817897,*resting-state fmri
16707,33817897,*thyroid-associated ophthalmopathy
16708,33599843,diplopia
16709,33599843,exophthalmos
16710,33599843,graves’ orbitopathy
16711,33599843,orbital decompression
16712,33446163,machine learning
16713,33446163,magnetic resonance imaging
16714,33446163,thyroid-associated ophthalmopathy cois
16718,34180765,cystic teratoma
16719,34180765,graves’ disease
16720,34180765,primary papillary thyroid carcinoma
16721,32940167,*graves'
16722,32940167,*clinical trials
16723,32940167,*diplopia
16724,32940167,*ocular ductions
16725,32940167,*orbitopathy
16726,32940167,*rehabilitation
16727,32940167,*squint surgery
16728,33849364,*graves’ orbitopathy
16729,33849364,*clinical activity score
16730,33849364,*glucocorticoids
16731,33849364,*interleukin-6
16732,33849364,*interleukin-8
16733,33849364,*interleukin–10
16735,32849306,*graves' disease
16736,32849306,*tsh secreting pituitary adenoma
16737,32849306,*tshoma
16738,32849306,*concomitant
16739,32849306,*thyrotropin
16740,32238669,agranulocytosis
16741,32238669,antithyroid drug
16742,32238669,hyperthyroidism
16743,32238669,malignancy
16744,32238669,potassium iodide
16745,31603857,graves’ disease
16746,31603857,children
16747,31603857,hyperthyroidism
16748,31603857,radioiodine ablation
16750,34431214,*graves' disease (gd)
16751,34431214,*stat4
16752,34431214,*autoimmune disease
16753,34431214,*mir-363-5p
16754,34431214,*regulatory t cells (tregs) cois
16755,32429706,graves’ disease
16756,32429706,igf-ir
16757,32429706,r1507
16758,32429706,rv001
16759,32429706,tepezza
16760,32429706,teprotumumab
16761,32429706,thyroid eye disease
16762,32429706,thyroid-associated ophthalmopathy
16763,32192806,cancer héréditaire
16764,32192806,carcinome thyroïdien familial
16765,32192806,cowden syndrome
16766,32192806,dicer1 syndrome
16767,32192806,familial adenomatous polyposis
16768,32192806,familial thyroid carcinoma
16769,32192806,hereditary cancer
16770,32192806,polypose adénomateuse familial
16771,32192806,syndrome dicer1
16772,32192806,syndrome de cowden
16774,34867796,*graves’ disease
16775,34867796,*children
16776,34867796,*metabolic pathway
16777,34867796,*serum metabolomics
16778,34867796,*untargeted metabolomics cois commercial or financial relationships that could be construed as a potential conflict of interest.
16779,33443817,*graves’ orbitopathy
16780,33443817,*neferine
16781,33443817,*adipocyte differentiation
16782,33443817,*autophagy
16783,33443817,*inflammation
16784,33443817,*oxidative stress cois topic of the manuscript.
16787,33481154,graves disease
16788,33481154,igf-1r
16789,33481154,r1507
16790,33481154,rv001
16791,33481154,tepezza
16792,33481154,teprotumumab
16793,33481154,thyroid eye disease
16794,33481154,thyroid-associated ophthalmopathy
16797,34889904,graves’ orbitopathy
16798,34889904,binding protein
16799,34889904,thyrostimulin
16800,34889904,thyrotropin receptor
16801,34889904,variant cois
16802,32823277,*nk cells
16803,32823277,*programmed cell death protein-1
16804,32823277,*autoimmune thyroid disease
16807,34122333,*graves’ disease
16808,34122333,*cross-sectional study
16809,34122333,*hyperthyroidism
16810,34122333,*iodine intake
16811,34122333,*thyroid autoimmune antibodies cois commercial or financial relationships that could be construed as a potential conflict of interest.
16812,32501499,*graves disease
16813,32501499,*autoimmune
16814,32501499,*genotyping
16815,32501499,*meta-analysis
16816,32501499,*polymorphism
16817,32501499,*thyroid
16818,34284740,diffusion tensor imaging
16819,34284740,lacrimal gland
16820,34284740,readout-segmented echo-planar imaging
16821,34284740,thyroid-associated ophthalmopathy cois
16822,33678636,graves’ disease
16823,33678636,graves’ disease associated cholestasis
16824,33678636,cholestasis
16825,33678636,clinical manifestation
16826,33678636,diagnosis
16827,33678636,treatment
16831,33906763,globe prominence
16832,33906763,proptosis
16833,33906763,thyroid eye disease cois therapeutics and osmotica pharmaceuticals.
16834,33858251,foxp3
16835,33858251,graves’ disease
16836,33858251,ethnicity
16837,33858251,meta-analysis
16838,33858251,polymorphism
16839,33858251,susceptibility cois conflict of interest.
16840,32090348,*mri t1 mapping
16841,32090348,*diplopia
16842,32090348,*extraocular muscles
16843,32090348,*fibrosis
16844,32090348,*graves ophthalmopathy
16845,32090348,*intravenous glucocorticoids
16846,32090348,*magnetic resonance imaging
16849,33551434,active surveillance
16850,33551434,graves’ disease
16851,33551434,papillary thyroid microcarcinoma
16852,33551434,radioactive iodine therapy
16853,33551434,tumor volume-doubling rate
16854,33193097,*dysthyroid optic neuropathy
16855,33193097,*grave’s disease
16856,33193097,*grave’s ophthalmopathy
16857,33193097,*orbital decompression
16858,33193097,*rituximab
16859,32495527,*chemokine
16860,32495527,*cytokine
16861,32495527,*graves' orbitopathy
16862,32495527,*interleukin-1β
16863,32495527,*tumor necrosis factor-α cois
16864,34488259,decompression
16865,34488259,eyelids
16866,34488259,graves ophthalmopathy cois
16868,33938028,*graves’ disease
16869,33938028,*graves’ ophthalmopathy
16870,33938028,*igg4
16871,33938028,*glucocorticoid therapy
16872,33682498,dexamethasone
16873,33682498,graves’ disease
16874,33682498,drug resistance
16875,33682498,hyperthyroidism
16876,33682498,inorganic iodine
16877,33682498,lithium carbonate
16878,33682498,methimazole cois conflict of interest.
16879,33517506,deep lateral decompression
16880,33517506,graves disease
16881,33517506,graves orbitopathy
16882,33517506,orbital decompression
16883,33517506,orbital surgery
16886,32814653,graves’ orbitopathy
16887,32814653,computed tomography
16888,32814653,computer-assisted image processing
16889,32814653,magnetic resonance imaging
16890,32814653,orbit
16892,33199029,dfnb4
16893,33199029,missense mutations
16894,33199029,next-generation sequencing
16895,33199029,pendred syndrome
16896,33199029,slc26a4 gene
16898,32074519,intractability
16899,32074519,polymorphism
16900,32074519,severity
16901,32074519,vegf receptor (vegfr)
16902,32074519,vascular endothelial growth factor (vegf)
16903,32374820,*mendelian randomization
16904,32374820,*tsh
16905,32374820,*coronary artery disease
16906,32374820,*mediation
16907,32374820,*stroke
16908,32374820,*thyroid function
16909,32893239,basedow disease
16910,32893239,amyotrophic lateral sclerosis
16911,32893239,soluble il-2 receptor
16912,32893239,thyrotoxic myopathy
16913,32893239,tongue atrophy
16915,34479513,cholestatic liver injury
16916,34479513,graves' disease
16917,34479513,methimazole
16918,34479513,rash
16919,34479513,turner syndrome cois
16923,33132244,graves’ disease
16924,33132244,pd-1
16925,33132244,t lymphocytes
16926,33132244,thyroid follicular cells
16928,34238277,cd160
16929,34238277,graves’ disease
16930,34238277,hashimoto’s thyroiditis
16931,34238277,polymorphism cois
16932,33423386,graves’ orbitopathy
16933,33423386,glucocorticoids
16934,33423386,long-circulating pegylated liposomal prednisolone
16935,33423386,methylprednisolone
16936,33423386,orbit
16937,32651061,*graves' disease
16938,32651061,*breastfeeding
16939,32651061,*hypothyroidism
16940,32651061,*postpartum thyroid dysfunction
16941,32651061,*postpartum thyroiditis
16942,32651061,*thyrotoxicosis
16944,33922887,antithyroid drug
16945,33922887,change
16946,33922887,ocular parameters cois
16949,34258936,dysthyroid optic neuropathy
16950,34258936,hospital anxiety and depression
16951,34258936,regional homogeneity
16952,34258936,resting-state fmri
16953,34258936,thyroid-associated ophthalmopathy cois
16954,33693700,*igf-1
16955,33693700,*il-38
16956,33693700,*m22
16957,33693700,*tgf-β1
16958,33693700,*orbital fibroblasts
16959,33693700,*thyroid-associated ophthalmopathy
16960,33386169,amino acid variants
16961,33386169,graves’ disease
16962,33386169,hla class ii
16963,33386169,hashimoto’s thyroiditis cois competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
16964,32825964,graves' disease
16965,32825964,hashimoto's thyroiditis
16966,32825964,prognosis
16967,32825964,thyroid cancer
16969,32025782,angio-oct
16970,32025782,choroid
16971,32025782,oct
16972,32025782,orbitopathy
16973,32025782,thyroid
16974,31900640,4-methylumbelliferone
16975,31900640,adipogenesis
16976,31900640,graves’ orbitopathy
16977,31900640,hyaluronic acid
16978,33488527,*graves’ disease
16979,33488527,*autoimmune thyroiditis
16980,33488527,*differential diagnosis
16981,33488527,*thyroid function test
16982,33488527,*thyrotoxicosis cois commercial or financial relationships that could be construed as a potential conflict of interest.
16983,33380308,graves’ disease
16984,33380308,thyroid
16985,33380308,cancer
16986,33380308,nodules
16987,33380308,surgery
16988,33380308,thyroidectomy.
16989,34018373,clinical analysis
16990,34018373,extraocular muscles
16991,34018373,magnetic resonance imaging
16992,34018373,thyroid associated ophthalmoathy
16994,33658150,graves ophthalmopathy
16995,33658150,cosmetic reconstructive surgery
16996,33658150,exophthalmos
16997,33658150,ophthalmologic surgical procedure
16998,33658150,orbital decompression
16999,33658150,proptosis
17000,33658150,surgical decompression
17001,33658150,surgical technique
17002,33658150,thyroid eye disease
17003,33658150,thyroid-associated ophthalmopathies
17004,33658150,transantral
17005,34315743,endocrinology
17006,34315743,thyroid disease cois
17007,33630733,t2 mapping
17008,33630733,magnetic resonance imaging
17009,33630733,optic nerve
17010,33630733,thyroid-associated ophthalmopathy
17011,31887836,cytokines
17012,31887836,dihydrotestosterone
17013,31887836,graves disease
17014,31887836,mice
17016,33382429,*genetics
17017,33382429,*hyperthyroidism
17018,33382429,*hypothyroidism
17019,33382429,*twin studies
17020,33009740,graves’ disease
17021,33009740,exophthalmos
17022,33009740,neurosurgery
17023,33009740,ophthalmopathy
17024,33009740,thyroid diseases.
17025,32485674,*graves’ disease
17026,32485674,*nf-κb
17027,32485674,*sirt1
17028,32485674,*thyroid
17029,32545570,agranulocytosis
17030,32545570,hyperthyroidism
17031,32545570,plasmapheresis
17032,32545570,thyroidectomy
17033,32545570,thyrotoxicosis cois
17036,32324288,*graves
17037,32324288,*bone
17038,32324288,*disease
17039,32324288,*fractures
17040,32324288,*immunoglobulins
17041,32324288,*menopause
17042,32324288,*osteoporosis
17043,32324288,*thyroid-stimulating
17045,34334593,acromegaly
17046,34334593,adenomatous goiter
17047,34334593,neurofibromatosis type 1
17048,34334593,primary hyperparathyroidism cois
17050,32500462,alemtuzumab
17051,32500462,graves’ ophthalmopathy
17052,32500462,immune-reconstitution inflammatory syndrome
17053,32500462,marine-lenhart syndrome
17054,34598656,*graves'
17055,34598656,"*disease, meta-analysis, radiation absorbed dose, radioiodine, systematic review cois research and training program 2014–2018 and national institute for health research (nihr) and funding from national health service to the nihr biomedical research centre at the royal marsden and the institute of cancer research and nihr royal marsden clinical research facility outside the work of the study. j.i.g. reports personal fees and honoraria from the eanm outside the work of the study."
17057,32612577,*foxp3
17058,32612577,*graves' disease
17059,32612577,*autoimmune thyroid disease
17060,32612577,*meta-analysis
17061,32612577,*polymorphism
17062,33853289,autoimmune thyroid disease.
17063,33853289,children and adolescents
17064,33853289,type 1 diabetes
17065,33853289,metabolic disorders
17067,32689994,molecular docking
17068,32689994,network pharmacology
17069,32689994,spica prunellae
17070,32689994,tao
17071,32689994,thyroid-associated ophthalmopathy cois
17072,32363975,orbital decompression
17073,32363975,thyroid eye disease
17074,32363975,transantral orbital decompression
17076,32983115,*addison's disease
17077,32983115,*cdcp1
17078,32983115,*graves' disease
17079,32983115,*hashimoto's thyroiditis
17080,32983115,*slamf1
17081,32983115,*plasma
17082,32983115,*proximity extension assay
17083,32983115,*type 1 diabetes
17084,34915605,*antithyroid agents
17085,34915605,*diabetes mellitus
17086,34915605,*graves disease
17087,34915605,*hyperthyroidism
17088,34915605,*radioiodine ablation cois was reported.
17090,34101720,*actemra
17091,34101720,*cellcept
17092,34101720,*rituxan
17093,34101720,*tepezza
17094,34101720,*adverse effects
17095,34101720,*corticosteroids
17096,34101720,*dosage
17097,34101720,*efficacy
17098,34101720,*eye
17099,34101720,*lactation
17100,34101720,*methylprednisone
17101,34101720,*mycophenolate mofetil
17102,34101720,*prednisone
17103,34101720,*pregnancy
17104,34101720,*rituximab
17105,34101720,*safety
17106,34101720,*teprotumumab
17107,34101720,*tocilizumab
17109,34863412,cord blood
17110,34863412,embarazo
17111,34863412,enfermedad de graves
17112,34863412,graves’ disease
17113,34863412,hipertiroidismo
17114,34863412,hyperthyroidism
17115,34863412,newborn
17116,34863412,pregnancy
17117,34863412,recién nacido
17118,34863412,sangre del cordón umbilical
17119,34863412,trab
17121,32227795,*graves’
17122,32227795,*disease
17123,32227795,*radiation thyroiditis
17124,32227795,*radioactive iodine
17125,33383445,anti-inflammation
17126,33383445,il-23/il-17 axis
17127,33383445,il-23r
17128,33383445,il-38
17129,33383445,pge(2)
17130,33383445,thyroid-associated ophthalmopathy
17133,32933065,graves’ disease
17134,32933065,hashimoto thyroiditis
17135,32933065,autoimmune thyroid disease
17136,32933065,vitamin d
17137,32933065,vitamin d receptor cois
17138,32537950,clinical activity score
17139,32537950,glucocorticoids
17140,32537950,graves' ophthalmopathy
17141,32537950,response rate cois
17146,34987480,*graves’ disease
17147,34987480,*adhesion molecules
17148,34987480,*carotid intima media thickness
17149,34987480,*hyperthyroidism
17150,34987480,*methimazole
17151,34987480,*propylthiouracil
17152,34987480,*pulse wave velocity
17153,34987480,*vascular atherosclerosis cois commercial or financial relationships that could be construed as a potential conflict of interest.
17155,33643223,*graves’ orbitopathy
17156,33643223,*t cells
17157,33643223,*immune
17158,33643223,*mucosa
17159,33643223,*paranasal sinus cois commercial or financial relationships that could be construed as a potential conflict of interest.
17160,33504525,clinical diagnostic tests
17161,33504525,hip prosthesis implantation
17162,33504525,neurology (drugs and medicines)
17163,33504525,psychiatry (drugs and medicines)
17164,33504525,rehabilitation medicine cois
17165,32893386,*graves' orbitopathy
17166,32893386,*extra-ocular muscles
17167,32893386,*eye diseases
17168,32893386,*eye muscles
17169,32893386,*muscle mri
17170,32893386,*myasthenia gravis
17171,32893386,*quantitative mri
17173,32522908,graves’ disease
17174,32522908,neonatal thyroid dysfunction
17175,32522908,tsh receptor antibody
17176,34287665,*foxo1
17177,34287665,*genetic susceptibility
17178,34287665,*graves’ disease
17179,34287665,*il2ra
17180,34287665,*mir182
17181,34287665,*mir27a
17183,33234032,*cas
17184,33234032,*cd20
17185,33234032,*graves' disease
17186,33234032,*graves' orbitopathy
17187,33234032,*cytokine release syndrome
17188,33234032,*dysthyroid optic neuropathy
17189,33234032,*rituximab
17190,33221730,*genetics
17191,33221730,*immunology
17192,33221730,*orbit cois
17194,34963497,antineutrophil cytoplasmic antibody-associated vasculitis
17195,34963497,drug-induced anca-associated vasculitis
17196,34963497,graves’ disease
17197,34963497,hypertrophic pachymeningitis
17198,34963497,myeloperoxidase-antineutrophil cytoplasmic antibody cois
17200,34523298,graves´ disease
17201,34523298,immune reconstitution therapy
17202,34523298,multiple sclerosis
17203,34523298,ocrelizumab
17204,33669123,fnah
17205,33669123,tshr
17206,33669123,central hypothyroidism
17207,33669123,familial non-autoimmune autosomal dominant hyperthyroidism
17208,33669123,radioiodine ablation therapy cois
17211,34124812,*graves' disease
17212,34124812,*hypercalcemia
17213,34124812,*hyperparathyroidism
17214,34124812,*parathyroid surgery
17215,34124812,*radioactive iodine
17216,33152840,graves ophthalmopathy
17217,33152840,macula lutea
17218,33152840,optic disk
17219,33152840,optic nerve diseases
17220,33152840,regional blood flow
17221,33152840,"tomography, optical coherence"
17223,31972501,*active graves’ orbitopathy
17224,31972501,*newly diagnosed graves’ disease
17225,31972501,*potential markers
17226,31972501,*pro-inflammatory cytokines
17227,31972501,*selenium cois competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
17228,34218976,exophthalmos
17229,34218976,graves hyperthyroidism
17230,34218976,graves ophthalmopathy
17231,34218976,orbital decompression
17232,34218976,quality of life
17234,33295879,*graves’ disease
17235,33295879,*autoimmune hyperthyroidism
17236,33295879,*autoimmune thyroid disease
17237,33295879,*genetic and epigenetic factors
17238,32729365,iodine
17239,32729365,endemic
17240,32729365,goiter
17241,32729365,nodule
17242,32729365,thyroid
17243,32729365,ultrasound
17244,34681587,aitd
17245,34681587,graves’ disease
17246,34681587,autoimmunity
17247,34681587,methimazole
17248,34681587,regulatory b cells
17249,34681587,thyroid cois
17251,33870911,*graves’ orbitopathy
17252,33870911,*perk
17253,33870911,*endoplasmic reticulum stress
17254,33870911,*protein kinase rna-like endoplasmic reticulum kinase
17255,33870911,*thyroid eye disease
17256,34888290,*covid-19
17257,34888290,*covid-19 vaccines
17258,34888290,*graves' disease
17259,34888290,*sars-cov-2
17260,34888290,*autoimmunity
17261,34888290,*thyroiditis cois commercial or financial relationships that could be construed as a potential conflict of interest.
17262,33451885,intraoperative neuromonitoring
17263,33451885,recurrent laryngeal nerve injury
17264,33451885,thyroid surgery
17265,31902232,2a típusú multiplex endokrin neoplasia szindróma
17266,31902232,genetic testing
17267,31902232,genetikai vizsgálat
17268,31902232,medullaris pajzsmirigydaganat
17269,31902232,medullary thyroid cancer
17270,31902232,multiple endocrine neoplasia type 2a
17271,31902232,phaeochromocytoma
17272,31902232,primary hyperparathyroidism
17273,31902232,primer hyperparathyreosis
17274,34047397,*trab
17275,34047397,*fibroblast
17276,34047397,*inducible skin-associated lymphoid tissue (isalt)
17277,34047397,*pretibial myxedema (ptm) cois
17278,32053002,t2 mapping
17279,32053002,thyroid-associated ophthalmopathy
17280,32053002,magnetic resonance imaging
17281,32053002,region of interest
17282,32053002,staging
17283,34690936,*graves’ disease
17284,34690936,*anti-thyroid drug
17285,34690936,*heart failure
17286,34690936,*hyperthyroidism
17287,34690936,*radioiodine ablation cois authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
17288,34647604,cas
17289,34647604,eugogo classification
17290,34647604,nospecs classification
17291,34647604,orbital decompression
17292,34647604,thyroid eye disease
17296,34130446,*antithyroid agents
17297,34130446,*congenital abnormalities
17298,34130446,*graves disease
17299,34130446,*iodine
17300,34130446,*pregnancy
17301,34130446,*recurrence cois was reported.
17303,32880139,bony orbital decompression
17304,32880139,computerized perimetry
17305,32880139,dysthyroid optic neuropathy
17306,32880139,endonasal orbital decompression
17307,32880139,exophthalmos
17308,32880139,thyroid eye disease
17309,32681301,deep lateral wall resection
17310,32681301,exophthalmos
17311,32681301,graves’ disease
17312,32681301,orbit
17313,32681301,pterional decompression
17316,32096552,graves’ orbitopathy
17317,32096552,anti-thymocyte globulin
17318,32096552,dysthyroid optic neuropathy
17321,31996918,*graves’ disease
17322,31996918,*hashimoto’s thyroiditis
17323,31996918,*igm
17324,31996918,*subacute thyroiditis
17325,31996918,*thyroglobulin
17326,31996918,*thyroglobulin autoantibodies
17327,33980771,22q11.2 deletion syndrome
17328,33980771,graves’ disease
17329,33980771,hypocalcemia
17330,33980771,hypoparathyroidism
17335,32227311,addison’s disease
17336,32227311,autoimmune thyroid disease
17337,32227311,diabetes mellitus
17338,32227311,meta-analysis
17339,32227311,polyglandular autoimmune syndrome cois
17340,32252386,*autoimmune thyroid disease (aitd)
17341,32252386,*grave disease (gd)
17342,32252386,*hashimoto thyroiditis (ht)
17343,32252386,*polycystic ovary syndrome (pcos) cois
17344,34149627,*cd40
17345,34149627,*graves’ disease
17346,34149627,*gene
17347,34149627,*precision medicine
17348,34149627,"*variant cois application no: 63/120,514) entitled: “method for predicting patient response to cd40-targeted therapies” which is related to the current manuscript. yt declares that he also submitted two additional patent disclosures that are not related to the content of this manuscript. yt was previously (january 2015 to june 2017) the pi on a basic research project jointly funded by the juvenile diabetes research foundation and pfizer. the current manuscript is not related to that research project. gk consults for immunovant, usa, mediomics, usa, merck, germany, novartis, switzerland, and quidel, usa. the remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."
17349,33414766,*graves’ disease
17350,33414766,*graves’ ophthalmopathy
17351,33414766,*cholesterol
17352,33414766,*low-density lipoprotein cholesterol
17353,33414766,*parenteral corticosteroids cois commercial or financial relationships that could be construed as a potential conflict of interest.
17355,31842710,*graves disease
17356,31842710,*hashimoto's thyroiditis
17357,31842710,*active surveillance
17358,31842710,*cost-effectiveness
17359,31842710,*molecular markers
17360,31842710,*thyroid cancer
17361,31840740,*graves’ disease
17362,31840740,*radioactive iodine
17363,31840740,*radioiodine therapy
17364,31840740,"*thyroid radioactive iodine uptake cois association declaration of helsinki, and that all subjects provided written informed consent. the present study was approved by the irb of the second affiliated hospital, harbin medical university. the authors declare that there are no competing interests associated with the manuscript."
17365,32627588,deep lateral decompression
17366,32627588,lateral orbital wall distance
17367,32627588,removable surface area
17368,32627588,removable surface length
17369,32627588,sphenoid door jamb thickness
17370,32362875,*adolescents
17371,32362875,*autoimmune thyroid disease
17372,32362875,*children
17373,32362875,*gender difference
17374,32362875,*thyroiditis
17377,33297974,case report
17378,33297974,exophthalmos
17379,33297974,graves’ ophthalmopathy
17380,33297974,malformation
17381,33297974,ocular myasthenia gravis
17382,33297974,poland syndrome
17383,33297974,ptosis cois interest.
17384,33099562,*cystatin c
17385,33099562,*exophthalmos
17386,33099562,*serum
17387,33099562,*thyroxine
17388,33099562,*triiodothyronine cois
17389,33025559,*autoimmune thyroid disease (aitd)
17390,33025559,*graves’ disease (gd)
17391,33025559,*hashimoto’s thyroiditis (ht)
17392,33025559,*mettl3
17393,33025559,*polymorphism
17394,32592913,choroidal thickness
17395,32592913,inactive graves’ orbitopathy
17396,32592913,optical coherence tomography angiography
17397,32592913,retinal vessel density
17398,32592913,spectral domain-optical coherence tomography
17400,34142359,activating tshr pathogenic variant
17401,34142359,case report
17402,34142359,familial non-autoimmune hyperthyroidism
17403,34142359,functional study
17404,34142359,radioiodine ablative treatment
17405,34142359,repeated thyroid surgery
17408,34277969,*graves’ disease
17409,34277969,*antithyroid drugs
17410,34277969,*hyperthyroidism
17411,34277969,*index patient
17412,34277969,*international surveys
17413,34277969,*long‐term follow‐up
17414,34277969,*radioactive iodine
17415,34277969,*thyroidectomy
17416,34277969,"*treatment options cois calissendorff, mikael lantz, bengt hallengren, helena filipsson nyström, tereza planck, göran wallin: none of the authors have competing financial interests."
17417,32999132,anti-neutrophil cytoplasmic antibody
17418,32999132,hearing loss
17419,32999132,otitis media
17420,32999132,propylthiouracil
17421,32999132,vasculitis
17422,32699051,*colour vision
17423,32699051,*field of vision
17424,32699051,*orbit cois
17425,34179589,carotid cavernous fistula
17426,34179589,graves-basedow disease
17427,34179589,graves’ ophthalmopathy
17428,34179589,orbit
17429,34179589,orbital inflammation
17430,34049504,"extraocular paralysis, case report"
17431,34049504,gq1b antibody
17432,34049504,graves’ disease
17433,34049504,limb weakness cois interest.
17435,32958019,graves’ orbitopathy
17436,32958019,predictive factors
17437,32958019,radiotherapy
17438,32958019,timing cois
17439,32656666,bradycardia
17440,32656666,calcitonin
17441,32656666,calcium test
17442,32656666,cut-off
17443,32656666,medullary thyroid cancer cois perceived as prejudicing the impartiality of the research reported.
17444,33488522,*graves’ orbitopathy
17445,33488522,*pcsk9
17446,33488522,*adipogenesis
17447,33488522,*inflammation
17448,33488522,*oxidative stress
17449,33488522,*proprotein convertase subtilisin/kexin type 9
17450,33488522,*thyroid eye disease cois commercial or financial relationships that could be construed as a potential conflict of interest.
17451,32729394,*graves'
17452,32729394,*dietary iodine
17453,32729394,*disease
17454,32729394,*inorganic iodine
17455,32729394,*radioiodine
17456,32729394,*therapeutic effects
17457,31900992,il-13
17458,31900992,il-4
17459,31900992,il-5
17460,31900992,il-6
17461,31900992,autoimmune thyroid diseases
17462,31900992,polymorphism
17463,32911689,graves’ orbital fibroblasts
17464,32911689,graves’ orbitopathy
17465,32911689,igf1r
17466,32911689,igf1r antibodies
17467,32911689,tshr
17468,32911689,tshr antibodies
17469,32911689,hyaluronan
17470,32911689,receptor crosstalk cois targeting tshr and igf-1r.
17471,32376473,*circular rna
17472,32376473,*rna sequencing
17473,32376473,*thyroid-associated ophthalmopathy cois
17474,33327837,"*hyperthyroidism, graves' disease"
17475,33327837,*liver abnormalities
17476,33327837,*liver dysfunction
17478,32854689,coexistent primary and secondary hyperthyroidism
17479,32854689,graves’ disease
17480,32854689,tsh-secreting pituitary adenoma
17481,32854689,tshoma
17482,32854689,thyrotropinoma cois disorders editorial board.
17483,32573180,*graves’ disease
17484,32573180,*autoimmunity
17485,32573180,*peptides
17486,32573180,*thyroid
17488,32199749,*trab
17489,32199749,*antithyroid drugs
17490,32199749,*hyperthyroidism
17491,32199749,*methimazole
17492,32199749,*propylthiouracil cois of interests.
17494,32977740,*graves' orbitopathy
17495,32977740,*hif-1α
17496,32977740,*caveolin-1
17497,32977740,*deiodinase 3
17498,32977740,*enos
17499,32977740,*oxidative stress
17500,34494503,*pd-1
17501,34494503,*pd-l1
17502,34494503,*pd-l2
17503,34494503,*regulatory t cell
17504,34494503,*severity
17505,34494503,*single nucleotide polymorphism
17506,33541945,hyperthyroidism
17507,33541945,thyrotoxicosis
17508,33541945,valvar diseases cois
17509,33153489,*adipogenesis
17510,33153489,*gene modification
17511,33153489,*graves’ ophthalmopathy
17512,33153489,*phosphatase of regenerating liver-1
17513,33153489,*placenta-derived mesenchymal stem cells cois
17514,32605565,case report
17515,32605565,graves’ disease
17516,32605565,hypercalcemia
17517,32605565,osteoporosis
17518,32605565,thymic enlargement cois
17519,32342657,*graves’ disease
17520,32342657,*association analysis
17521,32342657,*sex-specific
17522,32342657,*single nucleotide polymorphism cois
17525,31910101,*graves' disease
17526,31910101,*muscle strength
17527,31910101,*quality of life
17528,31910101,*thyrotoxicosis
17529,31910101,*vitamin d
17530,34867801,*cd40
17531,34867801,*graves’ disease
17532,34867801,*association analysis
17533,34867801,*expression quantitative trait locus
17534,34867801,*single nucleotide polymorphisms cois commercial or financial relationships that could be construed as a potential conflict of interest.
17538,34074094,*graves disease
17539,34074094,*hashimoto disease
17540,34074094,*immune checkpoint inhibitor
17541,34074094,"*polymorphism, single nucleotide"
17542,34074094,*programmed cell death 1 ligand cois was reported.
17545,32088015,endoscopic modified lothrop procedure
17546,32088015,endoscopic sinus surgery
17547,32088015,frontal sinusitis
17548,32088015,graves’ orbitopathy
17549,32088015,orbital decompression cois related with this paper.
17551,32483756,"thyroid stimulating hormone receptor, antagonist, thienopyrimidine, thyroid gland"
17552,31926048,anti-programmed death 1 therapy
17553,31926048,graves’ disease
17554,31926048,"type 1 diabetes cois k.k. and eli lilly japan k.k. hiroshi kagamu is a scientific advisor of immunit research inc; has received honoraria from astrazeneca k.k., bristol‐myers squibb co. and ono pharmaceutical co.; and research funding from boehringer ingelheim pharmaceuticals inc. the other authors declare no conflict of interest."
17555,33935970,*graves’ ophthalmopathy
17556,33935970,*corticosteroids
17557,33935970,*cytokines
17558,33935970,*rituximab
17559,33935970,*teprotumumab
17560,33935970,*tocilizumab cois commercial or financial relationships that could be construed as a potential conflict of interest.
17563,33719776,*thyroid-associated ophthalmopathy
17564,33719776,*blood flow velocity
17565,33719776,*fractal analysis
17566,33719776,*functional slit-lamp biomicroscopy
17567,33675209,addison’s disease
17568,33675209,graves’ disease
17569,33675209,adrenal insufficiency
17570,33675209,autoimmune polyglandular syndrome type 2
17571,33675209,"thyrotoxicosis cois design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication."
17572,32820337,*case-control
17573,32820337,*grave's disease (gd)
17574,32820337,*hyperthyroidism
17575,32820337,*intestinal microbiota
17576,32820337,*prospective
17577,32820337,*thyroid-stimulating antibodies (tsab) cois manuscript.
17578,34831419,*graves’ orbitopathy
17579,34831419,*igf-1
17580,34831419,*rock inhibitor
17581,34831419,*orbital fibroblast
17582,34831419,*prostanoid ep2 agonist
17583,34831419,*three-dimension (3d) cell culture cois
17584,33473054,acute respiratory distress syndrome (ards)
17585,33473054,coronavirus disease 2019 (covid-19)
17586,33473054,severe acute respiratory syndrome (sars)
17587,33473054,severe acute respiratory syndrome coronavirus-2 (sars-cov-2)
17588,33473054,thyroid
17590,31237221,graves’ ophthalmopathy
17591,31237221,thyroid disorders
17592,31237221,age-related macular degeneration
17593,31237221,amiodarone
17594,31237221,diabetic retinopathy
17595,31237221,ocular metastasis.
17596,31978406,anti-thyroid drugs
17597,31978406,graves’ disease
17598,31978406,hyperthyroidism
17599,31978406,lysophosphatidylserine
17600,31978406,phosphatidylserine-specific phospholipase a1
17601,31978406,thyroid hormones
17602,34899596,*igf1r
17603,34899596,*tsab
17604,34899596,*tshr
17605,34899596,*adipogenesis
17606,34899596,*hyaluronan
17607,34899596,*thyroid eye disease cois commercial or financial relationships that could be construed as a potential conflict of interest.
17608,33776929,*dosimetry—radiation
17609,33776929,*hyperthyroidism (graves’ disease)
17610,33776929,*hyperthyroidism—diagnosis
17611,33776929,*hypothyroidism
17612,33776929,*radioiodine
17613,33776929,*radioiodine (131i) treatment cois distribute the software generated in this article. the remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
17615,32957802,graves’ orbitopathy
17616,32957802,ethmoid sinus volume
17617,32957802,proptosis reduction
17618,32957802,thyroid eye disease
17619,33583620,*endocrinology
17620,33583620,*h1n1 infection
17621,33583620,*influenza
17622,33583620,*thyroid storm cois
17623,32187946,"decompression, surgical"
17624,32187946,diplopia
17625,32187946,esotropia
17626,32187946,graves ophthalmopathy
17627,32187946,ophthalmologic surgical procedures
17628,32471411,early hypothyroidism
17629,32471411,graves’ disease
17630,32471411,radioactive iodine
17631,32471411,therapy cois publication of this paper.
17633,34061946,*addison’s disease
17634,34061946,*additional autoimmune disease
17635,34061946,*autoimmune polyglandular syndrome
17636,34061946,*autoimmune thyroid disease
17637,34061946,*type 1 diabetes mellitus
17638,33998766,case-control study
17639,33998766,dipeptidyl peptidase-4
17640,33998766,"graves' disease cois lectures and received research funding from some organizations as described below. there was no financial support for this study. akinobu nakamura received research funding from mitsubishi tanabe pharma co. and ono pharmaceutical co. ltd. hideaki miyoshi received honoraria for lectures from astellas pharma inc., dainippon pharma co., eli lilly, mitsubishi tanabe pharma co., msd, novartis pharma, novo nordisk pharma, kowa pharmaceutical co., ltd., nippon boehringer ingelheim co., ono pharmaceutical co. ltd. and sanofi, and received research funding from astellas pharma inc., daiichi sankyo, dainippon pharma co., eli lilly, mitsubishi tanabe pharma co., novo nordisk pharma, kowa pharmaceutical co., abbott japan co., nippon boehringer ingelheim co., ono pharmaceutical co. ltd. and taisho toyama pharmaceutical co., ltd. tatsuya atsumi received honoraria for lectures from mitsubishi tanabe pharma co., chugai pharmaceutical co. ltd., astellas pharma inc., takeda pharmaceutical co. ltd., pfizer inc., abbvie inc., eisai co. ltd., daiichi sankyo co. ltd., bristol‐myers squibb co., ucb japan co. ltd., eli lilly japan k.k., and received research funding from astellas pharma inc., takeda pharmaceutical co. ltd., mitsubishi tanabe pharma co., chugai pharmaceutical co. ltd., daiichi sankyo co. ltd., otsuka pharmaceutical co. ltd., pfizer inc. and alexion inc. the other authors declare no conflict of interest."
17642,33138008,*graves’ disease
17643,33138008,*human leukocyte antigen (hla)
17644,33138008,*recurrence
17645,33138008,*subacute thyroiditis cois
17646,34742035,*alemtuzumab
17647,34742035,*autoimmunity
17648,34742035,*crohn's disease
17649,34742035,*graves' disease
17650,34742035,*igg
17651,34742035,*igg4
17652,34742035,*multiple sclerosis
17653,32062033,autoimmunity
17654,32062033,graves' disease
17655,32062033,hashimoto's autoimmune thyroiditis
17656,32062033,single nucleotide polymorphism (snp)
17657,32062033,toll-like receptors (tlrs)
17658,32062033,type 1 diabetes mellitus (t1dm)
17660,32880061,bavans
17661,32880061,detachable steel wire-rimmed retractor
17662,32880061,kn retractor
17663,32880061,vans
17664,32880061,video-assisted neck surgery
17666,33211376,graves' disease
17667,33211376,cohort
17668,33211376,systemic lupus erythematosus
17672,32359703,graves disease
17673,32359703,leukemia lymphocytic chronic b-cell
17674,32359703,neoplasms/secondary
17675,32359703,prostatic neoplasms
17676,32359703,pruritus
17677,32466854,*hypocalcemia
17678,32466854,*thyroidectomy
17679,32466854,*vitamin d deficiency
17681,31980336,*autoimmunity
17682,31980336,*graves' disease
17683,31980336,*t-cells
17684,31980336,*tsh receptor
17685,31980336,*thyroid cois patent application pct/us2016/067775 for using small molecules to block hla-dr3. dr. tomer also submitted 2 additional provisional patent disclosures that are not related to the content of this manuscript. dr. tomer was previously (1/2015–6/2017) the pi on a basic research project jointly funded by the juvenile diabetes research foundation and pfizer. the current manuscript is not related to that research project. the other authors have nothing to declare.
17686,33758937,*graves’ disease
17687,33758937,*programmed cell death 1
17688,33758937,*regulatory t cells
17689,33758937,*thyroid hormone
17690,34470463,*autoimmune thyroid disease
17691,34470463,*intractability
17692,34470463,*polymorphism
17693,34470463,*severity
17694,34470463,*vitamin a
17695,33234057,*16s rrna sequencing
17696,33234057,*graves' disease
17697,33234057,*alpha diversity
17698,33234057,*gut microbiota
17699,33234057,*metabolism cois
17700,34975767,*graves’ disease
17701,34975767,*bacterial translocation
17702,34975767,*intestinal barrier
17703,34975767,*intestinal fatty acid-binding protein
17704,34975767,*leaky gut
17705,34975767,*lipopolysaccharide
17706,34975767,*quality of life cois commercial or financial relationships that could be construed as a potential conflict of interest.
17707,32666771,thyroid ophthalmopathy
17708,33587909,*3-dimension (3d) tissue culture
17709,33587909,*ep2 agonist
17710,33587909,*grave's disease
17711,33587909,*grave's orbitopathy
17712,33587909,*human orbital fibroblast
17713,33587909,*pgf2α agonist
17714,33587909,*rock inhibitor
17715,33587909,*rho-associated coiled-coil containing protein kinase (rock)
17716,33437990,*antinuclear antibodies
17717,33437990,*indirect immunofluorescence
17718,33437990,*systemic autoimmune disease
17719,32061922,*graves' ophthalmopathy fibroblasts
17720,32061922,*insulin-like growth factor 1 receptor
17721,32061922,*receptor crosstalk
17722,32061922,*tsh receptor stimulating antibodies
17723,32061922,*thyroid-stimulating hormone receptor cois of interest.
17724,31969085,*adipogenesis
17725,31969085,*chondrogenesis
17726,31969085,*muscle-derived stem cells
17727,31969085,*myogenesis
17728,31969085,*osteogenesis
17729,33476778,*dysthyroid optic neuropathy
17730,33476778,*grave disease
17731,33476778,*grave orbitopathy
17732,33476778,*orbit decompression
17734,32707005,*thyroid eye disease
17735,32707005,*insulin-like growth factor i receptor
17736,32707005,*monoclonal antibody
17737,32707005,*teprotumumab
17738,32707005,*thyrotropin receptor
17741,33298481,gynaecological cancer
17742,33298481,stroke
17743,33298481,thyrotoxicosis cois
17744,33645503,*covid-19
17745,33645503,*epidemics
17746,33645503,*influenza
17747,33645503,*predict
17748,33645503,*virus
17749,33196862,antithyroid medication
17750,33196862,antithyroid-induced arthritis syndrome
17751,33196862,arthritis
17752,33196862,fever
17753,33196862,thiamazole
17754,33498689,graves’ ophthalmopathy
17755,33498689,eear fluids
17756,33498689,ehyroid-associated ophthalmopathy
17757,33498689,exosomes
17758,33498689,extracellular vesicle
17759,33498689,eytokines cois
17760,33877318,*akt1
17761,33877318,*egfr/pi3k/akt signaling
17762,33877318,*lncrna lpal2
17763,33877318,*mir-1287-5p
17764,33877318,*orbital fibroblast activation
17765,33877318,*thyroid eye disease
17767,32425952,*autoantibodies
17768,32425952,*autoimmune
17769,32425952,*nephropathy
17770,32425952,*phospholipase a2 receptor
17771,32425952,*thyroid disease
17773,33745401,"*“thyroid eye disease, thermal imaging, ocular surface temperature, caruncular  temperature”"
17776,34752648,graves’ disease
17777,34752648,hyperthyroidism
17778,34752648,thyroid-stimulating hormone receptor antibody cois
17780,34680057,*graves’ ophthalmopathy
17781,34680057,*c-jun n-terminal kinase
17782,34680057,*orbital fibroblast
17783,34680057,*p38
17784,34680057,*pirfenidone
17785,34680057,*transforming growth factor-β1 cois
17786,33121876,*graves' disease
17787,33121876,*interferon
17788,33121876,*interleukin
17789,33121876,*thyroid-stimulating hormone receptor antibody
17790,33121876,*tumor necrosis factor
17791,33868176,*graves’ orbitopathy
17792,33868176,*t cell immunity
17793,33868176,*effector t cell
17794,33868176,*fibrocyte
17795,33868176,*orbital fibroblast
17796,33868176,"*thyroid-associated ophthalmology cois (81930024, 81761168037, 81770974, 81800695, 82071003, 82000879, 81570883, 81600766, 31701046, 31600971, and 31500714), the national key r&d program of china (2018yfc1106100, 2018yfc1106101), the shanghai sailing program (18yf1412300), the research grant of the shanghai science and technology committee (20dz2270800, 17dz2260100, 19410761100, and 19dz2331400), the clinical research plan of shdc (shdc2020cr3051b), the project of medical robots (imr-nph202002) from the clinical joint research center of the institute of medical robots, shanghai jiaotong university-shanghai ninth people’s hospital, the collaborative research project of translational medicine collaborative innovation center, shanghai jiaotong university school of medicine (tm201718), the shanghai municipal education commission—gaofeng clinical medicine grant support (20152228), the shanghai jiaotong university translational medicine crossed research grant (zh2018zda12, zh2018qna07), the sample database project of shanghai ninth people’s hospital (ybkb201901), and the joint innovation team for young physicians of shanghai ninth people’s hospital (qc202002).the authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."
17797,33419752,emergency medicine
17798,33419752,respiratory medicine cois
17799,34887833,*graves’ disease
17800,34887833,*hla variants
17801,34887833,*ptpn22 gene
17802,34887833,*genetic predictors
17803,34887833,*treatment cois commercial or financial relationships that could be construed as a potential conflict of interest.
17804,32519199,association
17805,32519199,graves’ disease
17806,32519199,mica
17807,32519199,thionamide-induced agranulocytosis
17808,32253999,*antithyroid drug
17809,32253999,*hyperthyroidism
17810,32253999,*long-term treatment
17812,34916298,*graves’ disease
17813,34916298,*organoids
17814,34916298,*thyroid
17815,33781112,*graves’ ophthalmopathy
17816,33781112,*tepezza
17817,33781112,*hearing loss
17818,33781112,*teprotumumab
17819,33781112,*thyroid eye disease
17820,34887857,*: autoimmune disease
17821,34887857,*autoimmunity
17822,34887857,*gastric cancer
17823,34887857,*risk
17824,34887857,*standardized incidence rate cois commercial or financial relationships that could be construed as a potential conflict of interest.
17825,34355625,trab
17826,34355625,thyroid function
17827,34355625,hysterosalpingography (hsg)
17828,34355625,infertility
17829,34355625,thyrotoxicosis
17830,34949642,*graves’ disease
17831,34949642,*autoimmune
17832,34949642,*fibrocyte
17833,34949642,"*thyroid cois therapeutic targeting of igf-i receptor in autoimmune diseases (to t.j.s. and held by the university of california, los angeles, and the lundquist institute). he is a consultant for horizon therapeutics."
17834,32419081,*cd40
17835,32419081,*ctla4
17836,32419081,*graves’ disease
17837,32419081,*pparg
17838,32419081,*ptpn22
17839,32419081,*polymorphism
17840,32372394,children and adolescents
17841,32372394,low-dose radioactive iodine (131i)
17842,32372394,outpatients treatment
17843,32372394,radiation exposure
17844,32874051,orbital decompression
17845,32874051,pneumocephalus
17846,32874051,thyroid eye disease cois
17847,32797475,graves’ disease
17848,32797475,antioxidant parameters
17849,32797475,hyperthyroidism
17850,32797475,lipid peroxidation
17851,32797475,thyroid orbitopathy
17853,33653401,children
17854,33653401,glucocorticoid pulse therapy
17855,33653401,graves’ disease
17856,33653401,thyroid antibodies
17857,33653401,thyroid function cois
17862,34381538,acromegaly
17863,34381538,case report
17864,34381538,empty sella
17865,34381538,grave´s disease
17866,34381538,hyperthyroidism cois
17868,32246145,*graves’ disease
17869,32246145,*hashimoto’s thyroiditis
17870,32246145,*genetic risk
17871,32246145,*heterogeneity
17872,32246145,*large chinese cohort
17873,33322192,*graves’ orbitopathy
17874,33322192,*exophthalmos
17875,33322192,*intraocular pressure
17876,33322192,*topical medications cois
17878,32328068,*graves' disease
17879,32328068,*hashimoto's thyroiditis
17880,32328068,*follicular helper t cells
17881,32328068,*lymphoid tissue–inducer-like cells
17882,32328068,*regulatory t cells
17883,32328068,*thyroid autoimmune disease
17884,33597925,*erk
17885,33597925,*graves’ ophthalmopathy
17886,33597925,*ras homolog family member a (rhoa)
17887,33597925,*rho‑associated protein kinase (rock)
17888,33597925,*y-27632
17889,33597925,*myofibroblast
17890,33597925,*p38
17891,33597925,*simvastatin cois commercial or financial relationships that could be construed as a potential conflict of interest.
17895,34271828,*ait
17896,34271828,*trab
17897,34271828,*amiodarone
17898,34271828,*autoimmunity
17899,34271828,*thyrotoxicosis
17900,32545596,grave´s disease
17901,32545596,hashimoto’s thyroiditis
17902,32545596,non-celiac wheat sensitivity
17903,32545596,celiac disease
17904,32545596,gut microbiota
17905,32545596,iodine
17906,32545596,iron
17907,32545596,probiotics
17908,32545596,thyroid
17909,32545596,thyroid cancer cois
17910,32338082,*b-cell activating factor
17911,32338082,*cytokines
17912,32338082,*graves’ disease
17913,32338082,*hashimoto’s thyroiditis
17914,32338082,*autoimmune thyroid disease
17915,33912135,*graves’ disease
17916,33912135,*rna sequencing
17917,33912135,*t cell receptor sequencing
17918,33912135,*persistent graves’ disease
17919,33912135,*refractory graves’ disease
17920,33912135,*regulatory t cell cois commercial or financial relationships that could be construed as a potential conflict of interest.
17921,32116430,goiter
17922,32116430,thyroid
17923,32116430,thyroidectomy
17924,32121432,somatostatin analog
17925,32121432,cancer
17926,32121432,carcinoid
17927,32121432,lanreotide
17928,32121432,neuroendocrine tumor
17929,32121432,octreotide
17930,32121432,pasireotide
17931,32121432,"pituitary adenoma cois novartis, and pfizer as speaker fees, served on an advisory board, and received lecture fees and sponsorship for travel and accommodation in international scientific meetings from ipsen, novartis, and pfizer. none of them had role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results."
17932,32572659,hypothyroidism
17933,32572659,goitre
17934,32572659,hyperthyroidism
17935,32572659,physiology
17936,32572659,thyroid carcinoma
17937,33040848,ct
17938,33040848,cancer
17939,33040848,goiter
17940,33040848,mr imaging
17941,33040848,surgical implications
17942,33040848,thyroid
17943,33040848,thyroid nodules cois
17944,32342248,hypoparathyroidism
17945,32342248,recurrent nerve injury
17946,32342248,thyroid carcinoma
17947,32342248,thyroid surgery
17948,32342248,thyroidectomy
17949,32234570,*central neck lymph node dissection
17950,32234570,*hypocalcemia
17951,32234570,*hypoparathyroidism
17952,32234570,*thyroidectomy
17953,31941844,adipogenesis
17954,31941844,caffeine
17955,31941844,graves’ orbitopathy
17956,31941844,oxidative stress
17957,31941844,thyroid eye disease
17958,33167878,bowel perforation
17959,33167878,gastrointestinal mucormycosis
17960,33167878,mucormycosis
17961,33167878,rhizopus microsporus
17962,33167878,streptococcus pyogenes
17963,33167878,toxic shock syndrome cois
17964,34653776,*graves' disease
17965,34653776,*sars-cov-2
17966,34653776,*type 1 diabetes mellitus
17967,34653776,*vaccine
17968,32896170,*graves’ disease
17969,32896170,*zinc transporter
17970,32896170,*children
17971,32896170,*non-toxic nodular goiter
17972,32896170,*thyroid tissue
17973,34956094,*contrast-enhanced ultrasound (ceus)
17974,34956094,*partially cystic papillary thyroid carcinomas (pcptcs)
17975,34956094,*partially cystic thyroid nodules
17976,34956094,*thyroid carcinomas
17977,34956094,*thyroid ultrasonography cois commercial or financial relationships that could be construed as a potential conflict of interest.
17978,33208049,*graves' disease
17979,33208049,*hla-dr3 mice
17980,33208049,*t cells
17981,33208049,*tetramer assay
17982,32734637,*asian
17983,32734637,*cosmesis
17984,32734637,*minimally invasive video-assisted thyroidectomy
17985,32734637,*neck scar
17986,32734637,*thyroidectomy
17987,35130216,"thyroidectomy, harmonic scalpel, classical ligation, suture hemorrhage, recurrent  laryngeal nerve injury."
17990,33939906,thyroid nodule
17991,33939906,ablation techniques
17992,33939906,ethanol
17993,33939906,nodular goiter
17994,32950466,covid-19
17995,32950466,free t3
17996,32950466,free t4
17997,32950466,hypothyroidism
17998,32950466,hypothyroïdie
17999,32950466,orbitopathie
18000,32950466,orbitopathy
18001,32950466,sars-cov-2
18002,32950466,t3l
18003,32950466,t4l
18004,32950466,tsh
18005,32950466,thyrotoxicose
18006,32950466,thyrotoxicosis
18007,33754530,anaplastic thyroid carcinoma
18008,33754530,leucocytosis; goitre
18010,33665799,turkey
18011,33665799,elderly people
18012,33665799,goitre
18013,33665799,hyperthyroidism
18014,33665799,hypothyroidism
18015,33665799,iodized salt
18016,34721289,*clnm
18017,34721289,*lasso
18018,34721289,*llnm
18019,34721289,*ptc
18020,34721289,*cn0 cois commercial or financial relationships that could be construed as a potential conflict of interest.
18021,32303903,*hereditary non-autoimmune hyperthyroidism
18022,32303903,*inverse agonist and antagonists
18023,32303903,*somatic and germline mutation
18024,32303903,*tsh receptor
18025,32303903,*toxic adenoma
18026,32303903,*toxic multinodular goitre cois
18028,33202999,*case-control studies
18029,33202999,*cohort studies
18030,33202999,*hearing loss
18031,33202999,*hyperthyroidism
18032,33202999,*sudden cois
18033,33339489,frank hartley
18034,33339489,clubfoot
18035,33339489,exstrophy of the bladder
18036,33339489,facial neuralgia
18037,33339489,goiter
18038,33964951,ck19
18039,33964951,follicular
18040,33964951,hbme1
18041,33964951,niftp
18042,33964951,papillary cois
18043,33402480,braf mutation
18044,33402480,microrna
18045,33402480,papillary thyroid cancer cois
18046,33466826,cohort
18047,33466826,diet
18048,33466826,iodine
18049,33466826,pregnancy
18050,33466826,"thyroid cois develop the myfood24 online dietary assessment system for use in research, teaching and for health. the remaining authors have nothing to declare. the funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript or in the decision to publish the results."
18051,33459001,*hashimoto disease
18052,33459001,*adolescent
18053,33459001,*child
18054,33459001,*goiter
18055,33459001,*hypothyroidism cois
18056,33213335,*hyperthyroidism
18057,33213335,*raiu test
18058,33213335,*graves' disease
18059,33213335,*multinodular
18060,33213335,*pathology
18061,33213335,*thyroid scan
18062,33213335,*toxic
18063,32518973,benign neoplasm
18064,32518973,goiter
18065,32518973,thyroid cancer
18066,32733376,*children
18067,32733376,*hypertrichosis
18068,32733376,*pituitary hypertrophy
18069,32733376,*severe autoimmune hypothyroidism
18070,32733376,*symptoms
18071,32267105,* metastasis
18072,32267105,* multinodular goiter
18073,32267105,*thyroid carcinoma
18074,33412925,*goiter
18075,33412925,*statins
18076,33412925,*thyroid cancer
18077,33412925,*thyroiditis
18078,33412925,*thyrotoxicosis
18081,33812374,macroadenoma
18082,33812374,pituitary
18083,33812374,pregnancy
18084,33812374,thyrotoxicosis cois
18085,32697397,doppler ultrasound
18086,32697397,graves disease
18087,32697397,graves orbitopathy
18088,32697397,central retinal artery
18089,32697397,ophthalmic artery
18090,32697397,toxic goiter
18091,33980057,*decision aid tool
18092,33980057,*levothyroxine dosage
18093,33980057,*patient tailored
18094,33980057,*pharmacokinetic modeling
18095,33980057,*thyroidectomy cois
18096,32149464,* thyroid surgery
18097,32149464,*ent
18098,32149464,*hyperthyroidism
18099,32149464,*thyroid
18100,32149464,*thyroid cancer
18102,31868128,*alu element
18103,31868128,*tg
18104,31868128,*congenital hypothyroidism
18105,31868128,*goiter
18106,31868128,*novel mutation
18107,31868128,*thyroglobulin cois
18108,32939627,ectopic thyroid tissue
18109,32939627,follicular adenoma
18110,32939627,goiter
18111,32939627,lung
18112,32939627,thoracoscopic surgery
18114,32909177,ancient rome
18115,32909177,fine arts
18116,32909177,goiter
18117,32909177,hans christian gram
18118,32909177,history
18119,32909177,hyperthyroidism
18121,32372240,egypt
18122,32372240,endemic goiter
18123,32372240,hashimoto’s thyroiditis
18124,32372240,papillary thyroid carcinoma
18125,32372240,thyroid cancer
18126,33619709,mri
18127,33619709,genetic diseases
18128,33619709,goitre
18129,33619709,haemochromatosis
18130,33619709,iron
18131,33619709,iron overload
18132,33619709,liver biopsy
18133,33619709,thyroid
18134,32377868,goiter
18135,32377868,graves’ disease
18136,32377868,hashimoto’s thyroiditis
18137,32377868,iodine-induced hyperthyroidism
18138,32377868,thyroid autonomy
18139,34378152,*congenital hypothyroidism
18140,34378152,*dyshormonogenesis
18141,34378152,*goiter
18142,34378152,*thyroid cancer
18143,33135832,*māori health
18144,33135832,*head and neck
18145,33135832,*thyroid surgery
18146,33319230,*hypothyroidism
18147,33319230,*chronic diseases
18148,33319230,*comorbidity
18149,33319230,*network analysis
18150,34637944,early diagnosis
18151,34637944,hamartoma syndrome
18152,34637944,hereditary
18153,34637944,multiple
18154,34637944,neoplastic syndromes
18155,34637944,pten phosphohydrolase
18156,34637944,phenotype
18158,33905626,thyroid cancer
18159,33905626,mrna expression
18160,33905626,polymorphism
18161,33905626,transforming growth factor-β
18162,33779362,thyroid
18163,33779362,hypocalcaemia
18164,33779362,meta-analysis
18165,33779362,prevalence
18166,33779362,risk factor cois conflicts of interest.
18168,33910357,complications − recurrent nerve
18169,33910357,hypoparathyroidism − lethality
18170,33910357,thyroid surgery
18171,34479126,diffuse thyroid diseases
18172,34479126,grave’s diseases
18173,34479126,hashimoto’s thyroiditis
18174,34479126,shear wave elastography
18175,34479126,ultrasonography
18176,33008929,*amiodarone-induced thyroid dysfunction
18177,33008929,*autoimmunity
18178,33008929,*destructive thyroiditis
18179,33008929,*hyperthyroidism
18180,33008929,*toxic multinodular goiter
18181,33008929,*toxic thyroid adenoma
18182,32458745,*goiter
18183,32458745,*iodine
18184,32458745,*iodine deficiency
18185,32458745,*salt
18186,32458745,*universal salt iodization cois
18187,34841823,*cohort studies
18188,34841823,*goiter
18189,34841823,*hyperthyroidism
18190,34841823,*hypothyroidism
18191,33072219,relapse risk
18192,33072219,benign focal pathology
18193,33072219,nodular goiter
18194,33072219,thyroid gland
18195,33028642,*ewing's sarcoma
18196,33028642,*multinodular goiter
18197,33028642,*neoplasm of the genitourinary tract
18198,34425332,gene expression
18199,34425332,klln
18200,34425332,multinodular goiter
18201,34425332,pten
18202,34425332,papillary thyroid carcinoma
18203,33914231,*goiter
18204,33914231,*iodine
18205,33914231,*iodized salt
18206,33914231,*thyroid
18207,33914231,*thyroid autoimmunity cois
18208,33749812,bethesda classification
18209,33749812,thyroid cancer
18210,33749812,thyroid nodule
18211,32838791,*breast cancer
18212,32838791,*genetic pleiotropy
18213,32838791,*hyperthyroidism
18214,32838791,*mammographic density cois
18215,32930933,congenital hypothyroidism
18216,32930933,duox2
18217,32930933,newborn screening
18218,32930933,tg
18219,32930933,tpo
18220,32930933,tshr
18221,32765423,*congenital hypothyroidism
18222,32765423,*dyshormonogenesis
18223,32765423,*genes
18224,32765423,*goiter
18225,32765423,*iodine
18226,32765423,*screening
18227,32765423,*thyroid hypoplasia
18228,34382851,cervical stitch sinus
18229,34382851,deep neck infection
18230,34382851,diabetes
18231,34382851,suture granuloma
18232,34382851,thyroidectomy
18233,34382851,wound
18234,34382851,wound healing
18236,31960358,mitochondria
18237,31960358,oxidative stress
18238,31960358,ros
18239,31960358,selenium
18240,31960358,thyroid
18242,34121740,autoimmune disease
18243,34121740,hashimoto's thyroiditis
18244,34121740,hypocalcemia
18245,34121740,thyroid peroxidase antibody
18246,34121740,thyroidectomy cois
18247,32505587,resistance to thyroid hormone
18248,32505587,thrb gene
18249,32505587,thyroid hormone receptor beta cois
18250,34426423,endoscopy
18251,34426423,surgery
18252,34426423,thyroid disease
18253,34426423,thyroiditis cois
18254,34051706,*goiter
18255,34051706,*nodule
18256,34051706,*thyroid
18257,32582023,*hashimoto's thyroiditis
18258,32582023,*hashitoxicosis
18259,32582023,*autoimmune thyroiditis (ait)
18260,32582023,*goiter
18261,32582023,*thyroid autoantibodies
18262,33901280,"*8-oxo-7,8-dihydro-2’-deoxyguanosine"
18263,33901280,"*8-oxo-7,8-dihydroguanosine"
18264,33901280,*graves disease
18265,33901280,*hyperthyroidism
18266,33901280,*oxidative stress
18267,33901280,*toxic nodular goiter
18268,34093427,*langerhans cell histiocytosis
18269,34093427,*chemotherapy
18270,34093427,*spontaneous thyroid hemorrhage
18271,34093427,*thyroid
18272,34093427,*thyroidectomy cois commercial or financial relationships that could be construed as a potential conflict of interest.
18275,33796075,*gh
18276,33796075,*igf-i
18277,33796075,*acromegaly
18278,33796075,*comorbidity
18279,33796075,*complication
18280,33796075,*pituitary adenoma cois commercial or financial relationships that could be construed as a potential conflict of interest.
18281,32792004,denosumab rebound
18282,32792004,fracture
18283,32792004,hypercalcemia
18284,32792004,hyperparathyroidism
18285,32792004,osteoporosis cois
18286,34219897,hyperthyroidsm
18287,34219897,thyroid neoplasms
18288,34219897,thyrostatic drugs cois interest. this article does not include any studies with human participants or animals performed by any of the authors.
18289,34937506,thyroid disorders
18290,34937506,male infertility factor
18291,34937506,pathospermia
18292,34248839,*congenital hypothyroidism
18293,34248839,*familial origin
18294,34248839,*high throughput molecular screening
18295,34248839,*oligogenicity
18296,34248839,*thyroid dyshormonogenesis cois commercial or financial relationships that could be construed as a potential conflict of interest.
18298,33052461,edge
18299,33052461,localization
18300,33052461,oxidative stress
18301,33052461,thyroid
18302,33052461,tumor
18303,34431326,covid-19
18304,34431326,sars-cov-2
18305,34431326,goiter
18306,34431326,surgery
18307,34431326,thyroid cancer
18308,34431326,thyroidectomy
18309,32178945,aberrant left subclavian artery
18310,32178945,non-recurrent inferior laryngeal nerve
18311,32178945,right-sided aortic arch
18312,32178945,thyroid surgery cois disclosed on this work.
18313,34196952,cost-effectiveness analysis
18314,34196952,intraoperative nerve monitoring
18315,34196952,recurrent laryngeal nerve palsy
18316,34196952,total thyroidectomy
18317,34196952,visual nerve identification
18318,32606189,thyroid
18319,32606189,malignancy
18320,32606189,microcalcifications
18321,32606189,nodule
18322,32606189,shape cois
18325,34889796,disfigurement
18326,34889796,horner syndrome
18327,34889796,steroids
18328,34889796,thyroidectomy cois
18331,33004747,follicular thyroid adenoma
18332,33004747,follicular thyroid carcinoma
18333,33004747,ultrasound signal cois
18334,32253953,*interventional ultrasonography
18335,32253953,*ablation techniques
18336,32253953,*high-intensity focused ultrasound ablation
18337,32253953,*nodular goiter
18338,32253953,*ultrasound imaging
18339,33459000,*graves disease
18340,33459000,*adolescent
18341,33459000,*antithyroid agents
18342,33459000,*child
18343,33459000,*hyperthyroidism cois
18344,33250466,alkaline phosphatase
18345,33250466,body pain
18346,33250466,muscle weakness
18347,33250466,normocalcemic hyperparathyroidism cois
18350,33194956,*kashmir
18351,33194956,*hypothyroidism
18352,33194956,*thyroid dysfunction
18353,33194956,*tribal population
18354,33194956,*urinary iodine
18355,32897650,*dicer1
18356,32897650,*cytology
18357,32897650,*fine-needle aspiration
18358,32897650,*follicular neoplasm
18359,32897650,*papillary thyroid carcinoma
18360,32897650,*poorly differentiated thyroid carcinoma
18361,32897650,*thyroid
18362,32430544,benign goiter
18363,32430544,case number threshold
18364,32430544,routine data
18365,32430544,vocal cord palsy
18366,32430544,volume outcome
18367,32458504,mitochondria
18368,32458504,mitochondria-eating protein
18369,32458504,mitophagy
18370,32458504,oncocytic cell tumor
18371,32458504,thyroid cois
18372,33541277,deficiency
18373,33541277,goiter
18374,33541277,magnitude
18375,33541277,micronutrient
18376,33541277,prevalence
18377,33541277,urine iodine cois
18379,32621001,*endocrine dysfunction
18380,32621001,*hemorrhagic stroke
18381,32621001,*ischemic stroke
18382,32621001,*pituitary
18383,31952842,*cervical embryonal rhabdomyosarcoma
18384,31952842,*dicer1-related multinodular goiter
18385,31952842,*ovarian sex-cord stromal tumors
18386,31952842,*pleuropulmonary blastoma
18387,31952842,"*sertoli-leydig cell tumors of the ovary cois private company with a mission to develop liquid biopsy diagnostics for rare cancers which includes dicer1-related cancers described in this work. none of the diagnostics under development are discussed in this work. dr. stewart provides contract telegenetics services to genome medical, inc."
18388,34670545,hyperthyroidism
18389,34670545,icm
18390,34670545,iodinated contrast media
18391,34670545,iodine-induced
18392,34670545,tachycardia cois
18393,32189188,*distant metastases
18394,32189188,*ft-ump
18395,32189188,*mi-ftc
18396,32189188,*radioiodine therapy
18397,32189188,*wdt-ump
18398,32081771,*biomarker
18399,32081771,*follicular thyroid adenoma
18400,32081771,*follicular thyroid carcinoma
18401,32081771,*roc curve analysis
18402,32081771,*real-time pcr
18403,32081771,*microrna cois
18406,33119125,dielectric properties
18407,33119125,open-ended coaxial line
18408,33119125,thyroid nodules
18409,32974689,ablation techniques
18410,32974689,high-intensity focused ultrasound ablation
18411,32974689,interventional ultrasonography
18412,32974689,nodular goiter
18413,32974689,ultrasonic imaging
18417,33932399,*change
18418,33932399,*expression
18419,33932399,*s hla-g
18420,33932399,*thyroid cancer
18421,33932399,*mir-199b-5p
18422,32088313,*congenital hypothyroidism
18423,32088313,*genotype-phenotype analysis
18424,32088313,*next-generation sequencing
18425,32088313,*thyroid peroxidase cois
18426,31867598,*tg
18427,31867598,*tpo
18428,31867598,*congenital hypothyroidism
18429,31867598,*goiter
18430,34191415,thyroid cancer
18431,34191415,endoscopic
18432,34191415,goiter
18433,34191415,surgery
18434,34191415,thyroidectomy
18436,32757959,* dioscorea bulbifera l
18437,32757959,*8-epidiosbulbin e acetate
18438,32757959,*diosbulbin b
18439,32757959,*hepatotoxicity
18440,32757959,*metabolic activation
18442,34706470,*anxiety
18443,34706470,*depression
18444,34706470,*obesity
18445,34706470,*personality
18446,34706470,*temperament
18447,34008223,dicer1
18448,34008223,follicular thyroid carcinoma
18449,34008223,histology
18450,34008223,macrofollicular variant
18451,34008223,mutation
18454,33331320,adenoma
18455,33331320,diagnosis
18456,33331320,hürthle cell tumor
18457,33331320,thyroid gland
18459,34050759,*adolescents
18460,34050759,*goiter
18461,34050759,*hyperthyroidism
18462,34050759,*hypothyroidism
18463,34050759,*thyroid
18464,34050759,*type 2 diabetes
18465,33210503,adenoma
18466,33210503,cyst
18467,33210503,follicular cancer
18468,33210503,thyroid gland
18469,33210503,ultrasound examination
18470,33329389,*diagnosis
18471,33329389,*hyperthyroidism
18472,33329389,*pathogenesis
18473,33329389,*pituitary adenoma
18474,33329389,*thyroid-stimulating hormone-secreting pituitary adenoma
18475,33329389,*treatment cois commercial or financial relationships that could be construed as a potential conflict of interest.
18476,34695620,pericardial effusion
18477,34695620,pleural effusion
18478,34695620,pleural hemangioma
18479,34695620,recurrent
18483,33180037,tshr mutation
18484,33180037,hyperthyroidism
18485,33180037,neonatal
18486,33180037,nonautoimmune
18487,32484412,diode
18488,32484412,laser
18489,32484412,metastatic
18490,32484412,thyroid
18491,32484412,trachea
18494,33722923,18f-fdg
18495,33722923,pet/ct
18496,33722923,breast metastasis
18497,33722923,follicular thyroid carcinoma
18498,33722923,iodine scan
18499,33393527,follicular carcinoma
18500,33393527,malignant
18501,33393527,neoplasm
18502,33393527,ovary
18503,33393527,struma ovarii
18504,33393527,teratoma cois
18505,33405016,*dysphagia
18506,33405016,*dysphonia
18507,33405016,*reflux disease
18508,33405016,*swallowing
18509,33405016,*thyroid
18510,33405016,*thyroid weight
18511,33405016,*thyroidectomy
18512,33405016,*voice cois
18513,33690170,*braf
18514,33690170,*mmp2
18515,33690170,*cancer
18516,33690170,*invasion
18517,33690170,*mutation
18518,33690170,*oncogene
18519,33690170,*thyroid cancer
18520,33970434,global health
18521,33970434,goiter
18522,33970434,telemedicine
18523,33970434,thyroid cancer
18524,33970434,thyroid ultrasound
18525,33970434,"ultrasound cois technology have financial stake in medical innovation and technology which works on developing technology to bring medical imaging to rural areas. all other authors have no financial disclosures. the manuscript and its contents were produced by the university of rochester and medical imaging ministries of the americas authors without financial conflict. the medical innovation and technology authors previewed the document, and any changes were subject to approval from the university of rochester and medical imaging ministry of the americas authors."
18526,32228164,*dicer1
18527,32228164,*child
18528,32228164,*follicular thyroid carcinomas
18529,32228164,*multinodular goiter
18531,33557336,alternative diet
18532,33557336,diet
18533,33557336,iodine
18534,33557336,iodine deficiency
18535,33557336,vegetarian diet cois
18536,34069656,mediterranean diet
18537,34069656,sars-cov-2 infection
18538,34069656,dietary habits
18539,34069656,healthcare professionals cois
18540,32631402,graves’ disease
18541,32631402,hyperthyroidism
18542,32631402,scintigraphy
18543,32631402,thyroid uptake
18544,32631402,thyrotoxicosis cois
18546,34418036,"synchronous thyroid malignancies, papillary thyroid carcinoma, lymphoma"
18547,32166365,*child
18548,32166365,*congenital hypothyroidism
18549,32166365,*gland
18550,32166365,*intrathyroid thymus
18551,32166365,*nodules
18552,32166365,*thyroid
18553,32166365,*thyroiditis
18554,32166365,*ultrasonography
18555,33676861,*endoscopic surgery
18556,33676861,*minimally invasive surgery
18557,33676861,*toetva
18558,33676861,*thyroidectomy
18559,34219881,fine-needle biopsy
18560,34219881,galectin-3
18561,34219881,reverse transcriptase polymerase chain reaction
18562,34219881,thyroid neoplasms
18563,34219881,thyroid nodule
18564,33319473,*oligometastasis
18565,33319473,*small cell lung cancer
18566,33319473,*thyroid metastasis
18568,32731688,follicular thyroid adenoma
18569,32731688,follicular thyroid cancer
18570,32731688,recurrent laryngeal nerve palsy
18571,32731688,elective lymph node dissection
18572,32731688,follicular variant of papillary thyroid cancer
18573,32645970,covid-19 infection
18574,32645970,dietary habits
18575,32645970,lockdown
18576,32645970,obesity cois
18577,32703500,braf mutation
18578,32703500,fine-needle aspiration
18579,32703500,papillary thyroid carcinoma
18580,32703500,thyroid nodule
18585,34230069,hyperthyroidism
18586,34230069,molecular imaging
18587,34230069,thyroid functional autonomy
18588,34230069,thyroid nodules
18589,33507638,men 2
18590,33507638,thyroid gland surgery
18591,33507638,thyroid nodule
18592,33507638,thyroidectomy
18595,31566142,intestinal microbiota
18596,31566142,autoimmune thyroid diseases
18597,31566142,gut dysbiosis
18598,31566142,hyperthyroidism
18599,31566142,hypothyroidism
18600,31566142,thyroid hormones.
18601,33077306,epithelial mesenchymal transition
18602,33077306,papillary thyroid carcinoma
18603,33077306,six1
18604,33077306,tgf-β/smad2/3 cois
18605,33028431,*iodine deficiency
18606,33028431,*iodine supplementation
18607,33028431,*lipiodol capsules
18608,33028431,*thyroid disease
18609,33028431,*women
18610,34855191,rathke
18611,34855191,cleft cysts
18612,34855191,headache
18613,34855191,hyperprolactinaemia
18614,34855191,hypopituitarism
18615,34855191,pituitary incidentaloma
18616,32436480,*adults
18617,32436480,*iodine fortification
18618,32436480,*serum iodine
18619,32436480,*thyroid autoimmunity
18620,32436480,*urinary iodine
18622,33007517,ccna1 gene
18623,33007517,cyclin a1
18624,33007517,diagnostic
18625,33007517,molecular marker
18626,33007517,papillary thyroid cancer
18627,33007517,protein expression
18628,33656790,afirma genomic sequencing classifier
18629,33656790,atypia of undetermined significance
18630,33656790,de quervain's thyroiditis
18631,33656790,molecular tests
18632,33176840,autosomal genetic disease
18633,33176840,gene mutation
18634,33176840,thyroid hormone
18635,33176840,thyroid hormone receptor β
18636,33176840,thyroid hormone resistance cois
18637,34803909,*biomarker
18638,34803909,*complement c4-a
18639,34803909,*papillary thyroid carcinoma
18640,34803909,*plasminogen
18641,34803909,*prediction cois commercial or financial relationships that could be construed as a potential conflict of interest.
18642,33750374,complication
18643,33750374,gasless trans-axillary endoscopic thyroidectomy
18644,33750374,hypoglossal nerve palsy cois
18645,33445950,thyroid surgery − transoral endoscopy – toetva − case report of the first toetva  patient at university hospital brno
18646,33213237,intratracheal ectopic thyroid
18647,33213237,adenomatous hyperplasia
18648,33213237,diagnosis
18649,33213237,ectopic
18650,33213237,thyroid
18651,33213237,treatment cois conflict of interest.
18653,33868182,*autoimmune thyroid disease
18654,33868182,*epigenetic effect
18655,33868182,*resistance to thyroid hormone
18656,33868182,*thyroid dysgenesis
18657,33868182,*thyroid hormone receptor
18658,33868182,*variant of unknown significance cois commercial or financial relationships that could be construed as a potential conflict of interest.
18660,32037778,*fine needle aspiration cytology
18661,32037778,*focus number
18662,32037778,*malignancy
18663,32037778,*predictivity
18664,32037778,*thyroid nodules
18666,32286703,*dapk
18667,32286703,*dna methylation
18668,32286703,*pten
18669,32286703,*diagnosis
18670,32286703,*thyroid nodules
18671,31808043,*fasting glucose
18672,31808043,*observational studies
18673,31808043,*randomized controlled trials
18674,31808043,*time restricted feeding
18675,31808043,*weight loss
18676,32816208,dropouts
18677,32816208,obesity
18678,32816208,treatment failure
18679,32816208,weight management cois
18680,33346472,covid-19
18681,33346472,russia
18682,33346472,epidemic
18683,33346472,iodine deficiency
18684,33346472,iodized salt
18686,33112496,dicer1
18687,33112496,autopsy
18688,33112496,prostate
18689,33112496,rhabdomyosarcoma
18690,32760349,*lymph node metastasis
18691,32760349,*papillary thyroid cancer
18692,32760349,*thyroglobulin antibodies
18693,32760349,*thyroid nodule
18694,32760349,*thyroidectomy
18697,33310924,*iodine supply
18698,33310924,*iodized salt
18699,33310924,*jódellátottság
18700,33310924,*jódozott só
18701,33310924,*pregnant women
18702,33310924,*várandós anyák
18703,33310924,*“silent” prophylaxis
18704,33310924,*„silent” profilaxis
18705,33921293,gluten sensitivity
18706,33921293,gut microbiota
18707,33921293,gut mycobiota
18708,33921293,mental status cois
18709,33773966,congenital hypothyroidism
18710,33773966,gland in situ
18711,33773966,monoallelic mutations
18712,33773966,thyroid dysgenesis
18713,33773966,thyroid transcription factors
18714,33740798,anxiety
18715,33740798,depression
18716,33740798,primary hyperparathyroidism
18717,33333891,rthβ
18718,33333891,thrb
18719,33333891,hypercholesterolemia
18720,33333891,hypothyroidism
18721,33333891,resistance to thyroid hormones
18722,33333891,thyroid
18723,33333891,thyroid hormone receptor cois
18724,32687189,* saliva iodine
18725,32687189,*iodine status
18726,32687189,*thyroid function
18727,32676935,covid-19; sars-cov-2
18728,32676935,subacute thyroiditis
18729,32676935,viral thyroiditis cois
18730,34803920,*cardiac arrhythmias
18731,34803920,*hypothyroidism
18732,34803920,*levothyroxine
18733,34803920,*osteoporosis
18734,34803920,*replacement therapy
18735,34803920,*thyroid cois commercial or financial relationships that could be construed as a potential conflict of interest.
18736,33631011,*duox system genes
18737,33631011,*clinical phenotype
18738,33631011,*congenital hypothyroidism
18739,33631011,*targeted region sequencing
18740,33631011,*thyroid gland
18741,32500518,*covid-19
18742,32500518,*endocrine emergencies
18743,32500518,*endocrine surgery
18744,32500518,*thyroid cancer cois
18746,34400129,economic impact
18747,34400129,hypocalcemia
18748,34400129,hypocalcémie
18749,34400129,hypoparathyroidism
18750,34400129,hypoparathyroïdie
18751,34400129,impact économique
18752,34400129,quality of life
18753,34400129,qualité de vie
18754,34400129,thyroidectomy
18755,34400129,thyroïdectomie
18756,32811342,*elderly
18757,32811342,*hyperthyroidism
18758,32811342,*methimazole
18759,32811342,*radioiodine
18760,33582938,china
18761,33582938,morbidity
18762,33582938,thyroid nodules
18763,33582938,urinary iodine concentration cois
18765,33147928,dose effect
18766,33147928,iodine
18767,33147928,thyroid nodule
18768,33147928,u-shaped curve
18769,33147928,urine
18770,31983029,*lateral lymph node metastasis
18771,31983029,*papillary thyroid carcinoma
18772,31983029,*predictive model
18773,31983029,*risk stratification
18774,31983029,*treatment strategy
18775,31789139,ccl5
18776,31789139,cav-1
18777,31789139,chemokine
18778,31789139,hashimoto’s thyroiditis
18779,31789139,pparγ
18780,31789139,pioglitazone.
18782,34594299,*autoimmune thyroid antibodies
18783,34594299,*fine needle aspirate (fna)
18784,34594299,*microcalcification
18785,34594299,*thyroid cancer
18786,34594299,*tumor size cois commercial or financial relationships that could be construed as a potential conflict of interest.
18787,33460435,*dicer1 mutation
18788,33460435,*thyroid cancer genes
18789,33460435,*thyroid nodules
18790,33106852,*hypothyroidism
18791,33106852,*levothyroxine
18792,33106852,*meta-analysis
18793,33106852,*systematic review
18794,33106852,*thyroidectomy
18795,33106852,*weight gain
18796,32988358,thyroid carcinoma
18797,32988358,aggressive
18798,32988358,breast carcinoma
18799,32988358,diagnostic algorithm
18800,32988358,radiopharmaceuticals
18801,32988358,synchronous
18802,34376229,cardiac metastasis
18803,34376229,case report
18804,34376229,follicular thyroid carcinoma
18805,34376229,hurthle cell carcinoma
18806,34376229,multisite metastases
18807,34376229,pancreatic metastasis
18808,34376229,unusual metastases cois
18809,33111192,*toetva
18810,33111192,*tort
18811,33111192,*transoral endoscopic thyroidectomy
18812,33111192,*transoral robotic thyroidectomy
18814,34010443,desiccated thyroid extracts
18815,34010443,hypothyroidism
18816,34010443,iodine
18817,34010443,levothyroxine
18818,34010443,liothyronine
18819,34010443,selenium
18820,34010443,survey
18821,34010443,thyroid hormones
18822,33772338,thyroid
18823,33772338,malignancy
18824,33772338,nodule
18825,33772338,ultrasonography
18826,33406977,*salt iodization
18827,33406977,*thyroid autoantibodies
18828,33406977,*thyroid dysfunction
18829,31928176,*tibetan
18830,31928176,*iodine nutrition
18831,31928176,*oxygen-deficient plateau
18832,31928176,*thyroid disorders
18834,33645517,ptc
18835,33645517,tpoab
18836,33645517,tgab
18837,33645517,extrathyroidal extension
18838,33645517,lymph node metastasis
18839,32696176,*gli3 gene
18840,32696176,*glis3 gene
18841,32696176,*thyroid dysgenesis
18842,32696176,*thyroid hemiagenesis
18843,32696176,*whole-exome sequencing cois
18844,34126658,autoantibody
18845,34126658,autoimmune thyroiditis
18846,34126658,pediatrics
18847,34126658,thyroid cancer
18848,34126658,thyroid nodule
18849,33643218,*radiofrequency ablation
18850,33643218,*technique
18851,33643218,*thermal ablation
18852,33643218,*thyroid nodules
18853,33643218,*ultrasound cois commercial or financial relationships that could be construed as a potential conflict of interest.
18855,32276716,*graves’ disease
18856,32276716,*outpatient surgery
18857,32276716,*pediatric surgery
18858,32276716,*thyroid cancer
18859,32276716,*thyroid nodule
18860,32276716,*thyroidectomy cois conflicts of interest to disclose.
18861,34539567,*biallelic variant
18862,34539567,*characteristic
18863,34539567,*hypothyroidism
18864,34539567,*oligogenic variant
18865,34539567,*whole-exome sequencing cois commercial or financial relationships that could be construed as a potential conflict of interest.
18866,34284528,cns tumor
18867,34284528,plurihormonal pituitary adenoma
18868,34284528,sella turcica
18869,33827539,hyperparathyroidism
18870,33827539,intrathyroidal parathyroid
18871,33827539,parathyroid cancer
18872,33827539,surgical approach
18873,33827539,thyroid cancer cois
18874,33683595,*chek2
18875,33683595,*dna repair
18876,33683595,*familial non-medullary thyroid carcinoma (fnmtc)
18877,33683595,*founder pathogenic variant
18878,33683595,*thyroid
18880,33104041,*hyperthyroidism
18881,33104041,*parkinson’s disease
18882,33104041,*hypothyroidism
18883,33104041,*neurodegenerative disorder
18884,33104041,*pathophysiology
18885,33104041,*thyroid disease
18886,33104041,*thyroid dysfunction
18889,33254347,"diagnosis, surgical procedures, operative"
18890,33254347,root of neck neoplasms cois relevant financial relationships with commercial interests to disclose.
18891,34644122,*chloride channel
18892,34644122,*chloride exchanger
18893,34644122,*drug discovery
18894,34644122,*epithelium
18895,34644122,"*solute carrier proteins cois applications for chloride transport modulators, which are owned by their respective universities."
18896,33920190,*ages
18897,33920190,*mage
18898,33920190,*rage
18899,33920190,*glycation
18900,33920190,*oxidative stress
18901,33920190,*thyroid gland pathology cois
18903,33751486,autoimmune thyroid disease
18904,33751486,children and adolescents
18905,33751486,dna methylation
18906,33751486,hashimoto thyroiditis
18907,33751486,melting curve analysis
18908,33751486,ptpn22
18909,33035689,*cell free mtdna
18910,33035689,*nd4/nd1
18911,33035689,*thyroid cancer
18912,33035689,*mtdna copy number
18913,33035689,*mtdna integrity
18914,32430758,*ovarian sertoli-leydig cell tumors
18915,32430758,*slcts
18916,34171097,*cancer
18917,34171097,*carcinoma
18918,34171097,*follicular
18919,34171097,*mutation
18920,34171097,*thyroid
18921,34171097,*whole-genome
18922,32910988,*cysteine cathepsins
18923,32910988,*non-canonical trafficking
18924,32910988,*nuclear forms
18925,32910988,*proliferation-promoting
18926,32910988,*thyroid cancer cois competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
18927,33004735,ablation techniques
18928,33004735,consensus
18929,33004735,guideline
18930,33004735,nodular goiter
18931,33004735,thyroid neoplasms cois
18933,34080176,*hysterosalpingography
18934,34080176,*iodine excess
18935,34080176,*lactation
18936,34080176,*oil-soluble iodinated contrast
18937,34080176,*pregnancy
18938,33096991,*autoimmune thyroid disease
18939,33096991,*cardiac tamponade
18940,33096991,*hypothyroidism
18941,33096991,*pericardial effusion
18942,33096991,*turner syndrome cois
18943,32675393,papillary thyroid carcinoma
18944,32675393,genetic variation
18945,32675393,lncrna
18946,32675393,thyroid function
18947,32072403,fscn1
18948,32072403,immunohistochemistry
18949,32072403,methylation
18950,32072403,promoter
18951,32072403,thyroid cancer
18953,33124651,*tsh
18954,33124651,*congenital hypothyroidism
18955,33124651,*cutoff
18956,33124651,*newborn screening
18958,32188421,maternal and neonatal complications
18959,32188421,pregnancy
18960,32188421,urinary iodine concentration cois
18961,32851577,*cd71
18962,32851577,*primary immune deficiency
18963,32851577,*tfr1
18964,32851577,*a mutation in tfrc
18965,32851577,*combined immunodeficiency cois
18966,32899424,mir-146b
18967,32899424,mir-181b
18968,32899424,mir-21
18969,32899424,mir-221
18970,32899424,mir-222
18971,32899424,papillary thyroid carcinoma
18972,32899424,plasma cois
18973,32842364,detection rate
18974,32842364,fluorescence intensity
18975,32842364,influencing factor
18976,32842364,parathyroid glands
18977,32714280,*cushing's disease
18978,32714280,*dicer1
18979,32714280,*corticotropinoma
18980,32714280,*disease-modifying gene
18981,32714280,*pituitary neuroendocrine tumor
18982,34740022,*acromegaly
18983,34740022,*igf-1
18984,34740022,*risk factors
18985,34740022,*thyroid nodules
18987,31964247,*cost-effectiveness
18988,31964247,*decision-analytic modeling
18989,31964247,*effectiveness
18990,31964247,*iodine deficiency-related diseases
18991,31964247,*systematic review
18992,33036505,axillary approach
18993,33036505,"surgical procedures, minimally invasive"
18994,33036505,thyroid neoplasms
18995,33036505,thyroidectomy
18997,32075540,*china
18998,32075540,*iodine
18999,32075540,*prevalence
19000,32075540,*thyroid disorders
19001,32075540,*universal salt iodization
20497,23646218,benign thyroid hypertrophy
20498,23646218,giant goiter
20499,23646218,goiter
20500,23646218,multinodular goiter
20501,23646218,thyroidectomy
20510,23136541,nodular goiter
20511,23136541,peri-operative treatment
20512,23136541,surgical intervention. cois
20513,23998691,hyperthyroidism
20514,23998691,hypothyroidism
20515,23998691,menopause
20516,23998691,nodular goiter
20517,23998691,thyroid hormone function
20531,22362641,congenital hypothyroidism
20532,22362641,dyshormonogenetic goiter
20533,22362641,euthyroid
20534,22362641,follicular lesion
20535,22362641,follicular neoplasm
20538,24847400,large goiter
20539,24847400,morbidity
20540,24847400,thyroidectomy
20550,23688788,complications
20551,23688788,goiter
20552,23688788,levothyroxine
20553,23688788,lobectomy
20554,23688788,mng
20555,23688788,multinodular
20556,23688788,recurrence
20557,23688788,resection
20558,23688788,thyroid
20559,23688788,thyroidectomy
20568,24117750,minimally invasive surgery
20569,24117750,retrosternal goiter
20570,24117750,robot-assisted surgery
20571,24227901,lingual thyroid goiter
20572,24227901,thyroid ectopias
20573,24227901,transoral robotic surgery
20599,24239133,bocio endotorácico
20600,24239133,esternotomía
20601,24239133,intrathoracic goiter
20602,24239133,mediastino posterior
20603,24239133,posterior mediastinum
20604,24239133,sternotomy
20605,24239133,thoracotomy
20606,24239133,thyroidectomy
20607,24239133,tiroidectomía
20608,24239133,toracotomía
20631,25047208,extracervical scarless neck thyroidectomy (esnt)
20632,25047208,minimal neck incision thyroidectomy (mnit)
20633,25047208,minimally invasive video-assisted thyroidectomy (mivat)
20634,25047208,nodular goitre
20635,25047208,thyroid cancer
20643,24239215,chirurgie oculo-motrice
20644,24239215,chirurgie palpébrale
20645,24239215,corticosteroids
20646,24239215,corticothérapie
20647,24239215,dysthyroid orbitopathy
20648,24239215,décompression orbitaire
20649,24239215,eyelid surgery
20650,24239215,graves’ disease
20651,24239215,graves’ orbitopathy
20652,24239215,maladie de basedow
20653,24239215,multidisciplinaire
20654,24239215,multidisciplinary
20655,24239215,oculomotor surgery
20656,24239215,orbital decompression surgery
20657,24239215,orbitopathie basedowienne
20658,24239215,orbitopathie dysthyroïdienne
20659,24239215,radiation therapy
20660,24239215,radiothérapie
20687,24043977,airway stenting
20688,24043977,radiofrequency ablation
20689,24043977,thyroid goiter
20749,23993801,airway obstruction
20750,23993801,caesarean section
20751,23993801,fibreoptic intubation
20752,23993801,thyroidectomy
20773,24211307,carcinome papillaire de la thyroïde
20774,24211307,goitre multi-nodulaire
20775,24211307,hyperthyroidie
20776,24211307,hyperthyroidism
20777,24211307,multinodular goiter
20778,24211307,panuveitis
20779,24211307,panuvéite
20780,24211307,papillary thyroid carcinoma
20781,24211307,vascularite veineuse
20782,24211307,venous vasculitis
20787,23337610,graves’ disease
20788,23337610,hyperthyroidism
20789,23337610,suicide
20798,23838540,deafness
20799,23838540,enlarged vestibular aqueduct
20800,23838540,pendred syndrome
20801,23838540,pendrin
20802,23838540,slc26a4
20808,24211158,anxiety disorders
20809,24211158,autoimmune thyroiditis
20810,24211158,depression
20811,24211158,goiter
20812,24211158,hashimoto's thyroiditis
20816,23685895,nob1
20817,23685895,papillary thyroid carcinoma
20818,23685895,clinical significance
20819,23685895,immunohistochemistry
20820,23685895,quantitative rt–pcr
20852,23650151,delhi
20853,23650151,iodine deficiency disorders
20854,23650151,iodized salt
20855,23650151,urinary iodine excretion
20859,24327568,fine-needle cytology
20860,24327568,mantel zone lymphoma
20861,24327568,micrornas
20862,24327568,primary thyroid lymphoma
20863,24327568,thyroid cancer
20867,24043280,goiter
20868,24043280,neonatal graves’ disease
20869,24043280,respiratory failure
20870,24043280,thyroid
20871,23690528,airway management
20872,23690528,anesthesia
20873,23690528,general
20874,23690528,thyroidectomy
20879,23428758,agreement
20880,23428758,bocio
20881,23428758,concordancia
20882,23428758,goitre
20883,23428758,interobservador
20884,23428758,interobserver
20887,23645248,oestrogen
20888,23645248,progenitor cells
20889,23645248,thyroid nodules
20890,23645248,thyroid stem cells
20892,24082285,radioiodine
20893,24082285,hyperthyroidism
20907,24144816,benign multinodular goiter
20908,24144816,complications
20909,24144816,incidental thyroid cancer
20910,24144816,jóindulatú multinodularis golyva
20911,24144816,szövődmények
20912,24144816,tapasztalatok
20913,24144816,total thyreoidectomia
20914,24144816,total thyroidectomy
20915,23303305,endocrinology
20916,23303305,intensive care
20917,23303305,neonatology
20944,24249820,laryngeal nerve palsy
20945,24249820,methimazole
20946,24249820,pediatric graves’ disease
20947,24249820,reversible
20948,24249820,vocal cord paralysis
20989,24222113,braf mutations
20990,24222113,"hras, kras and nras mutations"
20991,24222113,kras codon 59 deletion
20992,24222113,follicular-patterned thyroid lesions
21001,22987562,carotid sheath dissection
21002,22987562,intraoperative neuromonitoring
21003,22987562,recurrent laryngeal nerve
21004,22987562,thyroid surgery
21005,22987562,vagal nerve stimulation
21040,24376294,endemic goitre
21041,24376294,parathyroid surgery
21042,24376294,video-assisted parathyroidectomy
21043,24376294,video-assisted thyroidectomy
21058,23473435,bisturí armónico
21059,23473435,bocio multinodular
21060,23473435,budget impact
21061,23473435,harmonic scalpel
21062,23473435,impacto económico
21063,23473435,multinodular goitre
21064,23473435,thyroidectomy
21065,23473435,tiroidectomía
21101,22351646,fine-needle aspiration
21102,22351646,malignant melanoma
21103,22351646,thyroid cyst wall atypia
21122,25103076,graves disease
21123,25103076,thyroidectomy
21124,25103076,volume
21142,24629864,graves' disease
21143,24629864,childhood
21144,24629864,hyperthyroidism
21149,23918194,nerve monitoring
21150,23918194,parathyroid surgery
21151,23918194,recurrent laryngeal nerve
21152,23918194,thyroid surgery
21162,24411211,acute pericarditis
21163,24411211,graves' disease
21164,24411211,thyroid crisis
21165,24034725,adaptive thresholding
21166,24034725,contrast enhancement
21167,24034725,image segmentation
21168,24034725,morphology
21169,24034725,planar scintigraphy
21170,24034725,radioiodine therapy
21171,24034725,thyroid volume estimation
21172,24034725,ultrasonography
21212,22511831,decompression
21213,22511831,optic neuropathy
21214,22511831,radiation
21215,22511831,steroid
21216,22511831,thyroid eye diseases cois
21226,24070662,anti–thyroid peroxidase antibodies
21227,24070662,autoimmune thyroiditis
21228,24070662,hashimoto's thyroiditis
21229,24070662,quality of life
21230,24070662,thyroidectomy
21238,24199816,basedow graves’ disease
21239,24199816,cas
21240,24199816,proptosis
21241,24199816,thyroid
21248,24704350,graves ophthalmopathy
21249,24704350,diplopia
21250,24704350,exophthalmos
21251,24704350,keratitis
21252,24704350,natural orifice transluminal endoscopic surgery
21258,22991383,laser ablation
21259,22991383,multinodular goiter
21260,22991383,thyroid nodules
21262,24291390,at
21263,24291390,angiogenesis
21264,24291390,anti-tpo
21265,24291390,anti-tg
21266,24291390,autoantibody
21267,24291390,ci
21268,24291390,edn1
21269,24291390,ednra
21270,24291390,endothelin 1
21271,24291390,endothelin family
21272,24291390,endothelin receptor type a
21273,24291390,gd
21274,24291390,graves' disease
21275,24291390,hwe
21276,24291390,hardy–weinberg equilibrium
21277,24291390,icam1
21278,24291390,intercellular adhesion molecule 1
21279,24291390,mmi
21280,24291390,or
21281,24291390,odds ratio
21282,24291390,ophthalmopathy
21283,24291390,ptu
21284,24291390,polymorphism
21285,24291390,snps
21286,24291390,tnfα
21287,24291390,trab
21288,24291390,tsh
21289,24291390,tsh receptor antibody
21290,24291390,tumor necrosis factor α
21291,24291390,utr
21292,24291390,untranslated region
21293,24291390,vegf
21294,24291390,anti-thyroglobulin
21295,24291390,anti-thyroid
21296,24291390,anti-thyroid peroxidase
21297,24291390,confidence interval
21298,24291390,methimazole
21299,24291390,propylthiouracil
21300,24291390,single nucleotide polymorphisms
21301,24291390,thyroid-stimulating hormone
21302,24291390,vascular endothelial growth factor
21305,23518423,brain infarction
21306,23518423,encephaloduroarteriosynangiosis (edas)
21307,23518423,graves’ disease
21308,23518423,hyperthyroidism
21309,23518423,moyamoya disease
21345,23868574,goiter
21346,23868574,iodized salt
21347,23868574,thyroid
21348,23868574,urinary iodine excretion
21376,24311524,orbit
21382,23482353,medicare
21383,23482353,age-associated disease
21384,23482353,comorbidity
21385,23482353,disease onset
21386,23482353,older people
21387,23482353,time trends
21389,24154901,autoimmune thyroiditis
21390,24154901,inferior thyroid artery
21391,24154901,thyroid doppler sonography
21392,23329888,asian populations.
21393,23329888,graves' disease
21394,23329888,hla-b*46
21395,23329888,meta-analysis cois
21409,23477757,embarazo
21410,23477757,enfermedad de graves
21411,23477757,gestational transient thyrotoxicosis
21412,23477757,graves’ disease
21413,23477757,hiperemesis gravídica
21414,23477757,hipertiroidismo
21415,23477757,hyperemesis gravidarum
21416,23477757,hyperthyroidism
21417,23477757,pregnancy
21418,23477757,tirotoxicosis gestacional transitoria
21428,22952313,graves
21429,22952313,graves disease
21430,22952313,hyperthyroidism
21431,22952313,myasthenia gravis
21432,22952313,ophthalmoplegia
21433,22952313,ptosis
21434,22952313,thyroid
21478,23535627,asian continental ancestry group
21479,23535627,graves ophthalmopathy
21480,23535627,psychiatric status rating scales
21500,23709442,graves’ orbitopathy
21501,23709442,tsh-receptor autoantibody
21502,23709442,disease activity
21503,23709442,severity cois
21506,23835254,anestesia
21507,23835254,anesthesia
21508,23835254,cirugía de descompresión orbitaria
21509,23835254,embarazo
21510,23835254,graves-basedow
21511,23835254,oftalmopatía
21512,23835254,ophthalmopathy
21513,23835254,orbital decompression surgery
21514,23835254,orbitopathy
21515,23835254,orbitopatía
21516,23835254,pregnancy
21524,22416184,autoimmunity
21525,22416184,cag-a
21526,22416184,graves’ disease
21527,22416184,hashimoto’s thyroiditis
21528,22416184,helicobacter pylori
21529,22416184,hyperthyroidism
21530,22416184,hypothyroidism
21547,24119625,graves' disease
21548,24119625,moyamoya syndrome
21549,24119625,antithyroid therapy
21567,23796613,(131)i
21568,23796613,children
21569,23796613,edad pediátrica
21570,23796613,enfermedad de graves
21571,23796613,graves disease
21572,23796613,i(131)
21573,23796613,radioiodine therapy
21574,23796613,radioyodo
21575,23538281,cáncer de tiroides
21576,23538281,enfermedad de graves
21577,23538281,graves’ disease
21578,23538281,pequeñas-moléculas
21579,23538281,receptor de la tsh
21580,23538281,small molecules
21581,23538281,tsh-receptor
21582,23538281,thyroid
21583,23538281,thyroid cancer
21584,23538281,thyrotropin (tsh)
21585,23538281,tiroides
21586,23538281,tirotropina (tsh)
21595,24646903,enfermedad de la superficie ocular
21596,24646903,graves’ ophthalmopathy
21597,24646903,lentes de contacto mini esclerales
21598,24646903,mini-scleral contact lenses
21599,24646903,ocular surface disease
21600,24646903,oftalmopatía de graves
21612,23962080,autoimmune thyroid disease
21613,23962080,intractability
21614,23962080,polymorphism
21615,23962080,severity
21616,23962080,thyrotropin receptor
21657,24231095,graves' ophthalmopathy
21658,24231095,bulbar conjunctiva
21659,24231095,dry eye
21660,24231095,impression cytology
21661,24231095,in vivo confocal microscopy
21662,24135759,adipogenesis
21663,24135759,orbital fibroblasts
21664,24135759,proliferation
21665,24135759,thyroid eye disease
21667,22985335,graves’ disease
21668,22985335,hypoparathyroidism
21669,22985335,thyroid cancer
21670,22985335,thyroidectomy
21671,22985335,thyrotoxicosis
21678,23806737,ca-125
21679,23806737,ct
21680,23806737,hyperthyroidism
21681,23806737,meigs syndrome
21682,23806737,pleural effusion
21683,23806737,tfts
21684,23806737,tg-ab
21685,23806737,tpo-ab
21686,23806737,tsh
21687,23806737,tsh receptor
21688,23806737,tshr
21689,23806737,tshr-ab
21690,23806737,thyroid cancer
21691,23806737,us
21692,23806737,cancer antigen-125
21693,23806737,computed tomography
21694,23806737,thyroglobulin autoantibodies
21695,23806737,thyroid function tests
21696,23806737,thyroid peroxidase autoantibodies
21697,23806737,thyrotropin
21698,23806737,thyrotropin receptors
21699,23806737,thyrotropin receptors autoantibodies
21700,23806737,ultrasound
21728,23060717,acquired lower eyelid epiblepharon
21729,23060717,graves ophthalmopathy
21730,23060717,lower eyelid epiblepharon repair
21731,23060717,lower eyelid retraction cois
21735,23728841,dicer1
21736,23728841,family history
21737,23728841,multinodular goiter
21738,23728841,ovarian sertoli-leydig cell tumors
21739,23728841,tumor surveillance
21757,24029729,graves' disease
21758,24029729,rhesus monkeys
21759,24029729,thyrotropin receptor a-subunit
21765,24629859,fetal diseases
21766,24629859,goiter
21767,24629859,graves disease
21768,24629859,humans
21769,24629859,hyperthyroidism
21770,24629859,hypothyroidism
21771,24629859,maternal–fetal exchange
21772,24629859,pregnancy
21773,24629859,thyroid diseases: drug therapy
21774,24629859,thyroxine: administration and dosage
21782,24307850,agranulocytosis
21783,24307850,graves disease
21784,24307850,guillain-barre syndrome cois
21799,23757290,disease intractability
21800,23757290,disease severity
21801,23757290,hashimoto’s disease
21802,23757290,il-10
21803,23757290,single nucleotide polymorphism
21822,24177168,autoimmune thyroid diseases
21823,24177168,erythropoietin
21824,24177168,intractability
21825,24177168,severity
21826,24177168,single nucleotide polymorphism
21827,23954851,antioxidants
21828,23954851,biomarkers of oxidative stress
21829,23954851,chondroitin sulfate
21830,23954851,graves' disease
21856,23849367,asian patients
21857,23849367,hypokalemia
21858,23849367,paralysis
21859,23849367,thyrotoxicosis
21860,23849367,weakness
21874,24227294,gwas
21875,24227294,causal variants
21876,24227294,colocalisation
21877,24227294,genetic association
21879,22907781,graves' disease
21880,22907781,minimal-incision thyroidectomy
21881,22907781,minimally invasive surgery
21882,22907781,postoperative complications
21883,22907781,thyroid
21908,24289805,gpr174
21909,24289805,graves' disease
21910,24289805,poland
21911,24289805,x chromosome
21912,24289805,association
21913,24289805,autoimmune disease
21914,24289805,rs3827440
21915,24289805,single nucleotide polymorphism
21916,23756266,drug-induced cholestasis
21917,23756266,plasmapheresis
21918,23756266,thyrotoxicosis
21932,23954255,autoimmune thyroid disease
21933,23954255,ci
21934,23954255,caga
21935,23954255,edta
21936,23954255,ethylene diamine tetraacetic acid
21937,23954255,ft3
21938,23954255,ft4
21939,23954255,gd
21940,23954255,graves disease
21941,23954255,h. pylori
21942,23954255,hla
21943,23954255,helicobacter pylori
21944,23954255,human leukocyte antigen
21945,23954255,igg
21946,23954255,immunoglobulin g
21947,23954255,or
21948,23954255,pcr
21949,23954255,spss
21950,23954255,statistical product and service solutions
21951,23954255,tpoab
21952,23954255,trab
21953,23954255,tsh
21954,23954255,tgab
21955,23954255,confidence intervals
21956,23954255,cytotoxin-associated gene a
21957,23954255,dntp
21958,23954255,deoxy-ribonucleoside triphosphate
21959,23954255,free thyroxine
21960,23954255,free triiodothyronine
21962,23954255,odds ratio
21963,23954255,polymerase chain reaction
21964,23954255,thyroglobulin antibody
21965,23954255,thyroid peroxidase antibody
21966,23954255,thyroid stimulating hormone
21967,23954255,thyrotrophin receptor antibody
21975,24124099,diplopia
21976,24124099,endoscopic orbital floor decompression
21977,24124099,inferomedial orbital strut
21978,24124099,orbital decompression
21996,23839980,endoscopic orbital decompression
21997,23839980,graves' orbitopathy
21998,23839980,complications
21999,23839980,exophthalmos
22000,23839980,sinonasal
22008,22972028,*pingmu decoction
22009,22972028,*apoptosis
22010,22972028,*adipocytes
22011,22972028,*graves' ophthalmophathy
22024,24311923,epidemiology
22025,24311923,graves ophthalmopathy
22026,24311923,korea
22027,24311923,prevalence
22028,24311923,risk factors cois
22053,24411304,hashimoto's thyroiditis
22054,24411304,metastatic burden
22055,24411304,metastatic disease
22056,24411304,multi-nodular goiter
22057,24411304,thyroglobulin
22058,24411304,thyroid cancer
22059,24411304,thyroidectomy
22060,24411304,thyroiditis
22063,23827012,anticorps anti-cytoplasme des polynucléaires neutrophiles
22064,23827012,antineutrophil cytoplasmic antibodies
22065,23827012,benzylthio-uracile
22066,23827012,benzylthiouracil
22067,23827012,graves’ disease
22068,23827012,maladie de basedow
22069,23827012,vascularite
22070,23827012,vasculitis
22074,23667180,complex traits
22075,23667180,endocrinology
22076,23667180,genetics
22077,23667180,genome-wide
22078,23667180,thyroid disease
22082,25443353,hashimoto's thyroiditis
22083,25443353,autoimmune thyroiditis
22084,25443353,encephalopathy
22085,25443353,hallucinations
22086,25443353,steroids
22095,22787382,bullous systemic lupus erythematosus
22096,22787382,drug-induced lupus erythematosus
22097,22787382,graves disease
22098,22787382,methimazole
22113,23919315,graves' disease
22114,23919315,cardiomegaly
22115,23919315,forensic autopsy
22116,23919315,forensic science
22117,23919315,hyperthyroidism
22118,23919315,sudden unexpected death
22121,24456861,atrophic renal parenchyma-like tumor
22122,24456861,comparative genomic hybridization
22123,24456861,humara
22124,24456861,kidney
22125,24456861,thyroid-like renal tumor
22152,24011567,graves’ disease
22153,24011567,incidental malignancy
22154,24011567,surgical therapy
22178,23681867,endocrine diseases
22179,23681867,pharmacotherapy
22185,23901889,b lymphocytes
22186,23901889,graves' disease
22187,23901889,t lymphocytes
22202,23973401,cryptococcal meningitis
22203,23973401,lupus
22204,23973401,opportunist infection
22205,23578170,anti-gal
22206,23578170,increased immunogenicity
22207,23578170,tumour vaccine
22208,23578170,wound healing
22209,23578170,α-gal epitopes
22213,24095912,autoimmun thyreoiditis
22214,24095912,autoimmune thyroiditis
22215,24095912,diabetes mellitus
22216,24095912,fertility
22217,24095912,meddőség
22218,24095912,selenium
22219,24095912,szelén
22231,24334133,autoimmunity
22232,24334133,autoimmunitás
22233,24334133,infertility
22234,24334133,meddőség
22235,24334133,pajzsmirigy
22236,24334133,post partum periódus
22237,24334133,postpartum period
22238,24334133,pregnancy
22239,24334133,terhesség
22240,24334133,thyroid
22251,23845451,(131)i-iodide
22252,23845451,cáncer folicular de tiroides
22253,23845451,enfermedad metastásica
22254,23845451,follicular thyroid cancer
22255,23845451,metastatic disease
22256,23845451,radioiodine therapy
22257,23845451,spect
22258,23845451,terapia con yodo radioactivo
22259,23845451,yodo radioactivo (131)i cois this work there are no financial or ethical conflicts of interest.
22262,23664858,cox
22263,23664858,cox-2
22264,23664858,il
22265,23664858,il-1β
22266,23664858,nf
22267,23664858,nf-κb
22268,23664858,pg
22269,23664858,pge(2)
22270,23664858,tao
22271,23664858,cyclooxygenase
22272,23664858,interleukin
22273,23664858,nuclear factor
22274,23664858,orbital fibroblast
22275,23664858,pirfenidone
22276,23664858,prostaglandin
22277,23664858,thyroid-associated ophthalmopathy
22279,23958483,octreotide
22280,23958483,somatostatin analogs
22281,23958483,tsh-secreting pituitary tumor
22282,23958483,thyrotropinoma
22288,23958398,antibodies
22289,23958398,apoptosis
22290,23958398,proliferation
22291,23958398,ros-signaling
22292,23958398,tsh receptor
22293,23958398,thyrocyte
22337,24335091,thyroid carcinoma
22338,24335091,cancer
22339,24335091,endocrine surgery
22340,24335091,follicular carcinoma
22341,24335091,neoplastic thrombus
22353,24250332,jaundice
22354,24250332,thionamides
22355,24250332,thyrotoxicosis
22364,24291398,cox-2
22365,24291398,cellular antioxidant defense mechanisms
22366,24291398,cerebral cavernous malformations
22367,24291398,free radicals
22368,24291398,krit1
22369,24291398,reactive oxygen species
22370,24291398,c-jun
22375,22386642,ait
22376,22386642,amiodarone
22377,22386642,bmi
22378,22386642,body mass index
22379,22386642,chd
22380,22386642,congenital heart defects
22381,22386642,cyanosis
22382,22386642,drug toxicity
22383,22386642,hyperthyroidism
22384,22386642,lvef
22385,22386642,t3
22386,22386642,t4
22387,22386642,tsh
22388,22386642,amiodarone-induced thyrotoxicosis
22390,22386642,congenital heart disease
22391,22386642,left ventricular ejection fraction
22392,22386642,thyroid stimulating hormone
22393,22386642,thyroxine
22394,22386642,triiodothyronine
22399,23553532,thyroid disorders
22400,23553532,epidemiology
22401,23553532,otolaryngology
22402,23553532,specialty
22403,23553532,thyroid nodule
22404,23553532,thyroidectomy
22423,24273003,cd-44
22424,24273003,hbme-1
22425,24273003,fine needle aspiration cytology
22426,24273003,galectin-3
22427,24273003,papillary thyroid carcinoma
22437,23838336,angiosarcoma
22438,23838336,haematoma
22439,23838336,haemothorax
22440,23838336,pleural metastasis
22444,23569858,granuloma
22445,23569858,thyroid
22446,23569858,tuberculosis cois
22455,24189283,at
22456,24189283,autoimmune thyroiditis
22457,24189283,ccl
22458,24189283,cd
22459,24189283,cia
22460,24189283,cs
22461,24189283,csf
22462,24189283,cxcl
22463,24189283,cxcl10
22464,24189283,cxcr3
22465,24189283,circulating cxcl10 levels
22466,24189283,cryoglobulinemia
22467,24189283,gad
22468,24189283,gd
22469,24189283,go
22470,24189283,graves
22471,24189283,graves' disease
22472,24189283,graves' ophthalmopathy
22473,24189283,graves’ disease
22474,24189283,graves’ ophthalmopathy
22475,24189283,gtx
22476,24189283,hepatitis c virus infection associated mixed cryoglobulinemia
22477,24189283,ifn
22478,24189283,ifn-γ-induced protein 10
22479,24189283,il
22480,24189283,ip-10
22481,24189283,jia
22482,24189283,juvenile idiopathic arthritis
22483,24189283,mc
22484,24189283,mc+hcv
22485,24189283,mcp-1
22486,24189283,mdc/ccl22
22487,24189283,mig
22488,24189283,mmi
22489,24189283,mp
22490,24189283,nf-kb
22491,24189283,nk
22492,24189283,npsle
22493,24189283,ppar-γ
22494,24189283,ptc
22495,24189283,papillary thyroid cancer
22496,24189283,peroxisome proliferator-activated receptor-γ
22497,24189283,psa
22498,24189283,psoriatic arthritis
22499,24189283,ra
22500,24189283,rankl
22501,24189283,rantes
22502,24189283,ret/ptc
22503,24189283,rheumatoid arthritis
22504,24189283,sf
22505,24189283,sle
22506,24189283,ss
22507,24189283,ssc
22508,24189283,st
22509,24189283,sjögren syndrome
22510,24189283,systemic lupus erythematosus
22511,24189283,systemic sclerosis
22512,24189283,t helper
22513,24189283,t1d
22514,24189283,tarc/ccl17
22515,24189283,tfc
22516,24189283,tnf
22517,24189283,tng
22518,24189283,tr
22519,24189283,th
22520,24189283,thyroid follicular cells
22521,24189283,thyroiditis
22522,24189283,toxic nodular goiter
22523,24189283,type 1 diabetes
22525,24189283,cerebrospinal fluid
22526,24189283,chemokine (c–c motif) ligand
22527,24189283,chemokine (c–x–c motif) ligand
22528,24189283,chemokine (c–x–c motif) receptor 3
22530,24189283,cluster of differentiation
22531,24189283,collagen-induced arthritis
22532,24189283,corticosteroid
22533,24189283,glutamic acid decarboxylase
22535,24189283,hyperthyroid gd
22536,24189283,interferon
22537,24189283,interleukin
22539,24189283,macrophage-derived chemokine/ccl22
22540,24189283,methimazole
22541,24189283,methylprednisolone
22542,24189283,mixed cryoglobulinemia
22543,24189283,monocyte chemotactic protein-1
22544,24189283,monokine induced by ifn-γ
22545,24189283,natural killer
22546,24189283,neuropsychiatric sle
22547,24189283,normal t cell expressed and secreted
22548,24189283,nuclear factor-kappa b
22552,24189283,rearranged in transformation/ptc
22553,24189283,receptor activator of nuclear factor kappa-b ligand
22555,24189283,scxcl10
22556,24189283,synovial fluid
22557,24189283,synovial tissue
22560,24189283,teleradiotherapy
22561,24189283,thymus and activation regulated chemokine/ccl17
22564,24189283,tumor necrosis factor
22583,23808516,bronchoscopy
22584,23808516,cardiothoracic surgery
22585,23808516,critical care medicine
22586,23808516,intervention techniques
22587,23808516,ventilation
22592,24484950,ectopic thyroid
22593,24484950,laryngeal location
22594,24484950,surgical treatment
22595,24484950,leczenie chirurgiczne
22596,24484950,lokalizacja krtaniowa
22597,24484950,tarczyca ektopowa
22622,23572163,differentiated thyroid carcinoma
22623,23572163,follow-up
22624,23572163,neck ultrasound
22625,23572163,radioiodine remnant ablation
22626,23572163,recurrence
22627,23572163,thyroglobulin
22632,24292913,case-based learning
22633,24292913,self-directed learning
22634,24292913,soft skills
22645,23240978,cowden syndrome
22646,23240978,pten
22647,23240978,ganglioneuromas
22648,23240978,hamartomatous polyps
22649,23240978,mosaicism
22658,23780707,clinicopathological characteristics
22659,23780707,incidental
22660,23780707,nonincidental
22661,23780707,papillary thyroid microcarcinoma
22662,23780707,surgical treatment
22668,24077472,case-control studies
22669,24077472,congenital hypothyroidism
22670,24077472,iran
22671,24077472,logistic regression
22672,24077472,propensity score
22673,23881987,lymphoma
22674,23881987,primary thyroid lymphoma
22675,23881987,thyroid
22676,23881987,thyroid malignancy
22677,23881987,thyroid surgery cois article.
22687,22431287,cowden disease
22688,22431287,cowden syndrome
22689,22431287,pathology
22690,22431287,surgical management
22691,22431287,thyroid
22693,24629858,dehal1 gene
22694,24629858,iyd
22695,24629858,congenital hypothyroidism
22696,24629858,iodide recycling
22697,24629858,mass spectrometry
22698,24629858,mental retardation
22699,24629858,neonatal screening
22705,23693108,"carcinoma, papillary, follicular"
22706,23693108,thyroid neoplasms
22710,24067547,t3
22711,24067547,amiodarone-induced thyrotoxicosis
22712,24067547,heart
22713,24067547,hyperthyroidism
22714,24067547,hypothyroidism
22715,24067547,thyroid hormone
22716,24067547,thyrotoxicosis
22717,24067547,triiodothyronine
22729,23933148,congenital hypothyroidism
22730,23933148,deletion
22731,23933148,inversion
22732,23933148,mutation
22733,23933148,thyroglobulin gene
22766,24301304,circulating biomarkers
22767,24301304,microrna
22768,24301304,papillary thyroid cancer
22769,24301304,recurrence
22770,24301304,tissue biomarkers
23130,21274344,pendred syndrome
23131,21274344,congenital hypothyroidism
23132,21274344,pseudo−pendred syndrome
23133,21274344,thyroid peroxidase defect
23163,21274318,thyrotropin receptor
23164,21274318,germline mutation
23165,21274318,nonautoimmune hyperthyroidism
23385,21274321,congenital hypothyroidism
23386,21274321,thyroxine
23455,21052505,clinical course
23456,21052505,optic nerve diseases
23457,21052505,risk factors
23458,21052505,thyroid-associated orbitopathy cois
23563,21274336,hyperthyroidism
23564,21274336,isolated
23565,21274336,neonatal
23566,21274336,sialadenitis
23567,21274336,submandibular
23600,21716594,biological assay
23601,21716594,graves disease
23602,21716594,"immunoglobulins, thyroid-stimulating"
23603,21716594,"receptors, thyrotropin"
23604,21716594,thyrotropin-binding inhibitory immunoglobulin cois
23646,20379454,depression
23647,20379454,graves ophthalmopathy
23648,20379454,quality of life cois
23668,20195406,graves disease
23669,20195406,thyroid neoplasms
23670,20195406,ultrasonography cois
23791,20157407,congenital fibrosis syndrome of the extraocular muscles
23792,20157407,congenital retraction
23793,20157407,epiblepharon
23794,20157407,lower eyelid retraction
23795,20157407,thyroid-associated ophthalmopathy
23844,22148004,destructive thyroiditis
23845,22148004,graves disease
23846,22148004,interferons
23894,20835551,immunohistochemistry
23895,20835551,ndrg1
23896,20835551,thyroid carcinoma
23897,20835551,thyroid gland
23898,20835551,tissue microarray
23969,20808683,mutation
23970,20808683,thyroid hormone receptor
23971,20808683,thyroid hormone receptors beta
23972,20808683,thyroid hormone resistance syndrom
23973,20808683,thyroid neoplasms
24183,25058777,sternotomy
24184,25058777,substernal goiter
24185,25058777,surgery
24186,25058777,treatment
24187,25047203,us elastosonography
24188,25047203,indeterminate nodules
24189,25047203,thyroid
24190,25047203,thyroid nodules
24191,25047203,thyroid ultrasound
24194,24622964,adenomatous multinodular goiter
24195,24622964,airway obstruction
24196,24622964,mediastinum
24197,24622964,neck mass
24198,24622964,pediatric
24200,25297557,plummer's disease
24201,25297557,cat
24202,25297557,hyperthyroidism
24203,25297557,thyroid
24204,25297557,thyrotoxicosis
24206,25976851,sternotomy
24207,25976851,substernal goiter
24208,25976851,thyroidectomy
24209,25363013,amniocentesis
24210,25363013,intrauterine therapy
24211,25363013,l-thyroxine
24212,25363013,labor dystocia
24213,25363013,polyhydramnios
24214,26327954,histology
24215,26327954,pre-sternale
24216,26327954,surgery
24217,26327954,thyroid enlargement
24218,25555013,riedel thyroiditis
24219,25555013,amiodarone-induced thyroiditis
24220,25555013,subacute thyroiditis
24228,25752670,complications
24229,25752670,electrocautery
24230,25752670,substernal goiter
24231,25752670,thyroidectomy
24232,25752670,ultrasonic devise
24238,26955411,granuloma
24239,26955411,multinodular goiter
24240,26955411,tuberculosis
24243,25157987,cervical approach
24244,25157987,complications
24245,25157987,elderly
24246,25157987,mediastinal goiter
24247,25157987,thyroidectomy
24251,24931349,goiter
24252,24931349,recurrent laryngeal nerve
24253,24931349,thyroid
24254,24931349,thyroid hormone
24255,24931349,thyroidectomy
24262,26161201,immunohistochemical examination
24263,26161201,goiter
24264,26161201,systemic amyloidosis
24274,26443487,deafness
24275,26443487,genetics
24276,26443487,genome
24277,26443487,hearing loss
24278,26443487,sequencing
24288,25499094,developing countries
24289,25499094,endemic goiter
24290,25499094,iodine deficiency
24291,25499094,thyroidectomy
24293,25242682,anaplastic thyroid carcinoma
24294,25242682,goiter
24295,25242682,survival
24299,24880605,cervico-mediastinal goiter
24300,24880605,recurrent laryngeal nerve palsy
24301,24880605,substernal goiter
24302,24880605,thyroid surgery
24303,24880605,total thyroidectomy
24309,26389933,epidemiology
24310,26389933,metabolic syndrome
24311,26389933,prevalence
24312,26389933,risk factor
24317,24519672,iodine deficiency
24318,24519672,children
24319,24519672,goiter prevalence
24321,25594634,multinodular goiter
24322,25594634,recurrence classification description: endocrinology
24323,25594634,thyroidectomy
24326,25981745,multinodular goiter
24327,25981745,proliferation
24328,25981745,proteomics
24329,25981745,ttf1
24337,25614405,doppler sonography
24338,25614405,calcification
24339,25614405,diffuse large b-cell lymphoma
24340,25614405,head and neck ultrasound
24341,25614405,nodular goiter
24342,25614405,sonography
24343,25614405,thyroid lymphoma
24346,26293122,basedow
24347,26293122,graves
24348,26293122,autoimmunity
24349,26293122,chemokines
24350,26293122,thyroid
24351,25629792,endemic
24352,25629792,goiter
24353,25629792,iodine
24354,25629792,pregnancy
24355,25629792,thyroid
24356,25667715,atrioventricular
24357,25667715,hyperthyroidism
24358,25667715,multinodular goiter
24360,25047199,epidemiology
24361,25047199,goitre
24362,25047199,iodine deficiency
24363,25047199,nodular goitre
24364,25047199,nodules
24365,25047199,review
24367,25613936,endemic goiter
24368,25613936,enquête épidémiologique
24369,25613936,epidemiological survey
24370,25613936,goitre endémique
24371,25613936,hormones thyroïdiennes
24372,25613936,iode urinaire
24373,25613936,iodine deficiency disorders
24374,25613936,thyroid hormones
24375,25613936,troubles dus à la carence en iode
24376,25613936,urinary iodine
24382,25592327,graves’ disease
24383,25592327,hyperthyroidism
24384,25592327,hypocalcemia
24385,25592327,recurrent laryngeal nerve palsy
24386,25592327,thyroidectomy
24387,25592327,toxic multinodular goiter
24388,25047207,goitre
24389,25047207,iodine deficiency
24390,25047207,iodine prophylaxis
24393,24651704,graves' disease
24394,24651704,autoimmune
24395,24651704,inflammation
24399,25047210,nodular goitre
24400,25047210,radioiodine
24401,25047210,recombinant human thyrotropin
24402,25047210,thyroid diseases
24403,25047201,alcohol
24404,25047201,environmental risk factors
24405,25047201,goitre aetiology
24406,25047201,insulin resistance
24407,25047201,oral contraceptives
24408,25047201,parity
24409,25047201,smoking
24410,25047201,twins
24414,25047205,cytology
24415,25047205,fine needle aspiration
24416,25047205,molecular diagnostics
24417,25047205,thyroid cancer
24418,24595624,airway management
24419,24595624,airway obstruction
24420,24595624,endotracheal intubation
24421,24595624,goiter
24422,24595624,intubation
24423,24595624,nodular
24425,24462913,autoinmunidad tiroidea
24426,24462913,bipolar disorder
24427,24462913,bocio
24428,24462913,goitre
24429,24462913,hipertiroidismo
24430,24462913,hipotiroidismo
24431,24462913,hyperthyroidism
24432,24462913,hypothyroidism
24433,24462913,lithium
24434,24462913,litio
24435,24462913,thyroid
24436,24462913,thyroid autoimmunity
24437,24462913,tiroides
24438,24462913,trastorno bipolar
24441,25047206,non-toxic goitre
24442,25047206,patient-reported outcome measure
24443,25047206,quality of life
24444,26337337,cardiac surgical procedures
24445,26337337,coronary artery bypass
24446,26337337,retrosternal goitre
24447,26337337,thyroidectomy
24449,25047202,nodular goitre
24450,25047202,nuclear medicine
24451,25047202,positron emission tomography
24452,25047202,scintigraphy
24453,25047204,fna
24454,25047204,cytology
24455,25047204,diagnostic pitfalls
24456,25047204,morphology
24457,25047204,nodular goitre
24462,25633667,compound heterozygous mutations
24463,25633667,congenital hypothyroidism
24464,25633667,cryptic splice site
24465,25633667,mutation
24466,25633667,thyroglobulin gene
24472,24628230,horner's syndrome
24473,24628230,carotid dissection
24474,24628230,multinodular goiter
24475,24628230,trigeminal autonomic cephalgia
24476,24589354,adenomatous goiter
24477,24589354,human thyroid
24478,24589354,leakiness
24479,24589354,nog mouse
24480,24589354,thymic lymphoma
24481,24589354,transplantation
24486,24706172,goitre
24487,24706172,risk factors
24488,24706172,sternotomy
24489,24706172,thyroid gland
24490,24706172,thyroidectomy
24491,24703798,graves' disease
24492,24703798,pericarditis
24493,24703798,thyrotoxicosis
24495,25896315,thyroid cancer
24496,25896315,thyroidectomy
24497,25896315,toxic nodular goiter
24501,26261619,intra-thyroid thyroglossal duct cyst (ittdc)
24502,26261619,nodule
24503,26261619,thyroid gland
24504,26261619,ultrasound (us)
24505,25047200,goitre
24506,25047200,oesophagus
24507,25047200,radioiodine
24508,25047200,swallowing
24509,25047200,thyroidectomy
24510,25047200,trachea
24511,25047200,upper airway obstruction
24512,27057257,inferior laryngeal nerve
24513,27057257,non-recurrent
24514,27057257,total thyroidectomy
24515,24759378,retrosternal goiter
24516,24759378,complications to surgery
24517,24759378,intrathoracic goiter
24518,24759378,nodular goiter
24519,24759378,recurrent laryngeal nerve injury
24520,24759378,substernal goiter
24521,24759378,surgical treatment
24540,26069028,allergy
24541,26069028,endocrinology
24542,26069028,nutrition
24548,26163018,acromegaly
24549,26163018,goiter
24550,26163018,thyroid autoimmunity
24551,26163018,thyroid nodules
24557,26039459,branchial cyst
24558,26039459,cervical sinus
24559,26039459,iodine deficiency
24560,26039459,thyroid goiter
24567,26826478,hypoparathyroidism
24568,26826478,outcome
24569,26826478,recurrent laryngeal nerve palsy
24570,26826478,surgery
24571,26826478,thyroid
24572,26826478,à venir
24576,24774362,acute pericarditis
24577,24774362,brown adipose tissue
24578,24774362,spodick's sign
24582,25167783,graves disease
24583,25167783,qol
24584,25167783,surgery
24585,25167783,thypro
24586,25167783,toxic goiter
24591,25667686,etiology
24592,25667686,ectopic intrathoracic goiter
24593,25667686,mediastinal cyst
24603,24530085,algorithmes
24604,24530085,algorithms
24605,24530085,anesthésie générale
24606,24530085,difficult intubation
24607,24530085,general anesthesia
24608,24530085,impossible mask ventilation
24609,24530085,intubation difficile
24610,24530085,thyroidectomy
24611,24530085,thyroïdectomie
24612,24530085,tracheostomy
24613,24530085,trachéotomie
24614,24530085,ventilation au masque impossible
24615,26504073,hashimoto's thyroiditis
24616,26504073,thyroid cancer
24617,26504073,intraglandular dissemination
24618,26504073,multinodular thyroid
24619,26504073,nodular goitre
24620,26504073,papillary carcinoma
24623,25113865,old people
24624,25113865,parathyroidectomy
24625,25113865,primary hyperparathyroidism
24626,25113865,thyroid nodules
24629,25389240,imp3
24630,25389240,immunohistochemistry
24631,25389240,nucleophosmin
24632,25389240,papillary carcinoma
24633,25389240,thyroid
24634,26824209,clinicopathologic characteristics
24635,26824209,familial
24636,26824209,papillary carcinoma
24637,26824209,thyroid carcinoma
24641,26194563,goiter
24642,26194563,medical diagnosis
24643,26194563,painting
24644,26194563,parmigianino
24650,25102228,adrenomedullin 2
24651,25102228,goiter
24652,25102228,immunohistochemistry
24653,25102228,intermedin
24654,25102228,iodine-deficiency
24658,26834286,cardiomyopathy
24659,26834286,extracorporeal membrane oxygenation
24660,26834286,heart failure
24661,26834286,hyperthyroidism
24662,26834286,"thyrotoxicosis cois financial, or other relationship with any healthcare-related business or other entity whose products or services are discussed in this paper."
24665,26405494,plunging goitre
24666,26405494,cervical region
24667,26405494,western algeria
24671,26514949,antithyroid drug
24672,26514949,graves’ disease
24673,26514949,maladie de basedow
24674,26514949,relapse
24675,26514949,récidive
24676,26514949,traitement médical antithyroïdien
24684,25661375,autophagy
24685,25661375,autophagy-related protein light chain 3 (lc3)-ii
24686,25661375,papillary thyroid cancer
24690,25847147,goiter
24691,25847147,hypoparathyroidism
24692,25847147,parathyroid
24693,25847147,substernal
24694,25847147,thyroidectomy
24703,26322488,aggregate risk
24704,26322488,cumulative risk
24705,26322488,goitrogens
24706,26322488,perchlorate
24707,26322488,probabilistic risk assessment
24708,26322488,regulatory rationality
24715,25824071,graves’ orbitopathy
24716,25824071,guidance
24717,25824071,referral pathways
24718,25824071,thyroid eye disease
24725,24456910,benign tumor
24726,24456910,chirurgie cervicale
24727,24456910,glande submandibulaire
24728,24456910,neck surgery
24729,24456910,submandibular gland
24730,24456910,thyroid
24731,24456910,thyroïde
24732,24456910,tumeur bénigne
24734,24974154,central neck dissection
24735,24974154,lymph node metastasis
24736,24974154,papillary thyroid carcinoma
24737,24974154,thymosin beta 10
24743,26662651,myocardial scintigraphy
24744,26662651,sestamibi
24745,26662651,thyroid autoimmune disease
24746,26662651,thyroid cancer
24747,26662651,thyroid nodules
24752,26610563,khyber pakhtunkhwa
24753,26610563,pakistan
24754,26610563,community engagement
24755,26610563,goitre
24756,26610563,iodine deficiency
24757,26610563,iodised salt
24758,26610563,urinary iodine concentration
24762,26414819,drainage
24763,26414819,hemostasis
24764,26414819,thyroidectomy
24765,26414819,valsalva maneuver
24768,26074258,complications
24769,26074258,inferior
24770,26074258,intraoperative neurophysiological monitoring
24771,26074258,laryngeal nerve
24772,26074258,recurrent laryngeal nerve palsy
24773,26074258,thyroid gland
24776,24713328,dissociative amnesia
24777,24713328,dissociative disorder
24778,24713328,graves' disease
24779,24713328,hyperthyroidism
24785,25043767,airway
24786,25043767,goiter
24787,25043767,hemorrhage
24788,25043767,tpa
24789,25043767,thyroid
24790,26254997,benign goiter
24791,26254997,hashimoto thyroiditis
24792,26254997,quality of life
24793,26254997,thyroidectomy
24796,25722226,antithyroid drugs
24797,25722226,glucocorticoids
24798,25722226,graves’ disease
24799,25722226,graves’ orbitopathy
24800,25722226,radioiodine
24801,25722226,thionamides
24802,25722226,thyroidectomy
24804,25726089,graves’ disease
24805,25726089,postoperative complications
24806,25726089,total thyroidectomy
24807,25366513,drinking-water
24808,25366513,goitre
24809,25366513,iodine excess
24810,25366513,iodised salt
24811,25366513,prevalence
24813,25745526,thyroid
24814,25745526,papillary carcinoma
24815,25745526,tuberculosis
24816,24726024,bocio
24817,24726024,cervicotomy
24818,24726024,cervicotomía
24819,24726024,esternotomía
24820,24726024,goitre
24821,24726024,mediastinal
24822,24726024,mediastino
24823,24726024,sternotomy
24828,25342401,airway management
24829,25342401,endotracheal intubation
24830,25342401,goitre
24831,25342401,retrosternal
24832,25342401,thyroidectomy
24834,25194170,catatonia
24835,25194170,graves' disease
24836,25194170,hyperthyroidism
24837,25194170,postpartum psychosis
24838,25194170,psychosis
24845,24795511,iodine deficiency disorder
24846,24795511,iodized salt
24847,24795511,thyroid functions
24848,24795511,urinary iodine concentration
24855,25914194,diagnostic accuracy
24856,25914194,fine-needle aspiration biopsy
24857,25914194,histopathology
24858,25914194,thyroid nodule
24859,25914194,ultrasonography
24864,25197416,ectopic thyroid tissue
24865,25197416,bilateral thyroid goiter
24866,25197416,the recurrent laryngeal nerve
24867,25197416,thyroiditis
24868,25197416,ultrasound
24878,25563504,drinking water
24879,25563504,iodine-deficiency disorders
24880,25563504,table salt
24881,25563504,urinary iodine content
24882,25066642,cáncer de tiroides
24883,25066642,enfermedad nodular tiroidea
24884,25066642,hormona paratiroidea
24885,25066642,nodular thyroid disease
24886,25066642,tsh
24887,25066642,thyroid cancer
24889,24670538,papillary thyroid carcinoma
24890,24670538,cyclo-oxygenase-2
24891,24670538,matrix metalloproteinase-9
24892,24670538,vascular endothelial growth factor
24904,26185318,adenolipoma
24905,26185318,cowden syndrome
24906,26185318,ganglioneuroma
24907,26185318,gastrointestinal polyps
24908,26185318,hamartoma
24909,26185318,pten
24910,26185318,pten-hamartoma tumor syndrome
24911,26185318,papillary carcinoma
24912,26185318,storiform collagenoma
24913,26185318,thyroid
24914,26457492,brafv600e mutation
24915,26457492,kras mutation
24916,26457492,rassf1a methylation
24917,26457492,fine-needle aspiration biopsy
24918,26457492,nodular goiter
24936,24525284,anesthésie péridurale cervicale
24937,24525284,cervical epidural anesthesia
24938,24525284,perioperative risk
24939,24525284,risque périopératoire
24940,24525284,thyroidectomy
24941,24525284,thyroïdectomie
24942,26117483,compression of tracheobronchial tree
24943,26117483,intrathoracic goitre
24944,26117483,pulmonary tuberculosis
24945,24962366,adenoid cystic pattern
24946,24962366,fine-needle aspiration
24947,24962366,hyaline globule
24948,24962366,spindle-cell thymoma
24949,24962366,type a thymoma
24955,25326671,intraoperative neuromonitoring
24956,25326671,palsied recurrent laryngeal nerve
24957,25326671,secondary thyroidectomy
24961,24876155,emergency department
24962,24876155,respiratory
24981,26834925,delayed diagnosis
24982,26834925,historical tumors
24983,26834925,socioeconomic level
25001,25421156,autoimmunity
25002,25421156,environment
25003,25421156,genetics
25004,25421156,graves’ disease
25005,25421156,hyperthyroidism
25012,25596664,age
25013,25596664,glucocorticoids
25014,25596664,graves’ disease
25015,25596664,graves’ orbitopathy
25016,25596664,natural history
25017,25596664,radiotherapy
25020,25637365,corticoides
25021,25637365,corticosteroids
25022,25637365,graves ophthalmopathy
25023,25637365,irradiación
25024,25637365,irradiation
25025,25637365,oftalmopatía de graves
25026,25637365,orbitopatía tiroidea
25027,25637365,radioterapia
25028,25637365,radiotherapy
25029,25637365,thyroid orbitopathy
25033,25313112,restrictive strabismus
25034,25313112,strabismus surgery
25041,24835350,corneal biomechanical properties
25042,24835350,corneal hysteresis
25043,24835350,thyroid eye disease
25044,24835350,visa classification
25055,26730171,dysfunction
25056,26730171,esophagopathy
25057,26730171,graves’ disease
25058,26730171,heartburn
25059,26730171,odynophagia
25061,25744236,calcification
25062,25744236,contrast-enhanced ultrasound
25063,25744236,roc curve
25064,25744236,thyroid nodules
25068,24661105,antibodies
25069,24661105,graves' disease
25070,24661105,hla drb1 haplotype
25071,24661105,phenotype
25072,24661105,severity
25079,26105719,antithyroid drugs
25080,26105719,basedow’s disease
25081,26105719,graves’ disease
25082,26105719,birth defects
25083,26105719,epidemiology
25084,26105719,incidence
25085,26105719,pregnancy
25086,26105719,spontaneous abortion
25087,26105719,stillbirth
25088,26105719,thy rotoxicosis
25089,26105719,thyroid disease
25095,24841498,dysthroid optic neuropathy
25096,24841498,orbital radiotherapy
25097,24841498,thyroid eye disease
25103,25953846,epidemiology
25104,25953846,orbit
25108,24510380,fish
25109,24510380,fna
25110,24510380,pax8/pparg
25111,24510380,ret/ptc
25112,24510380,thyroid cancer
25113,24891174,clinical practice guidelines
25114,24891174,clinical practice survey
25115,24891174,hyperthyroidism
25116,24891174,management
25119,25736544,25-hydroxyvitamin d
25120,25736544,graves’ disease
25121,25736544,hyperthyroidism
25122,25736544,prognosis
25123,25736544,radioiodine therapy
25124,25378983,graves disease
25125,25378983,renal infarction cois
25127,24830583,association
25128,24830583,graves’ disease
25129,24830583,polymorphisms
25130,24830583,toll like receptor
25137,25305147,estrogen
25138,25305147,fsh
25139,25305147,lh
25140,25305147,progesterone
25141,25305147,thyroid neoplasms
25147,24833206,euthyroidism
25148,24833206,graves disease
25149,24833206,methimazole
25150,24833206,remission
25154,25430040,graves' disease
25155,25430040,toll-like receptor
25156,25430040,association
25157,25430040,polymorphisms
25161,25746910,diabetes
25162,25746910,graves'
25163,25746910,ophthalmopath severity
25170,25239229,founder mutation
25171,25239229,haplotype analysis
25172,25239229,iran
25173,25239229,linkage analysis
25174,25239229,pendred syndrome
25175,25239229,slc26a4 gene
25180,26007334,graves’ disease
25181,26007334,vitamin d
25182,26007334,meta-analysis
25183,26007334,meta-regression
25184,26007334,sensitivity analysis
25201,25766333,graves’ disease
25202,25766333,magnetic resonance hydrography
25203,25766333,magnetic resonance imaging
25204,25766333,ureteral myxedema
25208,24409943,graves’ disease
25209,24409943,graves’ ophthalmopathy
25210,24409943,radioiodine
25211,24409943,thyroid eye disease
25213,25286078,graves' disease
25214,25286078,hashimoto's thyroiditis
25215,25286078,interleukin-4
25216,25286078,meta-analysis
25217,25286078,polymorphism
25221,24823620,brown adipose tissue (bat)
25222,24823620,glucose metabolism
25223,24823620,hyperthyroidism
25224,24823620,muscle
25225,24823620,positron-emission tomography and computed tomography (pet-ct)
25230,24505195,decompression
25231,24505195,exophthalmos
25232,24505195,graves ophthalmopathy
25233,24505195,orbit cois
25236,25253825,graves disease
25237,25253825,intrathyroid vascularity
25238,25253825,painless thyroiditis
25239,25253825,power doppler sonography
25240,25253825,superficial structures
25250,24994866,inflammatory cytokine
25251,24994866,lacrimal gland
25252,24994866,ocular surface
25253,24994866,tears
25254,24994866,thyroid-associated ophthalmopathy
25257,24970896,131i
25258,24970896,camera based uptake
25259,24970896,thyroid uptake probe
25263,25670394,autoimmune disease
25264,25670394,graves’ disease
25265,25670394,interleukin-23
25266,25670394,single nucleotide polymorphism
25275,25361748,orbit
25285,24502333,dysthyroid optic neuropathy
25286,24502333,graves orbitopathy
25287,24502333,intraocular pressure
25288,24502333,orbital decompression
25289,24502333,superior ophthalmic vein
25290,25244551,diplopia
25291,25244551,graves’ disease
25292,25244551,orbital decompression
25293,25244551,repeat
25294,25244551,thyroid ophthalmopathy
25295,25188661,hiv
25296,25188661,antiretroviral therapy
25297,25188661,hyperthyroidism
25298,25188661,hypothyroidism
25299,25188661,thyroid
25306,25444029,adolescent
25307,25444029,graves disease
25308,25444029,infarction
25309,25444029,magnetic resonance imaging
25310,25444029,middle cerebral artery
25311,25444029,muscular diseases
25314,25596774,basedow
25315,25596774,graves’ disease
25316,25596774,hashimoto
25317,25596774,ischémie sclérale
25318,25596774,ophtalmopathie
25319,25596774,ophthalmopathy
25320,25596774,plication
25321,25596774,plissement
25322,25596774,recession
25323,25596774,recul
25324,25596774,scleral ischemia
25325,25596774,surgical technique
25326,25596774,technique chirurgicale
25341,26505217,gaze-evoked amaurosis
25342,26505217,optic neuropathy
25343,26505217,thyroid eye disease
25354,24697361,autoimmune thyroid diseases
25355,24697361,ctla-4
25356,24697361,meta-analysis
25357,24697361,single nucleoside polymorphisms
25358,24697361,susceptibility
25362,24646814,clec16a
25363,24646814,graves’ disease (gd)
25364,24646814,hashimoto’s thyroiditis (ht)
25365,24646814,autoimmune thyroid diseases (aitds)
25366,24646814,complex genetics
25367,24646814,complex immunity
25368,24646814,infection
25369,24646814,innate immunity
25370,24646814,resistance
25371,24646814,single-nucleotide polymorphisms (snps)
25372,24646814,tolerance
25377,25543543,autoimmunity
25378,25543543,graves’ disease
25379,25543543,polymorphisms
25380,25543543,thyroid-stimulating hormone receptor
25387,26499253,creatinine
25388,26499253,estimated glomerular filtration rate
25389,26499253,standardized cystatin c
25390,26499253,thyroid hormone
25392,25558015,cancer de la thyroïde
25393,25558015,graves’ disease
25394,25558015,maladie de basedow
25395,25558015,nodule non-palpable
25396,25558015,non-palpable nodule
25397,25558015,thyroid cancer
25398,25558015,ultrasonography
25399,25558015,échographie
25404,24560831,cellulitis
25405,24560831,ecthyma gangrenosum
25406,24560831,graves’ disease
25407,24560831,pseudomonas aeruginosa
25423,25294349,"illness and disease, chronic"
25424,25294349,"illness and disease, experiences"
25425,25294349,interpretative phenomenological analysis (ipa)
25426,25294349,qualitative analysis
25427,25294349,quality of life
25428,25294349,rehabilitation
25429,25294349,"research, qualitative"
25435,25775381,epo
25436,25775381,erythrocytosis
25437,25775381,hif-1α
25438,25775381,hyperthyroidism
25440,25058606,cytokines
25441,25058606,graves disease
25442,25058606,thyroid
25443,25692426,fine needle aspiration biopsy
25444,25692426,hashimoto's thyroiditis
25445,25692426,papillary thyroid carcinoma
25449,26240504,biological assay
25450,26240504,chronic inactive graves' orbitopathy
25451,26240504,mc4-tsi
25452,26240504,thyroid-stimulating immunoglobulin
25453,26240504,thyrotropin-binding inhibitory immunoglobulin cois was reported.
25457,25342622,cd44
25458,25342622,cox-2
25459,25342622,hyaluronic acid
25460,25342622,orbital fibroblast
25461,25342622,thyroid-associated ophthalmopathy
25462,25028161,association
25463,25028161,graves’ disease
25464,25028161,toll like receptor
25465,25028161,case-control study
25466,25028161,single nucleotide polymorphisms
25467,24627146,il-1β
25468,24627146,hyaluronic acid
25469,24627146,hyaluronic acid synthase
25470,24627146,mitogen-activated protein kinase
25471,24627146,orbital fibroblast
25472,24627146,pirfenidone
25473,24627146,thyroid-associated ophthalmopathy
25477,25892161,thyroid eye disease
25478,25892161,decompression
25479,25892161,diplopia
25480,25892161,orbit
25481,25892161,proptosis
25490,25576458,graves’ orbitopathy
25491,25576458,ich guideline
25492,25576458,intravenous steroids
25493,25576458,medical dictionary for regulatory activities (meddra)
25494,25576458,safety
25495,24486115,autoinmunidad tiroidea materna
25496,24486115,children born from mothers with autoimmune thyroid disease
25497,24486115,enfermedad de graves en el embarazo
25498,24486115,hijo de mujer con enfermedad tiroidea autoinmunitaria
25499,24486115,hipotiroidismo
25500,24486115,hypothyroidism
25501,24486115,pregnancy in graves disease
25502,24486115,thyroid autoimmunity in pregnancy
25505,26321629,magnetic resonance imaging
25506,26321629,methylprednisolone pulse therapy
25507,26321629,proptosis
25508,26321629,thyroid-associated ophthalmopathy
25509,26321629,volume
25510,24742542,graves' disease
25511,24742542,polymorphism
25512,24742542,transforming growth factor β1
25517,25770161,epidemiology
25518,25770161,eye
25519,25770161,ophthalmology
25524,25223473,a1555g
25525,25223473,hearing loss
25526,25223473,heteroplasmy
25527,25223473,mt-rnr1
25528,25223473,pendred syndrome
25529,25223473,slc26a4
25531,25759125,autoantibody
25532,25759125,graves'
25533,25759125,disease
25534,25759125,latent virus
25535,25759125,pathogenesis
25536,25759125,plasma cell differentiation
25540,24714170,carcinoma
25541,24714170,goiter
25542,24714170,thyroidectomy
25545,25937486,"anti-neutrophil cytoplasmic antibodies,"
25546,25937486,"drug-induced,"
25547,25937486,"graves’ disease,"
25548,25937486,"propylthiouracil,"
25549,25937486,small vessel vasculitis
25553,24989709,diplopia
25554,24989709,image-guided surgery
25555,24989709,proptosis
25556,24989709,strabismus
25557,24989709,thyroid eye disease
25558,24989709,visual acuity
25559,24989709,visual field
25565,25290043,deafness
25566,25290043,iran
25567,25290043,slc26a4
25568,25290043,enlarged vestibular aqueduct
25569,25290043,genetic linkage
25570,25290043,goiter
25571,25290043,mutation screening
25581,25768836,graves’ disease
25582,25768836,autoantibodies
25583,25768836,glycoprotein-hormone receptor
25584,25768836,small molecule ligands
25585,25768836,thyroid cancer
25586,25768836,thyroid-stimulating hormone receptor cois received no payment in preparation of this manuscript.
25593,25257150,<sup>131</sup>i
25594,25257150,dose/response analysis
25595,25257150,graves’ disease
25596,25257150,hyperthyroidism
25597,25257150,radioiodine
25602,26028555,graves' disease
25603,26028555,hypothyroidism
25604,26028555,postpartum thyroid disease
25605,26028555,pregnancy
25606,26028555,thyrotoxicosis
25607,25836060,depression
25608,25836060,graves’ orbitopathy
25609,25836060,diplopia
25610,25836060,elevation
25611,25836060,vertical strabismus
25618,24938857,graves’ disease
25619,24938857,intraoperative blood loss
25620,24938857,thyroidectomy
25623,25207976,ipilimumab
25624,25207976,myositis
25625,25207976,thyroid eye disease
25626,25207976,thyroid orbitopathy
25627,25121573,asia-pacific
25628,25121573,graves’ orbitopathy
25629,25121573,survey
25635,24697978,contour
25636,24697978,eyelid surgery
25637,24697978,keratopathy
25638,24697978,lagophthalmos
25639,24697978,symmetry
25642,25208306,reactivation
25643,25208306,thyroid-associated orbitopathy
25644,25208306,traum
25649,25134846,b-cell epitopes
25650,25134846,graves’ disease
25651,25134846,igg subclasses
25652,25134846,intramolecular epitope spreading
25653,25134846,thyroglobulin autoantibodies
25654,25120780,autoimmune thyroid diseases (aitds)
25655,25120780,graves’ disease (gd)
25656,25120780,hashimoto’s thyroiditis (ht)
25657,25120780,t helper 22 (th22) cell
25658,25120780,interleukin 22 (il-22)
25659,24903731,autoimmune co-morbidity
25660,24903731,autoimmune gastritis
25661,24903731,autoimmune thyroid diseases
25662,24903731,coeliac disease
25663,24903731,thyroid-associated orbitopathy
25667,25046415,autoimmune thyroid disease
25668,25046415,intractability
25669,25046415,polymorphism
25670,25046415,severity
25671,25046415,vitamin d
25681,25741204,children
25682,25741204,congenital hypothyroidism
25683,25741204,diffuse thyroid disease
25684,25741204,nodule
25685,25741204,thyroid disease
25686,25741204,ultrasonography
25687,25109914,graves-kór
25688,25109914,graves’ disease
25689,25109914,graves’ orbitopathy
25690,25109914,biological therapy
25691,25109914,biológiai terápia
25692,25109914,endokrin orbitopathia
25693,25109914,selenium
25694,25109914,szelén
25695,24938636,alemtuzumab
25696,24938636,autoimmunity
25697,24938636,sickle cell disease
25698,24938636,stem cell transplant
25699,24938636,thyroid dysfunction
25700,24838983,autoimmunity
25701,24838983,echocardiography
25702,24838983,hyperthyroidism
25703,24838983,pulmonary hypertension
25707,24674955,stroke
25708,24674955,cerebrovascular disease
25709,24674955,hematologic disease
25710,24674955,hyperthyroidism
25711,24674955,steroids
25712,24674955,thrombotic angiopathy
25715,25039242,biological treatment
25716,25039242,graves’disease
25717,25039242,endocrine orbitopathy
25718,25039242,hyperthyroidism
25719,25039242,thyroid
25724,24862674,focus
25725,24862674,harmonic
25726,24862674,knot tie technique
25727,24862674,sutureless
25728,24862674,thyroidectomy
25729,24862674,ultracision
25730,25839128,cd28
25731,25839128,cd4(+)cd28(−) t cells
25732,25839128,graves’ disease
25733,25839128,t-lymphocyte subsets
25736,25207388,electromagnetic image guidance
25737,25207388,graves’ ophthalmopathy
25738,25207388,orbital decompression
25743,25373929,graves’ disease
25744,25373929,hyperthyroidism
25745,25373929,laser doppler fluxmetry
25746,25373929,postocclusive reactive hyperaemia
25747,25373929,skin microcirculation
25749,24726178,antithyroid medication
25750,24726178,graves’ disease
25751,24726178,neonatal thyroid dysfunction
25752,24726178,outcome
25755,25122677,histone modifications
25756,25122677,interferon
25757,25122677,thyroiditis cois
25765,24784317,autoimmune thyroid diseases
25766,24784317,t regulatory cells
25767,24784317,forkhead box p3
25768,24784317,gene polymorphism
25769,25283079,midkine (mk)
25770,25283079,multi-nodular goiter (mng)
25771,25283079,nuclear factor-kappa b (nf-κb)
25772,25283079,papillary thyroid cancer (ptc)
25773,25283079,receiver operating characteristic (roc) curves
25774,25283079,synchronous metastasis
25775,26163757,gene expression profiling
25776,26163757,granulomatosis with polyangiitis
25777,26163757,microarray analysis
25778,26163757,molecular pathology
25779,26163757,orbit pathology
25780,26163757,orbital pseudotumor
25781,24793198,ct analysis
25782,24793198,deep lateral wall
25783,24793198,exophthalmos reduction
25784,24793198,orbital decompression
25785,24793198,orbital fat
25788,25615025,cytotoxic t-lymphocyte antigen-4
25789,25615025,polymorphism
25790,25615025,thyroid-associated ophthalmopathy
25791,24617953,graves' ophthalmopathy
25792,24617953,drug therapy
25793,24617953,glucocorticoid
25794,24617953,meta-analysis
25796,25648436,antibiotics
25797,25648436,mediastinitis
25798,25648436,negative pressure therapy
25799,25648436,streptococcus
25800,25648436,thyroidectomy
25804,24801540,autoimmunity
25805,24801540,children
25806,24801540,cytokines
25807,24801540,serum
25808,24801540,thyroid
25815,26523178,basedow disease
25816,26523178,papillary carcinoma
25817,26523178,thyroid
25823,26593863,autoimmune thyroid disease (aitd)
25824,26593863,graves’ disease (gd)
25825,26593863,hashimoto's thyroiditis (ht)
25826,26593863,maladie de basedow (gd)
25827,26593863,maladies thyroïdiennes auto-immunes (mait)
25828,26593863,polymorphisme de nucléotide unique (snp)
25829,26593863,récepteur à la vitamine d (vdr)
25830,26593863,single nucleotide polymorphism (snp)
25831,26593863,thyroïdite de hashimoto (ht)
25832,26593863,vitamin d receptor (vdr)
25834,25876459,graves' orbitopathy
25835,25876459,quality of life
25836,25876459,strabismus surgery
25837,25876459,success criteria
25845,25455307,graves' disease
25846,25455307,sensory ataxia
25847,25455307,sensory evoked potentials
25848,25455307,thyrotoxicosis
25849,25132194,contact lens sensor
25850,25132194,glaucoma
25851,25132194,intraocular pressure
25852,25132194,thyroid eye disease
25864,26034078,immunology
25865,26034078,orbit
25866,25847746,anti tsh-receptor antibody
25867,25847746,immunoassay
25868,25847746,pre
25869,25550791,graves’ hyperthyroidism
25870,25550791,nuocytes
25871,25550791,cytokines
25872,25550791,transcription factors
25873,26373794,graves' disease (gd)
25874,26373794,hashimoto's thyroiditis (ht)
25875,26373794,il1f7
25876,26373794,il37
25877,26373794,autoimmune thyroid diseases (aitds)
25878,26373794,single nucleotide polymorphisms (snps)
25889,26180468,diplopia
25890,26180468,graves’ disease
25891,26180468,restrictive strabismus
25892,26180468,strabismus surgery
25893,26180468,thyroid orbitopathy cois
25895,25900177,graves’ disease
25896,25900177,hashimoto’s thyroiditis
25897,25900177,oxidative status
25898,25900177,prolidase
25900,25859801,dsa = digital subtraction angiography
25901,25859801,gd = graves disease
25902,25859801,graves disease
25903,25859801,mmd = moyamoya disease
25904,25859801,mra = mr angiography
25905,25859801,t3 = triiodothyronine
25906,25859801,t4 = thyroxine
25907,25859801,tia = transient ischemic attack
25908,25859801,tsh = thyroid stimulating hormone
25909,25859801,disease progression
25910,25859801,ft3 = free triiodothyronine
25911,25859801,ft4 = free thyroxine
25912,25859801,moyamoya disease
25913,25859801,stroke
25914,25859801,vascular disorders
25916,25736545,dysthyroid optic neuropathy
25917,25736545,thyroid eye disease
25918,25736545,thyroid stimulating immunoglobulins
25927,25988433,exophthalmos
25928,25988433,graves’ orbitopathy
25929,25988433,globe luxation
25930,25988433,malar hypoplasia
25931,25988433,orbital decompression
25932,24434244,graves' ophthalmopathy
25933,24434244,quality of life
25934,24434244,questionnaire
25937,25176403,indirect calorimetry
25938,25176403,metabolic syndrome
25939,25176403,resting energy expenditure
25940,25176403,tetraiodothyronine
25941,25176403,thyroid stimulating hormone
25942,25176403,triiodothyronine
25944,26256985,tsh receptor autoantibody
25945,26256985,total thyroidectomy
25946,26256985,thyroid benign mass
25947,26256985,thyroid cancer
25948,26256985,thyroid-associated orbitopathy cois
25950,25159204,graves' orbitopathy
25951,25159204,adipogenesis
25952,25159204,heme oxygenase-1
25953,25159204,inflammation
25954,25159204,orbital fibroblasts
25955,25159204,oxidative stress
25956,25159204,tanshinone iia
25959,24990808,autoimmune thyroid disease
25960,24990808,intractability
25961,24990808,mir-125a
25962,24990808,polymorphism
25963,24990808,severity
25969,24798189,autoimmune thyroid disease
25970,24798189,graves'
25971,24798189,hashimoto's thyroiditis
25972,24798189,disease
25973,24798189,single nucleotide polymorphism
25974,24798189,tumor necrosis factor α-induced protein 3
25977,26141364,endonasal approach
25978,26141364,endoscopic assisted
25979,26141364,optic nerve
25980,26141364,orbit
25981,26141364,paranasal sinuses
25982,26141364,skull base
25986,25708657,foxp3
25987,25708657,graves' disease
25988,25708657,regulatory t cell
25989,25708657,single nucleotide polymorphism
25995,24460515,dry eye syndrome
25996,24460515,graves’ disease
25997,24460515,graves’ orbitopathy
26001,26041458,graves’ disease
26002,26041458,tsh receptor antibody
26003,26041458,antithyroid drugs
26004,26041458,hyperthyroidism
26005,26041458,pregnancy
26007,25320726,drug induced liver injury (dili)
26008,25320726,endocrinology
26009,25320726,hepatotoxicity
26010,25320726,idiosyncratic hepatic injury
26011,25320726,risk factors cois
26015,26116233,graves' disease (gd)
26016,26116233,histone acetylation
26017,26116233,histone modifications
26018,26116233,peripheral blood mononuclear cells (pbmcs)
26028,26344731,eyelid retraction
26029,26344731,optic neuropathy
26030,26344731,orbit
26031,26344731,restrictive myopathy
26032,26344731,thyroid eye disease
26034,25310344,adult strabismus
26035,25310344,diplopia
26036,25310344,operation dosage
26037,25310344,orbit
26038,25310344,thyriod eye disease
26042,25120331,drug-related side effects and adverse reactions
26043,25120331,graves disease
26044,25120331,methimazole
26045,25120331,pancreatitis cois
26048,26564931,cyclotropia
26049,26564931,double maddox rod test
26050,26564931,strabismus surgery
26051,26564931,thyroid eye disease
26054,24510024,extraocular muscles
26055,24510024,magnetic resonance imaging
26056,24510024,orbit
26057,24510024,thyroid-associated orbitopathy
26058,24510024,ultrasound
26059,26113403,autoimmune disease
26060,26113403,graves’ disease
26061,26113403,interleukin 7
26062,26113403,soluble interleukin 7 receptor
26068,25936345,cd40
26069,25936345,ctla-4
26070,25936345,genetic polymorphism
26071,25936345,graves' disease
26072,24712973,linear morphoea
26073,24712973,localised scleroderma
26075,24777217,graves’ disease
26076,24777217,adverse drug reactions
26077,24777217,disease management
26078,24777217,methimazole
26079,24777217,pediatric
26082,25617714,dna methylation
26083,25617714,dnmts
26084,25617714,graves' disease
26085,25617714,icam1
26086,25617714,mbds
26087,25617714,medip-chip
26097,25256279,anca
26098,25256279,hyperthyroidism
26099,25256279,propylthiouracil
26100,25256279,vasculitis
26104,25172242,ccl2
26105,25172242,cxcl10
26106,25172242,chemokines
26107,25172242,extra-ocular muscles
26108,25172242,graves' ophthalmopathy
26111,25444703,goitre ovarien
26112,25444703,meigs syndrome
26113,25444703,ovarian goiter
26114,25444703,ovarian tumor
26115,25444703,struma ovarii
26116,25444703,syndrome de meigs
26117,25444703,teratome
26118,25444703,thyroid
26119,25444703,thyroïde
26120,25444703,tumeur ovarienne
26121,25444703,tératome
26122,25457466,compressive optic neuropathy
26123,25457466,graves' orbitopathy
26124,25457466,spontaneous decompression
26135,26415610,alkaline phosphatase
26136,26415610,graves disease
26137,26415610,hypocalcemia
26138,26415610,thyroidectomy
26142,25059686,decompression
26143,25059686,orbital surgery
26144,25059686,piezosurgery
26145,25059686,proptosis
26146,25059686,thyroid associated orbitopathy
26148,24576228,graves’ disease
26149,24576228,hyperthyroidism
26150,24576228,hypothyroidism
26151,24576228,prenatal care
26152,24576228,thyroidectomy
26153,25814196,aetiopathogenesis of warthin's tumour
26154,25814196,autoimmune diseases
26155,25814196,lymphatic-rich stroma
26156,25814196,warthin's tumour
26158,24478186,cd20
26159,24478186,cd4
26160,24478186,cd8
26161,24478186,foxp3
26162,24478186,graves’ disease
26163,24478186,hashimoto's thyroiditis
26164,24478186,regulatory t cells
26169,25455505,bone metastases
26170,25455505,cirugía
26171,25455505,dosimetry
26172,25455505,dosimetría
26173,25455505,metástasis ósea
26174,25455505,surgery
26175,25455505,thyroid
26176,25455505,tiroides
26177,25455505,rtsh
26181,26425054,graves disease
26182,26425054,plasmapheresis
26183,26425054,thyrotoxicosis cois
26192,25412700,graves' disease
26193,25412700,hashimoto's thyroiditis
26194,25412700,th17 cells
26195,25412700,interleukins
26196,25412700,regulatory t cells
26200,26600899,struma ovarii
26201,26600899,histopathology
26202,26600899,ovarian goiter
26203,26600899,ovarian teratoma
26204,26600899,thyroid
26205,25576242,adipokines
26206,25576242,graves׳ disease
26207,25576242,hashimoto׳s thyroiditis
26208,25576242,leptin
26209,25576242,pamp׳s
26211,24956560,cytokine
26212,24956560,graves disease
26213,24956560,graves ophthalmopathy
26214,24956560,parp-1
26215,24956560,polymorphism
26217,25989711,autoimmune thyroid disease
26218,25989711,graves' disease
26219,25989711,hashimoto's thyroiditis
26220,25989711,interferon regulatory factor 8
26223,25647271,autoimmune thyroid disease (aitd)
26224,25647271,graves’ disease (gd)
26225,25647271,hashimoto’s thyroiditis (ht)
26226,25647271,interleukin-21 (il-21)
26227,25647271,interleukin-21 receptor (il-21r)
26228,25281394,gd
26229,25281394,kir3dl1
26230,25281394,nk
26231,25281394,nkg2a
26232,25281394,nkg2d
26233,25281394,nkp30
26235,25434508,chester-erdheim disease
26236,25434508,diabetes insipidus
26237,25434508,diabetes insípida
26238,25434508,enfermedad de chester-erdheim
26239,25434508,hipopituitarismo
26240,25434508,histiocitosis de células de langerhans
26241,25434508,hypopituitarism
26242,25434508,langerhans cell histiocytosis
26250,25586901,marinelli
26251,25586901,thyroid nodules
26252,25586901,combined therapy
26253,25586901,dosimetry
26254,25586901,microwave ablation
26255,25586901,radioiodine therapy
26257,24958412,benign and malignant thyroid nodules
26258,24958412,contrast-enhanced sonography
26259,24958412,maximum intensity
26260,24958412,microvessel density
26261,24958412,superficial structures
26267,25161183,cancer
26268,25161183,elastography
26269,25161183,thyroid nodules
26272,26406404,papillary thyroid carcinoma
26273,26406404,mutation
26274,26406404,thyroperoxidase
26276,25960045,follicular thyroid neoplasia
26277,25960045,differential diagnostics
26278,25960045,goitre
26279,25960045,immunohistochemistry
26280,25960045,stem cell marker
26291,26048691,alström syndrome
26292,26048691,follicular variant of papillary thyroid carcinoma
26293,26048691,thyroid cancer
26294,26048691,thyroid goitre
26296,25328134,cancer
26297,25328134,contrast agents
26298,25328134,follicular adenoma
26299,25328134,goiter
26300,25328134,quantitative parameter
26301,25328134,thyroid
26302,25328134,time-intensity curve
26303,25328134,ultrasonography
26304,26191283,cytokeratin 17
26305,26191283,immunohistochemistry
26306,26191283,lymph node metastasis
26307,26191283,papillary thyroid carcinoma
26310,25400776,papillary thyroid carcinoma (ptc)
26311,25400776,percentage of brafv600e alleles
26312,25400776,preoperative risk stratification
26313,25400776,pyrosequencing
26314,25940693,autonomously functioning thyroid nodule
26315,25940693,meta-analysis
26316,25940693,nodular goitre
26317,25940693,scintigraphy
26318,25940693,thyroid
26319,25940693,thyroid-stimulating hormone
26324,25707564,graves disease
26325,25707564,hypocalcemia
26326,25707564,multinodular goiter
26327,25707564,papillary carcinoma of thyroid
26328,25707564,parathyroid
26329,25707564,parathyroid adenoma
26330,25707564,recurrent laryngeal nerve
26331,25707564,thyroid
26332,25054230,aa amyloidosis
26333,25054230,chronic renal disease
26334,25054230,cystic fibrosis
26335,25054230,goiter
26336,25054230,intestinal disorders
26337,25054230,proteinuria
26340,25868389,ffpe
26341,25868389,nanostring analysis
26342,25868389,biomarkers
26343,25868389,circadian clock
26344,25868389,papillary thyroid carcinoma cois
26345,26578494,cribriform variant
26346,26578494,papillary carcinoma
26347,26578494,sonography
26348,26578494,thyroid
26349,26578494,ultrasound
26351,26437373,antiepileptic drugs
26352,26437373,goiter
26353,26437373,metabolic risk
26354,26437373,subclinical hypothyroidism
26355,26437373,thyroid hormones
26358,25120855,africa
26359,25120855,surgical camp
26360,25120855,uganda
26375,27057249,harmonic focus curved shears
26376,27057249,hemostasis
26377,27057249,thyroid
26378,27057249,thyroidectomy
26390,24993783,child
26391,24993783,differentiated thyroid cancer
26392,24993783,goitre
26393,24993783,hypoparathyroidism
26394,24993783,lobectomy with isthmusectomy
26395,24993783,medullary thyroid cancer
26396,24993783,recurrent laryngeal nerve paralysis
26397,24993783,thyroidectomy
26399,24434360,autoimmunity
26400,24434360,hashimoto
26401,24434360,thyroiditis
26406,25524940,papillary thyroid carcinoma
26407,25524940,rt-pcr
26408,25524940,mir-146a
26409,25524940,mir-146b
26411,25017947,cost-benefit
26412,25017947,goiter
26413,25017947,thyroid cancer
26414,25017947,thyroidectomy
26418,24866072,incidental carcinoma
26419,24866072,microcarcinoma
26420,24866072,thyroid
26421,24862663,hypocalcemia
26422,24862663,parathyroid hormone
26423,24862663,thyroidectomy
26427,25601586,thyroid cancer
26428,25601586,complications of thyroid surgery
26429,25601586,intraoperative neuromonitoring
26430,25601586,patient outcomes
26431,25601586,recurrent laryngeal nerve injury
26446,25217004,percutaneous tracheostomy
26447,25217004,tracheostomy
26449,25889269,goiter
26450,25889269,nitrate
26451,25889269,nitrite
26452,25889269,thyroid cancer
26453,25889269,thyroid function
26457,26327979,hashimoto′s thyroitidis
26458,26327979,acute
26459,26327979,sickle cell anemia
26461,26905714,association
26462,26905714,hashimoto's thyroiditis
26463,26905714,histopathology
26464,26905714,medullary carcinoma of thyroid.
26469,25946974,nicotinamide phosphoribosyltransferase
26470,25946974,nodular goiter
26471,25946974,reverse transcriptase polymerase chain reaction
26472,25946974,thyroid cancer
26473,25946974,thyroid gland
26474,25946974,visfatin
26477,24550235,calcitonin
26478,24550235,fine-needle aspiration cytology
26479,24550235,medullary thyroid carcinoma
26483,24388198,cadmium toxicity
26484,24388198,preneoplastic lesions
26485,24388198,thyroid gland
26487,25556330,hyperthyroidism
26488,25556330,potassium chloride repletion
26489,25556330,thyrotoxic hypokalemic periodic paralysis
26490,25556330,ventricular arrhythmia
26491,25934417,hypoparathyroidism
26492,25934417,intra-operative parathyroid hormone
26493,25934417,parathyroid hormone decline
26494,25934417,total thyroidectomy
26496,25156133,graves’ disease
26497,25156133,hyperthyroidism
26498,25156133,hyperthyroïdie
26499,25156133,iode 131
26500,25156133,maladie de basedow
26501,25156133,radioiodine dose
26502,25156133,thyroid
26503,25156133,thyroïde
26513,25824846,drug overdose
26514,25824846,hyperthyroxinemia
26515,25824846,levothyroxine overdose
26516,25824846,thyroid crisis
26517,25824846,thyrotoxicosis
26518,25598424,differential diagnosis
26519,25598424,hydatid cyst
26520,25598424,thyroid
26521,25598424,unusual location
26522,25476178,ct
26523,25476178,hyperthyroidism
26524,25476178,incidental thyroid nodule
26525,25476178,mr imaging
26526,25476178,radioactive iodine scan
26527,25476178,thyroid cancer
26528,25476178,ultrasonography
26534,26210625,children
26535,26210625,hyperthyroidism
26536,26210625,hypothyroidism
26537,26210625,incidental
26538,26210625,nodule
26539,26210625,overt
26540,26210625,thyroid
26541,26210625,ultrasonography
26549,25873114,antiandrogens  prolactin
26565,24760746,graves' disease
26566,24760746,hashimoto's thyroiditis
26567,24760746,autoimmune thyroiditis
26568,24760746,erythrovirus b19
26569,24760746,parvovirus b19
26574,26347012,angiogenesis
26575,26347012,atherosclerosis
26576,26347012,cholesterol
26577,26347012,pleiotropic effect
26578,26347012,statins
26581,25480825,cancer
26582,25480825,nodules
26583,25480825,oncology
26584,25480825,pediatrics
26585,25480825,therapeutics
26586,25480825,thyroid cois article.
26590,24578322,double salt fortification
26591,24578322,human health
26592,24578322,micronutrient assessment
26593,24578322,mineral deficiency
26602,24768495,fine needle aspiration
26603,24768495,thyroid
26604,24768495,thyroid bed
26605,26374222,adenomatous hyperplasia
26606,26374222,brenner tumor
26607,26374222,mucinous cystadenoma
26608,26374222,papillary thyroid carcinoma
26609,26374222,serous cystadenoma
26610,26374222,struma ovarii
26611,26374222,strumal carcinoid
26612,25755717,cd147
26613,25755717,rna interference
26614,25755717,thyroid cancer-experimental
26615,25755717,genetics
26616,25755717,glycolysis
26617,25755717,pathology-thyroid
26618,24493789,barriers
26619,24493789,discharge
26620,24493789,outpatient
26621,24493789,thyroidectomy
26622,26823860,braf
26623,26823860,papillary thyroid cancer
26624,26823860,ras
26625,26823860,ret
26630,26406959,thyroid cancer
26631,26406959,diagnosis
26632,26406959,fine needle aspiration biopsy (fnab)
26633,26406959,transforming growth factor-β 1
26636,26475096,ectopic lymphoid tissue
26637,26475096,hashimoto's thyroiditis
26638,26475096,human parvovirus b19
26639,26475096,pathogenesis
26640,26475096,positive regulatory domain zinc finger protein 1
26642,24750986,difficult thyroidectomy
26643,24750986,difficulty scale
26644,24750986,graves disease
26645,24750986,hashimotos thyroiditis
26646,24750986,risk adjustment
26647,24750986,thyroid
26652,26408676,thyroid sarcoma
26653,26408676,clinical sign
26654,26408676,review
26655,26408676,thyroid imaging
26657,25487217,131i therapy
26658,25487217,benign thyroid disease
26659,25487217,dosimetry
26665,26417067,ccm
26666,26417067,ros
26667,26417067,autophagy
26668,26417067,endothelial‐to‐mesenchymal transition (endmt)
26669,26417067,mtor
26670,25639351,saccharomyces cerevisiae
26671,25639351,antioxidants
26672,25639351,avenanthramides
26673,25639351,biofactors
26674,25639351,cerebral cavernous malformation
26675,25639351,metabolic engineering
26676,25639351,phenolic compounds
26677,25639351,plant secondary metabolites
26681,26302664,*iodine intake
26682,26302664,*iodized salt
26683,26302664,*nutrición yódica
26684,26302664,*sal yodada
26685,26302664,*urinary iodine concentrations
26686,26302664,*yoduria
26688,25829390,ambulatory surgical procedures
26689,25829390,outpatient
26690,25829390,perioperative complications
26691,25829390,revisits
26692,25829390,surgery
26693,25829390,thyroid surgery
26694,25829390,thyroidectomy
26695,25041837,galectin-3
26696,25041837,hbme-1
26697,25041837,immunohistochemistry
26698,25041837,thyroid nodules
26702,25593151,dietary intake
26703,25593151,dietary supplements
26704,25593151,folate
26705,25593151,folic acid
26706,25593151,"vitamin b-9 cois the scientific advisory boards of conagra, inc., mccormick spice, the mushroom council, the california walnut commission, and bay state milling; and is a consultant to nestle, inc. kl wiemer and kb miller are employees of general mills, inc. o dary, ma philbert, v tarasuk, and cl taylor, no conflicts of interest. cl keen serves on advisory boards of advocare, herbalife, mars, inc., mccormick spice, and theralogix. jc king serves on the scientific advisory board for conagra; has received research funding from the almond board of california, the california walnut commission, thrasher foundation, harvest plus, the nestle foundation, usda, and nih; and has provided consultation to the alliance for potato research and education and ilsi north america. pc gaine and ab jarvis were employees of ilsi north america when the manuscript was prepared. rl bailey is a government liaison to the ilsi north america committee on fortification."
26708,25968604,founder effect
26709,25968604,mutation
26710,25968604,structural modeling
26711,25968604,tpo
26712,25968604,thyroid dyshormonogenesis
26714,25193578,adjuvant therapy
26715,25193578,differentiated thyroid carcinoma
26716,25193578,radioiodine ablation
26717,25193578,total thyroidectomy
26718,25193578,urinary iodine
26719,25175810,new sporadic neoplastic syndrome
26720,25175810,papillary and medullary carcinomas
26721,25175810,urothelial
26722,25917998,levothyroxine
26723,25917998,preoperative localization
26724,25917998,primary hyperparathyroidism
26725,25917998,sestamibi scintigraphy
26726,25917998,ultrasound
26732,25837167,braf
26733,25837167,dna
26734,25837167,biomarker
26735,25837167,papillary thyroid carcinoma
26736,25837167,plasma cois
26738,24582076,cleft lip and palate
26739,24582076,ex utero intrapartum treatment (exit)
26740,24582076,fetal diagnosis
26741,24582076,micrognathia
26742,24582076,prenatal consultation
26744,26119458,acoustic radiation force impulse
26745,26119458,elastography
26746,26119458,thyroid nodule
26747,26119458,ultrasound
26750,25111330,chinese population
26751,25111330,fine-needle aspiration biopsy
26752,25111330,genetic alterations
26753,25111330,thyroid nodules
26758,25836323,dicer1
26759,25836323,embryonal rhabdomyosarcoma
26760,25836323,ovary
26761,25836323,pediatric tumors
26762,25836323,mirna
26764,26342107,papillary thyroid carcinoma
26765,26342107,undifferentiated thyroid carcinoma
26766,26342107,vegf
26767,26342107,mir-205
26768,26342107,microrna
26772,26041374,h271d
26773,26041374,resistance to thyroid hormones
26774,26041374,thyroid hormone receptor beta gene (thrβ)
26776,25155806,dairy product
26777,25155806,iodized salt
26778,25155806,urinary iodine
26779,25486933,cerebrovascular disorders
26780,25486933,endothelium
26781,25486933,genetics
26782,25486933,hemorrhage
26783,25486933,stroke
